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Foreword
In facing the world drug problem, all countries find their destinies intertwined. For over a century, 
the international community has recognized that this problem is one that cannot be addressed effec-
tively if it is not addressed collectively. The United Nations drug control conventions were elabo-
rated by the community of nations acting in concert. They are the product of discussion and 
compromise and reflect a widespread consensus among States which today is evidenced by the fact 
that nearly every country on Earth is party to them. 
The international drug control conventions are often portrayed by their detractors as instruments 
of prohibition and punishment. Even the most cursory reading of these important documents 
reveals such an interpretation to be misguided. As reflected in the preamble to the Single Convention 
on Narcotic Drugs of 1961,1 the goal of the United Nations legal framework on drugs is the safe-
guarding of the health and welfare of humankind. In the pursuit of this important objective, the 
conventions regulate the licit trade in narcotic drugs and psychotropic substances and are designed 
to ensure that these substances are available for use in medical treatment to those who need them, 
regardless of where they live. In the conventions, States are enjoined to take measures to foster the 
prevention of drug abuse, treatment and social reintegration, including as alternatives to punitive 
sanctions. The conventions also provide a framework for extradition, mutual legal assistance and 
cooperation among States to counter drug trafficking and the violence and suffering with which 
this scourge is associated. 
Like all international conventions, the United Nations drug control treaties lay out a set of binding 
legal norms and entrust States with the adoption of legal, administrative and policy measures to imple-
ment their treaty obligations. While the choice of these measures is the prerogative of States, such 
measures must respect the limits that the international community has set for itself in the interna-
tional legal order. One of the most fundamental principles underpinning the international drug con-
trol framework, enshrined in both the 1961 Convention and in the Convention on Psychotropic 
Substances of 1971,2 is the limitation of use of narcotic drugs and psychotropic substances to medi-
cal and scientific purposes. This legal obligation is absolute and leaves no room for interpretation.
Also, as the Board has often reiterated, drug control measures do not exist in a vacuum; in their 
implementation of these measures, States must comply with their international human rights obli-
gations. While the Board is heartened by the progress made by members of the international com-
munity in adopting drug control measures that are consistent with internationally recognized human 
rights standards, much remains to be done. That includes, for instance, steps to be taken in rela-
tion to the full implementation of the Convention on the Rights of the Child,3 in which States par-
ties agreed to take all appropriate measures to protect children from the illicit use of narcotic drugs 
and psychotropic substances and to prevent the use of children in the illicit production and traf-
ficking of such substances. While the determination of specific sanctions applicable to drug-related 
offences remains the prerogative of States, the Board again encourages those States which retain 
and continue to impose the death penalty for drug-related offences to consider abolishing the death 
penalty for such offences. 
Over the years, the Board has continually stressed the need to adopt a comprehensive, integrated 
and balanced approach to implementing the provisions of the international drug control treaties in 
order to respond to the world drug problem together. With the upcoming special session of the 
 1 United Nations, Treaty Series, vol. 520, No. 7515.
 2 Ibid., vol. 1019, No. 14956.
 3 Ibid., vol. 1577, No. 27531.
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General Assembly on the world drug problem to be held in 2016, this principle is worth revisit-
ing; it is the subject of chapter I of the present report.
One important element in taking balanced and proportionate action is to ensure that drugs are 
available for medical and scientific purposes. Acting under its mandate to assess the licit use of 
internationally controlled drugs, the Board was among the first bodies at the international level to 
draw attention to major discrepancies among various regions in terms of the availability of such 
drugs. For the past two decades, the Board has paid particular attention to that concern and called 
Governments to action. Despite the progress made in some regions, the fact remains that approx-
imately three quarters of the world’s population live in countries with inadequate or non-existent 
access to medicines containing narcotic drugs and psychotropic substances, which leads to unneces-
sary pain and suffering. 
In addressing this problem, the Board cannot act alone. The Board is particularly appreciative of 
the tireless efforts of civil society organizations, which have contributed to bringing about improved 
access for patients to these drugs for medical purposes in some countries. Governments must strive 
to achieve a well-functioning national and international system for managing the availability of nar-
cotic drugs and psychotropic substances that provides relief from pain and suffering by ensuring 
the safe delivery of affordable drugs to those patients who need them while preventing over-
prescription and the diversion of drugs for the purpose of abuse. 
A balanced approach also presupposes that drug demand reduction interventions are mainstreamed 
into the strategies and action plans of Governments. Depleting the supply of drugs and reducing 
the demand for them have a mutually reinforcing effect. A comprehensive array of demand reduc-
tion measures, including primary, secondary and tertiary prevention strategies, should be among 
the foremost priorities of Governments. Without demand reduction, supply reduction cannot be 
effective in the long run. 
In some countries, socioeconomic factors may contribute to the illicit drug phenomenon. These 
factors need to be taken into consideration as relevant elements of a comprehensive, integrated and 
balanced approach. Illicit cultivation of drug crops tends to be intertwined with socioeconomic 
 factors such as lack of alternative livelihoods, lack of access to health care and education, disen-
franchisement and weak governance. Thus, the reduction and elimination of illicit crop cultivation 
also needs to be addressed in the broader context of sustainable development.
The past year has seen its share of humanitarian crises in the form of natural disasters and armed 
conflict, which have led to a sudden and acute need for medicines containing internationally con-
trolled substances. The Board again draws attention to this plight and to the obligation that par-
ties to armed conflicts have under international humanitarian law not to impede the provision of 
medical care to civilian populations located in territories under their effective control or to impede 
their access to necessary medicines, and reminds Governments of the simplified procedures devel-
oped with the World Health Organization for this purpose. 
In the run-up to the special session of the General Assembly on the world drug problem to be held 
in 2016, the international community should commit to carrying out a constructive international 
dialogue which is frank, inclusive, comprehensive and forward-looking. This dialogue must also be 
balanced, recognizing the significant achievements made and identifying areas that are in need of 
improvement. Through its monitoring of the international drug control treaties, the Board will con-
tribute to this endeavour. 
In tackling the world drug problem, all countries face shared challenges and have a common pur-
pose in promoting the health and welfare of their peoples and, together, of humankind. To this 
vend, the international community will continue to count on the drug control treaties, international 
instruments that have withstood the test of time and remain relevant to addressing future  challenges. 
All that is required is the continued commitment of all States to act in concert in the effective 
implementation of those instruments. 
 Lochan Naidoo
 President
 International Narcotics Control Board
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Explanatory notes
Data reported later than 1 November 2014 could not be taken into consideration in preparing this report.
The designations employed and the presentation of the material in this publication do not imply the expression of 
any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any coun-
try, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
Countries and areas are referred to by the names that were in official use at the time the relevant data were collected.
References to dollars ($) are to United States dollars, unless otherwise stated.
The following abbreviations have been used in this report:
3,4-MDP-2-P 3,4-methylenedioxyphenyl-2-propanone
5-MeO-DALT N,N-diallyl-5-methoxytryptamine
ADHD attention deficit and hyperactivity disorder
AIRCOP Airport Communication Project
AMT alpha-methyltryptamine
APAAN alpha-phenylacetoacetonitrile
ASEAN Association of Southeast Asian Nations
ATS amphetamine-type stimulants
BZP N-benzylpiperazine
CARICOM Caribbean Community
CICAD Inter-American Drug Abuse Control Commission
ECOWAS Economic Community of West African States
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
Europol European Police Office
GCC Cooperation Council for the Arab States of the Gulf
GHB gamma-hydroxybutyric acid
ha hectare
I2ES International Import and Export Authorization System
INCB International Narcotics Control Board
INTERPOL International Criminal Police Organization
ISAF International Security Assistance Force
LSD lysergic acid diethylamide
MDMA methylenedioxymethamphetamine
MDPV methylenedioxypyrovalerone
OAS Organization of American States
P-2-P 1-phenyl-2-propanone
PEN Online Pre-Export Notification Online
PICS Precursors Incident Communication System
SADC Southern African Development Community
S-DDD defined daily doses for statistical purposes
TFMPP 1-(3-trifluoromethylphenyl)piperazine
THC tetrahydrocannabinol
UNODC United Nations Office on Drugs and Crime
WCO World Customs Organization
WHO World Health Organization
11. Given its multifaceted and dynamic nature, the world 
drug problem is one of the most complex challenges 
 facing the contemporary world. It directly or indirectly 
affects everyone and poses a serious threat to health, both 
as a result of the illicit cultivation, production, manufac-
ture, sale, demand, trafficking and distribution of narcotic 
drugs and psychotropic substances, and as a consequence 
of the abuse of prescription drugs. The world drug prob-
lem affects the dignity, safety and well-being of all human-
ity, in particular children and youth, families and 
communities. The drug phenomenon has a detrimental 
impact on social cohesion, health care, the environment, 
national security, regional and international stability, 
international peace and the sovereignty of States. It 
undermines respect for human rights and the rule of law, 
socioeconomic and political stability, democratic institu-
tions and sustainable development. At the same time, the 
world drug problem is itself the result of weak rule of 
law, unstable socioeconomic and political conditions, 
poverty, marginalization and corrupt political, juridical 
and economic institutions. The fact that the world drug 
problem can be both a reason for and a result of difficult 
economic, social and political conditions is what makes 
addressing it so challenging. The fast proliferation and 
the extent of use of new psychoactive substances illus-
trates the dynamic nature of the drug problem.
2. Since the 1990s, all political declarations, action 
plans and resolutions adopted under the auspices of the 
United Nations to address the world drug problem in 
general have indicated the following prerequisites for 
successful action in tackling the drug phenomenon: full 
compliance with, and universal application of, the pro-
visions of the three international drug control conven-
tions; and the implementation of two fundamental 
principles, namely a common and shared responsibility 
for tackling the world drug problem, and a comprehen-
sive, integrated and balanced approach to addressing the 
problem. None of these elements represents an incite-
ment to an undefined “war on drugs”, nor do any of them 
impose a purely prohibitionist regime or condone the 
repression of human rights. The international drug con-
trol conventions, the ultimate goal of which is to ensure 
the health and welfare of humankind, constitute the 
agreed response of the international community to the 
world drug problem, and form the primary legal frame-
work for drug control. The principle of common and 
shared responsibility provides a framework for coopera-
tion among States parties based on a shared understand-
ing of the drug problem, a common goal and the necessity 
of common and coordinated action. The principle of a 
comprehensive, integrated and balanced approach pro-
vides the strategic direction and vision for attaining the 
commonly agreed goal by taking into consideration and 
placing appropriate emphasis on all mutually inter-
dependent aspects of the world drug problem.
3. The preparations for the special session of the General 
Assembly on the world drug problem to be held in 2016 
provide the international community with an opportu-
nity to assess the progress made in the implementation 
of the 2009 Political Declaration and Plan of Action on 
International Cooperation towards an Integrated and 
Balanced Strategy to Counter the World Drug Problem,4 
to analyse the achievements, gaps and challenges in coun-
tering the world drug problem and to establish priorities 
for further action. This process is based on the outcomes 
of the 2014 high-level review by the Commission on 
Narcotic Drugs of the implementation by Member States 
 4 See Official Records of the Economic and Social Council, 2009, 
 Supplement No. 8 (E/2009/28), chap. I, sect. C.
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of the 2009 Political Declaration and Plan of Action. The 
preparatory process and the special session of the General 
Assembly to be held in 2016 represent good opportuni-
ties to discuss best practices and exchange views on mod-
els and methods to analyse various aspects of the world 
drug problem.
4. The International Narcotics Control Board has iden-
tified, and continues to identify, in its annual reports and 
communications various gaps and challenges in imple-
menting the international drug conventions. The Board 
has also emphasized the centrality of the two fundamen-
tal principles outlined in paragraph 2 above. In its annual 
report for 2012, the Board discussed the principle of 
shared responsibility in international drug control. The 
need to adopt a comprehensive, integrated and balanced 
approach to the world drug problem has been an issue 
that the Board has stressed continually in its activities, 
communications and annual reports, either in relation to 
various aspects of the drug problem that constitute the 
elements of such an approach (for example the issue of 
social cohesion, social disintegration and illicit drugs and 
the need for a multidisciplinary approach to addressing 
these matters)5 or as the main topic of its annual report, 
as in 2004. In the light of the upcoming special session 
of the General Assembly on the world drug problem, the 
Board considers that revisiting the principle of a bal-
anced, integrated and comprehensive approach is highly 
relevant in the current context, in which the different 
dimensions of the world drug problem affect countries 
in diverse ways, to the extent that not only is the prob-
lem perceived differently, but it can also have a different 
impact in each country.
A. Principle and aims
5. The principle of a comprehensive, integrated and bal-
anced approach to the world drug problem is strategic in 
nature. It requires Member States to ensure that con-
trolled substances are available for medical and scientific 
purposes. Member States should place equal emphasis on 
supply and demand reduction strategies, as well as on 
issues related to formulating a joint response to the world 
drug problem through international cooperation in an 
integrated and mutually reinforcing manner, while  taking 
into consideration and addressing all of its aspects in a 
comprehensive manner. Observing and fully implement-
ing this principle will enhance the ability of Member 
States to respond in a consistent and efficient manner to 
present and emerging challenges, and to formulate 
 5 Report of the International Narcotics Control Board for 2011, chap. I.
policies and programmes that address the phenomenon 
in all its forms and manifestations.
6. The implementation of a comprehensive, integrated 
and balanced approach to addressing the world drug 
problem is not an end in itself but rather a means to an 
end. The ultimate goal of such an approach must be to 
achieve the overall aim of the drug control conventions, 
namely to ensure the mental and physical health and wel-
fare of humankind. A key element in that regard, which 
has been politically agreed and translated into interna-
tional law, is to limit the availability of controlled sub-
stances exclusively to medical and scientific purposes, 
while preventing and significantly and measurably reduc-
ing, or eliminating, the illicit production of, trafficking in 
and use of such substances.
7. The implementation of a comprehensive, integrated 
and balanced approach requires the full commitment of 
Member States to implementing the provisions of the 
three international drug control conventions in good 
faith, and the willingness and ability of Governments to 
take practical measures at all levels and to allocate appro-
priate funding for all of the elements involved, including 
in a situation of economic and financial constraints.
B. Origins and development
8. The principle of a comprehensive, integrated and bal-
anced approach to addressing the world drug problem 
evolved over time. The early drug control conventions 
preceding the Single Convention on Narcotic Drugs of 
19616 focused mainly on the supply side of the drug prob-
lem. The amended version of article 38 contained in the 
1972 Protocol amending the Single Convention on 
Narcotic Drugs of 19617 reflected the need to adopt a 
multidisciplinary approach to the problem of narcotic 
drugs. Article 38 stipulates the legal obligation of States 
to take all practicable measures for the prevention of 
abuse of drugs and for the early identification, treatment, 
education, aftercare, rehabilitation and social integration 
of the persons involved. The same provision underlines 
the importance of promoting both personnel training and 
awareness campaigns. The Commentary on the Protocol 
Amending the Single Convention on Narcotic Drugs, 1961, 
explains that article 38 reflects the general acceptance of 
the view that a system of administrative controls and 
penal sanctions for the purpose of keeping narcotic drugs 
from actual or potential victims is not sufficient and 
 6 United Nations, Treaty Series, vol. 520, No. 7515.
 7 Ibid., vol. 976, No. 14152.
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should not form the sole subject of international cooper-
ation. Article 38 deems drug addiction a complex prob-
lem and indicates that treatment, aftercare, rehabilitation 
and social reintegration represent the four stages of reme-
dial measures that are widely held to be necessary to 
restore the well-being and social usefulness of persons 
affected by drug addiction.8 Article 20 of the 1971 
Convention on Psychotropic Substances9 reflects the same 
approach in relation to psychotropic substances.10 
9. The explicit formulation and development of such an 
approach can be found in the Political Declaration 
adopted by the General Assembly at its twentieth special 
session,11 in 1998, as well as the Declaration on the 
Guiding Principles of Drug Demand Reduction12 and 
other documents adopted at that session, and in the 2009 
Political Declaration and Plan of Action, various resolu-
tions of the General Assembly, Economic and Social 
Council and Commission on Narcotic Drugs, and min-
isterial statements adopted at the midterm review ses-
sions. The 1998 Political Declaration elevated the issue of 
implementing a comprehensive, integrated and balanced 
approach to the status of a fundamental principle in 
addressing the world drug problem. That principle 
remained at the core of the strategy adopted in the 2009 
Political Declaration and Plan of Action. The centrality 
of that principle was reiterated in the Joint Ministerial 
Statement of the 2014 high-level review by the Commission 
on Narcotic Drugs of the implementation by Member 
States of the Political Declaration and Plan of Action.13 
C. Elements of a comprehensive, 
integrated and balanced approach
Availability of internationally controlled 
substances for medical and scientific purposes
10. The outcome of a comprehensive, integrated and 
balanced approach to addressing the world drug problem 
 8 Commentary on the Protocol Amending the Single Convention on 
Narcotic Drugs, 1961 (E/CN.7/588), commentary on article 38.
 9 United Nations, Treaty Series, vol. 1019, No. 14956.
 10 The amended version of article 38 took over, with minor drafting 
changes and mutatis mutandis, the text of article 20 of the 1971 Conven-
tion on Psychotropic Substances.
 11 General Assembly resolution S-20/2, annex.
 12 General Assembly resolution S-20/3, annex. In that Declaration, the 
Assembly stressed that “the most effective approach to the drug problem 
consists of a comprehensive, balanced and coordinated approach, by which 
supply control and demand reduction reinforce each other, together with 
the appropriate application of the principle of shared responsibility”.
 13 See Official Records of the Economic and Social Council, 2014, 
 Supplement No. 8 (E/2014/28), chap. I, sect. C.
must be not only to prevent (or at least significantly 
reduce) illicit production of, trafficking in and use of nar-
cotic drugs and psychotropic substances, but also to facil-
itate the availability of controlled substances for medical 
and scientific purposes. Properly implemented, such an 
approach must lead to an optimal balance between restric-
tive and facilitating measures so as to ensure the health 
and welfare of humankind and reduce human suffering.
11. Ensuring the availability of controlled substances for 
medical and scientific purposes is a fundamental objec-
tive of the drug control system and an obligation of States 
parties under the international drug control conventions. 
The 1961 Convention, as amended by the 1972 Protocol, 
and the 1971 Convention stress that medical use of nar-
cotic drugs and psychotropic substances is indispensable 
for the relief of pain and suffering and that adequate pro-
vision must be made to ensure the availability of interna-
tionally controlled substances for medical and scientific 
purposes. Article 9 of the 1961 Convention, as amended 
by the 1972 Protocol, expressly stipulates that States par-
ties are responsible for ensuring the availability of narcotic 
drugs for licit purposes, and gives the Board the mandate 
to monitor the availability of controlled substances for 
legitimate purposes.
12. Acting under its mandate to assess licit consump-
tion of controlled substances in Member States, the Board 
was among the first to signal that major discrepancies 
existed among various regions in terms of the availabil-
ity of narcotic drugs, and that inadequate access to con-
trolled substances affected a great number of countries. 
For the past two decades, the Board has paid particular 
attention to this concern in its relations with Governments 
and other relevant stakeholders, and has recommended 
measures to address the situation.14 Data on the availa-
bility of opioid analgesics indicate that, despite progress 
made in some regions, i.e. Latin America and West, East 
and South-East Asia, approximately 5.5 billion people, or 
three quarters of the world’s population, live in countries 
with low levels of, or non-existent, access to medicines 
containing narcotic drugs and have inadequate access to 
treatment for moderate to severe pain, while 92 per cent 
of the world’s morphine is consumed by 17 per cent of 
the world’s population, primarily in North America, 
Oceania and Western Europe. The Board also indicated 
on several occasions that comparable discrepancies 
existed in relation to access to appropriate amounts of 
psychotropic substances for licit purposes.15 
 14 See Report of the International Narcotics Control Board on the 
Availability of Internationally Controlled Drugs: Ensuring Adequate Access 
for Medical and Scientific Purposes (E/INCB/2010/1/Supp.1).
 15 See, for example, E/INCB/2010/1/Supp.1, para. 6.
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13. The analysis of the data provided by Member States 
shows that the amount of opiate raw material available 
for the production of opioid analgesics for pain relief is 
more than sufficient to satisfy the requirements and con-
sumption reported by Governments, and that global 
stocks are increasing. The low demand for opioid anal-
gesics for pain relief in many countries is obviously not 
the result of a shortage of licitly produced raw materi-
als. As the Board has repeatedly stressed, the situation 
could be substantially improved through corrective 
action by States parties to address the regulatory, attitu-
dinal, knowledge-related, economic and procurement-
related problems identified as the main causes of 
inadequate availability of opioids. The Board encourages 
States to cooperate with the World Health Organization 
(WHO) and other relevant stakeholders on this matter, 
and reiterates its openness and readiness to continue 
assisting countries in achieving better results in this area. 
To that end and as a contribution to the special session 
of the General Assembly on the world drug problem to 
be held in 2016, the Board will issue an updated version 
of its 2010 special report entitled Availability of 
Internationally Controlled Drugs: Ensuring Adequate 
Access for Medical and Scientific Purposes, which will pro-
vide updated data on and analysis of the consumption 
and availability of internationally controlled drugs for 
medical and scientific use.
14. A proper application of the international drug con-
trol conventions and the implementation of a compre-
hensive, integrated and balanced approach to addressing 
the world drug problem would promote access to appro-
priate amounts of controlled substances for medical and 
scientific purposes and prevent the non-legitimate and 
excessive use of such substances.16 
Demand reduction and related measures
15. The origin and development of the principle of a 
comprehensive, integrated and balanced approach to the 
world drug problem are strongly linked to the need to 
place a greater emphasis on and to mainstream demand 
reduction.
 16 The Board has addressed, in most of its annual reports, the issue of 
availability of internationally controlled substances for medical and sci-
entific purposes, and issued recommendations in that regard. It has also 
repeatedly drawn attention in many of its publications to the abuse of 
prescription drugs, for example, by highlighting the issue under special 
topics in its reports for 2009, 2012 and 2013. In 2000, the Board devoted 
its thematic chapter to a review of the overconsumption of internation-
ally controlled substances; in 2013, prescription drug disposal initiatives 
were discussed under special topics.
16. The Board has repeatedly stressed the importance of 
drug demand reduction as an indispensable element of 
such an approach, and has also stressed that depleting 
illicit supply and reducing demand have a mutually rein-
forcing effect. The Board has continually encouraged 
Member States to implement a comprehensive package of 
demand reduction measures as one of the first priorities 
of their drug control policies. The Board has also clarified 
that different approaches are required in relation to the 
two objectives. The legal framework for measures to coun-
ter illicit drug manufacture, production, transport, traf-
ficking and diversion must be established at the 
international level. Preventing illicit drug use and abuse 
involves communications strategies that should take into 
consideration the social, cultural and economic back-
grounds of the target population groups. In addition, the 
provision of treatment and rehabilitation for drug abusers 
can take place only within the existing sociocultural con-
text of each country. Demand reduction policies and pro-
grammes, including the relevant legal frameworks, should 
be designed and implemented primarily at the national 
and local levels in order to be effective and efficient in 
achieving the goals established in the international drug 
control conventions and related instruments.17 
17. The international drug control conventions stipulate 
clear obligations and provide guidelines for the policies 
to be adopted by States parties in the field of demand 
reduction. Article 38 of the 1961 Convention, as amended 
by the 1972 Protocol, and article 20 of the 1971 Convention 
stipulate that States parties shall take all practicable meas-
ures for the prevention of abuse of narcotic drugs and 
psychotropic substances and for the early identification, 
treatment, education, aftercare, rehabilitation and social 
reintegration of the persons involved. Those two articles 
also encourage the training of personnel involved in all 
stages of demand reduction activities and call for the pro-
motion of public awareness campaigns. Article 14, para-
graph 4, of the United Nations Convention against the 
Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 198818 requires States parties to adopt 
appropriate measures aimed at eliminating or reducing 
illicit demand for narcotic drugs and psychotropic sub-
stances, with a view to reducing human suffering and 
eliminating financial incentives for illicit traffic.
18. The assessment of progress made in the area of 
demand reduction since the twentieth special session of 
the General Assembly, contained in the Plan of Action 
on International Cooperation towards an Integrated 
 17 Report of the International Narcotics Control Board for 2007, 
para. 278.
 18 United Nations, Treaty Series, vol. 1582, No. 27627.
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and Balanced Strategy to Counter the World Drug 
Problem, indicated that only limited results had been 
attained, owing largely to the lack of implementation of 
a comprehensive, integrated and balanced approach. 
The Plan of Action stressed that Member States should 
“pursue a  balanced and mutually reinforcing approach 
to supply and demand reduction, devoting more effort 
to the realization of demand reduction with a view to 
achieving proportionality of effort, resources and inter-
national cooperation in addressing drug abuse as a 
health and social issue, while upholding the law and its 
enforcement”.19 
19. Demand reduction as a policy objective requires 
understanding drug addiction as a multifactorial health 
disorder that requires an evidence-based approach and 
involves a wide variety of complex measures that provide 
a continuum of education, prevention and care in health 
and social services, from primary prevention through 
early intervention to treatment, rehabilitation and social 
reintegration, as well as in related support services,  taking 
into consideration the specificities of various target 
groups. Access to these programmes must be provided in 
a non-discriminatory manner. These programmes and 
interventions should be based on appropriate evaluation 
and assessment of the drug situation, and should make 
full use of available scientific evidence. The evidence-
based approach is equally relevant for all aspects of 
demand reduction. Consideration should also be given 
to social factors, threats to social cohesion and factors 
leading to social disorganization. A comprehensive 
approach to the demand aspect of the drug problem 
implies the involvement and cooperation of various 
actors, including educational and religious institutions; 
health-care, social-care, justice, enforcement and employ-
ment agencies; non-governmental organizations; and rel-
evant civil society entities. It also implies the coordination 
of all of these actors, and should take full advantage of 
the expertise and activities of non-governmental and civil 
society organizations. Such an approach would further 
need to reflect the willingness of States parties to reor-
ganize their priorities relating to drug control policy and 
allocate resources to demand reduction efforts. 
Supply reduction
20. Supply reduction is another essential element of a 
comprehensive, integrated and balanced approach. Supply 
reduction strategies and measures are aimed at eliminat-
ing or significantly reducing the quantity of narcotic drugs 
and psychotropic substances available for illicit use while 
 19 See E/2009/28, chap. I, sect. C, Plan of Action, para. 2 (a).
ensuring their availability for medical and scientific pur-
poses. Supply reduction measures utilizing law enforce-
ment, judicial cooperation and sustainable alternative 
development programmes are designed with the purpose 
of combating illicit crop cultivation and dismantling 
organized criminal groups involved in the illicit produc-
tion and trafficking of controlled substances. The long his-
tory of supply reduction efforts and the experience gained 
have led to the conclusion that success in reducing the 
availability of controlled substances for illicit use cannot 
be achieved without placing equal emphasis on demand 
reduction, making equal efforts in that regard and over-
coming other root causes of the world drug problem. 
21. Progress in the area of supply reduction is depend-
ent on several factors. Of essential importance is the for-
mulation and effective implementation of drug supply 
reduction policies based on appropriate national legisla-
tion that is in full compliance with the three international 
drug control treaties, and provision of the proper legis-
lative framework for international cooperation and tech-
nical assistance. The 2009 Plan of Action also identified 
other factors that needed to be addressed in order to 
achieve better results in the area of supply reduction, for 
example “inadequate information-sharing and monitor-
ing and control mechanisms and the lack of coordinated 
law enforcement operations, as well as the insufficient and 
unstable allocation of resources”.20 
22. The proper implementation of a comprehensive, 
integrated and balanced approach with regard to the 
efforts of Member States to combat the illicit cultivation 
of crops and illicit drug production, manufacture, distri-
bution and trafficking, as well as other drug-related 
crimes, should also facilitate efforts to respond effectively 
to such new challenges as the rapid proliferation of new 
psychoactive substances, emerging threats from shifting 
drug trafficking routes, new drug trafficking trends and 
the use of new communication technologies in drug-
related organized crime. Specific efforts should be focused 
on comprehensive measures aimed at depriving the illicit 
drug economy of its commercial attractiveness, as well as 
at dismantling its socioeconomic basis. In this context, a 
comprehensive set of measures should be formulated and 
implemented to disrupt illicit financial flows connected 
to drug trafficking, undermine links between illicit drugs 
and other forms of criminal activity, prevent people from 
being recruited by drug traffickers by addressing the 
socio economic conditions that contribute to their involve-
ment in the illicit drug economy, and strengthen ties with 
relevant industries to ensure the use of precursor chem-
icals only for licit purposes.
 20 Ibid., para. 21.
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23. Money-laundering is a global phenomenon that has 
a debilitating effect on social, political and economic sta-
bility and development. It fuels organized crime and cor-
ruption. The links between the illicit drug economy and 
money-laundering are well known. The first international 
legal instrument to include provisions dealing with and 
criminalizing the laundering of money derived from illicit 
drug trafficking is the 1988 Convention, in its article 3, 
paragraph (1), and article 5. The ability to prevent and 
detect money-laundering represents an effective means of 
identifying criminals and disrupting their activities. In 
their efforts to combat this phenomenon, States parties 
should establish or update their national legislation, 
enhance their cooperation and implement the relevant 
international instruments, such as the 1988 Convention, 
the United Nations Convention against Transnational 
Organized Crime,21 the United Nations Convention against 
Corruption22 and the International Convention for the 
Suppression of the Financing of Terrorism,23 as well as the 
recommendations of the Financial Action Task Force on 
Money-Laundering. The implementation of these norms 
has led to improvements in the lifting of financial secrecy 
in certain cases, but concerns remain, in particular in rela-
tion to offshore banking centres, or so-called financial 
havens, that make criminal investigations more difficult, 
along with the use of the Internet and the new money-
laundering techniques that avert detection. 
24. The growing emergence in recent years of non- 
controlled new psychoactive substances has become a 
major public health threat and a truly global phenomenon. 
These substances are often presented as “legal” or “natu-
ral” alternatives to controlled substances, leading to the 
misconception that the fact that they are not controlled 
under the international drug control conventions makes 
them safe. Although it is impossible to estimate precisely 
the number of new psychoactive substances on the mar-
ket, the United Nations Office on Drugs and Crime 
(UNODC) has reported that the number of such sub-
stances in use more than doubled during the 2009-2013 
period, surpassing the number of drugs that are under 
international control.24 A particular challenge to the efforts 
of Governments in responding to the emergence of new 
psychoactive substances is the difficulty of identifying 
those substances in a timely manner, given the rapid arrival 
of new substances on the market, the various ways these 
 21 United Nations, Treaty Series, vol. 2225, No. 39574.
 22 Ibid., vol. 2349, No. 42146.
 23 Ibid., vol. 2178, No. 38349.
 24 There are 234 internationally controlled substances: 119 controlled 
under the 1961 Convention; and 115 under the 1971 Convention. The 
United Nations Office on Drugs and Crime (UNODC) indicates that 348 
new psychoactive substances had been reported by December 2013 
 (UNODC, World Drug Report 2014, chap. 1, sect. H).
substances enter the market, their inconsistent chemical 
composition, the lack of technical and pharmacological 
data and reference material, and insufficient forensic and 
toxicological capacity on the part of some States. The legal 
framework established by the international drug control 
treaties provides for the possibility of States adopting 
national control measures beyond those mandated at the 
international level. The monitoring and analysis of trends 
will also serve as a repository of information and provide 
a basis for effective evidence-based policy responses. Closer 
cooperation among Governments at the national and 
international levels, as well as collaboration with UNODC 
and other relevant international organizations in sharing 
information, exchanging best practices and developing 
common strategies, will be crucial in addressing the global 
substance abuse challenge.
Socioeconomic aspects
25. Poverty, food insecurity, economic inequality, social 
exclusion, deprivation owing to migration and displace-
ment, a shortage of comprehensive educational and rec-
reational facilities and employment prospects, poor 
parental engagement and guidance during early child-
hood, and exposure to violence and abuse are some of 
the socioeconomic factors that have an impact on both 
the supply and demand sides of the drug problem, and 
that affect the interaction between the two sides. There 
is no direct causality between these factors and illicit drug 
use and abuse or involvement in the supply side, in the 
sense that not all people affected by these factors are 
neces sarily involved in one form or another in the drug 
problem. However, these are important drivers of the 
illicit drug phenomenon and they need to be deemed as 
relevant elements to be taken into consideration within 
a comprehensive, integrated and balanced approach to 
the world drug problem.
26. In relation to drug control, socioeconomic aspects 
have been discussed mainly in the context of alternative 
development and treated as a matter related to supply 
reduction. The 2009 Plan of Action noted that there was 
a lack of reliable and up-to-date data on illicit crop cul-
tivation, and no increase in and ineffective utilization of 
data on human development and socioeconomic aspects.25 
The report of the Board for 2005 indicated that there was 
no country that had thus far implemented a preventive 
alternative development programme, and that reactive 
programmes had been implemented under the most dif-
ficult conditions. The lesson learned is that these pro-
grammes need to entail a combination of incentives and 
 25 See E/2009/28, chap. I, sect. C, Plan of Action, para. 42.
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disincentives—law enforcement, eradication and legiti-
mate alternative livelihoods—and target not just commu-
nities growing illicit crops but all communities affected 
by the illicit drug economy. It was noted that distinctions 
between consumer and producer countries were no 
longer relevant, and that it would be counterproductive 
to pursue alternative development to reduce illicit drug 
supply without introducing prevention and treatment 
programmes for drug abusers. Since then, the need for 
Member States to ensure the sustainability of crop con-
trol strategies, including preventive alternative develop-
ment, in coordination with other development measures 
in order to contribute to poverty eradication and to the 
sustainability of social and economic development has 
been stated in most of the General Assembly and 
Commission on Narcotic Drugs resolutions on alterna-
tive development. In implementing programmes for sus-
tainable alternative development, States parties should 
take into consideration the Lima Declaration on 
Alternative Development and the International Guiding 
Principles on Alternative Development, adopted at the 
high-level International Conference on Alternative 
Development in November 2012,26 which, inter alia, stress 
that “an integrated and complementary approach to alter-
native development programmes and strategies is crucial 
and should be implemented in concert with broader drug 
control policies, including demand reduction, law 
enforcement, illicit crop elimination and awareness- 
raising, taking into account demographic, cultural, social 
and geographic considerations, as appropriate, and in line 
with the three drug conventions”.27 
27. International cooperation and commitment among 
Governments, development organizations and international 
financial institutions must be enhanced in order to ensure 
the sustainability of development programmes and the 
incorporation of drug control into the broader development 
agenda. Emphasis has to be placed on the affected popula-
tions and on the provision of medical, educational and 
social services, the strengthening of the rule of law and the 
development of physical infrastructure aimed at addressing 
the isolation of certain areas. Those development measures 
should be applied in a non-discriminatory manner. In order 
to achieve optimal results and to reflect the needs of tar-
geted populations, the development programmes must 
ensure the full participation of affected communities, as 
well as national, regional and local authorities, civil society 
organizations and all other relevant stakeholders, at every 
stage, from planning to implementation to monitoring to 
evaluation. The main goal of such programmes and 
 strategies must be to create an environment in which it is 
 26 General Assembly resolution 68/196, annex.
 27 Ibid., appendix, para. 8.
possible to lead a life in which involvement in the illicit 
drug supply chain or illicit drug consumption is not 
 perceived as unavoidable and is not normalized.
Sociocultural aspects
28. Cultural attitudes have a significant impact on the 
world drug problem. Certain symbolic meaning is asso-
ciated with the use or non-use of narcotic drugs and psy-
chotropic substances. Such attitudes and meanings also 
influence the likelihood of a person becoming involved 
in illegal activities.
29. Influencing or changing people’s perceptions in rela-
tion to illicit drugs is seen as mainly a prevention mat-
ter, but it is also affected to a certain extent by the overall 
structure of drug control policy and the image it projects. 
Imbalanced approaches to different aspects of the drug 
problem could have a negative effect on drug control 
 policies and diminish public support for them. 
30. As is the case with other phenomena, for example, the 
fight against corruption, the main element of sustainable 
success with regard to confronting the world drug problem 
is not reactive approaches alone but rather the fostering of 
a preventive culture. The Board has earlier addressed, in its 
report for 1997, the issue of preventing drug abuse in an 
environment of illicit drug promotion. In that report, the 
Board highlighted the need for a balanced debate and for 
finding the right balance between influencing attitudes and 
restricting the availability of illicit drugs. The problems iden-
tified at that time, such as the promotion of drug use in 
popular culture and the relevance of education, remain rel-
evant today. In fact, those aspects have become far more 
problematic and therefore should be considered elements to 
be addressed as an integral part of a balanced, integrated 
and comprehensive approach.
Security and stability 
31. Security and stability are basic requirements for 
solving national and international problems that are of 
an economic, social, cultural or humanitarian nature and 
in promoting and encouraging respect for human rights.
32. Violence and corruption undermine the stability 
and legitimacy of States, including the rule of law, and in 
extreme cases may lead to conflict. Violence is not an 
inherent feature of illegal drug markets, but it can occa-
sionally occur if certain conditions are met. Most of the 
violence associated with the illicit drug economy is found 
in regions or countries where the presence of the State 
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or its control over territory is weak, the national institu-
tions lack the capacity to ensure the protection of the 
State’s citizens and to enforce the law, and respect for legal 
norms is low because laws appear to benefit only specific 
groups and because the institutions mandated to apply 
those laws are mistrusted owing to their corruption, 
impunity and partiality. As is the case with the existence 
of organized criminal groups, the conditions that facili-
tate violence and corruption often precede the eruption 
of the drug problem. In its 2010 report, the Board 
addressed the relationship between the illicit drug phe-
nomenon and corruption, and stressed the highly debil-
itating effect corruption has on international and national 
efforts to tackle the drug problem and curtail other forms 
of transnational organized crime. The complex relation-
ship among many social negatives and drugs adds to the 
web of challenges facing all drug policy efforts.
33. Concerns related to the major challenges posed by 
the increasing links between drug trafficking, corruption 
and other forms of transnational organized crime, 
including trafficking in human beings, trafficking in fire-
arms, cybercrime and, in some cases, terrorism and 
money-laundering, including money-laundering in con-
nection with the financing of terrorism, have been for-
mulated in the two Political Declarations and reiterated 
by the General Assembly in its annual resolutions on 
international cooperation against the world drug prob-
lem. This nexus has also been a matter of concern for 
the Security Council for a number of years. The Council 
has stressed the importance, as a matter relating to the 
maintenance of international peace and stability, of 
countering the illicit production of, demand for and traf-
ficking in drugs, and of identifying emerging trends in 
drug trafficking.
34. Reducing or eliminating the violence and corrup-
tion associated with the illicit drug economy must be 
achieved through the proper and full implementation of 
the international drug control conventions within the 
strategic framework of a comprehensive, integrated and 
balanced approach and the institutional strengthening 
required to make countries less vulnerable to external 
shocks, such as an increase in demand for foreign illicit 
drugs. The international drug control conventions have 
an important role to play in relation to security and sta-
bility aspects and, together with other relevant interna-
tional conventions, such as the Organized Crime 
Convention and the Protocols thereto,28 the Convention 
against Corruption and the relevant international con-
ventions and protocols related to terrorism, they form a 
 28 United Nations, Treaty Series, vols. 2225, 2237, 2241 and 2326, 
No. 39574.
comprehensive legal framework for strengthening inter-
national peace, stability and security.
D. Respect for human rights norms 
as an integral element of a 
comprehensive, integrated and 
balanced approach
35. One of the common elements in all declarations, 
action plans and resolutions that underline the principle 
of a comprehensive, integrated and balanced approach 
to addressing the world drug problem is the commit-
ment to ensuring compliance with human rights norms. 
Human rights has been highlighted as a crosscutting 
issue for international drug policy, notably with regard 
to supply reduction, demand reduction and international 
cooperation. Even without such references, it is clear that 
the human rights conventions form an important clus-
ter of binding international legislation that needs to be 
taken into consideration while implementing any inter-
national treaty, be it related to drugs, corruption or the 
environment, among other things.
36. It is notable, since 2004, how many actors critical 
of the existing drug control regime based at least part of 
their arguments on the premise that the drug control con-
ventions would stand in contradiction to human rights 
norms. This human rights discourse needs to be analysed 
and validated through the prism of existing human rights 
legal norms and their authoritative interpretation by con-
cerned human rights treaty bodies.
37. The usage of the term human rights has to make 
specific reference to legal rights as stipulated in existing 
international legal instruments, notably the nine core 
human rights conventions.29 Moreover, the human rights 
treaties employ the same language and rationale as used 
in the preambles to the drug control treaties. This 
 29 Convention against Torture and Other Cruel, Inhuman or Degrad-
ing Treatment or Punishment (United Nations, Treaty Series, vol. 1465, 
No. 24841); Convention on the Elimination of All Forms of Discrimination 
against Women (United Nations, Treaty Series, vol. 1249, No. 20378); Con-
vention on the Rights of Persons with Disabilities (United Nations, Treaty 
Series, vol. 2515, No. 44910); Convention on the Rights of the Child  (United 
Nations, Treaty Series, vol. 1577, No. 27531); International Convention for 
the Protection of All Persons from Enforced Disappearance (General 
 Assembly resolution 61/177, annex); International Convention on the 
Elimination of All Forms of Racial Discrimination (United Nations, Treaty 
 Series, vol. 660, No. 9464); International Convention on the Protection of 
the Rights of All Migrant Workers and Members of Their Families (United 
Nations, Treaty Series, vol. 2220, No. 39481); International Covenant on 
Civil and Political Rights (General Assembly resolution 2200 A (XXI), 
 annex); and International Covenant on Economic, Social and  Cultural 
Rights (General Assembly resolution 2200 A (XXI), annex).
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suggests a convergence rather than a divergence of 
human rights norms and the international drug control 
conventions.
38. The international drug control system was estab-
lished out of concern for the health and welfare of 
humankind, and with the aim of meeting the medical 
and scientific needs for narcotic drugs and psychotropic 
substances while preventing the illicit use of controlled 
substances. This core objective is fully supportive of the 
key elements—children, young people, health and well-
being—referred to in the Political Declaration adopted 
by the General Assembly at its twentieth special session 
and in the Political Declaration on International 
Cooperation towards an Integrated and Balanced Strategy 
to Counter the World Drug Problem. It also has a direct 
link to human rights treaties.30 Member States should give 
due consideration to the human rights norms relevant in 
the context of each element of a comprehensive, inte-
grated and balanced approach, according to their legal 
obligations. They should also, if necessary, seek out the 
advice of human rights treaty bodies for the implemen-
tation of such norms. 
E. Recommendations
39. The special session of the General Assembly on the 
world drug problem to be held in 2016 is critically impor-
tant for readdressing the centrality of the principle of a 
balanced and comprehensive approach to addressing the 
world drug problem. It also provides a good opportunity 
for examining practical measures that Member States 
must take in order to ensure that such an approach goes 
beyond rhetoric and becomes the guiding principle of 
their drug control strategies, policies and programmes. 
This should constitute one of the main criteria in judg-
ing the successes and failures of national and interna-
tional drug policy and in establishing the way forward.
40. In order to assist Member States with the implemen-
tation of the principle of a balanced and comprehensive 
approach within the legal framework of the international 
drug control conventions, the International Narcotics 
Control Board makes the following recommendations:
 30 See, for example, article 33 of the Convention on the Rights of the 
Child, which stipulates the legal obligation to protect children from illicit 
drug use and prevent the use of children in the illicit production and traf-
ficking of such substances; article 24 of that Convention, on the right of 
the child to health; and article 12 of the International Covenant on 
 Economic, Social and Cultural Rights, on the right of everyone to the en-
joyment of the highest attainable standard of physical and mental health.
 (a) Given that a comprehensive, integrated and 
balanced approach is not an end in itself but rather a 
strategic principle applicable within the legal framework 
of the international drug control conventions, the Board 
invites Governments to give due consideration to the uni-
versally recognized principles of international law in 
respecting their obligations assumed by ratification of the 
drug control conventions and in interpreting the provi-
sions of those conventions;
 (b) All of the elements of such an approach need 
to be dealt with in a balanced, multidisciplinary and com-
prehensive manner, involving cooperative efforts from 
various stakeholders at the national, regional and inter-
national levels, and could benefit from the experience and 
activities of religious institutions, religious leaders and rel-
evant non-governmental and civil society organizations. 
To that end, the Board invites Governments to ensure and 
encourage the participation and cooperation of all rele-
vant stakeholders in the strategic planning, implementa-
tion and monitoring of their drug control policies;
 (c) The Board invites Governments to give due 
consideration to their obligation to ensure the availabil-
ity of controlled substances for medical and scientific 
purposes. It is recommended that Member States con-
tinue and enhance their cooperation with the Board, 
WHO and other relevant stakeholders in this area, and 
make full use of the Board’s 2010 special report entitled 
Availability of Internationally Controlled Drugs: Ensuring 
Adequate Access for Medical and Scientific Purposes, and 
the 2012 Guide on Estimating Requirements for Substances 
under International Control, developed by the Board and 
WHO, which is aimed at assisting competent national 
authorities in calculating the quantities of controlled sub-
stances required for medical and scientific purposes and 
in preparing the estimates and assessments of annual 
requirements for controlled substances;
 (d) The Board encourages Governments to ensure 
that demand reduction is one of the first priorities of their 
drug control policies and that all aspects of the drug 
problem are addressed in a balanced and comprehensive 
manner, taking into consideration the national and local 
specificities of the drug problem, and to make full use of 
available scientific evidence. The Board recommends that 
Member States put a greater emphasis on, and provide 
political support and appropriate resources to, efforts 
relating to prevention, treatment and rehabilitation in 
order to achieve a balance of such efforts;
 (e) Efforts to reduce the demand for and the sup-
ply of illicit drugs could be futile if the relevant socio-
economic factors that function as drivers of the drug 
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problem are not addressed in an effective and sustainable 
manner. The Board recommends that Governments address 
those factors as part of a comprehensive, integrated and 
balanced approach and that they incorporate drug control 
into the broader socioeconomic development agenda; 
 (f) The Board encourages Governments to respect 
all relevant human rights norms in designing drug-
related strategies and policies, to make full use of the 
complex international legal framework in order to pro-
tect children from the illicit use of narcotic drugs and 
psychotropic substances, to prevent the use of children 
in the illicit production and trafficking of such sub-
stances, and to ensure that national and international 
drug control strategies and policies take into considera-
tion the principle of the best interests of the child;
 (g) The most effective approach to the world drug 
problem is a comprehensive, integrated and balanced one 
which places equal emphasis on supply and demand 
reduction strategies in an integrated and mutually rein-
forcing manner, taking into consideration other elements 
such as the socioeconomic, sociocultural, security and 
stability factors that promote the illicit demand for and 
supply of drugs. Such an approach requires a wide vari-
ety of complex measures. Given that some of those meas-
ures do not fall under the immediate authority and 
mandate of the various organizations and institutions 
concerned with drug control, the Board invites other 
United Nations organizations and bodies to become 
involved, in accordance with their mandates, and to use 
their expertise in this effort and to support Governments 
in the implementation of such an approach. The Board 
also invites those entities to use their capacities to pro-
mote the dual aim of the drug control system, namely to 
ensure the availability of controlled substances for med-
ical and scientific purposes while preventing, significantly 
reducing or eliminating the illicit production of, traffick-
ing in and abuse of such substances;
 (h) The Board invites Governments to use the 
opportunity provided by the upcoming 2016 special ses-
sion of the General Assembly on the world drug prob-
lem to make a critical assessment of their drug control 
policies and of the extent to which the principle of a bal-
anced, integrated and comprehensive approach is reflected 
in practice in their national policies and in the allocation 
of resources.
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Chapter II.
Functioning of the international drug control 
system
A. Promoting the consistent 
application of the international  
drug control treaties
41. In pursuance of the mandate conferred upon it by 
the international community, the Board engages with 
Governments in an ongoing dialogue with the aim of 
assisting them in the implementation of their treaty obli-
gations as set forth in the international drug control 
conventions. 
42. Cooperation between the Board and Governments 
takes many forms, including regular consultations, exten-
sive correspondence, responses to enquiries received 
from national competent authorities on technical matters, 
training activities and country missions. 
43. This sustained dialogue has been instrumental in 
the work of the Board to assist Governments in strength-
ening the concerted efforts of the international commu-
nity in areas such as monitoring licit trade in narcotic 
drugs, psychotropic substances and precursor chemicals, 
ensuring adequate availability and rational use of narcotic 
drugs and psychotropic substances for medical purposes, 
preventing diversion and trafficking, and fostering pre-
vention and treatment, rehabilitation and social reinte-
gration of individuals affected by addiction.
Status of adherence to the international drug 
control treaties
44. As at 1 November 2014, the number of States par-
ties to the 1961 Convention or that Convention as 
amended by the 1972 Protocol stood at 186. Of those 
States, 184 were parties to the 1961 Convention as 
amended by the 1972 Protocol and 2 States (Afghanistan 
and Chad) remained to accede to the 1972 Protocol, 
being parties to the Convention in its unamended form. 
A total of 11 States have yet to accede to the 1961 
Convention as amended by the 1972 Protocol: 2 States in 
Africa (Equatorial Guinea and South Sudan), 2 in Asia 
(State of Palestine31 and Timor-Leste) and 7 in Oceania 
(Cook Islands, Kiribati, Nauru, Niue, Samoa, Tuvalu and 
Vanuatu).
45. The number of States parties to the 1971 Convention 
remained 183, with a total of 14 States having yet to 
become parties to that Convention: 3 States in Africa 
(Equatorial Guinea, Liberia and South Sudan), 1 in the 
Americas (Haiti), 2 in Asia (State of Palestine and Timor-
Leste) and 8 in Oceania (Cook Islands, Kiribati, Nauru, 
Niue, Samoa, Solomon Islands, Tuvalu and Vanuatu).
46. With the accession by Timor-Leste to the 1988 
Convention, the number of States parties to that 
Convention stood at 188. A total of 9 States have yet to 
become parties to that Convention: 3 States in Africa 
(Equatorial Guinea, Somalia and South Sudan), 1 in Asia 
(State of Palestine) and 5 in Oceania (Kiribati, Palau, 
Papua New Guinea, Solomon Islands and Tuvalu).
47. The Board welcomes the near universal ratification 
of the drug control conventions by States, which demon-
strates broad-based support for the drug control frame-
work established by the international community through 
 31 Pursuant to General Assembly resolution 67/19 of 29 November 
2012, Palestine has been accorded the status of a non-member observer 
State. The name “State of Palestine” is now used in all United Nations 
documents.
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these instruments. The Board reminds those States that 
have not yet become party to one or more of these con-
ventions of the importance of doing so and invites them 
to take all necessary steps to accede to the conventions 
without further delay. 
B. Ensuring the implementation of 
the provisions of the international 
drug control treaties
48. To monitor compliance with the international drug 
control treaties, the Board examines action taken by 
Governments to implement the treaty provisions aimed 
at preventing the diversion of controlled substances into 
illicit channels or, in the case of precursor chemicals, used 
in the illicit manufacture of narcotic drugs and psycho-
tropic substances, while ensuring the availability of inter-
nationally controlled substances for legitimate use. Over 
the years, the treaty provisions have been supplemented 
with additional control measures adopted by the 
Economic and Social Council and the Commission on 
Narcotic Drugs to enhance their effectiveness. In the pre-
sent section, the Board highlights action that needs to be 
taken to implement the international drug control sys-
tem, describes problems encountered in that regard and 
provides specific recommendations on how to deal with 
those problems.
1. Preventing the diversion of 
controlled substances
(a) Legislative and administrative basis
49. Governments have to ensure that national legisla-
tion is in line with the provisions of the international 
drug control treaties. They also have the obligation to 
amend lists of substances controlled at the national level 
when a substance is included in a schedule of an inter-
national drug control treaty or transferred from one 
schedule to another. Inadequate legislation or implemen-
tation mechanisms at the national level or delays in 
bringing lists of substances controlled at the national level 
into line with the schedules of the international drug con-
trol treaties will result in inadequate national controls 
being applied to substances under international control 
and may lead to the diversion of substances into illicit 
channels. The Board is therefore pleased to note that, as 
in previous years, Governments have continued to  furnish 
information to the Board on legislative or administrative 
measures taken to ensure compliance with the provisions 
of the international drug control treaties.
50. With regard to zolpidem, a substance which was 
included in 2001 in Schedule IV of the 1971 Convention, 
Governments are required to introduce an import require-
ment for that substance in accordance with Economic and 
Social Council resolutions 1985/15, 1987/30 and 1993/38. 
In response to the Board’s request made in its annual 
report for 2012, a number of additional Governments 
have provided the requisite information. Thus, as at 
1  November 2014, relevant information is now available 
for 123 countries and territories. Of those, 113 countries 
and territories have introduced an import authorization 
requirement, and 2 countries (Indonesia and the United 
States of America) require a pre-import declaration. Six 
countries and territories do not require an import author-
ization for zolpidem (Cabo Verde, Ireland, New Zealand, 
Singapore, Vanuatu and Gibraltar). Furthermore, imports 
of zolpidem into Azerbaijan are prohibited, and Ethiopia 
does not import the substance. At the same time, infor-
mation on the control of zolpidem remains unknown for 
91 countries and territories. The Board therefore invites 
the Governments of those countries and territories to sup-
ply it with information on the control status of zolpidem 
as soon as possible.
51. The Board wishes to remind Governments that 
gamma-hydroxybutyric acid (GHB) has been transferred 
from Schedule IV to Schedule II of the 1971 Convention 
in accordance with Commission on Narcotic Drugs deci-
sion 56/1 of 13 March 2013. The decision of the 
Commission became fully effective with respect to each 
party on 4 December 2013. The Board therefore requests 
all Governments that have not yet done so to amend the 
list of substances controlled at the national level accord-
ingly, and to apply to GHB all control measures foreseen 
for the substances in Schedule II of the 1971 Convention, 
including the introduction of an import and export 
authorization requirement.
52. With regard to precursor chemicals, on 19 March 
2014, the Commission on Narcotic Drugs adopted deci-
sion 57/1, in which it decided to include alpha-phenyl-
acetoacetonitrile (APAAN) and its optical isomers in 
Table I of the 1988 Convention. The Board notes that, in 
a number of countries, the necessary legislation with 
respect to such precursor chemicals may still not be in 
place. More often, however, weaknesses are the result of 
a lack of effective implementation of existing legislation. 
As a Government’s domestic regulatory system is also a 
prerequisite for being able to notify importing countries 
of exports of chemicals prior to their departure, 
Governments are requested to adopt and implement 
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national control measures to effectively monitor the move-
ment of precursor chemicals. In addition, Governments 
are also requested to further strengthen existing precur-
sor control measures, should any weaknesses be identi-
fied. By implementing those measures, countries will limit 
their exposure to the risk of being targeted by illicit drug 
traffickers.
(b) Prevention of diversion from 
international trade
Estimates and assessments of annual 
requirements for controlled substances
53. The system of estimates and assessments of annual 
licit requirements for narcotic drugs and psychotropic 
substances is the cornerstone of the international drug 
control system. It enables exporting and importing coun-
tries alike to ensure that trade in these substances stays 
within the limits determined by Governments of import-
ing countries, and that diversions of controlled substances 
from international trade are effectively prevented. For 
narcotic drugs, such a system is mandatory under the 
1961 Convention, and the estimates furnished by 
Governments need to be confirmed by the Board before 
becoming the basis for calculating the limits on manu-
facture or import. The system of assessments of annual 
requirements for psychotropic substances was adopted by 
the Economic and Social Council, and the system of esti-
mates of annual requirements for selected precursors was 
adopted by the Commission on Narcotic Drugs, in its 
resolution 49/3, to help Governments to prevent attempts 
by traffickers to divert controlled substances into illicit 
channels. The assessments of annual requirements for 
psychotropic substances and estimates of annual require-
ments for selected precursors help Governments to iden-
tify unusual transactions. In many cases, the diversion of 
a controlled substance has been prevented when the 
exporting country refused to authorize the export of the 
substance because the quantities of the substance to be 
exported would have exceeded the quantities required in 
the importing country.
54. The Board regularly investigates cases involving 
possible non-compliance by Governments with the sys-
tem of estimates or assessments, as such non-compliance 
could facilitate the diversion of controlled substances 
from licit international trade into illicit channels. In that 
connection, the Board provides advice to Governments 
on the details of the system for estimates or assessments, 
as necessary.
55. Governments have the obligation to comply with 
the limits on imports and exports of narcotic drugs pro-
vided for under articles 21 and 31 of the 1961 Convention. 
Article 21 stipulates, inter alia, that the total of the quan-
tities of each drug manufactured and imported by any 
country or territory in a given year shall not exceed the 
sum of the quantity consumed for medical and scientific 
purposes; the quantity used, within the limits of the rel-
evant estimates, for the manufacture of other drugs, prep-
arations or substances; the quantity exported; the quantity 
added to the stock for the purpose of bringing that stock 
up to the level specified in the relevant estimate; and the 
quantity acquired within the limit of the relevant estimate 
for special purposes. Article 31 requires all exporting 
countries to limit the export of narcotic drugs to any 
country or territory so that the quantities imported fall 
within the limits of the total of the estimates of the 
importing country or territory, with the addition of the 
amounts intended for re-export.
56. As in previous years, the Board found that the sys-
tem of imports and exports generally continues to be 
respected and works well. In 2014, a total of 15 countries 
were contacted regarding possible excess imports or 
excess exports identified with regard to international 
trade in narcotic drugs that had been effected during 
2013. Four cases were clarified as being the result of 
errors in reporting on imports or exports, and two cases 
were the result of the reporting of a wrong substance or 
trading partner. However, three countries confirmed that 
excess exports or excess imports had actually occurred. 
The Board contacted the Governments concerned and 
requested them to ensure full compliance with the rele-
vant treaty provisions.
57. With respect to psychotropic substances, pursuant to 
Economic and Social Council resolutions 1981/7 and 
1991/44, Governments are requested to provide to the 
Board assessments of annual domestic medical and scien-
tific requirements for psychotropic substances in Schedules 
II, III and IV of the 1971 Convention. The assessments 
received are communicated to all States and territories to 
assist the competent authorities of exporting countries 
when approving exports of psychotropic substances. As at 
1 November 2014, the Governments of all countries and 
territories, except for the Government of South Sudan, had 
submitted at least one assessment of their annual medical 
requirements for psychotropic substances.
58. The Board recommends that Governments review 
and update the assessments of their annual medical and 
scientific requirements for psychotropic substances at 
least once every three years. However, 25 Governments 
have submitted neither a full revision of their assessment 
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of legitimate requirements for psychotropic substances 
nor a modification of their assessments regarding one or 
more psychotropic substances for more than three years. 
The assessments valid for those countries and territories 
may therefore be obsolete and no longer reflect their 
actual medical and scientific requirements for psycho-
tropic substances.
59. When assessments are lower than actual legitimate 
requirements, the imports of psychotropic substances 
needed for medical or scientific purposes may be delayed. 
When assessments are significantly higher than legitimate 
needs, the risk of psychotropic substances being diverted 
into illicit channels may be increased. The Board calls upon 
all Governments to review and update their assessments 
on a regular basis and to keep it informed of all modifi-
cations, with a view to preventing any non-legitimate 
imports and/or accumulation of excessive stocks while at 
the same time preventing undue delays in licit trade in 
psychotropic substances needed for medical purposes.
60. As in previous years, the system of assessments of 
annual requirements for psychotropic substances continues 
to function well and is respected by most countries. In 2013, 
the authorities of only 13 countries and one territory issued 
import authorizations for substances for which they had not 
established any such assessments or in quantities that sig-
nificantly exceeded their assessed requirements. In most of 
those cases, the transactions concerned imports destined for 
re-export. Also, most exporting countries paid attention to 
the assessed requirements established in importing countries 
and did not knowingly export psychotropic substances in 
quantities exceeding those requirements. The Board wishes 
to remind Governments that, since 2013, Governments have 
no longer been required to include in their annual assess-
ments for psychotropic substances quantities destined for 
export or re-export.
61. In its resolution 49/3, the Commission on Narcotic 
Drugs requested Governments to provide the Board with 
estimates of annual legitimate requirements for imports 
of four substances commonly used in the illicit manufac-
ture of amphetamine-type stimulants. Governments of 
155 countries currently provide estimates for at least one 
of the substances, thus providing the competent author-
ities of exporting countries with at least an indication of 
the legitimate requirements of importing countries and 
thereby preventing diversion attempts.
Import and export authorization requirement
62. One of the main pillars of the international drug 
control system is the universal application of the 
requirement for import and export authorizations. Such 
authorizations are required for transactions involving any 
of the substances controlled under the 1961 Convention 
or listed in Schedules I and II of the 1971 Convention. 
Competent national authorities are required by those 
conventions to issue import authorizations for trans-
actions involving the importation of such substances into 
their country. The competent national authorities of 
exporting countries must verify the authenticity of such 
import authorizations before issuing the export authori-
zations required to allow shipments containing the sub-
stances to leave their country.
63. The 1971 Convention does not require import and 
export authorizations for trade in psychotropic sub-
stances listed in Schedules III and IV of the Convention. 
However, in view of widespread diversion of those sub-
stances from licit international trade in the 1970s and 
1980s, the Economic and Social Council, in its resolu-
tions 1985/15, 1987/30 and 1993/38, requested 
Governments to extend the system of import and export 
authorizations to cover those psychotropic substances 
as well.
64. Most countries and territories have already intro-
duced an import and export authorization requirement 
for psychotropic substances in Schedules III and IV of 
the 1971 Convention, in accordance with the above- 
mentioned Economic and Social Council resolutions. By 
1 November 2014, specific information had been made 
available to the Board by 204 countries and territories, 
showing that all major importing and exporting coun-
tries now require import and export authorizations for 
all psychotropic substances in Schedules III and IV of the 
1971 Convention.
65. To assist Governments, and to prevent traffickers 
from targeting countries in which controls are less strict, 
the Board has been disseminating to all competent 
national authorities a table showing the import authori-
zation requirements for substances in Schedules III and 
IV applied pursuant to the relevant Economic and Social 
Council resolutions. That table is published in the secure 
area of the Board’s website, which is accessible only to 
specifically authorized Government officials so that com-
petent national authorities of exporting countries may be 
informed as soon as possible of changes in import author-
ization requirements in importing countries.
66. Data on cases involving diversion indicate that traf-
fickers are quick to target countries in which controls are 
less strict than in others. The Board therefore urges the 
Governments of the few States in which national legisla-
tion does not yet require import and export authorizations 
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for all psychotropic substances, regardless of whether they 
are States parties to the 1971 Convention, to extend such 
controls to all substances in Schedules III and IV of the 
1971 Convention as soon as possible and to inform the 
Board accordingly.
67. The 1988 Convention does not require import and 
export authorizations for trade in precursor chemicals. 
However, Governments that do not apply some system 
of control over exports and imports of precursors are not 
in a position to comply with their treaty obligation to 
contribute to the prevention of diversion. This applies 
particularly to Governments that issue only general per-
mits or do not require any permits at all, leaving them-
selves open to the exploitation by traffickers of such weak 
controls.
Verifying the legitimacy of individual 
transactions, particularly those involving 
import authorizations
68. For the international control system for licit inter-
national trade in narcotic drugs and psychotropic sub-
stances to function well, it is indispensable that 
Government authorities verify the authenticity of all 
import authorizations that they consider to be suspicious. 
Such action is particularly necessary in cases in which 
authorizations show new or unknown formats, bear 
unknown stamps or signatures or are not issued by the 
recognized competent national authority, or are for sub-
stances known to be frequently abused in the region of 
the importing country. The Board notes with apprecia-
tion that the Governments of the major exporting coun-
tries have established the practice of verifying with the 
competent national authorities of importing countries the 
legitimacy of import authorizations or bringing to their 
attention documents that do not fully comply with the 
requirements for import authorizations set out in the 
international drug control treaties.
69. Most importing countries continue to actively 
implement the import authorization system. Many 
Governments of importing countries regularly inform the 
Board of changes in the format of their import authori-
zations and provide the Board with samples of revised 
certificates and authorizations for narcotic drugs, psycho-
tropic substances and precursor chemicals. The Board 
maintains a collection of samples of official certificates 
and authorizations, which can be compared with ques-
tionable import documents, thus allowing the Board to 
better assist the Governments of exporting countries in 
verifying the legitimacy of import authorizations.
70. In cases when the sample in the Board’s collection 
of official authorizations differs from a newly submit-
ted import authorization, or when there is no corre-
sponding sample in the collection, the Board, on behalf 
of the competent authorities of the exporting country, 
contacts the importing country to ascertain the legiti-
macy of the transaction. The Board wishes to remind 
the Governments of importing countries that failure to 
respond in a timely manner to all queries that they 
receive from competent authorities or from the Board 
regarding the legitimacy of transactions may hinder the 
timely identification of possible diversion attempts and/
or cause undue delays in legitimate trade in controlled 
substances.
Pre-export notifications for precursor chemicals
71. The 1988 Convention, specifically in its article 12, 
aids in the prevention of diversion of precursors from 
international trade. By invoking article 12, paragraph 10 (a), 
of the Convention, Governments of importing countries 
make it mandatory for exporting countries to inform them 
of any planned export of precursors to their territory. The 
importing country can use the pre-export notification to 
verify the shipment’s legitimacy. Currently, 107 States and 
territories have formally requested pre-export notifica-
tions. Although this represents an increase compared with 
the previous year, there is still a significant number of 
Governments and regions that remain unaware of, and 
vulnerable to, precursors entering their territory. The 
Board encourages the remaining Governments to invoke 
article 12, paragraph 10 (a), of the 1988 Convention with-
out further delay.
72. The Board’s Pre-Export Notification Online (PEN 
Online) system enables Member States to easily provide 
each other with information on planned exports of pre-
cursor chemicals and to raise alerts when the legitimacy 
of a given shipment is suspect. Since the launch of the 
PEN Online system in 2006, a total of 150 countries and 
territories have registered to use it. An increase in the 
use of the system has led to an average of more than 
2,100 pre-export notifications communicated each month. 
The Board is aware that some countries continue to 
export scheduled chemicals without sending pre-export 
notifications via the PEN Online system, in some cases 
despite the fact that the importing country requires such 
pre-export notifications. The Board calls on Governments 
to actively and systematically use the system and urges 
the remaining States that have not registered to do so as 
soon as possible.
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(c) Effectiveness of the control measures 
aimed at preventing the diversion of 
controlled substances from international trade
73. The system of control measures laid down in the 
1961 Convention provides effective protection of interna-
tional trade in narcotic drugs against attempts to divert 
such drugs into illicit channels. Similarly, as a result of 
the almost universal implementation of the control meas-
ures stipulated in the 1971 Convention and the related 
Economic and Social Council resolutions, in recent years 
there have been no identified cases involving the diver-
sion of psychotropic substances from international trade 
into illicit channels.
74. Discrepancies in Government reports on interna-
tional trade in narcotic drugs and psychotropic sub-
stances are regularly investigated with the competent 
authorities of the relevant countries to ensure that no 
diversion of narcotic drugs and psychotropic substances 
from licit international trade takes place. These investi-
gations may reveal shortcomings in the implementation 
of control measures for narcotic drugs and psychotropic 
substances, including the failure of companies to comply 
with national drug control provisions.
75. Since May 2014, investigations regarding trade dis-
crepancies for 2013 related to trade in narcotic drugs have 
been initiated with 30 countries. The responses indicated 
that the discrepancies were caused by clerical and tech-
nical errors in preparing the reports, reporting on exports 
or imports of preparations in Schedule III of the 1961 
Convention without indicating that fact on the form, and 
inadvertent reporting of transit countries as trading part-
ners. In some cases, countries confirmed the quantities 
they had reported, resulting in follow-up investigations 
with their respective trading partners. No cases that 
would indicate a possible diversion of narcotic drugs into 
illicit channels were identified.
76. Similarly, with regard to international trade in psy-
chotropic substances, investigations into 234 discrepan-
cies related to 2012 data were initiated with 57 countries. 
As of 1 November 2014, 40 countries had provided replies 
relating to 178 cases involving discrepancies, leading to 
the resolution of 104 of those cases. In all cases in which 
the data provided were confirmed by the responding 
countries, follow-up actions with the counterpart coun-
tries were initiated. All responses received so far indicate 
that the discrepancies were caused by clerical or techni-
cal errors, in most cases either the failure to convert 
amounts into anhydrous base or “overlapping”, i.e. an 
export in a given year was received by the importing 
country only at the beginning of the following year. None 
of the cases investigated showed a possible diversion of 
psychotropic substances from international trade.
77. The Board calls upon Governments to continue to 
monitor international trade in narcotic drugs and psy-
chotropic substances by using the tools mentioned above. 
Competent national authorities are encouraged to request 
the Board to assist in verifying the legitimacy of suspi-
cious individual transactions.
78. In accordance with Commission on Narcotic Drugs 
resolution 50/11, Governments are encouraged to notify 
the Board of seizures of internationally controlled sub-
stances ordered via the Internet and delivered through 
the mail, in order to assess the extent of and trends per-
taining to that issue. In 2014, only the Governments of 
Estonia and Finland reported such seizures, namely, 
buprenorphine, chlordiazepoxide, methylphenidate, 
pentobarbital, phenobarbital and zolpidem. In addition, 
the Government of India reported seizures of psycho-
tropic substances delivered through the mail: 1.9 kg of 
methaqualone destined for Australia, 1.78 kg of meth-
aqualone destined for Malaysia, and 38 g of ampheta-
mine-type stimulants, also destined for Malaysia. In 
addition, India reported a seizure of 240 g of ketamine, 
a substance not under international control.
79. In addition, in 2014 three countries reported to the 
Board other seizures of psychotropic substances. The 
Government of Chad reported a seizure of 282 capsules 
of diazepam, which had been smuggled into that coun-
try from Cameroon. Morocco reported 450,357 units of 
seized psychotropic substances, without specifying the 
type of substances, reporting that the substances had 
been seized from motor vehicles. In the most recent case, 
the Government of Malaysia informed the Board of two 
major seizures effected in May and June 2014, totalling 
536,050 tablets and 391,900 tablets, respectively, contain-
ing alprazolam, clobazam, diazepam, lorazepam, methyl-
phenidate, midazolam, pentazocine or zolpidem. The 
consignments, which were intercepted in the free trade 
zone of Kuala Lumpur International Airport, had origi-
nated in Pakistan and were declared as non-restricted 
items.
80. The Board wishes to commend the Governments 
mentioned above for their vigilance, and trusts that the 
competent authorities will investigate all such attempts to 
divert controlled substances so that the persons respon-
sible may be identified and prosecuted.
81. The implementation of control measures has helped 
with the effective monitoring of the movement of 
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precursor chemicals in international trade and has led, at 
least partly, to traffickers seeking to exploit weaknesses at 
the domestic level and using non-scheduled chemicals in 
the illicit manufacture of drugs. This evolving trend will 
pose challenges to existing control measures, and new 
approaches may be required. Regardless, some substances 
used in the illicit manufacture of amphetamine-type 
stimulants, in particular preparations containing the pre-
cursors ephedrine and pseudoephedrine, continue to be 
diverted from international trade.
(d) Prevention of diversion from domestic 
distribution channels
82. Since it has become more difficult for traffickers to 
obtain narcotic drugs, psychotropic substances and pre-
cursors from international trade, the diversion of such 
substances from licit domestic distribution channels has 
become a main source for supplying illicit markets. The 
narcotic drugs and psychotropic substances most fre-
quently diverted tend to be those which are most widely 
used for legitimate purposes. They are diverted mainly in 
the form of pharmaceutical preparations, predominantly 
for subsequent abuse.
83. For many substances found to have been diverted 
from domestic distribution channels, there is little knowl-
edge of the methods used to obtain them. As Governments 
have no obligation to bring to the attention of the Board 
individual cases of diversion from domestic distribution 
channels, there is little record of the point of diversion 
or of the actual methods used by traffickers or abusers to 
obtain those substances. While seizure data often provide 
an indication of problems experienced with regard to 
such diversion, other sources, such as data on substance 
abuse obtained through drug abuse surveys or from drug 
treatment and counselling centres, may indicate the avail-
ability of narcotic drugs and psychotropic substances on 
illicit markets. Lack of national legislation in line with 
the conventions, inadequate implementation of national 
legislation or insufficient monitoring of the implementa-
tion of that legislation are often the underlying causes for 
such diversion.
84. The Board recommends that Governments inform 
it regularly of major cases of diversion of controlled sub-
stances from domestic distribution channels in their 
countries so that the lessons learned from such diversion 
cases can be shared with other Governments.
85. Diversion from domestic distribution channels has 
become a major source of precursors used for illicit drug 
manufacture. To address the prevailing modi operandi 
used by traffickers of acetic anhydride in recent years, the 
Precursors Task Force of Project Cohesion in 2013 initi-
ated an international operation focusing on the verifica-
tion of legitimacy of domestic trade in, and end use of, 
acetic anhydride. The operation confirmed that the con-
trol measures applied to domestic trade in and distribu-
tion of acetic anhydride lag behind those used in 
international trade, and that the extent of control over 
domestic trade and distribution varies significantly from 
one country to another. More information on that topic 
has been reported in the report of the Board for 2014 on 
precursors. The Board encourages Governments to 
actively participate in the activities under Project Prism 
and Project Cohesion, the two international initiatives 
focusing on precursors used in the illicit manufacture of, 
respectively, amphetamine-type stimulants, and cocaine 
and heroin.
86. Diversion from domestic distribution channels also 
continues to fuel illicit manufacture of methampheta-
mine, often in the form of pharmaceutical preparations 
containing ephedrine and pseudoephedrine. This involves 
diversion both within the country of illicit manufacture 
and from domestic channels elsewhere, with subsequent 
smuggling across borders. The continued concerns raised 
by the Board about relatively high estimates of annual 
legitimate requirements for imports of ephedrine and 
pseudoephedrine in countries in West Asia have resulted 
in reduced estimates for some of the Governments con-
cerned. The Board commends those Governments and 
further encourages all Governments to regularly review 
their import requirements, as published,32 amend them 
as necessary utilizing the most recent market data and 
inform the Board accordingly.
2. Ensuring the availability of 
internationally controlled substances for 
medical and scientific purposes
87. In line with its mandate to ensure the availability of 
internationally controlled substances for medical and sci-
entific purposes, the Board carries out various activities 
related to narcotic drugs and psychotropic substances. 
The Board monitors action taken by Governments, inter-
national organizations and other bodies to support the 
availability and rational use of controlled substances for 
medical and scientific purposes.
 32 www.incb.org/documents/PRECURSORS/ANNUAL-LICIT- 
REQUIREMENTS/INCB_ALR_WEB.xlsx.
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(a) Supply of and demand for opiate  
raw materials
88. The Board has been given an important role in 
monitoring the cultivation, production, trade and con-
sumption of opiates. Pursuant to the 1961 Convention 
and the relevant resolutions of the Economic and Social 
Council and the Commission on Narcotic Drugs, the 
Board regularly examines issues affecting the supply of 
and the demand for opiates to meet licit requirements, 
and endeavours to ensure, in cooperation with 
Governments, a standing balance between that supply 
and demand.
89. To establish the status of the supply of and demand 
for opiate raw materials, the Board analyses the data pro-
vided by Governments on opiate raw materials and opi-
ates manufactured from those raw materials. In addition, 
the Board also analyses information on the utilization of 
those raw materials, estimated consumption for licit use 
and stocks at the global level. A detailed analysis of the 
current situation regarding supply of and demand for opi-
ate raw materials is contained in the 2014 technical report 
of the Board on narcotic drugs. The following paragraphs 
provide a summary of that analysis.
90. The Board recommends that global stocks of opiate 
raw materials be maintained at a level sufficient to cover 
global demand for approximately one year, in order to 
ensure the availability of opiates for medical needs in case 
of an unexpected shortfall of production, for example, 
one caused by adverse weather conditions in producing 
countries, and at the same time limit the risk of diver-
sion associated with excessive stocks.
91. In 2013, the area sown with opium poppy rich in 
morphine in major producing countries increased com-
pared with the previous year, despite the high level of 
stocks. India, the only country that produces opium for 
export¸ reduced its production by 75 per cent. Australia 
continued to be the largest producer in 2013, with an 
amount of 190 tons, followed by France, Spain and 
Turkey. Australia accounted for 37 per cent of global pro-
duction in morphine equivalent. Poppy straw is the main 
system used for the extraction of the alkaloid (95 per cent); 
opium accounts for the remaining 5 per cent. According 
to the information submitted by the Governments of the 
main producing countries, it is estimated that global pro-
duction of opiate raw materials rich in morphine will 
increase to 715 tons in morphine equivalent in 2015. 
Stocks of opiate raw materials rich in morphine (poppy 
straw, concentrate of poppy straw and opium) amounted 
to about 546 tons in morphine equivalent at the end of 
2013. Those stocks were considered to be sufficient to 
cover 14 months of expected global demand at 2014 lev-
els. Global demand by manufacturers for opiate raw 
materials rich in morphine has increased, with fluctua-
tions, since 2000, reaching 456 tons in morphine equiv-
alent in 2012. In 2013, global demand for opiate raw 
materials rich in morphine decreased to 432 tons in mor-
phine equivalent. It is expected to increase again in 2014 
and 2015: to about 460 tons in 2014 and about 480 tons 
in 2015.
92. In 2013, the cultivation of opium poppy rich in the-
baine increased in Australia and Hungary (by 33 per cent 
and 43 per cent, respectively, in the area actually har-
vested) and decreased in France (by 11 per cent). With 
3,574 ha of cultivation, Spain remained at the same level 
as during the previous year. Global production of opiate 
raw materials rich in thebaine increased each year 
between 2010 and 2013, to 364 tons33 in thebaine equiv-
alent. It is expected to increase only slightly in 2014 to 
368 tons, however, and to decrease considerably in 2015, 
to 325 tons. In 2013, Australia accounted for 86 per cent 
of the global total, Spain for 9 per cent, and France, India 
and Hungary for the rest. Global demand by manufac-
turers for opiate raw materials rich in thebaine has also 
been increasing in recent years, albeit also with fluctua-
tions. In 2013, total demand decreased to 232 tons of the-
baine equivalent from 261 tons in 2012. Global demand 
for raw materials rich in thebaine is expected to rise to 
about 260 tons of thebaine equivalent in 2014 and reach 
270 tons in 2015. Demand for thebaine-based opiates is 
concentrated mainly in the United States and has 
increased sharply since the late 1990s, although it 
decreased to 108 tons in 2013. It is likely to rise in future 
years, partly because the consumption of such opiates is 
expected to increase in countries other than the United 
States. Global demand is anticipated to reach approxi-
mately 130 tons of thebaine equivalent in 2014 and 
140  tons in 2015. Stocks of opiate raw materials rich in 
thebaine (poppy straw, concentrate of poppy straw and 
opium) are sufficient to cover expected global demand at 
2014 levels for about 12 months. Global stocks of opiates 
based on thebaine-rich raw material (oxycodone, the-
baine and a small quantity of oxymorphone) are suffi-
cient to cover global demand for such opiates for about 
22 months.
93. The cultivation of opium poppy rich in codeine has 
increased. France has joined Australia (the only producer 
until 2013) and started cultivating this variety. The esti-
mated areas of cultivation of opium rich in codeine in 
 33 The analysis is based predominantly on raw materials obtained 
from opium poppy rich in thebaine but includes the thebaine alkaloid 
contained in opium poppy rich in morphine whenever appropriate.
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2014 for Australia and France were 2,142 ha and 2,050 ha, 
respectively. Both countries are expected to increase their 
cultivation further in 2015.
94. Over the past 20 years, the global consumption of 
opioids has more than tripled. The share of that con-
sumption comprised by consumption of opiates also fluc-
tuated during that period. Between 2010 and 2013, 
however, the ratio between the consumption of opiates 
and the consumption of synthetic opioids stabilized at 
about 60 per cent and 40 per cent, respectively. 
Throughout the period, the supply of opiate raw materi-
als from which opiates were obtained was sufficient to 
cover the increasing demand. It is expected that the 
demand for opiates will increase again in the future, 
while their share of the total consumption of opioids may 
decline, owing to the expected growth in the consump-
tion of synthetic opioids.
95. The data available indicate that the amount of opi-
ate raw materials available for the manufacture of nar-
cotic drugs for pain relief is more than sufficient to satisfy 
current demand levels as estimated by Governments. In 
addition, both production and stocks continue to increase. 
However, the data collected and analysed by the Board 
show that the consumption of drugs for pain relief and 
other medical purposes is still low in most countries. 
Access to these drugs is very uneven, with consumption 
concentrated primarily in countries in North America, 
Western Europe and Oceania. This imbalance is particu-
larly problematic, since the latest data show that many of 
the conditions requiring pain management are increasing 
in low- and middle-income countries. At the same time, 
it is important to recognize that, in countries with a high 
per capita consumption of opioid analgesics, there has 
been an increase in recent years in the abuse of prescrip-
tion drugs and in related overdose deaths.
96. The Board would like to remind Governments that 
the overall goal of the international drug control conven-
tions is a well-functioning national and international sys-
tem for managing the availability of narcotic drugs that 
should provide relief from pain and suffering by ensur-
ing the safe delivery of the best affordable drugs to those 
patients who need them and, at the same time, prevent 
the diversion of drugs for the purpose of abuse.
(b) Consumption of psychotropic 
substances
97. The 1971 Convention does not foresee the report-
ing of statistical data on the consumption of psychotropic 
substances to the Board. As a consequence, consumption 
levels for psychotropic substances continue to be calcu-
lated by the Board on the basis of data furnished by 
Governments on manufacture, international trade, quan-
tities used for industrial purposes and manufacturers’ 
stocks. That situation makes it more difficult to reach reli-
able conclusions than is the case for narcotic drugs, for 
which reporting of consumption data is a treaty obliga-
tion under the 1961 Convention.
98. To address that situation, the Commission on 
Narcotic Drugs, in its resolution 54/6, encouraged all 
Member States to furnish to the Board data on the con-
sumption of psychotropic substances. The number of 
Governments that are furnishing such data has steadily 
increased since 2010.
99. The Board is pleased to note that for 2013 a total 
of 55 Governments (of 52 States and three territories) 
have submitted information on consumption of some or 
all psychotropic substances in accordance with 
Commission resolution 54/6. This represents an increase 
of 6 per cent compared with 2012. Moreover, among 
those Governments are countries that are major manu-
facturers and consumers of psychotropic substances, such 
as Belgium, Canada, Denmark, France, Germany, the 
Netherlands, South Africa, the United Kingdom of Great 
Britain and Northern Ireland and the United States of 
America. That development will enable the Board to 
more accurately analyse the consumption levels for psy-
chotropic substances in the countries and territories con-
cerned and to better monitor consumption trends in 
countries and regions, with a view to identifying unusual 
or undesirable developments.
100. At the same time, an analysis of the consumption 
data received shows that, for most manufacturing coun-
tries, the reported consumption data differ in many cases 
from the consumption data calculated by the Board. This 
might be attributable to incomplete reporting by 
Governments of other data, for instance, data on manu-
facturers’ stocks or quantities used for industrial pur-
poses, which are key elements of the Board’s calculation 
of consumption data.
101. The Board trusts that all Governments that are 
not yet in a position to collect reliable data on consump-
tion levels of psychotropic substances on their territory 
and to report those data to the Board will take meas-
ures that would allow them to do so. That would greatly 
assist the Board in identifying unusual trends in the 
consumption of psychotropic substances in individual 
countries, with a view to recommending remedial action 
to ensure the adequate availability of psychotropic sub-
stances, if necessary.
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(c) High-level meeting of the General 
Assembly on the comprehensive review 
and assessment of the progress achieved 
in the prevention and control of  
non-communicable diseases
102. At the high-level meeting of the General Assembly 
on the comprehensive review and assessment of the pro-
gress achieved in the prevention and control of non- 
communicable diseases, held in New York on 10 and 11 
July 2014, the President of the Board referred to the 
importance of the appropriate use of internationally con-
trolled drugs, as both overconsumption and undercon-
sumption of those drugs created problems for public 
health. The President called upon Governments to take 
concrete action to ensure access to services for the pre-
vention and treatment of non-communicable diseases, 
including drug abuse, and underlined the Board’s commit-
ment to continue working with Governments to improve 
access to the essential medicines required for the treat-
ment of pain and mental and neurological disorders.
(d) Information on specific requirements 
for travellers who carry medical 
preparations containing controlled 
substances for personal use
103. The Commission on Narcotic Drugs, in its resolu-
tions 45/5, 46/6 and 50/2, encouraged States parties to 
the 1961 Convention and the 1971 Convention to notify 
the Board of restrictions currently applicable in their ter-
ritory to travellers under medical treatment with prepar-
ations containing substances under international control, 
and requested the Board to publish that information in 
a unified form in order to ensure its wide dissemination 
and facilitate the task of government agencies.
104. Since the publication of the report of the Board 
for 2013, more than 20 additional Governments have 
provided the requested information. Thus, as of 
1  November 2014, the Board had received from over 
100  Governments information on the legal provisions 
and/or administrative measures currently applicable in 
their countries to travel lers carrying medical preparations 
containing narcotic drugs or psychotropic substances for 
personal use. At the same time, in many cases, such infor-
mation has been provided in different formats, render-
ing it difficult for travel lers to easily understand the 
specific requirements in place in their countries of des-
tination. The Board has, therefore, put the information 
received into a standardized format, and requested the 
Governments concerned to examine the standardized 
information on their national requirements and to inform 
the Board of their approval of that information. Once 
approved, the standardized information will be posted on 
the website of the Board, alongside the full text of the 
relevant national legislation.
105. In that connection, the Board wishes to draw the 
attention of Governments to the international guidelines 
for national regulations concerning travellers under treat-
ment with internationally controlled drugs, which were 
prepared by the Board pursuant to Commission resolu-
tion 46/6. The main objective of those guidelines, which 
are available on the Board’s website, is to assist national 
authorities in introducing a regulatory framework to deal 
with situations in which patients under treatment with 
preparations containing internationally controlled drugs 
are travelling abroad and carrying with them small quan-
tities of such preparations for personal use. The guide-
lines present elements of unified procedures that can be 
implemented by national authorities responsible for the 
control of narcotic drugs and psychotropic substances 
who deal with issues pertaining to medical preparations 
containing controlled substances that are licensed in the 
country of departure of the traveller.
106. The Board calls on all Governments that have not 
yet done so to submit to it their current national regula-
tions and restrictions applicable to international travellers 
carrying medical preparations containing internationally 
controlled substances for personal use, and to notify the 
Board of any changes in their national legislation regard-
ing the scope of control of narcotic drugs and psycho-
tropic substances relevant to travellers under medical 
treatment with internationally controlled substances, in 
accordance with Commission resolutions 45/5, 46/6 and 
50/2.
C. Governments’ cooperation with 
the Board
1. Provision of information by 
Governments to the Board
107. Each year, the Board is mandated to publish two 
reports: the annual report and the report of the Board 
on the implementation of article 12 of the 1988 
Convention. The Board also publishes technical reports 
based on information that parties to the international 
drug control treaties are obligated to submit. Those pub-
lications contain detailed analyses on estimates and 
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assessments of requirements, manufacture, trade, con-
sumption, utilization and stocks of internationally con-
trolled substances.
108. The provision of data by Governments and the 
analysis of that data by the Board is a crucial element of 
the Board’s ability to monitor and evaluate treaty com-
pliance and the overall functioning of the international 
drug control system. The provision of data helps account 
for the legitimate use of narcotic drugs and psychotropic 
substances for medical and scientific purposes and helps 
with the identification of modi operandi used to divert 
drugs or precursors from licit into illicit channels and of 
non-scheduled chemicals used in illicit drug manufac-
ture. Measures may be recommended by the Board to 
help address issues relating to legitimate use of narcotic 
drugs, psychotropic substances and precursor chemicals 
and prevent their diversion into illicit markets.
2. Submission of statistical 
information
109. Governments are obliged to provide the Board, on 
an annual basis and in a timely manner, statistical reports 
containing information required under the international 
drug control conventions.
110. As at 1 November 2014, annual statistical reports 
for 2013 on narcotic drugs (form C) had been furnished 
by 149 States and territories (representing 70 per cent of 
the States and territories requested to submit such 
reports), although more Governments are expected to 
submit their reports for 2013 in due course. That trend 
is consistent with last year’s number of submissions. In 
total, 180 States and territories provided quarterly statis-
tics on their imports and exports of narcotic drugs for 
2013, amounting to 84 per cent of the States and territo-
ries required to provide such statistics. Those numbers 
are also in line with last year’s rate of submission. The 
lowest levels of compliance with the obligation to regu-
larly submit statistical information continue to be in 
Africa, Oceania and the Caribbean. Countries in those 
regions and subregion were reminded several times by 
the Board about the importance of providing informa-
tion in connection with the functioning of the interna-
tional drug control system.
111. As at 1 November 2014, annual statistical reports 
for 2013 on psychotropic substances (form P), in con-
formity with the provisions of article 16 of the 1971 
Convention, had been submitted to the Board by 
150  States and territories, amounting to 69 per cent of 
the States and territories required to provide such 
statistics. The Board is pleased to note that the rate of 
submission for 2013 is noticeably higher than that for 
2012. Furthermore, as is the case every year, it can be 
expected that some Governments will furnish form P for 
2013 at a later date. In addition, 116 Governments vol-
untarily submitted all four quarterly statistical reports on 
imports and exports of substances listed in Schedule II of 
the Convention, in conformity with Economic and Social 
Council resolution 1981/7, and a further 48 Governments 
submitted some quarterly reports.
112. It has been noted that the number of countries and 
territories that have not furnished form P to the Board 
is again highest in Africa, Oceania and the Caribbean. A 
total of 30 countries and territories in Africa (52 per cent) 
failed to furnish form P for 2013 to the Board. Likewise, 
50 per cent of the countries and territories in Oceania 
and 38 per cent in the Caribbean did not furnish form 
P for 2013. In contrast, form P for 2013 was furnished 
by all but two countries in Europe (Greece and 
Luxembourg) and by most countries in the Americas.
113. The Board notes with concern that among the 
countries that failed to submit form P before the dead-
line of 30 June 2014 were major manufacturing, import-
ing and exporting countries such as Australia, Brazil, 
China, France, Germany, India, Ireland, Japan, the 
Netherlands, Pakistan and the United Kingdom. The 
Republic of Korea and Singapore, which are significant 
importers or exporters of psychotropic substances, did 
not submit form P for 2013. Late submission and failure 
to submit statistical reports make it difficult for the Board 
to monitor licit activities involving controlled substances 
and delays the analysis by the Board of the worldwide 
availability of such substances for legitimate purposes. 
The Board therefore wishes to invite Governments to take 
steps to improve, as necessary, Government structures 
responsible for reporting to the Board, with a view to 
ensuring the timely collection and reporting of statistical 
data. This applies to the statistical reporting under all 
three conventions, namely that related to narcotic drugs, 
psychotropic substances and precursors.
114. The Economic and Social Council, in its resolu-
tions 1985/15 and 1987/30, requested Governments to 
provide the Board with details on trade (data broken 
down by countries of origin and destination) in sub-
stances listed in Schedules III and IV of the 1971 
Convention in their annual statistical reports on psycho-
tropic substances. For 2013, complete details on such 
trade were submitted by 134 Governments (89 per cent 
of all submissions of form P), which is about the same 
as for 2012. Only eight countries (Angola, Bahamas, 
Botswana, El Salvador, Equatorial Guinea, Haiti, Namibia 
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and Tonga) failed to submit any details on such trade 
for 2013.
115. The Board notes with appreciation that the num-
ber of countries submitting consumption data for psy-
chotropic substances on a voluntary basis in accordance 
with Commission on Narcotic Drugs resolution 54/6 has 
continued to increase. Thus, in 2013, a total of 55 coun-
tries and territories submitted data on consumption of 
some or all psychotropic substances, compared with 
52 countries and territories in 2012. The Board appreci-
ates the cooperation of the Governments concerned and 
calls upon all other Governments to furnish information 
on the consumption of psychotropic substances, as such 
data are key to an improved evaluation of the availabil-
ity of psychotropic substances for medical and scientific 
purposes.
116. With regard to precursor chemicals, pursuant to 
article 12 of the 1988 Convention, parties are obliged to 
report information on substances frequently used in the 
illicit manufacture of narcotic drugs and psychotropic 
substances. By providing this information annually on 
form D, Governments enable the Board to more effec-
tively identify and analyse emerging trends in trafficking 
in precursors and in the illicit manufacture of drugs. As 
at 1 November 2014, a total of 136 States and territories 
had submitted form D for 2013. However, 85 countries 
did not submit the form before the deadline of 30 June 
2014, therefore failing to meet their obligations.
117. Of the States and territories that provided data for 
2013, 65 Governments reported seizures of scheduled 
substances and 36 reported seizures of non-scheduled 
substances, slightly fewer than in 2012. Similarly to pre-
vious years, most of those Governments did not provide 
details on the methods of diversion and illicit manufac-
ture or on stopped shipments. In some cases, the Board 
is aware of other official sources, such as annual national 
drug situation reports and presentations by government 
officials at various drug control forums that sometimes 
include additional details and/or data for years for which 
no seizure information was submitted by the Government 
on form D. The Board urges Governments to put the rel-
evant mechanisms in place to ensure the comprehensive-
ness of the data submitted.
118. The Economic and Social Council, in its resolution 
1995/20, urged Governments to provide the Board, sub-
ject to the provisions of national legislation on confiden-
tiality and data protection, with information on licit trade 
in precursor chemicals. By accessing data related to trade 
in precursors, the Board is able to monitor legitimate 
international trade flows in order to identify patterns of 
suspected illicit activity, which can help to prevent the 
diversion of precursor chemicals. As at 1 November 2014, 
125 States and territories had provided relevant informa-
tion on licit trade for the 2013 reporting period and 
123 States and territories had informed the Board about 
the licit uses of and requirements for some or all of those 
substances.
119. Over the past year, the international community 
has used a variety of innovative tools to reinforce and 
bolster the precursors control regime. Domestic legisla-
tion was used by Afghanistan, Belize, China, the Czech 
Republic, Liberia and the Philippines to strengthen con-
trols over the manufacture, import and sale of precursor 
chemicals. In December 2013, the European Union also 
strengthened its precursor legislation.
120. The Precursors Incident Communication System 
(PICS), a secure online tool for enhanced worldwide 
and real-time communication and information-sharing 
between national authorities on precursor incidents (sei-
zures, shipments stopped in transit, diversions and diver-
sion attempts, illicit laboratories and associated equipment) 
has seen further growth, both in the number of users and 
the incidents communicated through it. PICS is now 
established as a key tool of the international precursor 
control regime that is also increasingly helping Governments 
to quickly communicate new trends such as the emergence 
of non-scheduled chemicals. As at 1 November 2014, there 
were nearly 400 registered users of PICS from 90 coun-
tries, representing almost 200  national agencies and 
8 international and regional agencies, which had used the 
system to communicate more than 250 incidents since 
1 November 2013.
3. Submission of estimates and 
assessments
121. Pursuant to the 1961 Convention, each year States 
parties are obliged to provide the Board with estimates 
of their requirements for narcotic drugs for the follow-
ing year. As at 1 November 2014, a total of 154 States 
and territories had submitted estimates of their require-
ments for narcotic drugs for 2015, representing 72 per cent 
of the States and territories required to furnish annual 
estimates for confirmation by the Board. Those numbers 
were in line with last year’s rate of submission. For the 
States and territories that had not submitted their esti-
mates on time, the Board had to establish estimates, in 
accordance with article 12 of the 1961 Convention.
122. As at 1 November 2014, the Governments of all 
countries except South Sudan and all territories had 
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submitted to the Board at least one assessment of their 
annual medical and scientific requirements for psycho-
tropic substances. The assessments of requirements for 
psychotropic substances for South Sudan were established 
by the Board in 2011, in accordance with Economic and 
Social Council resolution 1996/30, in order to allow that 
country to import such substances for medical purposes 
without undue delay.
123. Pursuant to Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of their annual medi-
cal and scientific requirements for psychotropic sub-
stances listed in Schedules II, III and IV of the 1971 
Convention. Assessments for psychotropic substances 
remain in force until Governments modify them to 
reflect changes in national requirements. The Board rec-
ommends that Governments review and update the 
assessments of their annual medical and scientific require-
ments for psychotropic substances at least once every 
three years.
124. In the 12 months following 1 November 2013, a 
total of 78 countries and 8 territories submitted fully 
revised assessments of their requirements for psycho-
tropic substances, and a further 94 Governments submit-
ted modifications to assessments for one or more 
substances. Governments of 24 countries and 1 territory 
have not submitted any revision of their legitimate 
requirements for psychotropic substances for over three 
years.
125. Failure to submit adequate estimates or assess-
ments for narcotic drugs and psychotropic substances 
may undermine drug control efforts. If estimates and 
assessments are lower than the legitimate requirements, 
the importation or use of narcotic drugs or psychotropic 
substances needed for medical or scientific purposes may 
be impeded or delayed. Submission of estimates or assess-
ments significantly higher than legitimate requirements 
increases the risk that imported narcotic drugs and psy-
chotropic substances will be diverted into illicit channels. 
The Board calls upon all Governments to ensure that 
their estimates and assessments are adequate but not 
excessive. When necessary, Governments should submit 
to the Board supplementary estimates for narcotic drugs 
or inform the Board of modifications to their assessments 
for psychotropic substances. The Board invites all 
Governments, in particular those of countries and terri-
tories with low levels of consumption of controlled sub-
stances, to use the Guide on Estimating Requirements for 
Substances under International Control, developed by the 
Board and WHO for use by competent national author-
ities and published in February 2012.
126. The Commission on Narcotic Drugs, in its reso-
lution 49/3, requested Member States to provide to the 
Board annual estimates of their legitimate requirements 
for four substances frequently used in the illicit 
 manufacture of amphetamine-type stimulants, namely 
3,4-methylenedioxyphenyl-2-propanone (3,4-MDP-2-P), 
pseudoephedrine, ephedrine and 1-phenyl-2-propanone 
(P-2-P), and preparations containing those substances. 
The expectation was that those data would provide the 
competent authorities of exporting countries with at 
least an indication of the legitimate requirements of 
importing countries, thus preventing diversion attempts. 
As at 1 November 2014, 157 Governments had provided 
estimates for at least one of the above-mentioned sub-
stances; Nepal, Saudi Arabia and Turkmenistan provided 
estimates for the first time. In 2014, the Board reviewed 
the annual legitimate requirements for countries in West 
Asia with relatively high estimates for imports of ephed-
rine and pseudoephedrine and requested concerned 
Governments to update their estimates as a matter of 
urgency.
127. The Board wishes to remind all Governments that 
the totals of estimates of annual medical and scientific 
requirements for narcotic drugs, as well as assessments 
of requirements for psychotropic substances, are pub-
lished in yearly and quarterly publications and that 
monthly updates are available on the Board’s website 
(www.incb.org). Updated information on annual esti-
mates of legitimate requirements for precursors of 
amphetamine-type stimulants is also available on the 
website.
4. Data examination and identified 
reporting deficiencies
128. As noted in previous reports of the Board, the pro-
vision of statistical data by Governments allows INCB to 
monitor the functioning of the international drug con-
trol system, which, in turn, assists Governments in their 
response to possible diversions and illicit uses of inter-
nationally controlled substances. The Board notes again 
with concern that some Governments, among them 
major manufacturing countries, have failed to provide to 
the Board data regarding the production, manufacture, 
utilization, export, import, consumption and stocks of 
controlled substances and regarding seizures related to 
precursor chemicals.
129. The international drug control system relies on the 
active participation of all Governments, and the Board 
remains concerned by the extent of late submissions and 
the submission of incomplete or inaccurate data. The 
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timely analysis and review of data by the Board becomes 
exceedingly difficult when Governments fail to submit 
accurate statistical data on time. To assist Governments, 
the Board has developed tools and kits for use by com-
petent national authorities that are available on its web-
site free of charge. Governments are requested to take all 
necessary measures to remedy the current reporting defi-
ciencies so that the international drug conventions are 
adequately implemented.
D. Evaluation of overall treaty 
compliance
1. Evaluation of overall treaty 
compliance in selected countries
130. The Board regularly reviews the drug control situ-
ation in different countries and overall compliance by 
Governments with the provisions of the international 
drug control treaties. The Board’s analysis covers various 
aspects of drug control, including the functioning of 
national drug control administrations, the adequacy of 
national drug control legislation and policy, measures 
taken by Governments to combat drug trafficking and 
abuse and to ensure the adequate availability of narcotic 
drugs and psychotropic substances for medical purposes 
and the fulfilment by Governments of their reporting 
obligations under the treaties.
131. The findings of the review and the Board’s recom-
mendations for remedial action are conveyed to the 
Governments concerned as part of the ongoing dialogue 
between the Board and Governments to enhance the 
implementation of the international drug control 
treaties.
132. In 2014, the Board reviewed the drug control situ-
ation in Papua New Guinea, the United States, Uruguay 
and Uzbekistan, as well as measures taken by the 
Governments of those countries to implement the inter-
national drug control treaties. In doing so, the Board took 
into account all available information, paying particular 
attention to new developments in drug control in those 
countries.
(a) Papua New Guinea
133. The Board continues to be concerned about the 
situation in Papua New Guinea with respect to drug con-
trol, including the lack of adequate legislation to address 
drug-related challenges in the country and inadequate 
mechanisms for coordination in the field of drug control 
among Government agencies. While noting the recent 
improvement in submission of information by the 
Government to the Board with regard to psychotropic 
substances, as required under the international drug con-
trol treaties, the Board remains concerned about the lim-
ited information available to the Board on the overall 
drug control situation in the country and the country’s 
compliance with its reporting obligations under the inter-
national drug control treaties with regard to narcotic 
drugs and precursors.
134. Papua New Guinea has established certain institu-
tional mechanisms to address the problems associated 
with illicit drug use. The Government created the National 
Narcotics Bureau to conduct education and awareness-
raising campaigns among the population, provide drug 
abuse treatment, rehabilitation and counselling, collect 
information pertaining to drugs and advise the 
Government on drug policy matters. The police and cus-
toms authorities are mandated, under the Dangerous 
Drugs Act, to enforce drug-related legislation in the 
country. The National Department of Health controls all 
pharmaceutical drugs under the Pharmaceutical Board 
Act and the Medicines and Cosmetics Act.
135. In the absence of official information from the 
Government, the Board must rely on secondary sources 
to ascertain the drug-related challenges in the country 
and to gauge the Government’s efforts to address them. 
Various reports indicate serious deficiencies in the distri-
bution of medications, with an ongoing shortage of drugs 
in medical facilities. Press reports indicate that the illicit 
cultivation of and trafficking in cannabis remain wide-
spread in the country, in particular in the highlands. 
There are also press reports that drug syndicates involv-
ing both national and foreign members are operating 
within the country. In addition, the manufacture of meth-
amphetamine in Papua New Guinea has been reported 
in the international media.
136. According to a statement made in March 2014 by 
representatives of the National Narcotics Bureau, the 
abuse of drugs and home-brewed alcohol is a major prob-
lem in the country, and community leaders should work 
together with young people to eliminate it. According to 
that statement, a team comprising officers from the 
Bureau and members of the national police drug squad 
had conducted an extensive drug awareness campaign 
and education programme in the country.
137. Papua New Guinea is a party to the 1961 and 1971 
Conventions. However, it has yet to accede to the 1988 
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Convention. In that context, the Board reminds those 
Governments that have not acceded to any of the three 
international drug control treaties that the General 
Assembly, in its resolution 53/115, which was adopted 
subsequent to its special session devoted to countering 
the world drug problem together, urged all States to rat-
ify or accede to and implement all the provisions of the 
international drug control conventions. At that special 
session, particular reference was also made to the impor-
tance of the adequate control of precursor chemicals, 
which fell under the purview of the 1988 Convention. 
The Board reiterates its readiness to assist the Government 
of Papua New Guinea in acceding to the 1988 Convention 
and improving its compliance with the international drug 
control treaties.
(b) United States of America
138. The Board continues to engage in a constructive 
dialogue with the Government of the United States on 
drug-related developments in that country, including 
with regard to cannabis, with a view to promoting com-
pliance by the Government with the requirements of the 
international drug control treaties.
139. The Board notes that, as discussed in more detail 
in chapter III of the present report, programmes for the 
use of cannabis for medical purposes continue to be 
introduced in several states of the United States. The 
Board notes that, under United States federal law, canna-
bis remains a controlled substance at the federal level, 
and has no current medical use in treatment.
140. During the reporting period, the states of Colorado 
and Washington continued to develop and enforce regu-
latory measures to establish recreational cannabis mar-
kets within their boundaries. On 1 January 2014, 
state-licensed cannabis retailers in the state of Colorado 
began selling cannabis for non-medical purposes. In July 
2014, the sale of cannabis for non-medical use also began 
in the state of Washington. In November 2014, voters in 
the states of Alaska and Oregon and in the District of 
Columbia approved ballot initiatives on the non-medical 
use of cannabis in their respective jurisdictions. The 
Board notes however, that, under United States federal 
legislation, cannabis remains a controlled substance.
141. The Government of the United States has taken 
certain measures to respond in part to the developments 
related to cannabis in many states in the country. On 
29  August 2013 and 14 February 2014, memorandums 
for all state attorneys were issued by the Department of 
Justice to provide guidance on all federal enforcement 
activity, including civil enforcement and criminal inves-
tigations and prosecutions, concerning cannabis in all 
states. Also on 14 February 2014, the Department of the 
Treasury issued its Guidance on Bank Secrecy Act 
Expectations Regarding Marijuana-related Businesses to 
provide guidance to financial institutions on the provi-
sion of services to cannabis-related businesses.
142. The Board notes the various measures undertaken 
and planned by the Government to monitor the imple-
mentation of cannabis-related regulations in certain states 
of the United States as they pertain to federal enforce-
ment priorities, as well as to examine the public health 
impact of those developments. The Board reiterates its 
concern that action by the Government to date with 
regard to the legalization of the production, sale and dis-
tribution of cannabis for non-medical and non-scientific 
purposes in the states of Alaska, Colorado, Oregon and 
Washington does not meet the requirements of the inter-
national drug control treaties. In particular, the 1961 
Convention as amended, establishes that the parties to 
the Convention should take such legislative and admin-
istrative measures as may be necessary “to limit exclu-
sively to medical and scientific purposes the production, 
manufacture, export, import, distribution of, trade in, use 
and possession of drugs”. This provision is strictly bind-
ing and not subject to flexible interpretation. In addition, 
the Convention establishes that States parties have “to 
give effect to and carry out the provisions of this 
Convention within their own territories”. This provision 
also applies to States with federal structures.
143. In April 2014, the United States Sentencing 
Commission voted unanimously to amend the federal 
sentencing guidelines, with a view to reserving the harsh-
est penalties for the most serious drug offenders. The 
amendment, first unveiled in January 2014, lowers by two 
levels the base offence associated with various drug quan-
tities involved in federal drug trafficking crimes. 
According to the Commission, the change would have an 
impact on nearly 70 per cent of all drug trafficking 
offenders, reduce the average sentence by 11 months, or 
nearly 18 per cent, and lower the prison population by 
6,550 within five years.
(c) Uruguay
144. On 20 December 2013, the Legislative Power of 
Uruguay passed Act No. 19.172, establishing a legal 
framework applicable to the control and regulation by the 
State of the importation, exportation, planting, growing, 
gathering, production, purchase, stocking, sale, distribu-
tion and use of cannabis and its derivatives.
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145. In May 2014, the regulatory provisions for the 
application of the law were adopted. Uruguay has become 
the first State party to the 1961 Convention to legalize 
the production, distribution, sale and consumption of 
cannabis and its derivatives for purposes other than med-
ical and scientific uses. That will not only have ramifica-
tions for drug control within Uruguay, but will also 
negatively affect the control of drugs, in particular can-
nabis, in other countries, both neighbouring and beyond.
146. The law adopted is inconsistent with the provisions 
of the 1961 Convention as amended, in particular arti-
cle 4, paragraph (c), and of the 1988 Convention, in par-
ticular article 3, paragraph (1) (a). Pursuant to article 4, 
paragraph (c), of the 1961 Convention, States parties are 
obliged to “limit exclusively to medical and scientific pur-
poses the production, manufacture, export, import, dis-
tribution of, trade in, use and possession of drugs”. 
Pursuant to article 3, paragraph (1) (a), of the 1988 
Convention, each State party is obliged to “adopt such 
measures as may be necessary to establish as criminal 
offences under its domestic law […] the production, 
manufacture, extraction, preparation, offering, offering 
for sale, distribution, sale, delivery on any terms whatso-
ever, brokerage, dispatch, dispatch in transit, transport, 
importation or exportation of any narcotic drug contrary 
to the provisions of the 1961 Convention”.
147. The Board takes note of public announcements 
made by the authorities of Uruguay to the effect that the 
implementation of the legislation, originally planned for 
April 2014, has been postponed until early 2015.
148. Cannabis is recognized internationally as a par-
ticularly dangerous drug that has serious consequences 
for the health of people and is under strict control in 
Schedules I and IV of the 1961 Convention. The inter-
national drug control conventions recognize the health 
dimensions of drug use. Under article 38 of the 1961 
Convention, parties are required to “give special attention 
to and take all practicable measures for the prevention of 
abuse of drugs and for the early identification, treatment, 
education, aftercare, rehabilitation and social reintegra-
tion of the persons involved”. Accordingly, the Board 
urges the Government of Uruguay to develop effective 
and comprehensive drug control measures that provide 
for a balanced approach aimed at reducing illicit demand 
for drugs through prevention, treatment and rehabilita-
tion programmes, while implementing effective law 
enforcement drug interdiction measures.
149. The Board would like to reiterate its serious con-
cern about the possible negative impact that the canna-
bis control legislation in Uruguay would have on the 
international drug control system. The Board stresses the 
importance of universal implementation of the interna-
tional drug control treaties by all States parties and urges 
the Government of Uruguay to take the necessary meas-
ures to ensure full compliance with those treaties.
150. As part of its ongoing dialogue with the Government 
of Uruguay, the Board, at its 109th session, held in 
February 2014, received a delegation from the Government. 
The representatives of the Government of Uruguay 
reported on recent measures taken in the field of drug 
control in that country and assured the Board of the 
Government’s commitment to drug control and full and 
unconditional cooperation with the Board. The Board 
will continue its dialogue with the Government of 
Uruguay, with a view to promoting the country’s 
 compliance with the international drug control treaties, 
including through the sending of a high-level mission of 
the Board to Uruguay. 
(d) Uzbekistan
151. The main factor adversely affecting the drug 
 control situation in Uzbekistan continues to be illicit drug 
production in Afghanistan and the flow of Afghan  heroin 
and opium along the “northern route” through the 
 territory of Uzbekistan. Opiates of Afghan origin enter 
Uzbekistan via the long, rugged and porous border with 
Tajikistan and directly from Afghanistan across the Amu 
Darya river. There are reports of seizures of drugs from 
trains, motorized vehicles and travellers coming from 
Tajikistan. In order to address the threat of drug traffick-
ing, Uzbekistan, a party to all three drug control treaties, 
has established drug-related units in almost all law 
enforcement agencies, which continue to carry out a 
number of targeted actions to detect drug trafficking 
channels, prevent and interdict drug trafficking and 
 eradicate drug crops in the country.
152. Although Uzbekistan is not a significant illicit pro-
ducer of narcotic drugs, Uzbek law enforcement author-
ities carry out annual “black poppy” operations, which 
are countrywide campaigns to eradicate illicitly cultivated 
drug crops.
153. The drug abuse situation in Uzbekistan is fuelled 
mainly by the trafficking in opiates from Afghanistan. 
Individuals abusing opiates, especially heroin, account for 
the vast majority of the overall number of those under-
going treatment in the country. Even though extensive 
research into the prevalence of drug abuse in the coun-
try was called for under the National Programme of 
Comprehensive Measures against Drug Abuse and 
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Trafficking for 2011-2015, Uzbekistan has yet to carry out 
such research. A network of drug treatment facilities has 
been created in Uzbekistan to provide specialized medi-
cal assistance for people suffering from drug addiction. 
Those persons who use psychoactive substances for non-
medical purposes can apply voluntarily or be directed by 
law enforcement authorities and/or medical facilities, to 
the drug treatment facilities for medical examination and, 
if necessary, further treatment.
154. Uzbekistan carries out several measures and initi-
atives aimed at preventing drug abuse. Health education 
initiatives, including drug abuse prevention, are organ-
ized under the “Healthy lifestyle” programme run by the 
Ministry of Education and are tailored to a range of dif-
ferent age groups. Round-the-clock advisory services are 
available to the public in all regions of the country 
through telephone hotlines. At the same time, national 
drug education, treatment and rehabilitation programmes 
are in need of further strengthening, in particular through 
the provision of the necessary equipment and additional 
training.
155. The Board notes with appreciation the continued 
cooperation it has received from the Government of 
Uzbekistan, including its effective compliance with its 
reporting obligations under the international drug con-
trol treaties and the submission of reports on the drug 
control situation in the country.
2. Country missions
156. In the context of its responsibility to promote the 
compliance of Governments with the international drug 
control conventions and to monitor the functioning of 
the international drug control system, the Board under-
takes missions to selected countries every year in order 
to maintain direct dialogue with Governments on mat-
ters relating to the implementation of the provisions of 
those conventions.
157. The purpose of the missions is to obtain detailed, 
first-hand information on the drug control policies in 
place in the countries visited and to discuss with compe-
tent national authorities their practical experience in 
implementing the conventions, including problems 
encountered, good practices identified and additional 
measures to be considered in order to optimize treaty 
compliance. 
158. The Board’s missions are aimed at appraising the 
prevailing situation in the countries visited on a wide 
variety of drug control matters within the ambit of the 
drug control conventions, including: national drug con-
trol legislation; supply reduction measures in place; regu-
latory aspects related to the provision of estimates, 
assessments, statistics and trade data to the Board; the 
availability of narcotic drugs and psychotropic substances 
for medical needs; precursor chemical control; and struc-
tures in place for the prevention of drug abuse and the 
treatment, rehabilitation and social integration of persons 
suffering from drug dependency and related health 
conditions.
159. In order to gain as comprehensive an overview as 
possible, the Board meets with senior officials from var-
ious institutional stakeholders at the political and regula-
tory levels within the country. In addition, the Board 
requests that the mission programme include visits to 
drug treatment facilities and social reintegration initia-
tives. Recognizing the important role played by non- 
governmental organizations and other civil society groups, 
the Board carries out meetings with such entities, identi-
fied in consultation with the Vienna NGO Committee on 
Drugs, within the context of its country missions.
160. Based on the outcome of meetings held and infor-
mation collected, the Board issues a series of confiden-
tial recommendations on possible measures to bolster the 
implementation by the Government concerned of its 
treaty obligations under the drug control conventions. 
The Board encourages all Governments to respond 
promptly and effectively to requests to conduct country 
missions, which constitute a pillar of treaty implementa-
tion monitoring.
161. During the period under review, the Board under-
took missions to Iceland, Nicaragua, Panama and the 
United Republic of Tanzania.
(a) Iceland
162. A mission of the Board visited Iceland in March 
2014. Iceland is a party to the three international drug 
control treaties. Discussions during the mission focused 
on the measures taken by the Government to exercise 
effective control over narcotic drugs, psychotropic sub-
stances and the chemicals needed for their illicit manu-
facture. It was the first mission of the Board to Iceland.
163. It is noted that, in 2012, Iceland had the highest 
calculated consumption of methylphenidate, in defined 
daily doses for statistical purposes (S-DDD) per 1,000 
inhabitants per day, in the world. The Government has 
taken several measures to respond to that problem; how-
ever, those measures have not resulted in a decline in 
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consumption. Therefore, the Board recommends that the 
Government of Iceland, in order to be able to effectively 
address this complex issue, should re-examine the mat-
ter and should endeavour to identify the reasons behind 
the extraordinarily high consumption of methylphenidate 
by, inter alia, monitoring and analysing prescription 
patterns.
164. The Board was informed that drug use in Iceland 
had been declining among secondary school students and 
students in higher education for several consecutive 
years. Drug use was higher for young people outside the 
school system; the Board invites the Government of 
Iceland to continue its efforts to address the needs of that 
group, which is particularly vulnerable to drug use, by 
implementing programmes that will assist young adults 
to lead healthy lifestyles and develop the resilience needed 
to resist drug use.
(b) Nicaragua
165. A mission of the Board visited Nicaragua in 
December 2013. Nicaragua is a party to all three inter-
national drug control treaties. The Board notes that, since 
its previous mission to Nicaragua, in 1993, the Government 
has taken important steps to strengthen its efforts relat-
ing to drug control, including by adopting comprehen-
sive national drug control legislation, establishing a 
national coordination committee on drug control and 
crime prevention and developing a national drug strat-
egy against drugs and crime. The national drug control 
policy is primarily focused on the prevention of drug 
abuse, and health services are provided free of charge to 
the entire population. The Government has also put in 
place a well-functioning administrative mechanism for 
licit drug control, in accordance with the international 
drug control treaties. At the same time, as demonstrated 
by recent large seizures of precursor chemicals smuggled 
into Nicaragua and seizures of amphetamine-type stim-
ulants from illicit laboratories, there is a need to further 
improve international cooperation to prevent the diver-
sion of precursor chemicals into illicit channels.
166. Nicaragua continues to be used as a transit coun-
try for illicit drug shipments, notably cocaine from South 
America that is destined for North America. The 
Government is aware of the challenge posed by drug traf-
ficking and has taken steps to address it. However, effec-
tive drug interdiction is seriously hampered by a limited 
State presence in the autonomous areas of the country’s 
Atlantic coast and by a lack of necessary equipment and 
personnel to effectively patrol the territorial waters.
167. The mission discussed with the Government, 
among other things, the availability of narcotic drugs for 
the treatment of pain, which is lower in Nicaragua than 
in some other countries in Central America. The mission 
noted that the current extent of drug abuse in the coun-
try was largely unknown to the authorities and that reli-
able data on drug abuse were scarce. The mission 
therefore discussed with the Government the need for an 
epidemiological study on the prevalence of drug abuse to 
enable a reliable assessment of the impact of existing 
 prevention initiatives.
(c) Panama
168. A mission of the Board to Panama in December 
2013 reviewed changes in the drug control situation in 
the country since the Board’s previous mission, in 2003. 
An additional aim of the mission was to review compli-
ance with the three international drug control conven-
tions to which Panama is a party. The Board notes that 
Panama has taken legislative and policy measures to meet 
its commitments under the conventions. The mission of 
the Board noted significant progress in terms of institu-
tional development and the adoption of the national drug 
strategy for the period 2012-2017.
169. There are indications that Panama may need to 
improve the availability of opioid analgesics and pallia-
tive care programmes, owing to a general reluctance of 
health-care professionals in the country to prescribe 
internationally controlled substances. The Government 
was encouraged to ensure the rational use of narcotic 
drugs and psychotropic substances for medical use.
170. The current magnitude of drug abuse in Panama 
may not be fully reflected by the most recent national 
surveys, which were conducted in 2003 and 2008. The 
Board encouraged Panama to conduct new national sur-
veys on drug abuse among the general and youth popu-
lations. Better analysis of trends will aid the country in 
providing adequate human and financial resources. The 
Board has also encouraged Panama to increase its sup-
port to drug demand and supply reduction policies and 
programmes.
(d) United Republic of Tanzania
171. A mission of the Board visited the United Republic 
of Tanzania from 14 to 18 October 2014. The country is 
a party to all three international drug control conven-
tions. The aim of the mission was to examine the avail-
ability of opioid medication for palliative care, to reengage 
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in dialogue with the Government of the United Republic 
of Tanzania and to follow-up on the progress made by 
the country since the previous mission of the Board in 
2000. 
172. The Board notes that the Government of the 
United Republic of Tanzania has followed up on a num-
ber of the Board’s recommendations since its previous 
mission. The country became a party to the 1971 
Convention in December 2000, designated the Drug 
Control Commission as the authority responsible for the 
coordination of most aspects of the Government’s policy 
on drugs, adopted a drug control master plan for the 
2002-2006 period and a programme of action on the 
implementation of the national drug control plan for the 
2005-2010 period.
173. The mission observed that access to opioid med-
ication for pain and palliative care remained extremely 
low. Therefore, the Board encourages the Government to 
develop and enact a comprehensive and balanced drug 
strategy, which should also address the issue of availa-
bility of narcotic drugs and psychotropic substances for 
medical purposes. In particular, the Government is 
invited to identify obstacles and take the necessary steps 
to ensure an adequate level of availability of opioids. The 
Board also recommends to the Government specific 
action to enhance the coordination of national drug 
 control efforts. 
3. Evaluation of the implementation 
by Governments of recommendations 
made by the Board following its country 
missions 
174. As part of its ongoing dialogue with Governments, 
the Board also conducts an annual evaluation of imple-
mentation by Governments of the Board’s recommenda-
tions pursuant to its country missions. In 2014, the Board 
invited the Governments of the following five countries, 
to which it had sent missions in 2011, to provide infor-
mation on progress made in the implementation of its 
recommendations: Costa Rica, El Salvador, Mexico, 
Serbia and Zimbabwe.
175. The Board wishes to express its appreciation to the 
Governments of Costa Rica, El Salvador, Mexico and 
Zimbabwe for submitting the information requested. 
Their cooperation facilitated the Board’s assessment of the 
drug control situation in those countries and of the com-
pliance by those Governments with the international 
drug control treaties.
176. In addition, the Board reviewed the implementa-
tion of the recommendations it had made following its 
2010 mission to Myanmar, as the Government of that 
country had not provided the requested information in 
time for review and inclusion in the annual report of the 
Board for 2013.
(a) Costa Rica
177. The Government of Costa Rica has acted on the 
recommendations made by the Board following its mis-
sion to the country in June 2011, and progress has been 
made in a number of areas of drug control. The Board 
welcomes the measures taken to increase coordination 
among ministries and institutions dealing with drug con-
trol, as reflected in the National Plan on Drugs, Money-
laundering and the Financing of Terrorism for the period 
2013-2017. Additional resources have been allocated to 
strengthen the monitoring of retail pharmacies and the 
storage of controlled substances.
178. In 2012, Costa Rica made important changes to its 
legal framework for the control of narcotic drugs and psy-
chotropic substances. Regulations were adopted on 
improving the monitoring of the reporting requirements 
for pharmacies, drugstores and pharmaceutical laborato-
ries with regard to narcotic drugs and psychotropic sub-
stances. In addition, measures were adopted to increase 
the safety of narcotic and psychotropic raw materials 
stored by pharmaceutical retailers, and specific measures 
were adopted to improve security in relation to the trans-
portation of controlled substances, including by shorten-
ing the period allowed for the transport of controlled 
products between warehouses and retail facilities.
179. The Board welcomes those measures and notes 
that continued efforts need to be made in the area of drug 
abuse prevention and treatment. The Board encourages 
the Government to increase its efforts relating to the pri-
mary prevention of drug abuse among young people and 
to ensure that activities in that area address all commonly 
abused controlled substances, including pharmaceutical 
preparations containing such substances.
180. Furthermore, the Board notes that limited progress 
has been made in ensuring the availability of narcotic 
drugs and psychotropic substances for medical purposes 
in Costa Rica. The level of availability of opioids for the 
treatment of pain in medical institutions continues to be 
below that considered adequate by the Board. The Board 
requests the Government to examine the current situa-
tion and to take the necessary steps to ensure that nar-
cotic drugs, particularly opioids, and psychotropic 
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substances are used rationally and that adequate amounts 
are made available for medical purposes. The Board 
encourages the authorities to identify and address bottle-
necks in that area, particularly those relating to capacity-
building and enhancing the know-how of health-care 
professionals, as required.
181. Costa Rica participated in Operation Icebreaker in 
October 2012, a regional operation to monitor the diver-
sion of chemical precursors used for the illicit manufac-
ture of methamphetamines. The Board invites the 
Government to further strengthen cooperation with it 
with regard to the control of precursors and to provide 
prompt responses to the Board’s enquiries regarding the 
legitimacy of orders for the export of precursors to Costa 
Rica, in particular by using the PEN Online system. 
(b) El Salvador
182. The Board notes that efforts have been made by 
the Government of El Salvador with regard to the imple-
mentation of the Board’s recommendations following its 
mission to that country in June 2011. The Government 
has adopted legislation to strengthen the national drug 
control framework, including legislation to counter 
money-laundering, and action against international drug 
trafficking networks remains a priority of the country’s 
national anti-drug strategy for the period 2011-2015. In 
the area of demand reduction, in 2012, as part of the 
national anti-drug strategy, the first national study on 
drug use was carried out among university students.
183. Progress has also been made in the rational use of 
narcotic drugs and psychotropic substances for medical 
purposes. Legislative amendments adopted in February 
2011 established the National Directorate for Medicines, 
which is responsible for streamlining controls on medi-
cinal products containing narcotic drugs and psycho-
tropic substances. Regulations concerning the control of 
retail pharmacies and storage of controlled substances by 
health-care providers have also been strengthened, and 
new regulations in respect of the prescription of narcotic 
drugs and psychotropic substances for medical purposes 
have entered into force. The Board trusts that the 
Government of El Salvador will continue to strengthen 
its efforts to ensure adequate availability of narcotic drugs 
and psychotropic substances for medical and scientific 
purposes through enhancing the capacity and know-how 
of health-care professionals, particularly with regard to 
the rational use of controlled substances, while prevent-
ing the diversion of narcotic drugs and psychotropic sub-
stances into illicit channels.
184. Welcoming those measures, the Board notes that 
continued efforts need to be made with regard to drug 
abuse prevention and treatment. The Board encourages 
the Government of El Salvador to continue its efforts to 
ensure that further progress is made in those areas, par-
ticularly with regard to the availability of facilities for the 
treatment of drug abuse and the establishment of relia-
ble data on the drug abuse situation in the country.
(c) Mexico
185. The Board notes that, following its mission to Mexico 
in 2011, the Government of that country has taken sub-
stantial measures to implement the Board’s  recommendations 
in a number of areas. In order to address the diversion of 
precursor chemicals and their use in the manufacture of 
synthetic drugs, the Government has placed nitroethane 
and monomethylamine under national control. Additionally, 
the Government has adopted legislative measures to com-
bat the abuse of new psychoactive substances through a 
decree to amend its Health Act to include mephedrone, 
1-(3-trifluoromethylphenyl)piperazine (TFMPP) and syn-
thetic cannabinoids as psychotropic substances subject to 
regulation. In accordance with that amendment, the author-
ities in Mexico have been monitoring those substances, and 
investigating and prosecuting unlawful conduct where 
neces sary. The Board commends the Government of 
Mexico for maintaining a leading role in Latin America in 
the area of precursor control and in the investigation of 
crimes involving the manufacture and sale of synthetic 
drugs, the confiscation and disposal of chemicals used in 
the manufacture of such drugs and the dismantling of 
 clandestine laboratories.
186. The Board notes steps taken by the Government 
of Mexico in the area of demand reduction, in particu-
lar the activities of the Youth Integration Centres 
(“Centros de Integración Juvenil”), which have been com-
plementing the activities of the addiction treatment cen-
tres known as “Centros Nueva Vida” by offering 
youth-oriented treatment, workshops, counselling and 
intervention services. The Board also acknowledges steps 
taken by the Government of Mexico to standardize forms 
(such as initial assessments and medical history, admis-
sion, discharge and consent forms) in its drug treatment 
centres in order to facilitate compliance with reporting 
procedures at all stages of patient registration. As a result, 
data have been compiled into the national system of 
health quality indicators and used to evaluate the pro-
ductivity of drug treatment centres and identify areas for 
improvement. Currently, 236 out of 335 addiction treat-
ment centres nationwide have implemented the standard-
ized reporting criteria.
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187. The Board notes that the Government of Mexico 
has reported making progress in several areas of drug 
control. The Government has been working with UNODC 
on the Integrated System for Illicit Crop Monitoring to 
develop and implement a scientific methodology for the 
detection and location of illicit cannabis and opium crops 
using satellite images and aerial photography, in coordi-
nation with complementary activities on the ground. The 
process has facilitated the carrying out of analysis, 
research and data activities to estimate the scale of drug 
production by measuring the area used for illicit crop 
cultivation in the country. The Board also notes actions 
taken by the Government to thwart the illicit manufac-
ture of and trafficking in drugs in the country, including 
the eradication of large quantities of illicit cannabis and 
opium poppy crops, the dismantling of laboratories used 
to manufacture heroin and the conducting of investiga-
tive activities aimed at identifying criminal groups and 
individuals involved in the diversion of chemical sub-
stances and the illicit manufacture of heroin. The aim of 
those activities has been to prevent the commission of 
offences, assist in criminal investigations and contribute 
to the disbanding of organized criminal groups and 
reduction of related violence.
188. The Board commends the Government of Mexico 
for using its Technical Group for Synthetic Drug Control 
as a coordinating body to facilitate information-sharing 
and concerted action by law enforcement agencies and 
other government agencies involved in demand reduc-
tion and licit drug control. The Board notes the progress 
that the Technical Group has made at the regulatory level, 
particularly in updating its list of chemical precursors 
subject to national control to include phenylacetic acid, 
its salts and derivatives, and methylamine, in addition to 
its classification of hydriodic acid and red phosphorus as 
essential chemical products. The Board also commends 
the Government for its continued participation in INCB 
activities such as Project Cohesion, which is aimed at the 
monitoring and controlling of precursor chemicals used 
in the illicit manufacture of heroin and cocaine.
189. While welcoming those positive developments, the 
Board notes with concern that progress is still limited in 
other areas with regard to which it has made recommen-
dations, particularly the availability of narcotic drugs and 
psychoactive substances for medical purposes. The con-
sumption of opioids and analgesics in Mexico remains 
very low. As administrative procedures for obtaining 
access to such medications continue to be onerous, the 
availability of such medications remains limited, many 
medical practitioners may still not have access to train-
ing on responsible prescription practices and pharmacists 
are often reluctant to stock and dispense narcotic drugs 
and psychotropic substances. While the Board is aware 
that some measures have recently been initiated by the 
Government of Mexico to address this problem, the 
Board encourages the Government to take further steps 
to ensure that progress is made in this area.
(d) Myanmar
190. The Board notes that, since its mission to Myanmar 
in 2010, the Government has taken steps to implement 
some of the Board’s recommendations in a number of 
areas. In 2013, Myanmar announced plans to extend its 
15-year drug elimination plan (for the period 1999-
2014)—a national drug strategy intended to eliminate 
narcotic drugs and upgrade the living standards of for-
mer poppy-growing farmers through a combination of 
supply reduction, demand reduction and law enforce-
ment measures—by five years. The Government of 
Myanmar has hosted several delegations from donor 
countries to increase awareness of its technical assistance 
needs and of potential opportunities for the further 
expansion of alternative development projects in the 
region. In 2013, the Government signed an agreement 
with the Government of the United States to run a new 
joint opium yield survey in the region. The Board notes 
that opium poppy cultivation remains a major issue of 
concern and calls upon the international community to 
provide adequate support to Myanmar’s efforts to address 
this problem.
191. Pursuant to the Board’s recommendation, the 
Government has begun using the PEN Online system to 
monitor import and export transactions involving pre-
cursor chemicals, as well as to verify that imports and 
exports of such substances are for licit purposes and are 
destined for legitimate companies with verified addresses. 
Additionally, law enforcement agencies have been seizing 
large amounts of amphetamine-type stimulants and their 
precursors, as well as other substances such as opium and 
heroin. They have also been making progress in identi-
fying the sources and routes of drugs and precursors illic-
itly entering and exiting the country.
192. The Board wishes to commend Myanmar for steps 
taken with regard to prevention and demand reduction, 
in particular its widespread implementation of preventive 
education programmes in schools and colleges, and for 
the establishment of several new drug treatment and 
rehabilitation centres throughout the country.
193. While noting these positive developments, the 
Board notes with concern that progress is still lacking in 
many of the areas regarding which it has made 
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recommendations, particularly steps taken to promote 
the adequate availability of narcotic drugs and psycho-
tropic substances for medical purposes and to promote 
the education and training of medical students and pro-
fessionals on substance abuse and the rational use of 
psycho active drugs. The Board would like to reiterate the 
need for the Government of Myanmar to adopt measures 
to address existing laws and regulations that may unneces-
sarily restrict licit manufacture, import, distribution, pre-
scription or dispensing of opioids and cause reluctance 
to prescribe or stock medicinal products containing them 
because of concerns about legal sanctions, and to pro-
mote education on the rational use of narcotics and 
 psychotropic substances for medical purposes.
194. In addition, the Board wishes to remind the 
Government of Myanmar of the importance of carrying 
out a comprehensive national assessment in order to 
determine the extent and nature of drug abuse in the 
country and to tailor its drug control policies to address 
those realities.
(e) Zimbabwe
195. The Board notes that, since its mission to Zimbabwe 
in 2011, the Government has taken certain measures to 
implement the recommendations of the Board. Zimbabwe 
has developed a drug master plan, which is aimed at com-
bating trafficking in drugs, reducing supply, preventing 
drug abuse and rehabilitating drug users. However, the 
drug master plan has not yet been launched at the 
national level owing to a lack of funding; the Government 
plans to launch it by the end of 2014. The Drug Control 
Committee, an interministerial coordination committee, 
has been established, with a mandate to coordinate the 
activities of the national agencies in addressing drug 
abuse and trafficking. The Drug Control Committee was 
functioning at the expert level, and the Government 
expected to establish it at the policymaking level by the 
end of 2014. The Board welcomes the steps taken by the 
Government and encourages the Government to launch 
the drug master plan and establish a national intermin-
isterial coordination committee at the policymaking level.
196. There has been a significant increase in the provi-
sion of resources for law enforcement authorities. As a 
result, the Criminal Investigation Department of the 
Zimbabwe Republic Police, a special police section deal-
ing with the most serious offences, including drug-related 
crimes, has deployed officers at all airports and border 
posts. The officers provide 24-hour surveillance at those 
ports of entry, which has resulted in a number of drug 
seizures at several border locations. Over the past year, 
the Zimbabwe Revenue Authority, in coordination with 
the Drugs Division of the Criminal Investigation 
Department, has deployed sniffer dogs at four border 
posts. The goal is for the Zimbabwe Revenue Authority 
to deploy sniffer dogs at all ports of entry by 2015. The 
Authority has also engaged in an extensive programme, 
in collaboration with foreign partner agencies, to train its 
officers on drug detection. Public awareness campaigns 
have been held at most ports of entry to inform the pub-
lic about the consequences of drug trafficking and drug 
use in general.
197. Drug abuse treatment and rehabilitation services 
are provided in psychiatric hospitals. No dedicated reha-
bilitation centres exist in the country, mainly because of 
a lack of funding. Several agencies and departments were 
working together to establish at least one such centre by 
the end of 2014. The Ministry of Health and Child Care 
has carried out several small-scale surveys on the extent 
of drug use, but the Government has yet to conduct a 
full-scale national study, mainly owing to a lack of finan-
cial support. The Ministry of Health and Child Care, 
together with the police, has been conducting several pro-
grammes to educate the public on the dangers of drug 
abuse. Awareness-raising campaigns have been carried 
out on national radio and television stations and through 
printed media. Several national programmes have been 
implemented to offer a platform to discuss issues relat-
ing to drug abuse and its effects on the community, offer-
ing the public opportunities to interact with the police 
and Ministry of Health and Child Care staff who deal 
with drug-related issues.
198. Zimbabwe remains a country with a very low con-
sumption of controlled substances, such as opioid anal-
gesics, for medical purposes, despite an increase in the 
consumption of pethidine, which resulted in an increase 
in the country’s assessment of requirements for that sub-
stance in 2013. The Government has carried out several 
consultative meetings with medical practitioners to raise 
awareness of the rational use of opioid analgesics for 
medical purposes. The Board reiterates its request to the 
Government to make an appropriate assessment of 
requirements for controlled substances, to improve the 
availability of such substances for medical purposes and 
to promote rational prescribing practices, in line with the 
relevant recommendations by WHO and the Board, 
including those contained in the Report of the International 
Narcotics Control Board on the Availability of Internationally 
Controlled Drugs: Ensuring Adequate Access for Medical 
and Scientific Purposes.34
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199. Zimbabwe continues to rely on international sup-
port to promote prevention and treatment of drug abuse. 
The country continues to actively participate in inter-
national and regional organizations that are aimed at 
addressing drug trafficking and abuse. In particular, the 
Drug Control Committee of Zimbabwe facilitated the 
organization of the African Union Continental Experts 
Consultation on developing and improving responses to 
counter drug trafficking and related challenges to human 
security, which was held in Harare from 15 to 17 October 
2013.
200. The Board notes that, despite some achievements, 
progress is lacking in some of the areas where it has 
made recommendations, including with regard to the 
availability of narcotic drugs and psychotropic sub-
stances for medical purposes and the treatment and 
rehabilitation of drug-dependent persons. The Board 
encourages the Government of Zimbabwe to take the 
necessary steps to achieve progress in those areas and 
calls upon the international community to step up its 
support to the Government of Zimbabwe in addressing 
those challenges.
E. Action taken by the Board to 
ensure the implementation of the 
international drug control treaties
1. Action taken by the Board pursuant 
to article 14 of the 1961 Convention and 
article 19 of the 1971 Convention
201. Article 14 of the 1961 Convention (and of that 
Convention as amended by the 1972 Protocol) and arti-
cle 19 of the 1971 Convention set out measures that the 
Board may take to ensure the execution of the provisions 
of those conventions. Such measures, which consist of 
increasingly severe steps, are considered by the Board 
when it has reason to believe that the aims of the con-
ventions are being seriously endangered by the failure of 
a State to comply with the treaty obligations contained 
therein.
202. The Board has invoked article 14 of the 1961 
Convention and/or article 19 of the 1971 Convention 
with respect to a limited number of States. The Board’s 
objective in doing so has been to encourage compliance 
with those conventions when other means have failed. 
The names of the States concerned are not publicly 
disclosed until the Board has decided to bring the situa-
tion to the attention of the parties, the Economic and 
Social Council and the Commission on Narcotic Drugs 
(as was done in the case of Afghanistan). Following sus-
tained dialogue with the Board according to the process 
set out in the above-mentioned articles, most of the States 
concerned have taken remedial measures, resulting in a 
decision by the Board to discontinue action taken under 
those articles vis-à-vis those States.
203. Afghanistan is currently the only State for which 
action is being taken pursuant to article 14 of the 1961 
Convention as amended by the 1972 Protocol.
2. Consultation with the Government 
of Afghanistan pursuant to article 14 of 
the 1961 Convention
204. Consultations between the Board and the Govern-
ment of Afghanistan pursuant to article 14 of the 1961 
Convention continued in 2014. On 16 January 2014, the 
Secretary of the Board met with Mobarez Rashidi, the 
newly appointed Minister of Counter Narcotics of 
Afghanistan, who outlined his immediate priorities in 
addressing drug-related threats in the country. Those pri-
orities included: (a) expanding partnerships in dealing 
with drug-related challenges; (b) closer engagement with 
neighbouring countries, especially in the area of control 
of precursor chemicals; and (c) strengthening efforts by 
Afghanistan in addressing drug abuse and addiction 
problems in the country through effective provision of 
the necessary shelters and referral to treatment centres in 
Afghanistan.
205. The Minister also committed himself to continu-
ing close cooperation with the Board and to inform the 
Board, at the earliest opportunity, about progress made 
with respect to matters falling under article 14 of the 1961 
Convention. The Secretary of the Board noted the open 
and constructive dialogue between the Government of 
Afghanistan and the Board over the past several years 
and reiterated the need for tangible progress under arti-
cle 14 of the 1961 Convention and, in particular, in 
addressing issues of concern, such as the alarming levels 
of illicit opium poppy cultivation, drug trafficking and 
drug abuse in Afghanistan.
206. In March 2014, on the margins of the fifty-seventh 
session of the Commission on Narcotic Drugs, held in 
Vienna, the President of the Board met with the delega-
tion of Afghanistan, which was headed by the Minister 
of Counter Narcotics. The Minister provided information 
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on measures taken by the Government of Afghanistan to 
address the drug control situation in the country, includ-
ing with respect to the development of alternative liveli-
hood programmes, the countering of opium poppy and 
cannabis plant cultivation, the strengthening of enforce-
ment measures to address the trafficking of precursors 
and the establishment of mechanisms to address drug 
abuse in the country.
207. Consultations between the Secretariat of the Board 
and the Permanent Mission of Afghanistan to the United 
Nations (Vienna) were held on a number of occasions 
during the year to follow up on the Government’s imple-
mentation of the international drug control treaties. The 
consultations also focused on the planning and organi-
zation of a high-level mission of the Board to Afghanistan, 
scheduled to take place following the conclusion of the 
electoral process in Afghanistan.
Cooperation with the Board
208. The Government has continued its effective coop-
eration with the Board in recent years. In February 
2014, the Government submitted its 2013 report to the 
Board reflecting the Government’s efforts with regard to 
the implementation of the international drug control 
treaties.
209. The Government of Afghanistan informed the 
Board that the law on accession to the 1972 Protocol 
amending the Single Convention on Narcotic Drugs of 
1961 had been adopted by both houses of parliament, 
approved by the judicial power of Afghanistan and signed 
by the President of Afghanistan. Afghanistan has not 
made any declarations or reservations with regard to this 
instrument. At the time of writing, the Ministry for 
Foreign Affairs was in the process of finalizing the sub-
mission of the instrument of accession.
210. The Government’s treaty-based reporting has sub-
stantially improved since 2009, with statistical data on 
narcotic drugs, psychotropic substances and precursors 
submitted to the Board regularly, as required under the 
international drug control treaties.
211. There is a lack of prioritization within the govern-
ment policy to address cultivation of cannabis plant in 
the country, evidenced by a lack of budgetary allocation 
to counter such cultivation. The Board urges the 
Government of Afghanistan to step up its efforts to pre-
vent and interdict cannabis plant cultivation and canna-
bis production in the country, including through seeking 
the support of the international community in this area.
Cooperation by the international community
212. Afghanistan continued to actively engage in 
regional and international cooperation to address drug-
related threats affecting the country.
213. On 27 March 2014, the Presidents of Afghanistan, 
Iran (Islamic Republic of), Pakistan and Tajikistan held 
a summit. In a joint statement, they reiterated the impor-
tance of constructive regional cooperation, including 
through their support for ongoing Afghan-led regional 
efforts within the framework of the Istanbul Process on 
Regional Security and Cooperation for a Secure and 
Stable Afghanistan, which among other things is dedi-
cated to the prevention and elimination of illicit drug cul-
tivation, production, trade and trafficking.
214. The third meeting of the steering committee of the 
regional programme for Afghanistan and countries in the 
region was held in Vienna on the margins of the fifty-
seventh session of the Commission on Narcotic Drugs, 
in March 2014. The meeting was attended by the eight 
countries concerned (Afghanistan, Iran (Islamic Republic 
of), Kazakhstan, Kyrgyzstan, Pakistan, Tajikistan, 
Turkmenistan and Uzbekistan) and by donors. The pro-
gress made during 2013 in the four subprogrammes 
(regional cooperation in law enforcement, criminal jus-
tice, demand reduction and research advocacy) was 
noted. At the same time, ministerial review meetings for 
the Tripartite Initiative, involving Afghanistan, Kyrgyzstan 
and Tajikistan, and the Triangular Initiative, involving 
Afghanistan, Iran (Islamic Republic of) and Pakistan, 
were also held to further strengthen on-the-ground col-
laboration throughout the region. The meeting on the 
Triangular Initiative concluded with the signing of a joint 
ministerial statement focused on enhancing cooperation 
in the areas of drug control and border management. On 
29 May 2014, the fourth Tripartite Initiative meeting of 
senior officials was held in Dushanbe, and a ministerial 
meeting was held on the following day. A declaration on 
counter-narcotics cooperation, emphasizing the need for 
better cooperation between law enforcement and judicial 
bodies, was adopted following discussions.
215. The Kandahar Food Zone programme, funded by 
the United States Agency for International Development, 
was launched and will be implemented for the next two 
years in seven districts of Kandahar Province. The 
Government, however, faces difficulties in the implemen-
tation of alternative livelihood programmes in those 
provinces where opium poppy is currently grown, due to 
lack of sufficient funding, poverty and low agricultural 
production. The Government informed the Board that 
illicit poppy cultivation “migrates” from areas that have 
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received governmental support to those where the 
Government has no or little control. According to the 
Government, in the past alternative livelihood projects 
have not been very effective, because many of them were 
implemented in more accessible areas while the major 
cultivation took place in the remote districts. Therefore, 
a memorandum of understanding was signed between 
the Government and the donor community to revise the 
projects so as to address those shortcomings. Nevertheless, 
according to the Government, the current level of fund-
ing and the number of projects were not sufficient to sus-
tain alternative livelihood initiatives.
Conclusions
216. Afghanistan continues to face several major chal-
lenges, which in the period under review have included 
presidential elections and their aftermath, the transition 
of security functions from international military assis-
tance to the national army and police, the ongoing 
national reconciliation process and increasing drug 
 trafficking and abuse in the country. Despite these chal-
lenges, the Government expressed its commitment to 
address the illicit cultivation of opium poppy and canna-
bis plant in the country, drug trafficking and drug abuse 
through eradication campaigns, law enforcement 
 measures, alternative livelihood initiatives and drug 
demand reduction efforts. The Government has taken 
steps to ratify the 1972 Protocol amending the Single 
Convention. The Government has been fully cooperative 
with the Board, including through its readiness to 
 facilitate a high-level mission of the Board to Afghanistan 
and its submission of a progress report on the drug-
related situation in the country.
217. The Board, while noting the commitment 
expressed by the Government, remains concerned about 
the deteriorating drug control situation in Afghanistan, 
which constitutes a significant challenge in the country 
and for drug control in the region as a whole. The Board 
recommends that the Government of Afghanistan con-
tinue strengthening its counter-narcotics capacity in line 
with the international drug control treaties. The Board 
also encourages the Government to continue seeking 
international assistance in addressing the drug problem 
and to strengthen its cooperation at the regional and 
international levels in addressing drug trafficking and 
abuse. The Board will continue to closely monitor the 
drug control situation in Afghanistan in cooperation 
with the authorities, as well as measures taken and pro-
gress made by the Government of Afghanistan in all 
areas of drug control.
F. Special topics
1. Control measures applicable to 
programmes for the use of cannabis for 
medical purposes pursuant to the 1961 
Single Convention on Narcotic Drugs
218. The Single Convention on Narcotic Drugs of 1961 
as amended by the 1972 Protocol limits the use of nar-
cotic drugs, including cannabis, to medical and scientific 
purposes. Like other narcotic drugs under international 
control, cannabis is subject to a variety of control meas-
ures aimed at preventing its diversion into illicit channels 
and its abuse. In recognition of the risks of cannabis 
abuse, the substance has been subjected to the highest 
levels of control under the Single Convention through its 
inclusion in its Schedules I and IV, the latter of which 
contains substances particularly liable to abuse and to 
produce ill effects. 
219. The Single Convention allows States parties to use 
cannabis for medical purposes. Reflecting concerns about 
abuse and diversion, the Single Convention establishes an 
additional set of control measures, which should be 
implemented in order for programmes for the use of can-
nabis for medical purposes to be compliant with the 
Single Convention. 
220. The Board reminds all governments in jurisdic-
tions having established programmes for the use of can-
nabis for medical purposes, or considering doing so, that, 
in addition to reporting and licensing obligations appli-
cable to all narcotic drugs, the Single Convention requires 
that States having such programmes comply with several 
specific obligations.
221. Pursuant to articles 23 and 28 of the Single 
Convention, States wishing to establish programmes for 
the use of cannabis for medical purposes that are con-
sistent with the requirements of the Single Convention 
must establish a national cannabis agency to control, 
supervise and license the cultivation of cannabis crops. 
The obligations incumbent upon national cannabis agen-
cies include the designation of the areas in which culti-
vation is permitted, the licensing of cultivators, and the 
purchase and taking of physical possession of crops; they 
also have the exclusive right of wholesale trading and 
maintaining stocks.
222. In addition, governments must work to prohibit 
the unauthorized cultivation of cannabis plants, and seize 
and destroy illicit crops, whenever the prevailing 
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conditions in their territories render such measures the 
most suitable course of action, in order to protect public 
health and prevent illicit traffic, in accordance with arti-
cles 2 and 22 of the Single Convention.
223. Finally, governments must adopt such measures as 
may be necessary to prevent the misuse of, and illicit 
 traffic in, cannabis leaves, in accordance with article 28 
of the Single Convention. 
224. The Board has reviewed the issue of cultivation of 
cannabis for personal medical use and has determined 
that, in the light of the heightened risk of diversion it 
represents, such cultivation does not meet the minimum 
control requirements set out in the Single Convention. 
Accordingly, the Board has consistently maintained the 
position that a State which allows individuals to cultivate 
cannabis for personal use would not be in compliance 
with its legal obligations under the Single Convention. 
225. In addition to the risks of diversion cited above, 
allowing private individuals to produce cannabis for per-
sonal medical consumption may present health risks, in 
that dosages and levels of tetrahydrocannabinol (THC) 
consumed may be different from those medically 
prescribed.
226. The Board reminds all governments in jurisdic-
tions that have established programmes for the use of 
cannabis for medical purposes, or that are considering 
doing so, about the aforementioned requirements of the 
Single Convention. The Board notes that the control 
measures in place under many existing programmes in 
different countries fall short of the requirements set out 
above, and encourages all governments in jurisdictions 
that have approved or plan to implement such pro-
grammes to take measures to ensure that these pro-
grammes fully implement the measures provided for in 
the Single Convention, which are aimed at ensuring that 
stocks of cannabis produced for medical use are reserved 
for the patients for whom they are prescribed and are not 
diverted into illicit channels.
227. The Board urges all governments in jurisdictions 
that have established programmes for the use of canna-
bis for medical purposes to ensure that the prescription 
of cannabis for medical use is performed with competent 
medical knowledge and supervision and that prescription 
practice is based on available scientific evidence and con-
sideration of potential side effects. The Board reiterates 
its invitation to WHO to evaluate the potential medical 
utility of cannabis and the extent to which cannabis poses 
a danger to human health, in line with its mandate under 
the Single Convention.
2. Availability of narcotic drugs and 
psychotropic substances in emergency 
situations
228. The objective of the international drug control 
conventions is to ensure adequate availability of narcotic 
drugs and psychotropic substances for medical and scien-
tific purposes while ensuring that they are not diverted for 
illicit purposes. The International Narcotics Control Board 
(INCB) is mandated to monitor the implementation of this 
treaty objective, and has repeatedly voiced its concern 
about the unequal and inadequate access to controlled sub-
stances for medical and scientific purposes worldwide.
229. The conventions established a control regime to 
serve a dual purpose: to ensure the availability of con-
trolled substances for medical and scientific ends while 
preventing the illicit production of, trafficking in and 
abuse of such substances. The Single Convention on 
Narcotic Drugs of 1961, while recognizing that addiction 
to narcotic drugs constitutes a serious evil for the indi-
vidual and is fraught with social and economic danger to 
humankind, affirms that the medical use of narcotic 
drugs continues to be indispensable for the relief of pain 
and suffering and that adequate provision must be made 
to ensure the availability of narcotic drugs for such pur-
poses. Likewise, in the Convention on Psychotropic 
Substances of 1971, parties expressed their determination 
to prevent and combat the abuse of certain psychotropic 
substances and the illicit traffic to which it gives rise, 
while recognizing that the use of such substances for 
medical and scientific purposes is indispensable, and that 
their availability for such purposes should not be unduly 
restricted. 
230. Most narcotic drugs and a large number of psy-
chotropic substances controlled under the international 
treaties are indispensable in medical practice. Opioid 
analgesics, such as codeine and morphine, and semi-syn-
thetic and synthetic opioids are essential for the treat-
ment of pain. Similarly, psychotropic substances such as 
benzodiazepine-type anxiolytics, sedative-hypnotics and 
barbiturates are indispensable for the treatment of neuro-
logical and mental disorders. Pharmaceutical prepara-
tions containing internationally controlled substances 
play an essential role in relieving pain and suffering.
231. During its missions, the Board discusses the avail-
ability of opioids for the treatment of pain with individ-
ual Governments and provides competent national 
authorities with informational material that always 
includes the WHO publication entitled Ensuring Balance 
in National Policies on Controlled Substances: Guidance 
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for Availability and Accessibility of Controlled Medicines. 
After each mission, it sends the Governments a letter with 
recommendations that may, if appropriate, include spe-
cific passages on ensuring the availability of opioids for 
the treatment of pain. The Board regularly addresses the 
availability of narcotic drugs in speeches at meetings of 
intergovernmental bodies, such as the twentieth special 
session of the General Assembly, sessions of the 
Commission on Narcotic Drugs, the Economic and Social 
Council and the World Health Assembly, and regional 
meetings of various international organizations.
232. Simplified control measures are in place for the 
provision of internationally controlled medicines for 
emergency medical care. Emergencies are defined as “any 
acute situation (e.g. earthquakes, floods, hurricanes, epi-
demics, conflicts, displacement of populations) in which 
the health conditions of a group of individuals are seri-
ously threatened unless immediate and appropriate action 
is taken, and which demands an extraordinary response 
and exceptional measures”.35 They occur in the wake of 
natural or man-made disasters that may lead to a sudden 
and acute need for medicines containing controlled sub-
stances. In 1996, the Board, together with WHO, devised 
simplified control procedures for the export, transport 
and import of controlled medicines for emergency med-
ical care. The simplified regulations would remove the 
need for import authorizations, provided that the import 
and delivery were handled by established international, 
governmental and/or non-governmental organizations 
engaged in the provision of humanitarian assistance in 
health matters recognized by the control authorities of 
the exporting countries. Those simplified procedures are 
available to all States in the Model Guidelines for the 
International Provision of Controlled Medicines for 
Emergency Medical Care.
233. Such an emergency situation arose following the 
devastating typhoon in the Philippines in November 
2013. The need to provide treatment to the many victims 
led to an acute shortage of medicines. Many of those 
needed medicines contained narcotic drugs, such as mor-
phine, and psychotropic substances, such as pentazocine, 
both of which are under international control. Under 
normal circumstances, the import and transport of those 
medications are subject to strict regulatory requirements. 
However, in catastrophic situations compliance may delay 
the urgent delivery of medications for emergency human-
itarian relief, as national authorities may be unable to take 
the administrative steps required.
 35 World Health Organization, Model Guidelines for the International 
Provision of Controlled Medicines for Emergency Medical Care (document 
WHO/PSA/96.17).
234. Responding to the humanitarian crisis caused by 
the typhoon, the Board took steps to hasten the supply 
of controlled medicines. As in earlier emergencies, it 
reminded all exporting countries that clear guidelines 
were in place for the international provision of con-
trolled medicines for emergency medical care. Soon 
after the typhoon struck the Philippines, the Board sent 
a letter to all countries to remind them that they could 
apply those simplified control procedures to hasten the 
supply of urgently needed medicines. The Board also 
informed providers of humanitarian assistance about the 
simplified regulations, including the International 
Federation of Red Cross and Red Crescent Societies, 
Médecins Sans Frontières, Merlin/Save the Children and 
Oxfam International.
235. This solution has been available for a number of 
years. The Board invites Governments and humanitarian 
relief agencies to bring to its attention any problems 
encountered in making deliveries of controlled medicines 
in emergency situations.
236. The Board would like to remind all Governments 
that, in acute emergencies, such as the situation follow-
ing the devastating typhoon in the Philippines, they can 
apply simplified control procedures for the export, trans-
portation and delivery of medicines containing controlled 
narcotic drugs or psychotropic substances, and compe-
tent authorities may allow their export to the affected 
country even in the absence of import authorizations or 
estimated requirements for substances under interna-
tional control. Emergency deliveries need not be included 
in the estimates of the receiving country, and exporting 
Governments may wish to use parts of their special stocks 
of narcotic drugs and psychotropic substances for this 
purpose.
237. The Board also reminds all States that, under 
international humanitarian law, parties to armed 
conflicts have an obligation not to impede the provi-
sion of medical care to civilian populations located in 
territories under their effective control. This includes 
access to  necessary narcotic drugs and psychotropic 
substances.
238. The Guidelines are available on the websites of 
INCB (www.incb.org) and WHO (www.who.int).
3. Use of methylphenidate
239. Methylphenidate, a central nervous stimulant 
listed in Schedule II of the 1971 Convention, is used for 
the treatment of various mental and behavioural 
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disorders, in particular attention deficit and hyperactiv-
ity disorder (ADHD) and narcolepsy.36
240. During the 1980s, use of methylphenidate was lim-
ited and at stable levels, but it started to increase notice-
ably at the beginning of the 1990s. In 1994, for example, 
global use amounted to more than five times the con-
sumption level of the early 1980s. That development was 
mainly a result of increasing consumption in the United 
States, although increasing consumption levels were also 
observed in several other countries and parts of the 
world. Since then, growth of global consumption of 
methylphenidate has continued unabated. In 2013, a new 
record of 71.8 tons (2.4 billion S-DDD) was attained, as 
can be seen in figure I below. The growing medical con-
sumption of methylphenidate can be attributed mainly to 
the increasing numbers of diagnoses of ADHD.
241. Since the mid-1990s, the Board, in its annual reports, 
has frequently brought to the attention of Governments 
the growing levels of consumption of methylphenidate and 
has expressed concern about diversion and abuse of the 
substance. In its report for 2009, the Board advised against 
promotional campaigns through various communication 
channels, including in advertisements directed at potential 
 36 See World Health Organization, The ICD-10 Classification of 
 Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic 
 Guidelines (Geneva, 1992, version 2010); and American Psychiatric 
 Association,  Diagnostic and Statistical Manual of Mental Disorders, 
5th ed. (Arlington, Virginia, 2013).
consumers, such as those prevalent in the United States, 
the main consumer of methylphenidate. In that same year, 
the Board called upon the Governments concerned to 
ensure that the control measures foreseen by the 1971 
Convention were fully applied to methylphenidate and to 
take additional measures to prevent both the diversion 
from licit distribution channels and the abuse of prepara-
tions containing that substance. The Board also encour-
aged all Governments to promote the rational use of 
internationally controlled substances, in accordance with 
the pertinent recommendations of WHO. 
242. Traditionally, methylphenidate has been pre-
scribed to people between the ages of 6 and 14 years, 
and predominantly for boys. As of 2011 in the United 
States, about 11 per cent of individuals aged between 4 
and 17 years had been diagnosed with ADHD, accord-
ing to the Centers for Disease Control. Furthermore, a 
growing number of younger children (as young as 2 and 
3 years of age) were also being prescribed methylpheni-
date. In Australia, 2-year-old children are increasingly 
being prescribed medication containing methylpheni-
date, with more than 2,000 children under 6 receiving 
the treatment. In addition to the increasing number of 
children treated, the treatment period has been extended, 
in many cases to several years. Furthermore, there has 
been an increase not only in the number of young 
patients but also in the number of adult patients. In 
Iceland, most ADHD patients taking methylphenidate 
are over 20 years of age. In Germany, the number of 
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Figure I. Global consumption of methylphenidate, 1990-2013
Source: Statistical data submitted by Governments in form P.
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diagnosed ADHD cases increased by 42 per cent in chil-
dren and adolescents under the age of 19 between 2006 
and 2011. 
243. Although the United States continues to account 
for more than 80 per cent of the calculated global con-
sumption of methylphenidate, the use of that substance 
in other countries has also significantly increased during 
the past decade. The countries reporting such an increase 
include Iceland, which has had the highest per capita con-
sumption of methylphenidate in the world for the past 
several years, as well as (in descending order by per cap-
ita consumption) Norway, Sweden, Australia, Belgium, 
Germany and Canada. 
244. Increased consumption may be attributable to 
various causes such as: (a) an increase in the number of 
patients who are diagnosed with ADHD; (b) a widen-
ing of the age group of patients likely to be prescribed 
methylphenidate; (c) increased use among adults; 
(d) misdiagnosis of ADHD and random prescription of 
methylphenidate; (e) a lack of appropriate medical 
guidelines for the prescription of methylphenidate; 
(f)  growing market supply in many countries; (g) influ-
ential commercial and/or aggressive marketing practices 
of the manufacturers of pharmaceutical preparations 
containing methylphenidate; and (h) public pressure, 
such as  parents’ associations lobbying for their children’s 
right to access to ADHD medication.
245. Overmedication and overprescribing of medicines 
containing methylphenidate may fuel illegal activities 
such as “doctor shopping”, trafficking and abuse, particu-
larly in school settings. Students are misleadingly tempted, 
particularly during exam periods, to use the substance in 
order to improve their ability to concentrate and study 
longer, and thus improve their performance. Hence, this 
substance is abused by a growing number of teenagers 
and young adults. Prescription drugs containing methyl-
phenidate are also often obtained from students who are 
under treatment for ADHD. 
246. The Board notes that some Governments have 
already taken measures to limit the use of methylpheni-
date to actual medical needs, in conformity with sound 
medical practice. The authorities of Iceland, concerned 
about the high level of use of methylphenidate in their 
country, have taken specific measures aimed at curbing 
its increasing use, in particular, among adults. These 
measures include an update of existing clinical guidelines 
for ADHD treatment and the limitation to specialists in 
psychiatry of authorization to prescribe it. Prescribers are 
urged to prescribe, as a first choice, “safer” pharma-
ceutical preparations containing methylphenidate (i.e., 
preparations that are less prone to misuse). Furthermore, 
new and more restrictive rules for the reimbursement of 
the costs of methylphenidate have been introduced, 
under which only specialists in psychiatry are allowed to 
initiate treatment with methylphenidate and apply to the 
health insurance scheme for reimbursement, by submit-
ting observations based on a detailed medical history of 
the patient, research and diagnosis, as well as a follow-
up programme. In Thailand, where overprescribing of 
methylphenidate had also been of concern, the following 
preventive measures were taken: (a) prohibition of the 
sale of methylphenidate in drugstores; (b) limitation of 
authorization to prescribe methylphenidate, so that only 
psychiatrists, including child psychiatrists, are allowed to 
prescribe it; (c) limitations on the formulation of pharma-
ceutical preparations containing methylphenidate to pro-
hibit them from containing more than two dosages; 
(d)  restriction on the procurement of methylphenidate 
by hospitals and clinics so that it can only be obtained 
from a central governmental office; and (e) inclusion of 
a standard drug information leaflet in all packages. 
247. The Board wishes to encourage the Governments 
of all countries with high consumption rates of methyl-
phenidate to identify the reasons for such elevated con-
sumption and to take action to limit consumption to 
actual medical needs. Such actions could include ade-
quate education of doctors and other health-care profes-
sionals on the rational use of psychoactive drugs. In 
particular, Governments must exercise vigilance to pre-
vent possible misdiagnosis of ADHD and inappropriate 
prescribing of methylphenidate. Governments are encour-
aged to monitor developments in the diagnosis of ADHD, 
as well as other behavioural disorders, and the extent to 
which methylphenidate is prescribed for their treatment. 
The Board requests Governments to ensure that methyl-
phenidate is prescribed in accordance with sound medi-
cal practice, as set forth in the 1971 Convention (article 9, 
paragraph 2). The Board will continue to carefully mon-
itor future developments in countries with high con-
sumption levels of methylphenidate and encourages 
Governments concerned to share with it and WHO infor-
mation concerning the use of methylphenidate, prescrip-
tion practices and misuse, as well as trafficking and abuse 
in their countries.
4. New psychoactive substances
248. Since the publication of its annual report for 2010, 
the Board has been warning the international commu-
nity about the growing problem of trafficking in and 
abuse of new psychoactive substances. New psychoactive 
substances are substances of abuse, either in a pure form 
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or a preparation, that are not controlled under the 1961 
Convention as amended by the 1972 Protocol or under 
the 1971 Convention, but that may pose a threat to pub-
lic health.37 They can be natural materials or synthetic 
substances, often deliberately chemically engineered to 
circumvent existing international and domestic drug con-
trol measures. New psychoactive substances generally 
encompass several groups of substances, such as synthetic 
cannabinoids, synthetic cathinones, phenethylamines, 
piperazines, tryptamines and plant-based substances.
249. The reporting of new psychoactive substances by 
Member States continues to grow, and they are now 
reported in every region of the world. The UNODC early 
warning advisory on new psychoactive substances, a sys-
tem that monitors the emergence of new psychoactive 
substances as reported by Member States, identified 388 
unique substances as at 1 October 2014, an 11 per cent 
increase from the 348 substances reported in 2013 (see 
figure II below). The majority of reported substances are 
synthetic cannabinoids, cathinones and phenethylamines, 
which together account for over two thirds of all the sub-
stances reported. Reports may refer to substances that 
have been encountered only once or to substances that 
are encountered more frequently.
Figure II. New psychoactive substances 
reported by Member States, 2009-2014
Source: UNODC early warning advisory on new psychoactive 
 substances.
a Substances reported as at 1 October 2014.
 37 Other definitions of new psychoactive substances may also be used 
 occasionally.
250. There have been several important developments 
in response to the growing problem of new psychoactive 
substances since the Board’s previous report. In December 
2013, the Board launched its operational project on new 
psychoactive substances, known as Project Ion (interna-
tional operations on new psychoactive substances). That 
international initiative supports the efforts of national 
authorities to prevent non-scheduled new psychoactive 
substances from reaching consumer markets. Project Ion 
activities are modelled on the experience gained in pre-
cursor control and are directed by the New Psychoactive 
Substances Task Force.
251. Reports often cite China as one of the main sources 
of new psychoactive substances. The Government of 
China has taken steps to control these substances, includ-
ing the placing of 12 new psychoactive substances38 under 
domestic control as of 1 January 2014. Additionally, the 
Board convened an operational meeting under the aus-
pices of Project Ion in Vienna in February 2014. 
Participants from 18 law enforcement and international 
agencies discussed detailed information provided by 
Chinese authorities involving a company under investi-
gation for allegedly shipping thousands of orders of new 
psychoactive substances and non-scheduled precursor 
chemicals to countries around the world.
252. The topic of new psychoactive substances was 
again discussed at length at the fifty-seventh session of 
the Commission on Narcotic Drugs, in March 2014. The 
United Kingdom, which on 23 January 2014 submitted 
its notification to the Secretary-General on the review 
of the scope of control of 4-methylmethcathinone 
(mephedrone), presented a background paper that raised 
the possibility of provisional control of that substance, 
in accordance with article 2, paragraph 3, of the 1971 
Convention. The deliberations at that session of the 
Commission resulted in Member States adopting reso-
lution 57/9, entitled “Enhancing international coopera-
tion in the identification and reporting of new 
psychoactive substances and incidents involving such 
substances”, in which Member States were invited to sup-
port and participate in activities under the New 
Psychoactive Substances Task Force, which are referred 
to as Project Ion.
253. The first meeting of the New Psychoactive 
Substances Task Force was held in Vienna in March 2014 
to exchange information related to suspicious shipments 
of, or trafficking in, new psychoactive substances. The 
 38 AM-694, AM-2201, JWH-018, JWH-073, JWH-250, methylenedi-
oxypyrovalerone (MDPV), 4-methylethcathinone (4-MEC), methylone, 
2C-H, 2C-I, N-benzylpiperazine (BZP) and khat (Catha edulis) plant 
 material.
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Task Force reconvened in October to discuss develop-
ments over the previous six months. Numerous special 
alerts were communicated by the Board in 2014, provid-
ing Project Ion focal points with relevant information for 
possible operational follow-up. As at 1 November 2014, 
more than 100 Governments and international agencies 
had established focal points to receive, disseminate and, 
where appropriate, act on such communications.
254. The United States, a significant market for new 
psychoactive substances, has been active in both emer-
gency scheduling and supporting international efforts to 
stop trafficking in such substances. In May 2014, the 
Drug Enforcement Administration, along with numerous 
federal and international agencies, announced the results 
of phase II of Project Synergy, an ongoing special oper-
ation targeting the global market for new psychoactive 
substances. Phase II, which lasted five months, resulted 
in the arrest of 150 persons and the seizure of hundreds 
of thousands of retail packages containing new psycho-
active substances, hundreds of kilograms of raw synthetic 
substances and more than $20 million in cash and assets. 
Although many substances seized were not specifically 
prohibited under domestic legislation, the Controlled 
Substance Analogue Enforcement Act allowed many of 
them to be treated as controlled substances if they were 
proven to be chemically and pharmacologically similar 
to controlled substances.
255. In June 2014, WHO convened the thirty-sixth 
meeting of its Expert Committee on Drug Dependence 
to advise it on the scientific assessment of substances for 
possible international control. The Committee reviewed 
26 non-scheduled substances, which included 4-methyl-
methcathinone (mephedrone) and other new psychoac-
tive substances. To improve efficiencies in the review 
process, strategies for assessing chemically similar sub-
stances with similar properties were also discussed at the 
meeting.
256. According to the relevant provisions of the 
international drug control conventions, the recom-
mendations of WHO on the scheduling of substances 
reviewed by its Expert Committee in 2014 will be 
transmitted for the consideration by the Commission 
on Narcotic Drugs at its fifty-eighth session, to be held 
in March 2015.39
 39 See www.unodc.org/unodc/commissions/CND/Mandate_ 
Functions/Mandate-and-Functions_Scheduling.html.
5. International electronic import and 
export authorization system for narcotic 
drugs and psychotropic substances
257. Pursuant to the 1961 and 1971 Conventions, 
import and export authorizations are required for most 
narcotic drugs and psychotropic substances. A well- 
functioning import and export authorization system is 
essential to enable drug control authorities to monitor 
international trade in those substances and to prevent 
their diversion.
258. As part of its endeavours to harness technological 
progress for the effective and efficient implementation of 
the import and export authorization regime for licit inter-
national trade in narcotic drugs and psychotropic sub-
stances, the Board has spearheaded efforts to develop an 
electronic tool to facilitate and expedite the work of com-
petent national authorities and to reduce the risks of 
diversion of those substances. The new tool, called the 
International Import and Export Authorization System 
(I2ES), is a web-based electronic system developed by the 
Board in cooperation with UNODC and with the sup-
port of Member States. The system will assist national 
drug control authorities in their daily work by function-
ing in a way that ensures full compliance with the require-
ments set out in the international drug control conventions 
and safeguards the data therein. 
259. The Commission on Narcotic Drugs, in its 
resolution 55/6 of 16 March 2012, encouraged Member 
States to provide the fullest possible financial and 
political support for developing, maintaining and 
administering an international electronic import and 
export authorization system, and invited Member States 
and other donors to provide extrabudgetary contribu-
tions for those purposes. Subsequently, in its resolution 
56/7 of 15 March 2013, the Commission welcomed the 
voluntary financial contributions of a number of 
Member States to support the initial phase of develop-
ment of the system, invited the secretariat of INCB to 
administer the system, in line with its mandate, and 
encouraged Member States to provide the fullest pos-
sible financial support for its administration, further 
development and maintenance.
260. In the report of INCB for 2013, the Board 
informed Governments of the progress made in the 
development of I2ES40 and noted with appreciation the 
invaluable political and financial support provided by the 
inter national community to that effect. 
 40 See E/INCB/2013/1, paras. 198-203.
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261. A first prototype of I2ES was presented to Member 
States on the margins of the fifty-sixth session of the 
Commission, held in March 2013. In March 2014, the 
first operational version of the system was demonstrated 
to Member States during the fifty-seventh session of the 
Commission.
262. A second pilot phase, involving selected competent 
national authorities from all regions of the world, was to 
be conducted between November 2014 and January 2015. 
An assessment of the second pilot phase will be presented 
to Member States at the fifty-eighth session of the 
Commission. In March 2015, I2ES will be launched for 
use by competent national authorities.
263. I2ES is designed to complement, but not replace, 
existing national electronic systems. Specifically, it will 
serve as a platform for uploading and exchanging import 
and export authorizations between importing and 
exporting countries, and will be able to link with other 
national electronic systems so that Governments will not 
need to modify their own systems. For countries with-
out national electronic systems, the new tool also allows 
them to generate and transmit import and export author-
izations electronically and to download and print them 
as necessary. 
264. A key feature of I2ES is the automatic checking of 
the quantity of a substance to be imported and/or 
exported against the latest estimate or assessment of 
requirements of the importing country for the narcotic 
drug or psychotropic substance in question, and to auto-
matically display warning messages in cases involving 
excess imports or exports. Furthermore, the system pro-
vides an online endorsement function, which will allow 
the authorities of importing countries to verify the quan-
tity of a shipment arriving in their territory, provide an 
endorsement confirming receipt of the shipment to the 
authorities of the exporting country as required by the 
1961 Convention and the 1971 Convention, and alert in 
real time the competent authorities of the exporting 
country in all cases in which the quantity of a substance 
actually received in the importing country is smaller than 
the quantity authorized to be exported. All of those 
important features are designed to help Governments 
meet their obligations under the international drug con-
trol treaties and will enhance the monitoring of interna-
tional trade in substances under international control and 
prevent their diversion.
265. In developing I2ES, the Board has ensured that the 
business rules underlying the system fully comply with 
the relevant provisions of the 1961 and 1971 Conventions 
regarding import and export authorizations and, in par-
ticular, that the format and content of those authoriza-
tions meet the requirements provided for in the 
conventions. At the same time, the system takes into 
account the needs of countries that do not yet have 
national electronic import and export authorization sys-
tems. It has been designed to be user-friendly and com-
patible with national systems to ensure the smooth 
exchange of data. 
266. During the initial implementation phase, I2ES will 
enable Governments to meet their needs in respect of the 
running of the import and export authorization systems 
for narcotic drugs and psychotropic substances. The mod-
ular structure of I2ES should permit the future develop-
ment of additional modules, provided that sufficient 
funding becomes available. Of priority would be a mod-
ule to enable automatic, secure communication between 
national electronic systems and I2ES so as to allow auto-
mated uploading to and downloading from I2ES for high-
volume trade transactions. The I2ES software will be 
provided to Governments upon request and free of charge.
267. While it has been possible to successfully conclude 
the development phase of I2ES entirely out of extrabudg-
etary resources, further funding is required in order to 
enable the secretariat of INCB to administer the system 
in line with its mandate and in accordance with 
Commission resolutions 55/6 and 56/7, as well as for its 
maintenance and the possible future development of fur-
ther modules. 
268. The Board wishes to express its appreciation to all 
Governments that have provided suggestions and recom-
mendations concerning the system. The Board is con-
vinced that I2ES will succeed and be effective only 
through joint international efforts. Once in operation, it 
should bring long-term benefits to all Governments and 
to the international drug control system as a whole. The 
Board therefore invites all Governments to provide both 
political and financial support to this important initia-
tive. Most importantly, the Board wishes to encourage all 
competent national authorities to consider utilizing I2ES 
as soon as possible. Only through its early and wide-
spread utilization will Governments be able to fully 
 benefit from the advantages that the system provides.
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Chapter III.
Analysis of the world situation
HIGHLIGHTS
• Parts of Africa continue to face significant challenges related to tackling the increased abuse and production of 
major drugs of concern. Subregions of the continent have witnessed an increase both in seizures of cannabis 
resin and in trafficking in amphetamine-type stimulants.
• Central America and the Caribbean continue to be exploited by local and international organized criminal groups 
as a trans-shipment route for illicit drugs originating in South America and destined for North America and Europe. 
Drug abuse appears to be on the increase in many countries of the region. 
• In the united States, the results of ballot initiatives in the states of Alaska and Oregon, and in Washington D.C., 
on the use of cannabis for non-medical purposes represent further challenges to the compliance by the Government 
of the united States with its obligations under the international drug control treaties. 
• The global supply of cocaine originating in South America has been curtailed to an extent that can have a per-
ceptible effect on major consumer markets, where its availability remains lower than at the peak levels reached 
around 2006.
• The expansion of illicit markets for amphetamine-type stimulants remains the biggest concern in East and South-
East Asia.
• In South Asia, the rise in manufacturing, trafficking and abuse of methamphetamine, as well the diversion and 
abuse of pharmaceutical preparations containing narcotic drugs and psychotropic substances, remain among the 
greatest drug-related challenges in the region. 
• In West Asia, political instability and strife have led to a deterioration in the ability of several States to exercise 
effective control over their borders and territory, allowing drug traffickers to further exploit those situations. 
Sustained growth in opiate abuse and illicit opium cultivation in Afghanistan pose major challenges to the region.
• In Europe, the availability and abuse of new psychoactive substances remain a major public health challenge, 
with a record number of such substances being newly identified. The involvement of organized criminal groups 
in the manufacture and trafficking of new psychoactive substances has also been detected. Eastern and South-
Eastern Europe register significantly higher prevalence rates than the global average both for people who inject 
drugs and for people who inject drugs and are also living with HIV. 
• In Oceania, concerns persist about the expanding markets for new psychoactive substances and comparatively 
high rates of drug abuse.
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A. Africa
1. Major developments
269. Parts of the African continent continue to strug-
gle to overcome the effects of armed conflict, long-term 
instability and persistent threats to peace and security. 
The deteriorating political situation in some African sub-
regions has spurred increases in illicit drug trafficking, 
thereby worsening public health problems related to drug 
use. West Africa, for example, has seen more manufac-
turing and trafficking of methamphetamine, while an 
apparent rise in drug trafficking into and out of Liberia 
has led to increased concerns relating to national secu-
rity there. 
270. Cannabis remains a major illicit drug of concern 
in Africa, and its production, trafficking and abuse con-
tinue to present significant challenges. Despite eradica-
tion efforts, cannabis is illicitly cultivated throughout the 
continent. The illicit production of cannabis resin is 
limit ed to a few countries in North Africa. Morocco has 
remained the largest producer of cannabis resin on the 
continent, and one of the largest producers of cannabis 
resin in the world, notwithstanding the fact that produc-
tion in that country is reportedly declining. North Africa 
has witnessed an increase in seizures of cannabis resin 
and remains the subregion of Africa with the largest 
amounts of reported seizures of the substance. In addi-
tion to being abused locally, cannabis resin is smuggled, 
mainly to Europe. 
271. The trafficking of opiates through Africa has con-
tinued, owing to limited law enforcement capacity in the 
region. East Africa is increasingly being used as a tran-
sit route for heroin originating in Asia and bound for 
markets in South Africa and West Africa. Southern Africa 
continues to be a key link in the global transit of heroin 
and cocaine. The well-developed transportation infra-
structure in Southern Africa facilitated the shipment of 
cocaine and heroin in 2013, as evidenced by large  seizures 
of heroin in South Africa. 
272. New trends relating to trafficking in amphetamine-
type stimulants indicate a growing domestic market 
throughout Africa, as well as the smuggling of ampheta-
mine-type stimulants to East and South-East Asia and 
Oceania. Recent seizures in South Africa point to an 
increase in the manufacture of methamphetamine, along 
with the emergence of small-scale manufacture of meth-
cathinone. The clandestine manufacture of methaqualone 
in the region has continued, as indicated by large-scale 
seizures of relevant precursors in both Mozambique and 
South Africa. 
2. Regional cooperation
273. The African Union has been implementing its Plan 
of Action on Drug Control and Crime Prevention for the 
2013-2017 period, which provides a strategic framework 
to guide the development of drug policy. The priority 
areas of focus for 2013-2014 include: (a) implementing 
the African common position on controlled substances 
and access to drugs for pain management; (b)  imple-
menting continent-wide minimum quality standards for 
the treatment of drug dependence; (c)  adopting policies 
aimed at channelling confiscated proceeds from drug 
trafficking and related offences to support demand reduc-
tion and treatment programmes; (d) strengthening 
research on drug control and on the monitoring and eval-
uation of drug abuse and trafficking trends; and (e) facil-
itating  continent-wide training for the treatment of drug 
dependence.
274. The African Union, with the support of UNODC, 
has held expert group meetings on the Plan of Action on 
Drug Control in Southern Africa. A conference on devel-
oping and improving responses to counter drug traffick-
ing was organized in Harare at the end of 2013. The 
outcomes included a suggestion to establish a regional 
intelligence centre in Africa and to improve data collec-
tion and analysis in African countries. 
275. In recognition of the seriousness of drug-related 
problems in Africa, UNODC has continued to implement 
tailored programmes in the region, including the 
Container Control Programme, implemented jointly with 
the World Customs Organization (WCO); the regional 
programmes on drugs and crime for East Africa for the 
2009-2015 period; and the Airport Communication 
Project (AIRCOP). The Southern African Development 
Community (SADC), assisted by UNODC, is implement-
ing a regional programme for the 2013-2016 period enti-
tled “Making the SADC region Safer from Crime and 
Drugs”. Covering the 15 member States of SADC, the 
programme is designed to address concerns about the 
escalation of crime at both the national and transnational 
levels, particularly as the region develops ways to make 
cross-border movement easier.
276. The Economic Community of West African States 
(ECOWAS) has continued to implement its Regional 
Action Plan to Address the Growing Problem of Illicit 
Drug Trafficking, Organized Crime and Drug Abuse in 
West Africa, which in 2013 was extended until 2015. As 
part of this effort, the West Africa Coast Initiative, imple-
mented with the International Criminal Police Organization 
(INTERPOL), is targeting Côte d’Ivoire, Guinea, Guinea-
Bissau, Liberia and Sierra Leone. Since 2013, the Policy 
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Committee of the Initiative has adopted a new regional 
approach that puts more emphasis on regional coopera-
tion among law enforcement authorities. Joint operations, 
for example, have been conducted between the police 
forces of Liberia and Sierra Leone.
277. The West Africa Commission on Drugs, a private 
non-governmental initiative which has brought together 
distinguished West Africans through the Kofi Annan 
Foundation, published a report in June 2014 on the con-
sequences of West Africa’s status as a new hub for global 
drug traffickers. While emphasizing that drug use is a 
public health issue rather than a criminal justice matter, 
the Commission has recommended more effective inte-
gration of counter-narcotics efforts into efforts to prevent 
corruption and money-laundering in the region. 
278. At the sixth session of the African Union 
Conference of Ministers for Drug Control and Crime 
Prevention, held in Addis Ababa from 6 to 10 October 
2014, the ministers assessed the progress in implemen-
tation of the African Union Plan of Action on Drug 
Control (2013-2017). A keynote statement by the presi-
dent of the International Narcotics Control Board empha-
sized the need to: (a) increase capacity to prevent and 
treat drug addiction, and to rehabilitate persons affected 
by drug abuse; (b) ensure adequate availability of con-
trolled substances for medical purposes; and (c) further 
train health-care professionals and competent authorities 
in the treatment, aftercare, rehabilitation and social rein-
tegration of persons affected by drug abuse.
3. National legislation, policy and 
action
279. An important component of investigating and 
combating illicit drugs is the strengthening of legislation 
and national capacities for implementation. The legal 
framework in place throughout much of Africa, however, 
does not match the urgency of rising drug use on the 
continent and its continuing status as a major transit and 
trafficking destination. In the past year, very few devel-
opments could be detected with respect to advancing 
national regulation and action.
280. South Africa adopted a national master plan on 
drugs for the 2013-2017 period, aimed at reducing the 
impact of substance abuse and at harmonizing and 
enforcing laws and policies. Moreover, the Drugs and 
Drug Trafficking Act of 1992 was amended in April 2014 
to classify as illegal the street-drug mixtures known 
locally as “nyaope” or “woonga” (which are comprised of 
mixtures of ingredients, mainly heroin and cannabis). 
Earlier, in March 2013, the Prevention of and Treatment 
for Substance Abuse Act of 2008 was promulgated. The 
Act promotes prevention, early intervention, community-
based interventions, aftercare services and reintegration 
in all nine South African provinces.
281. The Government of Ghana approved an amendment 
to the schedule of the Narcotic Drug (Control Enforcement 
and Sanctions) Law of 1990 to control certain new psycho-
active substances and other psychotropic substances, such 
as methamphetamine and its derivatives.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
282. Information regarding the cultivation, consump-
tion, production, manufacture and trafficking of narcotic 
drugs in Africa remains very limited.
283. North Africa continues to be the subregion with 
the largest amounts of seizures of cannabis resin, and, 
according to UNODC, the amounts have continued to 
increase. The largest seizures in the subregion were 
reported by Algeria, rising from 53 tons in 2011 to over 
211 tons in 2013, and Morocco, rising from 126 tons in 
2011 to 137 tons in 2012. In 2012, Morocco accounted 
for 11 per cent of global seizures of cannabis resin; in 
2013, it accounted for 12 per cent, according to prelimi-
nary figures. Other North African countries have also 
reported substantial seizures of cannabis resin. For exam-
ple, in 2013 Egyptian authorities seized over 84 tons of 
cannabis resin, 80 tons of which had been trafficked from 
Morocco on fishing boats.
284. At the same time, there are indications that the 
popularity of cannabis resin in Europe continues to 
decrease. According to UNODC, the amount of canna-
bis resin seized is now comparable to the amount of 
 cannabis herb seized, indicating an increased preference 
for cannabis herb in European markets, increasingly pro-
duced locally, over imported cannabis resin, primarily 
from Morocco, which continues to be the country of 
 origin of most of the cannabis resin seized in Europe.
285. Morocco remains the largest producer of cannabis 
resin on the continent, and cannabis herb continues to 
be cultivated in most African countries. The largest pro-
ducers in North and East Africa include Egypt, Ethiopia, 
Kenya, Morocco and the United Republic of Tanzania. In 
2013, Egyptian authorities seized over 212 tons of 
 cannabis herb.
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286. In most countries of Southern Africa, cannabis 
also continues to be produced and consumed locally, as 
well as trafficked to Europe on a small scale. Total sei-
zures of cannabis herb in South Africa in 2013 were esti-
mated at 196 tons by the South African Police Service. 
Most seizures occurred during the transportation of can-
nabis by road, while law enforcement at border posts each 
month seized approximately 100 kg of cannabis herb des-
tined for export, mainly to the United Kingdom. Southern 
African criminal groups are increasingly also engaged in 
the online sale of cannabis. 
287. Sierra Leone reported 17 cases and nearly 2 tons 
of cannabis herb seized in 2013, reflecting a growing con-
cern in that country regarding the cultivation of canna-
bis. Production of cannabis herb also continues to be an 
issue in Nigeria, where 205 tons of packaged cannabis 
herb were seized and 847 ha of cannabis plant were dis-
covered and destroyed.
288. Trafficking of heroin to and through East Africa 
has increased, as evidenced by large seizures reported by 
countries in the subregion. The coastlines of East Africa 
are seldom patrolled, making the subregion attractive to 
drug trafficking syndicates and vulnerable as a transit 
point for heroin shipments. Heroin originating in West 
Asia is trafficked through the subregion for onward traf-
ficking to South Africa and countries in West Africa. 
While heroin continues to be trafficked via air courier, it 
appears that maritime transport is becoming the pre-
ferred method of smuggling the drug. Between 2010 and 
2013, large seizures of heroin were reported by the 
Governments of Kenya and the United Republic of 
Tanzania, and totalled nearly 2 tons, including seizures 
made off the coast and inland. An additional 1 ton of 
heroin was seized in April 2014 by the Kenyan 
authorities. 
289. Countries in North Africa also reported significant 
seizures of heroin. According to national data provided, 
seizures of heroin in Egypt increased from nearly 75 kg 
in 2012 to 260 kg in 2013. The amount of heroin transit-
ing West Africa, largely via commercial air carriers, has 
continued to increase. Ghana and Nigeria have generally 
seen the most regular detections and seizures of medium-
sized shipments. There has also been a growing trend of 
heroin trafficking to and through Liberia, with a consid-
erable number of people involved currently serving as per-
sonnel of the military and police forces. This is supplemented 
by a growing domestic consumer market in Liberia. 
290. In Southern Africa, there has been an increase in 
trafficking of heroin by means of international mail and 
parcel services. In the past year, concealment methods 
have diversified and become more sophisticated. 
Development of new harbours such as Port Ngqura, and 
the expansion of existing ones such as Durban, both in 
South Africa, continue to be tested by traffickers as 
 possible entry points for drugs into Southern Africa. 
Nationals of Southern African countries continue to be 
detained as suspected drug couriers in South and South-
East Asia and South America. Women, especially those 
from low-income backgrounds, continue to be vulnera-
ble to recruitment as drug couriers. 
291. Seizures of cocaine reported by countries in East 
Africa have increased, notably in the United Republic of 
Tanzania. According to UNODC, it is estimated that 
cocaine worth $160 million is abused in Kenya and the 
United Republic of Tanzania annually. From 1 January 
2009 to 31 August 2014, the Tanzanian authorities seized 
more than 459 kg of cocaine and arrested more than 2,000 
persons. In December 2013, the Secretary-General of the 
United Nations cited UNODC figures showing that the 
estimated value of cocaine trafficked through West Africa 
and the Sahel had reached around $1.25 billion annually.
(b) Psychotropic substances
292. There are indications that the abuse of ampheta-
mine-type stimulants in Africa is on the rise, although 
comprehensive and current data for all countries in the 
region are not available.
293. In a worrying development, trafficking of ampheta-
mine-type stimulants through East Africa (e.g. Ethiopia and 
Kenya) for onward shipment by plane to East and South-
East Asia has continued. In 2012 and 2013, for example, 
the authorities of Kenya reported numerous  seizures of 
amphetamine-type stimulants, destined mainly for Japan 
and Malaysia, at the international airport of Nairobi. 
294. Large-scale seizures of methaqualone and its pre-
cursors continue to be made in Mozambique and South 
Africa. Over 3 tons of methaqualone were seized in 
Johannesburg, South Africa, in March 2014. In addition, 
recent seizures in northern Mozambique have included 
605 kg of N-acetylanthranilic acid, a precursor used in 
the illicit manufacture of methaqualone. The drug is 
believed to be manufactured for local consumption in 
Southern Africa, predominantly in South Africa. 
(c) Precursors
295. In 2013, the Governments of Kenya, Libya, Sierra 
Leone and Zimbabwe invoked their right, under article 12, 
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paragraph 10 (a), of the 1988 Convention and now require 
pre-export notification for all substances listed in Table I 
and Table II of the 1988 Convention, including for 
pharma ceutical preparations containing ephedrine and 
pseudoephedrine and for safrole-rich oils. As at 1 July 
2014, 14 out of 54 African countries had invoked arti-
cle 12,  paragraph 10 (a).
296. Africa continues to be affected by trafficking in 
precursor chemicals, notably ephedrine and pseudo-
ephedrine, used in the illicit manufacture of ampheta-
mine-type stimulants. According to information provided 
through PICS, the following African countries have been 
identified as having been involved in incidents reported 
since December 2013: Ethiopia, Kenya, Malawi, 
Mozambique, Nigeria, South Africa, United Republic of 
Tanzania and Zimbabwe. In 63 per cent of the cases 
reported during the period under review, African 
 countries, namely Ethiopia, Malawi and South Africa, 
were mentioned as destination countries for ephedrine 
and pseudoephedrine shipments originating in India. 
There has also been a marked increase in the diversion 
of precursors for manufacture of amphetamine-type 
 stimulants to West Africa. Only nine countries in Africa 
have registered with PICS so far. The Board calls on all 
Governments in the region to register with PICS in order 
to increase and facilitate the sharing of information 
related to the diversion and trafficking of precursors. 
(d) Substances not under international 
control
297. The abuse of tramadol, a prescription opioid not 
under international control, continues to raise concern in 
a number of African countries, notably in North Africa. 
In 2013, tramadol was placed under national control in 
Egypt, where the abuse of the substance was widespread. 
According to data provided by the Egyptian authorities, 
seizures of tramadol decreased from 650 million tablets 
in 2012 to 27 million tablets in 2013. This downward 
trend is reportedly attributed to the new stringent meas-
ures in place regarding the substance. Reportedly, the 
abuse and trafficking of tramadol have also recently been 
increasing in Libya. In addition, Nigeria has reported 
abuse of tramadol and has now scheduled it as a con-
trolled medicine.
298. Information regarding trafficking and abuse of new 
psychoactive substances in North and East Africa is lim-
ited. However, the prevalence of such substances in Africa 
seems to be lower than in other regions. Only 11 African 
countries reported the emergence of new psychoactive 
substances between 2008 and 2013.
299. Use of khat (Catha edulis), a plant-based substance 
not under international control, remains highly prevalent 
in some African countries and among communities of 
expatriates from those countries. Khat is cultivated in East 
Africa, predominantly in Ethiopia and Kenya, where its 
abuse is also widespread. Despite the health risks  associated 
with chewing the mildly hallucinogenic psychostimulant 
leaves, khat is consumed widely in the region, in  particular 
in Djibouti, Ethiopia and Somalia, and to a lesser extent 
in Madagascar. In addition, the substance is increasingly 
being exported or smuggled to other countries and regions 
to supply expatriate communities, mainly those from 
Ethiopia, Kenya, Somalia and Yemen. 
300. Concerns about the harm associated with khat, and 
the combination of khat with other substances, have led to 
its control in Eritrea, Madagascar, Rwanda, the Sudan and 
the United Republic of Tanzania. Nevertheless, seizures of 
khat in Africa have remained relatively low, which could 
be attributed to the fact that the substance is still legal in 
countries such as Djibouti, Ethiopia, Kenya and Somalia. 
According to UNODC, since 2004 reported seizures of 
khat in Africa have ranged between 1 and 10 tons per year.
301. Burkina Faso has reported the abuse of datura, a 
plant containing a combination of anticholinergic sub-
stances. Young people in Burkina Faso commonly ingest 
datura as a tea infusion. 
5. Abuse and treatment
302. Many countries in Africa lack the capacity and sys-
tems for monitoring drug abuse and collecting and ana-
lysing drug-related data. Therefore, assessing the extent 
and patterns of drug abuse in the region, including accu-
rate prevalence rates, remains a challenge for competent 
national authorities. Furthermore, national health-care 
systems are often inadequate and do not meet the needs 
of local populations with regard to the treatment and 
rehabilitation of drug-dependent persons. In some cases, 
such facilities are non-existent or depend on assistance 
from international or non-governmental organizations. 
303. Some countries in the region have taken concrete 
steps to improve national systems for the treatment of 
drug dependence. For example, such treatment has 
improved in Ethiopia, Kenya, Mauritius, Senegal, 
Seychelles and the United Republic of Tanzania, largely 
as a result of capacity-building and skills development 
initiatives. Better capacity to handle drug treatment has 
also been reported by Burundi, Eritrea and Madagascar. 
In Africa, the prevalence of HIV among people who 
inject drugs is 12.1 per cent.
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304. Eritrea has conducted its first workshop on drug 
counselling, while the national drug observatory of 
Kenya, which collects and analyses health and law 
enforcement data, has published two reports on the sub-
ject. A feasibility study to establish a similar national drug 
observatory in the United Republic of Tanzania has been 
conducted.
305. The Government of Kenya was planning to initi-
ate by the end of 2014 a national programme on meth-
adone treatment for opiate users. The aim of this initiative 
is to increase the quality of life of heroin users and pre-
vent new HIV and hepatitis infections among those who 
inject heroin. In Kenya, the Ministry of Health has devel-
oped and published a national policy for HIV prevention, 
treatment and care for people who inject drugs. According 
to the information available to the Board, there are nearly 
50,000 persons who abuse drugs by injection in Kenya, 
with heroin being the primary drug of injection. 
306. The annual prevalence of cannabis use remains 
high in many countries in Africa. Reportedly, about two 
thirds of persons who have registered to receive drug 
treatment in Africa have indicated cannabis as their pri-
mary drug of abuse. Prevalence of cannabis use in the 
adult population is highest in West and Central Africa, 
at about 12.4 per cent.
307. Although no comprehensive or robust nationwide 
surveys of drug-use levels have been conducted in any 
country in the Southern Africa subregion, there are indi-
cations from South Africa of an increase in the abuse of 
heroin, methamphetamine and methcathinone. Data 
from drug treatment centres in South Africa indicate a 
resurgence in methaqualone consumption and a decrease 
in cocaine consumption. 
308. In East and North Africa, amphetamine abuse has 
been reported only by Algeria, Egypt and Kenya. In 
Kenya, the lifetime prevalence of amphetamine abuse 
among secondary school children in Nairobi is 2.6 per cent. 
For other countries in the region, no recent data have 
been made available.
309. Nigeria saw an increase in cocaine and heroin 
abuse in 2013. Preparations for a national drug use sur-
vey, along with the design of a national drug monitoring 
system, commenced in Nigeria in that year. Drug law 
enforcement agencies from Togo have reported a general 
trend of increased abuse of medicines containing psycho-
tropic substances, as well as of tramadol. 
310. Reporting from throughout Africa has further 
highlighted that young people comprise a significant 
proportion of drug users. In Benin, for example, 
45 per cent of drug users are young people, with an aver-
age age of 22 years. In 2014, Cameroon reported that 
there had been an average of 5,000 to 6,000 patients 
treated in the capital annually for diseases related to the 
abuse of narcotics and psychotropic substances, and that 
between 75 and 80 per cent of hospitalizations for drug 
abuse had been for individuals between 15 and 39 years 
of age. A significant number of countries throughout 
Africa also lack any specialized treatment facilities for 
drug dependence, including rehabilitation facilities, or do 
not have the institutions or the logistical capacity for 
treatment countrywide.
B. Americas
Central America and the Caribbean
1. Major developments
311. Owing to its geographical location and weak gov-
erning institutions, the Central America and the 
Caribbean region continues to be exploited by local gangs 
and international organized criminal groups as a transit 
and trans-shipment route for illicit drugs originating in 
South America and destined for consumer markets in 
North America and Europe. Local consumption of ille-
gal drugs also appears to be growing in many countries 
of the region. In addition, security challenges associated 
with the drug trade, including high levels of violence, 
money-laundering, corruption and other illicit activities, 
are pressing issues for countries of the region.
312. Costa Rica and Honduras continue to be primary 
trans-shipment points. The amount of cocaine trafficked 
through Central America has increased, particularly 
along the border between Guatemala and Honduras, fol-
lowing an intensification of drug law enforcement efforts 
in Mexico. 
313. It is estimated that more than 80 per cent of all 
cocaine trafficked to the United States transits the region. 
There is also an increasing trend of illicit drugs being 
produced in the region. Cannabis is produced mainly in 
small quantities for local consumption. Guatemala is a 
minor, but growing, producer of opium poppy. Regionally, 
there is an increasing trend with regard to the produc-
tion and trafficking of new psychoactive substances. 
Traffickers in the region are turning to the importation 
of non-scheduled precursor chemicals to manufacture 
methamphetamine through alternative methods to avoid 
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stricter regional control measures that have been in place 
since 2011.
314. As cocaine trafficking remains the most lucrative 
source of income for organized criminal groups in Central 
America, the intensified competition in such trafficking 
has increased the level of violence in the region. The most 
recent wave of violence is particularly affecting the north-
ern part of Central America: Belize, El Salvador, 
Guatemala and Honduras. The homicide rate in Honduras 
continues to be one of the highest on record. The areas 
of greatest concern with regard to violence lie along the 
Honduran coast, on both sides of the Guatemalan/
Honduran border, and in Guatemala along the borders 
with Belize and Mexico. 
315. Countries with extremely high homicide rates, 
such as El Salvador, Guatemala and Honduras, are also 
significantly affected in other ways by drug trafficking 
through their territories. It is believed that the drug prob-
lem has contributed to high levels of street violence and 
drug-related corruption, which have further overloaded 
the criminal justice system. It is estimated that more than 
900 gangs, called “maras”, with a total of over 70,000 
members, are active in Central America. In El Salvador, 
Guatemala and Honduras, 15 per cent of homicides are 
gang-related, with significant ties to drug trafficking 
activities.
316. The Board takes note of recent discussions and 
debates within the region about how to tackle the chal-
lenges and consequences of illicit manufacture, traffick-
ing and abuse of drugs. These discussions and debates, 
significantly, have taken place under the aegis of the 
Organization of American States (OAS) and have sought 
to identify alternative methods of dealing with the chal-
lenge of illicit drug manufacture, trafficking and abuse. 
A significant driver of this debate is the quest for poli-
cies that would contribute to reducing crime, violence 
and corruption in the region. The Board wishes to under-
line that all such proposals must also be measured against 
their consistency with the international drug control trea-
ties to which all States of the region are parties. 
2. Regional cooperation
317. In April 2014, the UNODC regional programme 
for 2014-2016 in support of the Caribbean Community 
(CARICOM) crime and security strategy was launched. 
The programme has been developed in close collabora-
tion with the CARICOM secretariat, the CARICOM 
Implementation Agency for Crime and Security, the 
Regional Security System, the Caribbean Aviation Safety 
and Security Oversight System and member States in the 
region. It covers the fields of: (a) countering transnational 
organized crime, illicit trafficking and terrorism; (b) coun-
tering corruption and money-laundering; (c) preventing 
crime and reforming criminal justice systems; (d) drug 
use, prevention and treatment, and HIV/AIDS; and 
(e)  research, trend analysis and forensics. 
318. In April 2014, the Proceeds of Crime Conference 
took place in Dominica. The Conference was attended by 
financial investigators and prosecutors from 17 jurisdic-
tions in the eastern Caribbean.
319. The 2014 Trade Winds exercise was held in Antigua 
and Barbuda in June 2014. The Maritime Interdiction and 
Prosecution Summit took place in August 2014, bringing 
together maritime law enforcement personnel, land-
based police investigators, prosecutors and judges to 
improve regional coordination and national cooperation 
with regard to standardizing evidence collection proce-
dures and documenting investigative techniques.
320. In July 2014, the thirty-fifth regular meeting of the 
Conference of Heads of Government of the Caribbean 
Community took place in Antigua and Barbuda. The 
Heads of Governments agreed to establish a regional 
commission on cannabis to conduct an enquiry into the 
social, economic, health and legal issues surrounding 
cannabis use in Central America and the Caribbean and 
to advise on possible changes in the current drug classi-
fication of cannabis. 
321. In September 2014 in Guatemala City, the forty-
sixth special session of OAS brought together officials 
from the 35 members of the Organization to discuss 
counter-narcotics policies. During that session, the 
General Assembly of OAS adopted a resolution entitled 
“Reflections and guidelines to formulate and follow up 
on comprehensive policies to address the world drug 
problem in the Americas”, in which it recognized the 
importance of implementing the three United Nations 
conventions on drugs, which constituted the international 
system’s drug control framework, as well as the need for 
States to consider regularly reviewing the drug policies 
adopted, ensuring that they were comprehensive and 
focused on the well-being of the individual, in order to 
address their national challenges and assess their impact 
and effectiveness.
322. During 2014, the Caribbean Criminal Assets 
Recovery Programme provided support through “live 
case” mentoring to enhance the capability of financial 
intelligence units, financial investigators, prosecutors and 
the judiciary/magistracy in dealing with asset recovery, 
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cash seizures and money-laundering cases. The objective 
of this programme is to build capacity to combat serious 
organized crime, particularly drug trafficking, by fully 
utilizing the proceeds of crime and money-laundering 
legislation.
3. National legislation, policy and 
action
323. In November 2013, a seminar organized by the 
Interior Ministry of Costa Rica on the prevention of 
diversion of drug precursors in the Latin America and 
Caribbean region took place. Participants included the 
Drugs Police and the Financial Inspectorate, the Analytical 
Chemistry Department, the Forensic Science Department, 
the Judicial Investigation Department, the Joint Monitoring 
Unit of the Container Control Programme, the Prison 
Police Dog Unit, the Airport Police, the Aerial Surveillance 
Service, the Ministry of Justice Dog Unit and the 
Precursor Monitoring and Inspection Unit.
324. In February 2014, Costa Rica reported having 
adopted in 2013 Act No. 9161, which is a comprehensive 
amendment of Act No. 8204 on Narcotic Drugs, 
Psychotropic Substances, Illicit Drugs, Related Activities, 
Money-Laundering and the Financing of Terrorism. The 
amendment introduces legal tools and mechanisms to 
facilitate the management and disposal of assets seized in 
cases involving drug trafficking and organized crime.
325. In Barbados, the National Anti-Drug Plan for 
2014-2018 was prepared in 2013 and was expected to be 
approved in late 2014. The Barbados Drug Information 
Network has been established, along with a drug obser-
vatory, with the support of OAS, to further facilitate 
improvement of data collection and evaluation of drug-
related information and statistics.
326. In Grenada, the Integrity in Public Life Act was 
adopted in 2013. The new law requires all public serv-
ants to report their personal income and assets. In addi-
tion, Grenada has adopted the Protection of Witnesses 
Act 2014, along with legislation recognizing the 
International Criminal Court, and a new code for 
prosecutors. 
327. Jamaica has considered amendments to current 
legislation to allow for possession of up to 57 g of can-
nabis for personal use other than for medicinal purposes. 
Adoption of the amendments would be followed by the 
issuance of a legal and regulatory framework ensuring the 
conformity of the amendments with the country’s obliga-
tions under the international drug control conventions. 
Possession of two ounces (57 g) or less of cannabis would 
become a non-arrestable infraction, subject to a mone-
tary penalty which would not give rise to a criminal 
record. Furthermore, the offender would be referred to a 
drug treatment and rehabilitation programme.
328. El Salvador continues to implement its national 
anti-drug strategy for the period 2011-2015. The princi-
pal aim of that strategy is to reduce abuse of drugs and 
to combat illicit drug trafficking and drug-related crime. 
The strategy has a plan of action that is based on national 
and international drug control tools, such as the hemi-
spheric strategy for countering drugs of the Inter-
American Drug Abuse Control Commission (CICAD) 
of OAS.
329. In El Salvador, the Police Intelligence Centre and 
the Cybercrime Unit of the Investigations Division were 
working closely with UNODC to provide training work-
shops on criminal analysis. Furthermore, the Santo 
Domingo Pact-Central American Integration System-
UNODC mechanism is supporting the National Civil 
Police of El Salvador and the Judiciary Investigation 
Agency of Costa Rica with regard to strengthening their 
capacities to fight organized crime.
330. In Panama, national institutions continued the 
process of strengthening and/or restructuring their 
national intelligence systems. The National Directorate 
of Police Information, with support from UNODC, was 
strengthening its institutional development plan, enti-
tled Plan Orion, whose main objective was to optimize 
the capabilities of the Directorate with regard to the pro-
duction of intelligence on criminal targets that threaten 
public safety.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
331. Jamaica remains the largest illicit producer and 
exporter of cannabis herb in Central America and the 
Caribbean, accounting for approximately one third of 
cannabis herb produced in the Caribbean. Increased pro-
duction of the drug has been noted in other countries, in 
particular Dominica and Saint Vincent and the Grenadines. 
Jamaica has also become a hub for the trafficking of 
cocaine, owing to the displacement of trafficking routes 
as a result of the strengthening of drug trafficking coun-
termeasures in Latin America. Compounding the prob-
lem is the fact that Jamaican criminal groups are using 
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the elaborate networks originally established to traffic 
cannabis to traffic cocaine as well.
332. In Jamaica, drug trafficking takes place at airports 
(via drug couriers, baggage and air freight) and at sea-
ports (via containers, cargo vessels, underwater canisters 
attached to ship hulls, fishing vessels and speedboats). 
Illicit drugs are traded for money, guns and other goods, 
and much of the proceeds are used to foster criminal 
activities. The ports of Kingston and Montego Bay, which 
are used for the bulk movement of containerized ship-
ments of cannabis herb and cocaine to Europe and North 
America, continue to experience serious issues involving 
corruption, violence, intimidation and the circumvention 
of legal controls. In addition, illicit drugs are often attached 
to the bottom of shipping vessels destined for Guyana, 
Suriname and Trinidad and Tobago. In 2013, Jamaica had 
the Caribbean’s second-highest reported murder rate 
(behind the much smaller Saint Kitts and Nevis), with 
1,197 homicides, up 9 per cent from 1,099 in 2012.
333. In 2013, the Government of Jamaica eradicated 
247 ha of cannabis plant, compared with 711 ha in 2012. 
The total area of cannabis plant cultivation in Jamaica 
was estimated at 15,000 ha, out of total arable land of 
approximately 120,000 ha. Statistics indicate that 
30,900 kg of cannabis were seized in 2013, compared with 
66,832 kg in 2012. Cannabis trafficking organizations in 
Jamaica focus on trafficking directly to Canada and the 
United Kingdom, as well as to the Bahamas, the Cayman 
Islands, the Dominican Republic and Haiti, for onward 
shipment to Europe and North America. There has also 
been a significant increase in shipments of cannabis herb 
to Barbados, Guyana, Suriname, Trinidad and Tobago, 
and Curaçao, in some cases in exchange for cocaine traf-
ficked back to Jamaica. Heroin and “ecstasy” have entered 
the Jamaican domestic market in small amounts only 
during the past few years.
334. With respect to cocaine, official statistics indicate 
that 1,230 kg of cocaine were seized in Jamaica in 2013, 
compared with 338 kg in 2012. Organized criminal groups 
from South and Central America and local groups con-
tinue to take advantage of the country’s weak State and 
police structures. Corruption, along with porous mari-
time borders, with isolated beaches and coastal villages, 
and the country’s status as a popular tourist destination 
and major container trans-shipment point, further facili-
tate the trafficking of illicit drugs between Jamaica and 
North America, Europe and elsewhere in the Caribbean.
335. Barbados is not a major producer of illicit drugs; 
however, cannabis cultivation has been found in sugar-
cane fields, gullies and enclosed yards near private 
homes. Cocaine continues to be trafficked using private 
boats, cargo vessels, yachts, fishing vessels and “go-fast” 
boats. Shipments of illicit drugs may be transferred at 
sea at predetermined Global Positioning System (GPS) 
 coordinates for retrieval by local vessels at sea. The 
 shipments are later unloaded on deserted beaches in 
Barbados. The majority of cocaine is believed to be 
sourced from Colombia, trafficked through the Bolivarian 
Republic of Venezuela, Trinidad and Tobago and/or 
Guyana before entering Barbados, and then further 
 trafficked to Europe and/or North America. There are no 
reports of production, trafficking or consumption of 
methamphetamines or other designer drugs.
336. According to the Caribbean Human Development 
Report of the United Nations Development Programme, 
Barbados is one of two countries (Suriname being the 
other) out of seven countries surveyed41 where the 
 homicide rate, including gang-related killings, has not 
increased substantially in the past 12 years.
337. Belize is a trans-shipment country for cocaine and 
precursor chemicals used in the production of illegal 
drugs, including synthetic drugs. In 2012, Belizean 
authorities seized and destroyed 19.1 tons of cannabis, 
156 tons of precursor chemicals, 114.9 kg of cocaine, 
1.4  kg of “crack” cocaine and 4.9 kg of crystalline 
methamphetamine. 
338. The Dominican Republic continues to be an 
important transit point for cocaine being trafficked from 
South America, particularly Colombia and Venezuela 
(Bolivarian Republic of), to the continental United States, 
Puerto Rico, Canada and Europe. In 2013, Dominican 
authorities seized approximately 10 tons of cocaine, 60 kg 
of heroin and 1.3 tons of cannabis; they also dismantled 
a drug distribution laboratory.
339. Nicaragua is part of a major route for the traffick-
ing of cocaine from South America to the United States. 
Nicaragua’s poor economy, limited law enforcement capa-
bilities and border security, and sparsely populated 
regions provide an opportune environment for drug traf-
ficking organizations to transport drugs, weapons and 
cash, and to establish clandestine laboratories and ware-
house facilities.
340. Law enforcement entities in Trinidad and Tobago 
seized 110 kg of cocaine and 3.7 tons of cannabis between 
January and September 2013. A total of 328,600 mature 
cannabis plants were destroyed during the same period.
 41 The other five countries surveyed were Antigua and Barbuda, 
 Guyana, Jamaica, Saint Lucia and Trinidad and Tobago.
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341. Illicit cultivation of opium poppy in Central 
America is of increasing concern to Governments. 
Eradication reports suggest that such cultivation is 
increasing, in particular in Guatemala, which could pro-
vide a substitute for the declining production of opium 
in Colombia. Seizures of heroin also increased along 
Central American trafficking routes, indicating the like-
lihood of increased opium production and a greater 
 supply of heroin.
(b) Psychotropic substances
342. Manufacture of amphetamine-type stimulants is 
increasingly being reported by authorities in Central 
America. Illicit manufacture of amphetamine-type stimu-
lants has recently emerged in Belize, Guatemala and 
Nicaragua, countries with little or no previous history of 
such manufacture.
343. The non-medical use of pharmaceutical prepara-
tions containing stimulants is widespread in the region. 
Abuse of sedatives in the form of prescription medicines 
is a problem in Costa Rica and El Salvador. The sub-
stances are often obtained from pharmacies without a 
prescription or through the Internet. There are indica-
tions that there may be smuggling of such pharmaceuti-
cal preparations among the countries in the region.
(c) Precursors
344. Despite strengthened controls over precursors of 
amphetamine-type stimulants in the region, Central 
America continues to be affected by trafficking in precur-
sors, particularly non-controlled chemical substances, 
such as pre-precursors and made-to-order chemicals, 
which are not controlled under the 1988 Convention. 
This poses new challenges to regulatory and law enforce-
ment authorities, which have to identify which chemicals 
are being used in the production processes. For example, 
Mexican authorities have seized large amounts of methyl-
amine, a substance not under international control which 
is used in the illicit manufacture of methamphetamine, 
bound for Guatemala. An attempt at trafficking of methyl-
amine from Mexico to Nicaragua was reported for the 
first time in 2013.
345. Large quantities of precursor chemicals used in the 
production of methamphetamine and other illicit drugs 
were believed to be transiting Belize en route to Mexico. 
Over 156 tons of precursor chemicals were seized and 
destroyed in Belize in June 2012 alone. In October 2012, 
5 kg of crystalline methamphetamine were seized by 
Belizean police near the border with Guatemala.
346. In 2013, 15 clandestine laboratories were dismantled 
in Guatemala. In 2014, the General Subdirectorate on Anti-
Narcotics Analysis and Information, part of the country’s 
national police force, shut down a laboratory. In addition, 
authorities found 92 barrels and 176 cans of precursor 
chemicals, sacks of caustic soda, propane gas, oxygen 
 cylinders, sacks of methamphetamines and paraphernalia.
5. Abuse and treatment
347. The development and successful implementation 
of initiatives for the prevention and treatment of drug 
abuse in Central America and the Caribbean are largely 
restricted by the limited resources and institutional capa-
city of countries in the region. Given those constraints, 
Governments have had to strike a balance between com-
peting developmental priorities and the need to adopt 
drug abuse prevention and treatment measures.
348. In Central America and the Caribbean, use of can-
nabis and cocaine remains high; with the exception of 
amphetamine-type stimulants, the use of other illicit sub-
stances remains low. The estimated average prevalence of 
cocaine in Central America and the Caribbean, at 
0.6 per cent and 0.7 per cent, respectively, is higher than 
the global average. As regards the use of opioids and 
“ecstasy” in the region, UNODC has estimated annual 
prevalence at 0.2 per cent and 0.1 per cent, respectively, 
values which are well below the global average.
349. Demand reduction education in schools in 
Barbados is supported by the Drug Abuse Resistance 
Education programme of the United States. The National 
Council on Substance Abuse sponsors a “Drugs decision” 
programme in 45 primary schools. In February 2014, the 
Government of Barbados launched a drug treatment 
court programme. However, the main challenge remains 
the limited availability of drug treatment options. 
Treatment and rehabilitation are available at two centres, 
although there is no minimum standard of care for 
 persons with problems related to drug abuse.
350. A national survey of drug use among secondary 
school students was carried out in Costa Rica in 2012. In 
total, 5,508 students in seven provinces were interviewed. 
According to the survey, the average age of initiation of 
cannabis use was 14.3 years. The results of the survey 
indicate a significant increase in cannabis use over the 
past three years.
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351. The Board recognizes that a central problem in 
the design of effective prevention and treatment pro-
grammes is that, throughout Central America and the 
Caribbean, there is a lack of capacity for collection of 
drug-related data and a lack of centralized agencies 
mandated to assess that information. Although the 
amount and the quality of information regarding drug 
abuse patterns in the region have greatly improved, more 
research on consumption patterns and trends is needed 
to tailor treatment initiatives to meet local needs. The 
Board reiterates the need for capacity-building in the 
field of treatment and rehabilitation of drug-dependent 
people in the region.
North America
1. Major developments
352. In North America, the social and human costs of 
drug abuse remain considerable. The region continues to 
have the highest drug-related mortality rate of any sub-
region in the world (142.1 per million inhabitants aged 
15-64 years). In the United States alone, the Centers for 
Disease Control and Prevention noted that drug overdose 
deaths, primarily related to prescription opioids, now 
outnumber homicides and road accident fatalities. In 
2011, an average of 110 people died in the United States 
per day as a result of drug overdoses.
353. The tightening of regulatory controls for the dis-
pensing of prescription opioids, coupled with efforts by 
pharmaceutical companies to develop tamper-proof for-
mulations of commonly abused drugs, is believed to have 
contributed to a major resurgence in heroin abuse in 
North America, following several years of declining 
prevalence.
354. On 1 January 2014, state-licensed cannabis retail-
ers in the State of Colorado began selling cannabis for 
non-medical purposes. In July, sales of cannabis for non-
medical use also began in the State of Washington. In 
November 2014, voters in the states of Oregon and 
Alaska, as well as in the District of Columbia, approved 
ballot initiatives on the non-medical use of cannabis in 
their respective jurisdictions. These developments have 
occurred despite a conflict with the Controlled Substances 
Act, a federal statute which prohibits cannabis produc-
tion, trafficking and possession and classifies cannabis as 
a substance having a high potential for abuse and no 
scientifically proven medical value.
355. In the United States, 23 states and the District of 
Columbia have now enacted legislation allowing for the 
creation of medical cannabis programmes and establish-
ing vastly divergent regulatory frameworks with respect 
to eligibility of patients, health conditions for which the 
medical use of cannabis is permitted, prescription and 
dispensing practices by health-care professionals and 
commercial production by licensed suppliers.
2. Regional cooperation
356. Regional cooperation between the three countries 
in the region is extensive and generally considered to be 
effective. It includes high-level political summits, joint 
action plans, intelligence-sharing, joint law enforcement 
activities and border control initiatives. The Inter-
American Drug Abuse Control Commission remains the 
main vehicle for cooperation.
3. National legislation, policy and 
action
357. In July 2014, the United States Administration 
released its National Drug Control Strategy for 2014, 
which seeks to emphasize public health approaches to 
addressing the country’s drug problem. The Strategy 
identifies abuse of prescription drugs and heroin as major 
challenges that warrant particular attention and sets forth 
measures intended to limit the public health conse-
quences of such abuse. The strategy continues the focus 
of the Administration on prevention and treatment, the 
further integration of substance abuse disorder treatment 
into health-care services, the reform of criminal justice 
policy, supply reduction initiatives, the strengthening of 
international partnerships and the improvement of data 
collection and analysis. The Strategy contains recommen-
dations aimed at continuing the focus of the Administration 
on reducing drugged driving and preventing and address-
ing prescription drug abuse. Reflecting new and emerg-
ing challenges, it includes, for the first time, new action 
items to address the growing threat posed by new psycho-
active substances, such as synthetic cannabinoids and 
synthetic cathinones, and contains enhanced measures 
aimed at combating transnational organized crime.
358. To address the growing problem of prescription 
drug abuse, the ongoing implementation of the National 
Anti-Drug Strategy in Canada was reinforced through the 
allocation of nearly 45 million Canadian dollars (Can$) 
over a five-year period in the federal budget for 2014. 
The funding will be used to develop public-awareness 
measures to educate Canadian consumers on the safe use, 
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storage and disposal of prescription medications, enhance 
prevention and treatment services in First Nations com-
munities, increase inspections to minimize the diversion 
of prescription drugs from pharmacies for illegal sale and 
improve surveillance data on prescription drug abuse in 
Canada.
359. In order to remove unused, unneeded or expired 
prescription drugs from circulation and reduce the poten-
tial for their non-medical use, Governments in the region 
have continued to stage prescription drug “take-back” ini-
tiatives. Another series of measures in the United States 
and Canada has been the creation of prescription drug 
monitoring programmes and the adoption of measures 
to promote the interoperability of those programmes 
among subnational jurisdictions. According to informa-
tion released by the Government of the United States, 
29  states have now taken measures to share information 
related to the prescription and dispensing of prescription 
drugs contained within their prescription drug monitor-
ing programmes.
360. In Mexico, the availability of narcotic drugs and 
psychotropic substances for medical purposes remains 
low, limiting access by patients having legitimate medi-
cal needs for the substances. The National Commission 
against Addictions, through a partnership with the 
Mexican Association for the Study and Treatment of Pain, 
has identified obstacles to the availability of narcotic 
drugs and psychotropic substances, including the follow-
ing: slow and complex administrative procedures for 
obtaining those drugs; inadequate training of public 
health professionals, leading to a reluctance to prescribe 
and dispense such substances; and the refusal by many 
doctors to accept the use of opiates as a treatment option. 
In order to address these challenges, the Government of 
Mexico is currently examining changes to its regulatory 
structure to remove undue impediments to the prescrip-
tion and dispensing of narcotic drugs and psychotropic 
substances for medical use and is working with doctors 
to develop an awareness-raising campaign for medical 
practitioners involved in the treatment of chronic pain 
and diseases requiring palliative care.
361. In July 2014, the United States House of 
Representatives adopted the Ensuring Patient Access and 
Effective Drug Enforcement Act of 2014, which would 
amend the Controlled Substances Act so as to improve 
enforcement efforts related to preventing the diversion 
and abuse of prescription drugs and to ensure that patients 
have access to needed medications by promoting collab-
oration between government agencies, patients and indus-
try stakeholders. In particular, in order to limit the 
negative effects on patients caused by the revocation or 
suspension of a drug registration by the Attorney General, 
the Act would provide that the registrant be informed of 
the grounds for the proposed revocation or suspension 
and be allowed an opportunity to take corrective action 
prior to the suspension or revocation being enforced.
362. In June 2013, the Government of Canada intro-
duced Bill C-65, entitled the “Respect for Communities 
Act”, which was aimed at creating a legal framework 
applicable to requests for exemptions under the Controlled 
Drugs and Substances Act that would allow for the estab-
lishment and operation of supervised drug injection sites. 
The bill outlined a set of minimum requirements for such 
applications, to be considered by the Minister of Health, 
including proof of extensive consultations among all rel-
evant stakeholders, such as community groups and law 
enforcement authorities. Given the adjournment of 
Parliament in August 2013, before the bill could be put 
to a vote, the Respect for Communities Act has been rein-
troduced for legislative consideration (as Bill C-2) and is 
currently under deliberation. Consideration of the legis-
lation is occurring as the public health authorities in sev-
eral Canadian cities consider submitting applications to 
the federal Minister of Health for the opening of “drug 
injection rooms”. The Board looks forward to a continu-
ing dialogue with Governments that have permitted such 
“drug consumption rooms” and reiterates its concern that 
such facilities could be inconsistent with the provisions 
of the international drug control conventions.
363. Citing a surge in heroin-related overdose deaths in 
the United States since 2006, which he termed “an urgent 
public health crisis”, the United States Attorney General 
announced that his department would be seeking to 
address the problem through a combination of enforce-
ment and treatment. In his statement, he emphasized that 
law enforcement efforts led by the Drug Enforcement 
Administration targeting heroin traffickers had led to an 
increase of more than 320 per cent in seizures along the 
United States-Mexico border between 2008 and 2013. 
While underscoring the importance of education, preven-
tion and treatment, he also called upon states to increase 
the access of first responders to overdose treatment drugs 
such as naloxone.
364. In May 2014, the Governor of the State of Minnesota 
signed a bill into law which establishes a medical canna-
bis programme, sets out the duties of patients, health-care 
practitioners and manufacturers of medical cannabis and 
defines qualifying medical conditions which may give rise 
to an authorization for admission to the programme, 
including cancer, severe or chronic pain, glaucoma, HIV, 
Tourette’s syndrome, seizures and muscle spasms. The law 
restricts the use of cannabis for medical purposes to 
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tablet, vapour and oil form or to “any other method, 
excluding smoking, approved by the commissioner [of 
health]”. Consumption of cannabis in leaf form in the state 
will continue to be prohibited. In July 2014, the Governor 
of New York state signed into law a bill which allows doc-
tors to prescribe cannabis for medical purposes, in non-
smokable form, to patients suffering from “serious 
conditions”, including cancer, HIV/AIDS, amyotrophic 
lateral sclerosis, Parkinson’s disease and spinal cord inju-
ries. In order to qualify to use cannabis for medical pur-
poses, patients suffering from an enumerated condition 
must be residents of New York state or be undergoing 
medical treatment in the state. In November, Florida vot-
ers rejected a constitutional amendment which would 
have allowed the establishment of a medical cannabis pro-
gramme in the state.
365. In California, the first state to create a medical can-
nabis programme, a bill is under consideration that 
would strengthen the weak regulatory framework govern-
ing medical cannabis in the state. The bill is aimed at fos-
tering greater certainty and minimum statewide standards 
regarding the obligations of medical cannabis facilities 
through the imposition and enforcement of regulations 
to prevent unlawful cultivation and the diversion of can-
nabis to non-medical use. Specific measures under con-
sideration include the creation of a bureau of medical 
cannabis regulation, which would be responsible for issu-
ing licences to individuals who grow, process, transport 
and sell the drug. Under the proposed bill, it would be 
illegal for doctors to prescribe medical cannabis to 
patients they have not themselves examined, and physi-
cians with a financial interest in a cannabis dispensary 
would be barred from issuing prescriptions for the drug.
366. In June 2014, the Government of Canada proposed 
additional changes to the Marihuana for Medical Purposes 
Regulations and the Narcotic Control Regulations. The 
amendments would require licensed producers of canna-
bis for medical purposes to regularly report to provincial 
and territorial medical and nursing licensing bodies con-
cerning which doctors and nurses are authorizing canna-
bis use and in what quantities. The aim of the reporting 
is to enhance oversight by regulatory bodies and to pro-
vide them with investigative and disciplinary powers. The 
Government of Canada has continued to reform the 
country’s legal and regulatory framework governing med-
ical cannabis, including through a shift away from pro-
duction for personal use to a production and distribution 
framework supplied solely by licensed commercial pro-
ducers. The new regulations had been scheduled to take 
effect on 31 March 2014; however, in late March 2014, 
the Federal Court of Canada issued an interlocutory 
injunction suspending the application of certain 
measures contained within them, including the phasing 
out of cultivation for personal use, pending the final out-
come of a legal challenge as to the constitutionality of the 
new regulations.
367. The Board reminds all governments in jurisdic-
tions that have established medical cannabis pro-
grammes, or that are considering doing so, that the 
Single Convention on Narcotic Drugs of 1961 as 
amended by the 1972 Protocol sets out specific require-
ments for the establishment, administration and moni-
toring of such programmes. Those requirements are 
discussed in greater detail in chapter II of the present 
report. The Board encourages governments to take 
action to ensure that their medical cannabis programmes 
fully implement the measures set out in the Single 
Convention, which are aimed at ensuring that stocks of 
cannabis produced for medical use are reserved for the 
patients to which they are prescribed and are not diverted 
into illicit channels.
368. In March 2014, the Council of the District of 
Columbia enacted the Marijuana Possession Decrimin-
alization Amendment Act of 2014, which came into force 
in July. The Act reclassifies possession of one ounce 
(28.35  g) or less of cannabis as a “civil violation” result-
ing in the imposition of a fine and the seizure of any can-
nabis and “paraphernalia visible to the police officer at the 
time of the civil violation”. Possession of amounts of can-
nabis greater than one ounce, the sale of any amount of 
cannabis to another person, operating a vehicle under the 
influence of cannabis and consuming cannabis in public 
continue to be classified as criminal offences and are sub-
ject to criminal penalties. In addition, given the contin-
ued prohibition of possession of any amount of cannabis 
under federal law, federal law enforcement officers may 
arrest anyone in the District of Columbia for possession 
or use of any amount of cannabis as a violation of federal 
law. In November 2014, voters in the District of Columbia 
approved Measure No. 71, which makes it lawful under 
District law for persons 21 years of age or older to pos-
sess up to two ounces (56.7 g) of cannabis for personal 
use, to grow up to six cannabis plants and to transfer with-
out payment up to one ounce of cannabis to another 
 person who is 21 years of age or older.
369. In Mexico, initiatives have been proposed by a 
major political formation—an opposition political party—
at the state and federal levels which would affect the legal 
status of cannabis in the country. At the federal level, a 
bill introduced in February 2014 sought to provide for 
the creation of a national medical cannabis programme. 
Another bill, introduced in the lower chamber of the 
national legislative branch in May 2014, proposed the 
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legalization and regulation of a non-medical cannabis 
market. In the Federal District of Mexico, a bill intro-
duced in February 2014 also would have legalized the 
commercial sale of cannabis for non-medical purposes. 
Those measures were all defeated.
370. In February 2014, the Deputy Attorney General of 
the United States issued a memorandum for all state 
attorneys focusing on financial crimes associated with 
cannabis sales and providing guidance on the use of pros-
ecutorial discretion and the allocation of resources. That 
memorandum follows another memorandum issued by 
the Department of Justice in August 2013 that set out 
eight enforcement priorities with respect to cannabis, 
which included preventing distribution of cannabis to 
minors, preventing revenue from cannabis sales from 
going to criminal organizations and preventing state-
licensed activity from being used as a cover for illegal 
activity. The February 2014 memorandum instructs state 
attorneys that financial institutions intentionally provid-
ing services that involve the eight priorities listed in the 
August 2013 memorandum may be liable to prosecution. 
Also in February 2014, the United States Department of 
the Treasury issued its Guidance on Bank Secrecy Act 
Expectations Regarding Marijuana-related Businesses to 
establish conditions and provide guidance to financial 
institutions in the provision of banking services to can-
nabis-related businesses. The document lays out several 
measures that financial institutions should take with 
respect to such businesses so as to meet their Bank 
Secrecy Act obligations, particularly with regard to due 
diligence measures. This federal move enables cannabis 
entrepreneurs to use banking services.
371. In Mexico, the state of Morelos and the state of 
Mexico initiated the use of drug treatment courts in May 
and August 2014, respectively. These courts have been in 
operation in the state of Nuevo Leon since 2009. The 
courts are intended to foster treatment and rehabilitation 
of first-time offenders accused of minor offences in order 
to facilitate social reintegration. Two other states—
Chihuahua and Durango—are planning to introduce a 
similar system in the near future.
372. In July 2014, a federal grand jury in the United 
States approved the indictment of a major United States 
courier company for a variety of violations of federal 
law, including the Controlled Substances Act, relating 
to the widespread shipping and delivery of illegal and 
illegally distributed drugs sold by drug dealers and ille-
gal Internet pharmacies. The charges included conspir-
acy to distribute controlled substances, distribution of 
controlled substances and conspiracy to distribute mis-
branded drugs.
373. In April 2014, the Standing Committee on Health 
of the Parliament of Canada released a report on the 
Government’s role in addressing prescription drug abuse, 
which contained several recommendations addressed to 
Health Canada and the federal Government on dealing 
with the problem of prescription drug abuse in the coun-
try. Among the recommendations put forward were a 
review of the Controlled Drugs and Substances Act, to 
be carried out in consultation with stakeholders, to allow 
the Government to deal more effectively with prescrip-
tion drug abuse; a review of labelling regulations for pre-
scription drugs with a potential for addiction so as to 
better reflect their addictive properties; the development 
of national guidelines for the safe disposal of prescription 
drugs that contain controlled substances; the develop-
ment of public-awareness campaigns on the public health 
risks of prescription drug abuse; and an examination of 
the merits of tamper-resistant drug formulations in 
addressing prescription drug abuse. In June 2014, the 
Minister of Health of Canada announced plans to begin 
a public consultation process on proposals to regulate 
tamper-resistant properties for prescription drugs that are 
at a high risk of abuse.
374. In order to facilitate the provision of training in 
palliative care for front-line health-care providers, the 
Government of Canada announced in March 2014 that 
it would be investing Can$ 3 million in an initiative 
called “Building the future of palliative care together”, 
which is designed to equip more front-line health-care 
providers with the skills and knowledge they need to care 
for people with life-threatening conditions. The initiative 
also seeks to extend the reach of palliative care services 
to better meet the needs of Canadians living in rural or 
remote regions of the country, including aboriginal 
peoples.
375. In 2014, regulatory measures taken by the 
Governments in the region to stem the proliferation of 
new psychoactive substances have continued. In January 
2014, a decree came into force in Mexico amending the 
Health Act to classify mephedrone, piperazine, K2 (a syn-
thetic cannabinoid) and midazolam as psychotropic sub-
stances and to subject them to the national control 
measures applicable to that category of substances. As a 
result of the decree, the federal prosecution service can 
now investigate and prosecute unlawful conduct relating 
to the substances in question. In the United States, the 
Drug Enforcement Administration announced the tem-
porary placement of four synthetic cannabinoids into 
schedule I of the Controlled Substances Act and the final 
scheduling of 10 synthetic cathinones in the same sched-
ule. This action was based on a finding by the Deputy 
Administrator of the Drug Enforcement Administration 
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that the placement of those substances and their optical, 
positional and geometric isomers, salts and salts of iso-
mers into schedule I of the Act was necessary to avoid 
an imminent hazard to public safety.
376. In order to identify new drug trends and facilitate 
more timely and effective public health responses, the 
United States National Institute on Drug Abuse announced 
in July 2014 that it was developing the National Early 
Warning System. The focus of the project will be to iden-
tify new drugs as they emerge and to monitor new trends 
in the abuse of substances that are already known, facil-
itating timely responses to potential threats. In order to 
achieve this, an advisory board composed of leading sci-
entists, health-care practitioners and government officials 
will be created, a network to facilitate the sharing of 
information between these groups will be established, 
information collected through publications will be dis-
seminated, and social media will be monitored to gauge 
the extent and nature of emerging trends.
4. Cultivation, production, 
manufacture and trafficking 
377. According to drug seizure figures contained in the 
Illicit Trade Report of WCO for 2013, North American 
customs authorities reported the largest number of drug 
seizures of any region in the world, with 35,943 drug sei-
zures reported to WCO, through its Customs Enforcement 
Network, an increase over the 2012 figure of 29,712.
(a) Narcotic drugs
378. Following the adoption of stricter regulatory con-
trols on the prescription and distribution of synthetic opi-
oids, together with the shift to tamper-proof formulations 
for several commonly abused prescription opiates in 
order to render them more difficult to snort or inject, 
heroin abuse in the United States has seen a resurgence. 
Opiate-dependent drug users are increasingly turning to 
heroin, which is typically easier to source and cheaper 
than prescription opioids. Law enforcement authorities in 
the region have also identified significant increases in 
heroin purity. Increased demand for heroin has also been 
accompanied by the growing availability of the drug in 
the region, in particular in the United States. 
379. According to information provided by the 
Government of Canada to UNODC, Canada seized over 
39 tons of cannabis, 144 kg of heroin, 135 kg of opium 
(raw and prepared), 994 kg of cocaine, 34 kg of 
amphetamine, 220 kg of methamphetamine, 123 kg of 
“ecstasy”-type substances and over 10 tons of khat in 2013.
380. More than 81 per cent of opium seized in Canada 
in 2013 was found to have been produced in India, and 
68.6 per cent of opium seized was found to have trans-
ited the United Arab Emirates immediately prior to 
entering the country. In addition, 33.6 per cent of heroin 
seized was also found to have transited the United Arab 
Emirates immediately prior to entry. The majority of her-
oin seized was smuggled via air cargo, air passenger cou-
rier and by post. Shipments of opium and heroin were 
concealed in a variety of ways, including hidden in 
industrial parts, food shipments, picture frames, carpets 
and towels. 
381. Although seizures of cocaine fell by 44 per cent 
between 2007 and 2012 in North America, to 109 tons, 
they continue to be the largest outside the Andean region, 
ahead of seizures made in West and Central Europe 
(71  tons). The single largest cocaine seizures worldwide 
outside the Andean region are still reported by the United 
States (104 tons in 2012). Cocaine availability in the 
United States has been in decline since 2007, owing to a 
combination of factors, such as the success of supply 
reduction measures, conflict between and within Mexican 
trafficking networks and reductions in cocaine manufac-
ture in Colombia.
382. In contrast, the availability of cannabis in the 
region has continued to increase, driven by increased 
production in all three countries and tolerant policies in 
many states in the United States. Cannabis continues to 
be the most widely available and widely abused illicit 
drug in the region and is also the one that is most traf-
ficked between North American countries. According to 
the Drug Enforcement Administration, more than 1 mil-
lion kg of cannabis are seized annually along the United 
States-Mexico border. According to WCO, customs sei-
zures of cannabis in the United States in 2013 represented 
94 per cent of all seizures of the drug reported by cus-
toms authorities worldwide. Scientific analysis of canna-
bis herb seized in the region has also shown an increase 
in cannabis potency, with the percentage of THC in the 
United States having increased by 37 per cent between 
2007 and 2012.
383. Average THC content of non-domestic cannabis 
seized by the United States federal authorities increased 
by 75 per cent between 2003 and 2013 (from 7.2 per cent 
to 12.6 per cent). The overall increase in the THC con-
tent of tested cannabis was mainly the result of a grow-
ing proportion of seizures of high-THC-content cannabis 
containing sinsemilla, while the proportion of less potent 
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cannabis declined. The increases in the potency of both 
sinsemilla and “normal” cannabis were less pronounced 
(sinsemilla: 14.5 per cent in 2013, up from 14.0 per cent 
in 2003; “normal” cannabis: 6.7 per cent in 2013, up from 
5.6 per cent in 2003).
384. The Government of Canada reports large decreases 
in the trafficking of cannabis resin and in the number of 
cannabis plants seized in 2013. Whereas in previous years 
numerous large seizures of cannabis resin occurred at 
major seaports in eastern Canada, there was a limited 
number of seizures in 2013. In 2013, seizures of canna-
bis resin totalled 110.4 kg, down from over 1.6 tons in 
2012 and 4.8 tons in 2011. Law enforcement officials 
attribute this decrease to increased maritime seizures and 
law enforcement activities disrupting the operations of 
criminal organizations.
385. In 2013, Canada’s national eradication programme 
(Project SABOT), led by the Royal Canadian Mounted 
Police, seized over 42,000 plants from outdoor cannabis 
grow operations across the country, down from 63,000 
in 2012, 95,000 in 2011 and 171,000 in 2010. Officials 
attribute this decrease to the success of Canadian law 
enforcement activities and to the fact that Canadian 
organized criminal groups are relocating their operations 
to other more lucrative markets such as the United 
States, particularly to states in that country with more 
liberal cannabis laws and affordable real estate.
(b) Psychotropic substances
386. In 2013, the United States remained the country 
that had reported to WCO the largest number of ampheta-
mine seizures by customs and the largest quantities of the 
substance seized. Although the number of seizures rose 
from 220 in 2012 to 311 in 2013, the quantity seized 
decreased significantly, from 22.7 tons in 2012 to approx-
imately 1.9 tons in 2013. 
387. According to law enforcement officials in the 
region, methamphetamine manufacture has been on the 
increase, as reflected by higher seizure figures. According 
to UNODC, seizures of methamphetamine in North 
America in 2012 accounted for 64 per cent of the total 
amount seized worldwide; in the United States, almost 
13,000 methamphetamine laboratories were dismantled 
in 2012. Methamphetamine manufacture in Mexico has 
been increasing, with the United States continuing to be 
the largest market for the substance. Seizures of metham-
phetamine at the United States-Mexico border have also 
increased significantly, from just over 2 tons in 2008 to 
over 10 tons in 2012. According to the Drug Enforcement 
Administration, the greater availability of methampheta-
mine in the United States has led to a 70 per cent decrease 
in prices since 2007, while purity has increased by 
130 per  cent during that same period.
388. The most recent figures released by Governments 
in the region suggest that abuse of 3,4-methylenedioxym-
ethamphetamine (MDMA, commonly known as “ecstasy”) 
in the region is declining, although prevalence rates for 
“ecstasy” abuse remain more than twice the global aver-
age (0.9 per cent in North America as compared with 
0.4 per cent globally).
389. According to information provided for 2013 to 
UNODC by Canada, law enforcement officials noted a 
decrease in the amount of cocaine entering Canada com-
pared to previous years. The majority of cocaine seized 
was smuggled via air cargo, air passenger courier and by 
post, primarily entering the country from the Caribbean, 
Central and South America. Law enforcement officials 
also believe that cocaine is entering the country from the 
United States via land-based ports of entry in Ontario, 
Quebec and British Columbia.
390. In 2013, 40 per cent of methamphetamine seized 
was found to have transited the United States, while all 
34.7 kg of amphetamines seized were reported by 
Canadian officials to have transited China. 
(c) Precursors
391. Methamphetamine manufacture in the United States 
is dominated by small-scale street laboratories using 
 ephedrines and their preparations. However, more than 
95 per cent of the methamphetamine seized in the United 
States has been manufactured using the 1-phenyl-2- 
propanone (P-2-P) method. This type of methampheta mine 
is also illicitly manufactured in Mexico in industrial-type 
facilities from phenylacetic acid derivatives.
392. A detailed overview of the situation in North 
America with respect to the control of precursor chemi-
cals can be found in the 2014 report of the Board on the 
implementation of article 12 of the 1988 Convention.42
(d) Substances not under international 
control
393. As in other regions, the abuse of new psycho-
active substances has continued to gain momentum. In 
 42 E/INCB/2014/4.
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the United  States alone, there were 29,467 synthetic 
canna binoid drug reports in 2012 through the National 
Forensic Laboratory Information System, a 14-fold 
increase over 2009.
5. Abuse and treatment
394. A report issued by the United States Substance 
Abuse and Mental Health Services Administration in July 
2014 confirmed that initiation of substance abuse in ado-
lescence or early adolescence greatly increased the risk of 
developing drug dependency. According to data pre-
sented in the report, among individuals aged 18-30 years 
admitted for substance abuse treatment in the United 
States in 2011, 74 per cent had begun using substances 
at the age of 17 years or younger and 10.2 per cent had 
started using at the age of 11 years or younger. The study 
also showed a significantly higher rate of polydrug abuse 
among individuals admitted for treatment who had ini-
tiated substance abuse at age 11 years or younger 
(78  per  cent) compared with those who had initiated 
their substance abuse between the ages of 25 and 30 
(30.4 per cent). Among individuals having initiated abuse 
at the age of 11 years or younger, 38.6 per cent reported 
a co-occurring mental disorder.
395. According to figures released by the United States 
Department of Health and Human Services, past-year drug 
abuse among persons aged 12 years or older in the United 
States reached a 10-year high in 2012, mostly because of 
increased cannabis abuse, which rose from 11.5 per cent 
in 2011 to 12.1 per cent in 2012. As in previous years, 
increased cannabis abuse, particularly among young peo-
ple, has been linked to decreasing perceptions of risk. That 
has particularly been the case in the wake of the legaliza-
tion of non-medical use of cannabis in some states. Rates 
of non-medical use of psychotherapeutic drugs, including 
prescription opioids, rose from 5.7 to 6.4 per cent.
396. Figures released in the United States by the Drug 
Abuse Warning Network in June 2014 relating to emer-
gency department visits involving methamphetamine 
from 2007 to 2011 reveal a substantial increase, from 
67,954 visits in 2007 to 102,961 in 2011, with similar pat-
terns seen for males and females. According to the report, 
62 per cent of emergency department visits in 2011 
involving methamphetamine also involved other drugs, 
with 29 per cent of visits involving combinations with 
one other drug and 33 per cent involving combinations 
with two or more other drugs.
397. According to a study of data from the National 
Highway Traffic Safety Administration’s Fatality Analysis 
Reporting System for the period 1994-2011, undertaken 
by researchers at the University of Colorado School of 
Medicine, the proportion of drivers involved in fatal 
motor vehicle crashes in the State of Colorado who tested 
positive for cannabis has significantly increased since the 
commercialization of medical cannabis in 2009. The 
results of the analysis show that, while the percentage of 
fatal motor vehicle crashes in Colorado involving at least 
one driver testing positive for cannabis in 1994 was 
4.5  per cent, that figure had increased to 10 per cent by 
the end of 2011.
398. Several jurisdictions in North America have 
reported increases in overdose deaths related to changes 
in the chemical composition and potency of narcotic 
drugs sourced through the illicit market and to a resur-
gence of heroin abuse. In the state of Vermont, dispro-
portionately high increases in opioid drug and heroin 
abuse, drug overdose deaths and drug-related crime have 
been qualified by the Governor of Vermont as a “crisis”. 
Heroin overdoses in the state doubled between 2012 and 
2013, and admissions for opioid treatment have increased 
by 770 per cent since 2000, including a 250 per cent 
increase in the number of individuals receiving treatment 
for heroin addiction alone. There were also five times as 
many federal indictments against suspected heroin deal-
ers in the state in 2013 than there were in 2010.
399. In Canada, the Director of Public Health of 
Montreal issued an alert to public health practitioners in 
the city warning of a threefold increase in overdose 
deaths in the city related to heroin, cocaine and counter-
feit opioids caused by changes to the chemical composi-
tion of the drugs. Numerous overdose deaths in the 
region have also been attributed by public health author-
ities to counterfeit oxycodone tablets containing fentanyl, 
a highly potent narcotic drug.
400. According to information released by Health 
Canada in its Youth Smoking Survey 2012-2013, a bien-
nial survey that collects data from Canadian students 
between grades 6 and 12 (approximate ages 11-18 years) 
about alcohol, tobacco and illicit drug use, the main sub-
stances of abuse, after alcohol and tobacco, were canna-
bis and prescription pharmaceuticals. Cannabis was found 
to be the substance with the highest annual prevalence of 
use after alcohol, with one in five students  having reported 
using cannabis within the past 12 months.
401. According to the survey, 4 per cent of students 
reported having used at least one prescription pharma-
ceutical for non-medical purposes within the previous 
12 months. Among prescription pharmaceuticals included 
in the survey, opioid analgesics were found to have the 
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highest annual prevalence of use, at 3 per cent, although 
this figure represents a decrease from the 4 per cent 
observed in the 2010-2011 survey.
402. The 2012-2013 survey shows a decreasing trend in 
the annual prevalence of drug use for a number of sub-
stances. The prevalence rate for the use of “ecstasy” was 
found to have decreased from 5 per cent in 2010-2011 to 
3 per cent in 2012-2013. For both synthetic stimulants 
derived from piperazines and synthetic stimulants related 
to cathinones, the annual prevalence of use was found to 
be 1 per cent in 2012-2013. 
403. In terms of perceived drug accessibility, approxi-
mately 45 per cent of students in grades 7 to 12 (approx-
imate ages 12-18 years) reported that it would be “fairly 
easy” or “very easy” to obtain cannabis, while 33 per cent 
and 15 per cent reported that it would be “fairly easy” or 
“very easy” to obtain opioids and “ecstasy”/hallucinogens, 
respectively. 
404. Health Canada has identified three high-risk 
groups for drug abuse: homeless people, “street involved 
youth drug users” and recreational drug users (i.e., club, 
rave and bar attendees). In 2013, it conducted a survey 
establishing the annual prevalence of the most-used 
drugs within each high-risk group. Cannabis was found 
to have had the highest annual prevalence of use, with 
prevalence rates of 77 per cent among homeless people, 
and 89 per cent among each of the other two groups.
405. Mexico has continued to offer treatment for drug 
dependency through its network of addiction treatment 
centres known as “Centros Nueva Vida”, which are staffed 
by psychologists, medical doctors and social workers. The 
Government of Mexico has made significant investments 
in the training of staff at the treatment centres and in the 
recruitment of additional health professionals who are 
specialized in addiction treatment. The Government has 
also adopted quality control measures, such as a revision 
of the accreditation procedure for addiction treatment 
centres and evaluation visits aimed at assessing the treat-
ment given and the quality of the facilities. Based on the 
results of an analysis of the operation and performance 
of the treatment centres, the Government established a 
workplan for 2014 to strengthen existing administrative 
structures, improve processes for the administration of 
care and establish national standards to improve the qual-
ity and effectiveness of treatment. 
406. Cocaine abuse increased slightly in the adult popu-
lation of the United States in 2012, although it remained 
relatively stable among young people and declined mar-
ginally in 2013. Compared with 2006, annual prevalence 
of cocaine use among the general population fell by 
28  per  cent (from 2.5 per cent of the population aged 
12  years or older in 2006 to 1.8 per cent in 2012), while 
past-month prevalence fell by 40 per cent (from 1.0 to 
0.6  per cent). Annual prevalence of cocaine use among 
twelfth-grade students in the United States showed a 
decline of 54 per cent between 2006 and 2013 (from 
5.7  per cent to 2.6 per cent). Workforce testing results 
showed a decline of cocaine use of 70 per cent between 
2006 and 2012 (from 0.72 per cent in 2006 to 0.21 per cent 
in 2012). Those declines were mainly the consequence of 
reduced availability of cocaine. While perceptions of the 
harmfulness of cocaine use remained largely unchanged, 
the availability of cocaine was perceived to have declined.43 
This was the result of declining cocaine production in 
Colombia and intensified law enforcement efforts in 
Mexico. This led to higher purity-adjusted prices in the 
United States, which rose at the retail level by 54 per cent 
between 2006 and 2012 (from $121 to $186 per gram). 
Reduced availability and use of cocaine also resulted in a 
strong decline (56 per cent) in cocaine-related treatment 
admissions in the United States between 2006 and 2012 
(from 277,900 admissions in 2006 to 121,000 admissions 
in 2012).
407. Despite overall increasing drug abuse prevalence 
rates in the United States general population aged 
12 years or older, past-year use of any illicit drug among 
the population aged 12-17 years was the lowest in 
10  years, although it remained high, declining from 
19 per cent in 2011 to 17.9 per cent in 2012.
South America
1. Major developments
408. South America continues to be affected by the 
illicit cultivation of coca bush, cannabis plant and, in 
some countries, opium poppy, all of which are processed, 
usually in the country of cultivation, into the correspond-
ing plant-based drugs. Aside from being the source for 
virtually the entire supply of the world’s cocaine, the 
region has also come to account for a significant 
 43 According to the Monitoring the Future survey conducted by the 
National Institute of Drug Abuse in the United States, in 2006, 
46.5 per cent of twelfth-grade students reported that it was easy or fairly 
easy to obtain cocaine; that figure had fallen to 30.5 per cent in 2013. The 
perceived harmfulness of using cocaine regularly amounted to 
84.6 per cent of twelfth-grade students in 2006 and to 83.3 per cent in 
2013, and the perceived harmfulness of using cocaine once or twice 
amounted to 52.5 per cent in 2006 and to 54.4 per cent in 2013.
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proportion of global consumption of cocaine, including 
the smoking of “crack” cocaine and other base forms 
referred to by a variety of country-specific designations. 
Illicit use of cannabis and, to a lesser extent, ampheta-
mine-type stimulants also affect significant segments of 
the population in South America. The information 
 currently available indicates that illicit demand for 
 amphetamine-type stimulants is met mainly by traffick-
ing from outside the region, as well as by the diversion 
of prescription stimulants from the licit market.
409. Various indicators, notably the area under illicit cul-
tivation of coca bush, suggest that in recent years the global 
supply of cocaine originating in South America has been 
curtailed to an extent that can have a perceptible effect on 
major consumer markets. Based on data from UNODC, 
cultivation of coca bush peaked in 2007 in Colombia, in 
2010 in the Plurinational State of Bolivia and in 2011 in 
Peru. During the 2007-2013 period, the total area under 
cultivation for coca bush in those three countries fell by 
approximately one third. Although methodological issues 
limit the ability to quantify the production of coca leaf and 
the manufacture of cocaine at a global level, a decrease in 
the area under cultivation of this extent would be expected 
to have an impact on the accessibility of cocaine at the end 
of the supply chain. Indeed, indicators from North America 
and, albeit less clearly, from Western Europe suggest that 
availability remains significantly lower than during the 
peak levels reached around 2006.
410. The intensive discussions on drug policies that 
have recently taken place in the Americas, including in 
South America, continued in 2014. In June 2013, OAS 
adopted the Declaration of Antigua, Guatemala, “For a 
comprehensive policy against the world drug problem in 
the Americas”, initiating a process of consultation in var-
ious national and regional settings and encouraging the 
consideration of new approaches to the world drug prob-
lem. In June 2014, at the forty-fourth regular session of 
its General Assembly, OAS reaffirmed the commitments 
undertaken in that Declaration, while emphasizing that 
drug policies must be carried out with full respect for 
national and international law. Pursuant to provisions of 
the Declaration, a special session of the OAS General 
Assembly on the world drug problem was held in 
September 2014 in Guatemala City.
2. Regional cooperation
411. South America is characterized by a high level of 
awareness of the illicit supply of and demand for con-
trolled substances, in addition to a well-developed infra-
structure at the national and regional levels to monitor 
and counter this phenomenon. The high level of politi-
cal engagement in these areas is reflected in the large 
number of activities that bring together authorities, 
experts and institutions from the region to improve coop-
eration and exchange views on and experiences in law 
enforcement and the health-related aspects of drug con-
trol. The Board welcomes in particular the number of 
regional cooperation activities, including the provision of 
training and legal assistance, organized by the 
Governments of the countries in the region in coopera-
tion with CICAD and UNODC.
412. In 2013 and 2014, several of these activities empha-
sized aspects of drug supply reduction related to asset 
recovery, including non-conviction-based confiscation, 
financial intelligence and money-laundering. In 2013, a 
total of 19 courses and workshops were held under the 
auspices of CICAD on the handling and disposal of 
seized and forfeited assets, special investigation tech-
niques, strategic intelligence, investigations and simulated 
trials, in which around 800 officials from countries in the 
Americas participated. During 2013, UNODC and the 
Financial Action Group of South America44 organized the 
seventh and eighth meetings of the regional network on 
asset recovery with representatives from Latin American 
countries and international entities. The meetings were 
held in Colombia and Panama.
413. Other aspects that received reinvigorated attention 
dealt with efforts to combat trafficking in and diversion 
of precursors, maritime trafficking and abuse of smoka-
ble forms of cocaine.
414. In May 2014, high-level representatives from sev-
eral South American countries participated in the discus-
sions on drug policies at the first ministerial meeting of 
the Community of Latin American and Caribbean States 
on the world drug problem, held in Antigua, Guatemala.
415. In September 2014, at a special session, held in 
Guatemala City, the General Assembly of OAS adopted 
a resolution entitled “Reflections and guidelines to for-
mulate and follow up on comprehensive policies to 
address the world drug problem in the Americas”. In that 
resolution, the Assembly recognized the importance of 
effective implementation of the three United Nations 
drug control conventions, which constituted the frame-
work of the international drug control system, as well as 
the need for States to consider “regularly reviewing the 
drug policies adopted, ensuring that they are comprehen-
sive and focused on the well-being of the individual, in 
 44 Effective July 2014, the name of the group was changed to Finan-
cial Action Group of Latin America.
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order to address their national challenges and assess their 
impact and effectiveness”.
3. National legislation, policy and 
action
416. In March 2013, the Government of Peru approved 
a new regulation concerning chemicals, equipment and 
material used for the illicit manufacture of drugs, which 
had already been issued in a legislative decree in 
November 2012. The decree established measures for the 
registry, control and inspection of such goods.
417. Under the national strategy to combat drugs being 
implemented by Peru for the period 2012-2016, the erad-
ication of coca bush has intensified in the major coca-
growing regions of Huánuco and Ucayali. Peruvian 
authorities have proposed a new strategy, emphasizing 
the promotion of alternative crops while maintaining the 
eradication component, in order to reduce the level of 
cultivation in the third important zone: the Apurímac, 
Ene and Mantaro river valleys. 
418. Effective August 2014, Ecuador established a new 
system of categorization, in terms of maximum and min-
imum quantities, to classify offences related to trafficking 
in narcotic drugs and psychotropic substances into four 
degrees of severity and to prescribe minimum and max-
imum terms of imprisonment for each category. Although 
possession can qualify as an offence under the umbrella 
of trafficking-related activities, the quantities involved do 
not always constitute, by themselves, a means of distin-
guishing between trafficking and possession for personal 
use and consumption. Indeed, while the new regulation 
provides for punishment for trafficking offences involv-
ing arbitrarily small quantities (without a lower thresh-
old), it continues to differentiate between those offences 
and possession for personal use and consumption, which 
remains not punishable and restricted to certain indepen-
dently established maximum quantities, in accordance 
with an earlier regulation. 
419. In December 2013, the Senate of Uruguay approved 
new legislation, previously approved by the lower legisla-
tive chamber, that allows the State to assume control over 
and regulate activities related to the importation, produc-
tion, storage, sale or distribution of cannabis or its deriv-
atives, or the acquisition of any title related thereto, under 
certain terms and conditions, for the purpose of non-
medical use. The regulations governing the implementa-
tion of this law were fleshed out in a presidential decree 
in May 2014. Sales of cannabis to consumers were delayed, 
however, owing to difficulties in implementing the law. 
Such sales are expected to start in 2015. The Board notes 
that this legislation is contrary to the provisions of the 
international drug control conventions, specifically arti-
cle 4, paragraph (c), and article 36 of the 1961 Convention 
as amended by the 1972 Protocol and article 3, para-
graph  (1) (a), of the 1988 Convention.
420. In November 2013, the Government of the 
Plurinational State of Bolivia published the results of a 
study on the demand for coca leaf in that country, which 
estimated that licit national demand for coca leaf required 
a cultivation of 14,700 ha. Currently, Bolivian law pro-
vides for up to 12,000 ha of coca bush cultivation in cer-
tain areas of the country for the chewing of coca leaf and 
the consumption and use of coca leaf in its natural state 
for “cultural and medicinal purposes”, in accordance with 
the reservation expressed in 2013 when the country reac-
ceded to the 1961 Convention, as amended by the 1972 
Protocol.
421. In its strategic institutional plan for the 2013-2017 
period, the Paraguayan National Anti-Drug Secretariat 
set itself six main objectives, including the implementa-
tion of actions relating to integrated and sustainable alter-
native development. One proposed strategy to achieve 
that objective deals specifically with the cultivation of 
cannabis in the social and economic context of Paraguay. 
In addition, the National Anti-Drug Secretariat has made 
the elimination of the trafficking of cocaine paste one of 
its national priorities.
422. In response to a rebound in drug trafficking on 
non-commercial flights through Peruvian air space, the 
Peruvian Air Force is operating a non-lethal air traffic 
interdiction programme, with a view to dissuading pilots 
who are trafficking drugs from entering Peruvian terri-
tory. In April 2014, the Plurinational State of Bolivia 
promulgated a law which provides for the interception 
of and use of force against unauthorized flights. Similar 
laws are in force in Brazil, Chile and Venezuela (Bolivarian 
Republic of). The Board notes that such statutes may 
contravene the Convention on International Civil 
Aviation45 and other international obligations related to 
civil aviation.
423. In 2014, Brazil enacted new legislation to ensure 
the expeditious destruction of illicit crops and seized 
drugs, with the exception of small samples for forensic 
analysis and use in the criminal justice process. 
Discussions on other potential legislation with a possible 
impact on drug policy have also been initiated.
 45 United Nations, Treaty Series, vol. 15, No. 102.
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424. In 2014, the Government of Argentina created a 
new unit within the Ministry of Security specifically ded-
icated to the fight against drug trafficking, and trans-
ferred some aspects of the State’s drug supply reduction 
interventions from the Planning Secretariat for the 
Prevention of Drug Addiction and the Fight against 
Narcotrafficking to the Ministry of Security, including to 
the newly  created unit. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
425. In contrast with other illicit crops, no reliable esti-
mates of the total extent of illicit cultivation of cannabis 
in South America are available. However, seizures of can-
nabis plant and cannabis herb indicate that cultivation of 
cannabis plant and production of cannabis herb occur on 
a significant scale in South America.
426. Based on official replies to the annual report ques-
tionnaire, it appears that, in terms of cross-border traf-
ficking, Colombia and Paraguay are the most prominent 
source countries for cannabis herb in South America. 
While cannabis herb from Paraguay is trafficked to neigh-
bouring countries, cannabis herb from Colombia appears 
to reach countries in Central America and the Caribbean, 
in addition to neighbouring countries in South America.
427. For several years, Colombia has accounted for the 
largest aggregate annual quantities of cannabis herb 
seized in South America. Seizures in that country have 
maintained a generally increasing trend since 2002, 
reaching 408 tons in 2013 (compared with 77 tons in 
2002), equivalent to approximately one half of the South 
American total for 2012. There were also indications of 
evolving methods of cultivation and production. 
According to UNODC, 115 greenhouses producing can-
nabis herb were detected in 2012, but only 4 were detected 
in 2013. These increases in seizures and interdiction may 
have been the result of more effective enforcement meas-
ures, greater cultivation or both. 
428. Efforts in Paraguay to reduce the availability of 
drugs of abuse, including cannabis, were intensified in 
2013. Seizures of cannabis herb in Paraguay, as well as 
eradication of cannabis cultivation, more than doubled 
in 2013. Contrary to the pattern prevalent in many coun-
tries of cannabis herb being sourced domestically, demand 
for cannabis herb in some countries neighbouring 
Paraguay, notably Brazil and Argentina (both of which 
account for a relatively large number of users by virtue 
of the size of their populations) is met to a significant 
extent by cannabis herb trafficked from Paraguay.
429. During the 2000-2011 period, seizures of cannabis 
herb in Brazil, while among the highest in South America, 
were consistent with a stable market driven by domestic 
demand, fluctuating between 130 tons and 200 tons 
annually, according to UNODC data. In 2012, seizures of 
cannabis herb, cannabis plant and cannabis seedlings, as 
well as detections of cannabis plantations, each registered 
significant declines. In 2013, however, seizures of canna-
bis herb rose to 222 tons. The Governments of Brazil and 
Paraguay continue to cooperate on the eradication of can-
nabis cultivation in Paraguay. One joint operation 
between the National Anti-Drug Secretariat of Paraguay 
and the Brazilian Federal Police in February 2014 resulted 
in the eradication of 400 ha under cannabis cultivation 
in Amambay department in Paraguay.
430. Some of the largest quantities of cannabis plant 
seized or destroyed in South America have been regis-
tered by Bolivia (Plurinational State of) and Peru. 
However, in 2013 aggregate seizures of cannabis herb and 
cannabis plant in the Plurinational State of Bolivia fell to 
76 tons (from 403 tons in 2012). In Peru, seizures of can-
nabis plant rose sharply, to 980 tons in 2012; the corre-
sponding figure for 2013 (3.4 million plants), while not 
directly comparable, suggests a sustained increased level 
of eradication activities.
431. Among the drugs and psychotropic substances 
most frequently abused on a global scale, cocaine is the 
only one for which the illicit processes leading to the con-
sumable end product (cultivation, production and man-
ufacture) are largely confined to a specific region, namely 
South America. In particular, the illicit cultivation of coca 
bush is concentrated in the three countries of Bolivia 
(Plurinational State of), Colombia and Peru. 
432. In the Plurinational State of Bolivia, cultivation of 
coca bush fell to 23,000 ha in 2013, the lowest level since 
2002. In its national strategy for 2011-2015 to combat 
drug trafficking and reduce the amount of coca leaf pro-
duced, the Bolivian Government set itself the target of 
reducing cultivation of coca bush to 20,000 ha. This area 
is still in excess of the estimated requirements for sus-
taining the chewing, consumption and use of coca leaf, 
permitted for certain purposes on the territory of that 
country by virtue of its reservation to the 1961 Convention, 
as amended by the 1972 Protocol. In 2013, manual erad-
ication of coca bush, including voluntary eradication, 
continued to increase, reaching 11,407 ha, while seizures 
of coca leaf, cocaine salt and cocaine base all dropped 
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significantly in comparison with 2012. Aggregate seizures 
of cocaine (cocaine salt and cocaine base) amounted to 
22 tons, the lowest level since 2007, while the number of 
destroyed clandestine laboratories manufacturing cocaine 
hydrochloride continued to rise sharply, reaching 67 in 
2013. In addition, the number of establishments process-
ing coca leaf extracts into cocaine base that were destroyed 
(excluding maceration pits) reached 5,930, slightly more 
than in recent years and the highest number on record.
433. In Colombia, the lower level of coca bush cultiva-
tion (48,000 ha) achieved in 2012 was maintained into 
2013. However, the distribution of cultivation was not 
static, as Government efforts may have helped to concen-
trate the phenomenon in specific regions. Among the 
27  departments with a history of cultivation, five of the 
top six as of 2012 registered an increase, accounting for 
three quarters of the total in 2013 (up from 61 per cent 
in 2012). Manual eradication of coca bush fell by one 
quarter in 2013 to 22,056 ha, and a more pronounced 
decrease was registered in eradication by spraying, which 
fell by one half to 47,053 ha in 2013. Aggregate seizures 
of cocaine in Colombia, including various forms of 
cocaine base, remained the highest in South America, 
amounting to 243 tons in 2012 and 230 tons in 2013.
434. In Peru, the increases in the cultivation of coca 
bush during the 2005-2011 period were almost entirely 
reversed by 2013, when the net area under cultivation fell 
to 49,800 ha (from 60,400 ha in 2012). The high level of 
eradication of coca bush, carried out within the frame-
work of the integral and sustainable alternative develop-
ment programme of the Government of Peru, contributed 
significantly to this reduction. The eradicated area reached 
23,947 ha in 2013, significantly higher than the levels 
achieved throughout the 2000-2012 period. The eradica-
tion and post-eradication efforts made a substantial 
impact in two of the three zones most affected by the 
drug trade: Monzón-Tingo María-Aucayacu, and Palcazú-
Pichis-Pachitea. By the end of October 2014, 26,000 ha 
had been eradicated, with the target for eradication in 
2014 remaining at 30,000 ha. Seizures of cocaine paste in 
Peru peaked at 19.7 tons in 2012, but receded to 10.8 tons 
in 2013, while seizures of cocaine salt rose slightly to 
13.3  tons in 2013, remaining short of the levels seen in 
2008 and 2010.
435. The Government of Peru’s framework for alterna-
tive development (Integral and Sustainable Alternative 
Development) may be contributing to the reduction in 
coca cultivation. Programmes under that framework 
operate in 13 zones, located in seven departments of Peru 
and covering a population of approximately 800,000 peo-
ple. In these zones, the average area of coca bush 
cultivation per family fell by slightly more than one third 
between 2010 and 2013 (from 0.289 ha to 0.188 ha per 
family). As of 2012, the level of engagement of targeted 
families was highest in Huallaga Central, Alto and Bajo 
Mayo, Juanjui, Bajo Huallaga and Tocache, and had 
improved measurably in comparison with 2010.
436. Ecuador and Venezuela (Bolivarian Republic of) 
remain important staging posts for cocaine destined for 
both North America and Western Europe. The Bolivarian 
Republic of Venezuela was also identified as a country of 
provenance for cocaine by some countries outside of 
these well-established cocaine markets, specifically in 
Central Europe and West Asia. The Bolivarian Republic 
of Venezuela reported that cocaine transiting its territory 
had originated in Colombia, with which it shares an 
extensive land border. Ecuadorian authorities also iden-
tified Oceania as being among the destinations for cocaine 
trafficked through their country, and indicated that mar-
itime trafficking, exploiting Ecuador’s Pacific coast, 
remained the most important, although by no means the 
only, method of transportation. Brazil, with its extensive 
land borders with all three of the major cocaine-manu-
facturing countries and a long coastline on the Atlantic 
Ocean, remains an important transit country for cocaine 
trafficked to West and Central Africa, Europe and South 
Africa, in addition to being a major destination country 
for large amounts of cocaine. 
437. Although manufacture of cocaine occurs mainly in 
Bolivia (Plurinational State of), Colombia and Peru, pro-
cessing of coca leaf derivatives on a small scale does occur 
outside of these three countries. While the main end 
product intended for exportation to the lucrative markets 
of North America and Europe is cocaine hydrochloride, 
the demand for cocaine in South America is partly met 
by significant quantities of intermediate forms of cocaine 
base, sometimes with high levels of impurity. The pres-
ence of these products in the illicit market then occasion-
ally leads to further processing. In addition, some facilities 
serve to simply lower the purity before placing the prod-
uct on the retail market. Based on UNODC data, in 2012 
a total of 31 establishments processing coca leaf deriva-
tives were detected by Argentina,46 8 by Chile, 4 by 
Ecuador and 24 by Venezuela (Bolivarian Republic of).
438. There are reports and indirect indicators of culti-
vation of opium poppy on a small scale in South America. 
Colombia estimated the area under such cultivation in 
 46 This could include establishments dedicated to adulteration and 
packaging into small quantities, in addition to establishments perform-
ing the final steps in the synthesis of cocaine hydrochloride.
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2013 at 298 ha, and eradicated a further 514 ha. Peru 
seized 68.5 kg of opium of domestic origin in 2013.
439. Some of the opium produced in South America is 
processed into heroin and trafficked outside the region, 
in addition to catering for the limited demand for the 
drug in South America. Colombia consistently registers 
the highest quantities of heroin seized in South America, 
followed by Ecuador. However, seizures in Colombia 
continued to decline in 2013, amounting to 403 kg (sig-
nificantly below the peak level of 1.7 tons registered in 
2010), also of domestic origin. Seizures of heroin in 
Ecuador amounted to 123 kg in 2013. Colombia also dis-
mantled one heroin laboratory per year in 2011, 2012 
and 2013. 
(b) Psychotropic substances
440. Several countries in South America are affected by 
trafficking in “ecstasy”, but the region is mainly a con-
sumer market with respect to this substance. Based on 
the most recent available official data, “ecstasy” in South 
America continues to originate mainly in Europe. The 
most significant seizure levels of “ecstasy” in South 
America—in Argentina, Brazil and Colombia—reflect 
significant abuse of this substance in these countries. 
441. Aside from “ecstasy”, Argentina, Brazil, Chile and 
Colombia regularly report seizures of other hallucino-
gens, notably lysergic acid diethylamide (LSD). However, 
according to UNODC, forensic analysis of samples of 
substances sold as LSD obtained in three major Colombian 
cities in 2013 revealed the presence of synthetic phene-
thylamines rather than LSD. In 2012, the largest quanti-
ties of LSD seized in South America were accounted for 
by Argentina (87,605 doses) and Brazil (65,033 doses, 
dropping to 56,680 doses in 2013). 
442. In recent years, non-negligible amounts of ampheta-
mine or methamphetamine have been seized in some 
South American countries, notably Argentina and Brazil. 
Colombia also regularly reports significant seizures of 
sedatives and tranquillizers. In 2013, seizures in this cat-
egory in Colombia rose for the fourth consecutive year, 
reaching 63,641 tablets.
(c) Precursors
443. In 2012, South America accounted for approxi-
mately two thirds of global reported seizures of potas-
sium permanganate, which is a Table I substance, and 
more than half of global seizures of hydrochloric acid, 
ethyl ether, acetone and sulphuric acid, which are Table II 
substances.
444. For most precursors, as in previous years, the three 
coca-producing countries accounted for the largest 
amounts seized in South America. However, in a depar-
ture from this pattern, in 2012 Brazil seized the largest 
quantity of hydrochloric acid (91,697 litres) in South 
America, and the largest quantity worldwide of methyl 
ethyl ketone (3,308 litres).
445. In recent years, potassium permanganate used in 
the manufacture of cocaine in South America has itself 
been sourced to some extent from illicit manufacture, in 
addition to diversion from licit channels. In 2013, 
Colombia dismantled three illicit laboratories manufac-
turing potassium permanganate on a small scale.
(d) Substances not under international 
control
446. In June 2013, tapentadol, an opioid analgesic, was 
placed under national control in Colombia, specifically 
on the list of medications and substances under special 
control, alongside substances such as buprenorphine, 
 fentanyl and oxycodone. 
447. Ketamine has emerged as a drug of abuse in South 
America. In 2012, Argentina seized small quantities of 
the substance and also confirmed its abuse among the 
country’s population. In 2013, Colombia estimated the 
lifetime prevalence of ketamine abuse in the general pop-
ulation at 0.18 per cent.
448. According to UNODC, since mid-2012, Colombia 
has also reported the consumption of products derived 
from plants with psychoactive properties, such as Salvia 
divinorum and ayahuasca, as well as at least one synthetic 
phenethylamine (25B-NBOMe and/or 25C-NBOMe) 
reported to have hallucinogenic effects similar to those 
of LSD. In 2013, Chile seized a consignment of a related 
chemical (25I-NBOMe) that had originated in Spain. 
5. Abuse and treatment
449. Based on UNODC estimates of annual prevalence 
of drug abuse in 2012, the substances abused most 
broadly in South America are cannabis and cocaine. The 
estimates of prevalence of past-year abuse in South 
America for both cannabis (5.7 per cent among the gen-
eral population in the 15-64 age bracket) and cocaine 
(1.2  per cent) are higher than the global past-year 
66  INCB REPORT 2014
prevalence, but lower than the corresponding average fig-
ures for the Americas as a whole. In terms of the num-
ber of users, as of 2012 South America was estimated to 
account for almost one fifth of all past-year cocaine users 
globally, and slightly less than one tenth of cannabis 
users. One issue of special concern in South America is 
the consumption of smokable forms of cocaine.
450. Based on treatment data for the years 2010-2012 
published by UNODC, cocaine emerges as by far the 
most prominent primary drug of abuse among persons 
treated for drug addiction in South American countries, 
with the notable exception of Colombia. Treatment data 
for 2012 for Colombia indicate a complex drug abuse 
 scenario, with cannabis and cocaine each accounting 
for approximately one third of treatment demand, 
amphetamine- type stimulants for 10 per cent and heroin 
for 6.6  per  cent.
451. In July 2014, Colombia published the results of its 
2013 national study on drug use, the objectives of which 
included ascertaining trends in comparison with a sim-
ilar study done in 2008. One statistically significant 
change that emerged was an increase in the annual prev-
alence for abuse of cannabis, from 2.1 per cent of the 
general population in the 12-65 age group in 2008 to 
3.3  per cent in 2013, driven mainly by increases in the 
lower age categories (12-17 and 18-24 years of age). 
Abuse of cocaine salt and basuco (a smokable form of 
cocaine) did not show large variations. On the other 
hand, abuse of LSD increased significantly, and the life-
time prevalence for abuse of prescription opioids 
exceeded 1  per  cent in 2013.
452. Recent data also indicate an increase in canna-
bis abuse in Chile. As of 2013, almost one third 
(30.6  per  cent) of school students between the eighth 
year of primary school and the fourth year of second-
ary school reported having used cannabis during the 
previous year, up from 19.5 per cent in 2011. The same 
study also indicated a significant drop in the percep-
tion of risk associated with frequent consumption of 
cannabis. An increasing trend in cannabis consumption 
in Chile also emerges from slightly older data (for 2012) 
for the general population.
453. The results of the latest Global School-based 
Student Health Survey47 for Uruguay indicate a lifetime 
prevalence for abuse of cannabis herb of 13 per cent 
 47 The Global School-based Student Health Survey is a project 
 conducted by WHO in collaboration with the United States Centers for 
Disease Control and Prevention and implemented by authorities in 
 participating countries.
among students in the second and third years of middle 
school and the first year of high school, as of 2012. 
Dedicated surveys on drug abuse, focusing on different 
target populations, are also held regularly. These surveys 
suggest that the lifetime prevalence for abuse of canna-
bis herb among students48 peaked around 2007 and 
appeared to stabilize at around 16 per cent as of 2011, 
while annual prevalence for abuse of cannabis herb 
among the general population (aged 15-65) rose from 
1.4 per cent in 2001 to 8.3 per cent in 2011. 
454. A recent survey among college students in Brazilian 
state capitals and the federal district estimated the annual 
prevalence of abuse of cocaine powder among college stu-
dents (of all ages) at 3 per cent in 2009. Another study, 
based on the network scale-up method, employed the 
concept of “regular” use (defined as having used the sub-
stance on 25 days or more in the previous six months) 
and estimated the number of regular users of “crack” or 
other similar smokable forms of cocaine (thus excluding 
cocaine salts) in 2012 in the Brazilian state capitals and 
the federal district alone at approximately 370,000, or 
0.81 per cent of the general population (of all ages). 
Among these, 50,000 users were below the age of 18. 
Another study, done in parallel and using time-location 
sampling among a broader reference population, on the 
profile of regular users of these smokable forms of cocaine 
indicates that the population of adult regular users clearly 
tends to be concentrated among the younger age catego-
ries, a pattern that is even more pronounced outside of 
the state capitals. In addition, the proportion of males 
among users of these substances in Brazil was estimated 
to be in the range of 76-81 per cent.
455. The Government of Brazil has invested heavily in 
drug abuse prevention, treatment and rehabilitation. 
According to the most recent information available, the 
prevalence of HIV among people who inject drugs was 
estimated at 5.9 per cent as of 2009. The Ministry of 
Health has developed a programme for the prevention of 
HIV/AIDS, hepatitis C and other medical conditions 
associated with drug abuse. As part of its efforts to 
increase coverage of community-based mental health ser-
vices, the Government of Brazil increased the number of 
care centres from 424 in 2002 to 2,067 in 2012. The stated 
objectives of these centres include the prevention of drug 
abuse and the rehabilitation and social reintegration of 
people who have abused drugs.
 48 Specifically, students in the second year of middle school and the 
first and third years of high school, attending schools in towns with a 
population of 10,000 or more residents.
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456. South America is also affected by illicit consump-
tion of amphetamine-type stimulants. Some of the more 
recent data that point to continued or emerging abuse of 
amphetamine-type stimulants in South America relate to 
Colombia (with the prevalence rate among the general 
population aged 12-65 in 2013 estimated at 0.19 per cent 
for past-year abuse of “ecstasy” and 0.09 per cent for life-
time abuse of methamphetamine),49 Ecuador (past-year 
prevalence of illicit use of “ecstasy” among students in 
the 12-17 age bracket in 2012 estimated at 0.5 per cent) 
and the Plurinational State of Bolivia (lifetime prevalence 
of illicit use of amphetamine or methamphetamine among 
the student population in the second to fourth year of 
secondary school in 2012 estimated at 1.7 per cent).50 
457. Some countries in South America have also 
reported notable levels of illicit use of prescription stim-
ulants (such as anorectics), including Brazil (past-year 
prevalence of 1.7 per cent among students in the last four 
years of primary school and the first three years of sec-
ondary school in the 26 state capitals and the federal dis-
trict of Brazil, as of 2010) and Argentina (past-year 
prevalence of 1.4 per cent among students in the 15-16 
age bracket as of 2011).
C. Asia
East and South-East Asia
1. Major developments
458. East and South-East Asia have some of the largest 
and most established illicit markets for amphetamine-
type stimulants in the world. Further increases in the traf-
ficking and manufacture of those substances constitute 
the leading source of drug-related activity in the region. 
Amphetamine-type stimulants are already ranked as the 
most commonly abused drugs by a number of countries, 
and experts in the region have indicated that the demand 
for them, particularly for methamphetamine, has contin-
ued to grow and become more diversified. 
459. Sustained increases in illicit opium poppy cultiva-
tion and production in South-East Asia point towards 
another area of concern: since the mid-2000s, the upsurge 
in illicit cultivation in the region has more than doubled, 
 49 According to the Estudio Nacional de Consumo de Sustancias 
 Psicoactivas en Colombia 2013 (Bogota, June 2014).
 50 According to the Encuesta Global de Salud Escolar: Bolivia 2012 
(La Paz, November 2013).
offsetting the considerable gains made through eradica-
tion efforts during the previous decade. In 2013, over 
62,000 ha of opium poppy cultivation were recorded, 
mainly in Myanmar and the Lao People’s Democratic 
Republic. In 2006, by comparison, an area of 24,000 ha 
of illicit poppy cultivation had been recorded. With a 
total reported cultivation of 57,800 ha in 2013 (an increase 
of over 7,000 ha from the previous year), Myanmar con-
tinued to be the second-largest grower of opium poppy 
in the world after Afghanistan. Concurrently, cultivation 
in the Lao People’s Democratic Republic was estimated 
at 3,900 ha.
460. In a region where the huge demand for ampheta-
mine-type stimulants invariably creates sustained demand 
for precursor chemicals, drug syndicates have attempted 
to circumvent legislative control measures by replacing 
traditional precursors with pharmaceutical preparations 
containing such precursors or other non-scheduled pre-
cursors. Given the rather lengthy processes involved in 
making changes to the scope of control applicable to pre-
cursors, closer collaboration between industry and the 
authorities concerned has become much more important 
in efforts to curb this regional trend.
2. Regional cooperation
461. In the light of the objective of a drug-free region 
by 2015, the Association of Southeast Asian Nations 
(ASEAN) held a number of meetings to exchange infor-
mation on the current state of affairs, reiterate the 
Association’s political commitment and call for intensi-
fied collaborative efforts. This political determination was 
evident in the Chair’s statement issued on the occasion 
of the latest ASEAN Ministerial Meeting on Drug Matters, 
held in Bandar Seri Begawan in September 2013, and the 
statement made by the Asian group at the high-level seg-
ment of the fifty-seventh session of the Commission on 
Narcotic Drugs, held in Vienna in March 2014. Also, law 
enforcement agencies in the region discussed the latest 
assessment of the national drug situation and national 
progress in combating drugs during the 11th meeting of 
the ASEAN Inter-Parliamentary Assembly Fact Finding 
Committee to Combat the Drug Menace, held in 
Vientiane in May 2014, the 14th ASEAN Senior Officials 
Meeting on Transnational Crime, held in Bandar Seri 
Begawan in June 2014, and the 35th ASEAN Senior 
Officials Meeting on Drug Matters, held in Makati City, 
the Philippines, in July 2014.
462. In addition to ASEAN meetings, other regular 
regional meetings, such as the Asia-Pacific Operational 
Drug Enforcement Conference and the Anti-Drug Liaison 
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Officials’ Meeting for International Cooperation, as well 
as various subregional cooperation platforms, have facil-
itated the exchange of information and multilateral col-
laboration. For instance, participants at the latest meeting 
of senior officials from China and the six countries of the 
Greater Mekong subregion, which was held in Beijing in 
May 2014, expressed the need for a more coordinated 
approach to combating drugs. Challenges posed by the 
large amount of non-scheduled precursor chemicals and 
new psychoactive substances in the region were addressed 
during the International Conference on Precursor 
Control, jointly organized by INCB and UNODC in 
Bangkok in December 2013. Similarly, problems posed 
by synthetic drugs were discussed during the UNODC 
Global Synthetics Monitoring: Analyses, Reporting and 
Trends (SMART) programme Regional Workshop, held 
in Yangon, Myanmar, in August 2014. 
3. National legislation, policy and 
action
463. To further the regional goal of a drug-free ASEAN 
community in 2015, a number of policies and strategies 
have been launched or extended at the national level. In 
February 2013, the Government of Cambodia approved 
a new national strategic plan on drug control for 2013-
2015, which outlined the Government’s plan to further 
implement the country’s drug law. Similarly, in the Lao 
People’s Democratic Republic, the Government’s guiding 
drug control strategy document—the national drug con-
trol master plan for 2009-2013—was extended until 2015. 
In Myanmar, as the 15-year drug elimination plan came 
to an end, a new five-year drug elimination plan (for 
2014/15 to 2018/19) was adopted, as were programmes 
aimed at reducing supply and demand and at promoting 
law enforcement cooperation, both domestically and in 
conjunction with international organizations. Meanwhile, 
the Government of Indonesia declared 2014 the year to 
save drug abusers, as part of which demand reduction 
measures were strengthened through the promotion of 
treatment and rehabilitation.
464. Amendments to existing drug control legislation 
have been adopted in some countries in the region, 
although they differ in emphasis and approach. For 
instance, changes were made in Brunei Darussalam in 
2012 with regard to substances. New definitions for 
 “cannabis”, “cannabis mixture” and “cannabis resin” were 
adopted, and a new drug schedule was included in the 
2012 amendment to the country’s Misuse of Drugs Act. 
The old definition of “cannabis” as “any plant of the genus 
Cannabis from which the resin has not been extracted”, 
was replaced by “any plant of the genus Cannabis, or any 
part of such plant”. In Singapore, the focus of legislative 
action has been on amending drug-related provisions in 
the criminal law by introducing stricter punishments for 
repeat trafficking offenders and those who sell drugs to 
young or vulnerable persons. A new offence was intro-
duced to criminalize the organization of gatherings where 
drugs will be abused, and to impose higher penalties on 
those who involve young or vulnerable persons in such 
gatherings. The amendments came into effect in May 2013.
465. In the absence of a unified control framework at 
the international level, attempts were made to impose 
stricter control on new psychoactive substances at the 
national level. In Indonesia, a new ministerial regulation 
(number 13 of 2014) introduced monitoring and control 
for 18 new psychoactive substances. In late 2013, Thailand 
included two new psychoactive substances in the list of 
controlled substances in schedule I of its narcotics act, 
thereby prohibiting their production, import, export, dis-
posal and possession. Likewise, as of January 2014, China 
added several new psychoactive substances (including 
khat) to annex 2 of its list of controlled substances, 
thereby imposing greater control over the manufacture, 
usage, storage and transport of these substances. In 
Singapore, after the introduction in 2013 of a temporary 
schedule (the fifth schedule) that allowed the authorities 
to list new psychoactive substances for up to 24 months, 
the Government decided to place all substances listed 
under the fifth schedule on the first schedule. As a result, 
in May 2014, the trafficking, manufacture, sale, posses-
sion and consumption of any of these substances became 
a criminal offence.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
466. Illicit cultivation of opium poppy has increased in 
the region as a whole, driven by sustained increases in 
such cultivation in Myanmar since 2006. Despite the 
eradication of a total of around 13,000 ha reported by the 
Governments of the Lao People’s Democratic Republic, 
Myanmar and Thailand in 2013, the illicit cultivation of 
opium poppy has continued to rise. Cultivation in 
Myanmar has grown from 21,600 ha in 2006 to 57,800 ha 
in 2013, while that in the Lao People’s Democratic 
Republic was estimated at 3,900 ha in 2013. Looking into 
the near future, the risk of higher illicit cultivation in the 
Golden Triangle is expected to persist until sustainable 
solutions can be found to the long-term poverty in Shan 
State, Myanmar.
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467. Contrary to the global trend of dwindling heroin 
seizures, recent seizures of heroin in the Asia-Pacific 
region (Oceania, South Asia, East and South-East Asia) 
have edged up—from 10.5 tons in 2011 to 11.3 tons in 
2012, of which a significant proportion was reported by 
China. This trend seemed to persist in 2013, with more 
than 8.5 tons of heroin seized in China, the majority of 
which had originated in Myanmar. Concurrently, signif-
icant seizures were reported by Viet Nam (940 kg) and 
Malaysia (763 kg). After a period of limited heroin sei-
zures, a considerable increase was reported by the Lao 
People’s Democratic Republic (from 45 kg in 2012 to 
almost 290 kg in 2013). In Singapore, the situation 
remained stable following a record number of heroin-
related arrests (mainly related to drug abuse) in 2012.
468. By the end of 2013, China had a total of over 1.3 
 million registered heroin abusers. The aforementioned 
growth in opium production in the Golden Triangle also 
meant that the proportion of heroin seized in China that 
had originated in Myanmar increased again in recent 
years. As a consequence, the proportion of heroin that 
had  originated in Afghanistan declined from around 
30 per cent of the total seized in China in 2009 to around 
10 per cent in 2013. 
469. Cannabis has long been reported as one of the 
major drugs of abuse in Indonesia and the Philippines. 
Seizures of cannabis herb have now also been reported 
by Brunei Darussalam, Cambodia, the Lao People’s 
Democratic Republic, Malaysia and, recently, Thailand. A 
stable trend was observed in China and Viet Nam, which 
seized around 4.5 tons and 900 kg of cannabis herb, 
respectively. Meanwhile, seizures of cannabis resin were 
reported by Indonesia and Hong Kong, China, with a 
slight rise in Hong Kong, China, owing to substantial 
 seizures at the airport.
470. Although Cambodia, China (including Hong 
Kong, China, and Macau, China), Indonesia, Japan, 
Malaysia and Thailand were much less affected by cocaine 
than other regions in the world, these countries did 
report seizures of cocaine in 2013. Increases were 
observed in Malaysia (from 7.0 kg in 2012 to 73.9 kg in 
2013) and Thailand (from 17.9 kg in 2012 to 47.5 kg in 
2013), while a significant reduction was reported from 
Hong Kong, China (from 733.6 kg in 2012 to 453.8 kg 
in 2013), owing to the absence of large seizures.
(b) Psychotropic substances
471. After seizures of methamphetamine in the region 
reached their peak in 2012, no clear trend emerged in 
2013. In Cambodia, Japan, Malaysia, the Philippines 
and Hong Kong, China, total seizures of methampheta-
mine went up, while in China they dropped signifi-
cantly. In the Philippines, a total of 837 kg of 
meth amphetamine were seized in 2013, which stood in 
sharp contrast to the relatively small amount seized in 
2012 (around 113 kg). The amount of methampheta-
mine seized in Japan (847  kg in 2013) almost doubled 
compared with the previous year, and the country noted 
significant rates of meth amphetamine-related crime. In 
Hong Kong, China, the volume of methamphetamine 
seized also rose sharply, from 50 kg in 2012 to 258 kg 
in 2013, owing to a higher number of detections and 
seizures at the airport. After accounting for almost half 
of total seizures of meth amphetamine in the region in 
2012, China reported none in 2013 and instead reported 
significant seizures of amphetamine-type stimulants. 
Total seizures in China of all amphetamine-type stim-
ulants rose from almost 16.3 tons in 2012 to more than 
19.5 tons in 2013.
472. Most of the methamphetamine abused in East and 
South-East Asia is manufactured in clandestine laborato-
ries within the region. In addition, various other coun-
tries around the world have been identified as sources of 
the methamphetamine seized in the region. For instance, 
during the previous five years, much of the metham-
phetamine seized in Japan, Malaysia, the Philippines and 
Thailand had originated in West Africa. Meanwhile, 
information provided by the authorities in Turkey and 
data on seizures from Indonesia, Malaysia and Thailand 
confirmed that some methamphetamine smuggled from 
the Islamic Republic of Iran through Turkey was destined 
for East and South-East Asia. Experts in Thailand 
believed that their country was primarily a transit hub 
for methamphetamine en route from the Islamic Republic 
of Iran to Thailand’s neighbours. The latest reports from 
the authorities in Japan suggest an increasing influence 
of Mexican cartels on its domestic methamphetamine 
traffic.
473. A considerable proportion of the amphetamine-
type stimulants manufactured in the region was intended 
for domestic use, as reflected by the higher number of 
clandestine laboratories that were dismantled. Between 
2009 and 2011 in China, an average of 375 manufactur-
ing laboratories were dismantled each year, although no 
breakdown was available by type of substance manufac-
tured. In 2013, a total of 397 clandestine laboratories 
manufacturing methamphetamine were dismantled, up 
from 228 in the previous year. In Thailand, the number 
of small-scale methamphetamine laboratories detected 
also rose, to six, compared with an annual average of two 
during the previous few years. As most of those six 
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laboratories were located near Bangkok, they seemed to 
be servicing domestic demand only.
474. Seizure data for MDMA (commonly known as 
“ecstasy”) over the past few years seem to suggest that it 
is making a comeback in the region, though its impact 
seems to be much greater on a few countries in particu-
lar. Reaching a total of 5.4 million pills, the number of 
“ecstasy” tablets seized in East and South-East Asia more 
than tripled in 2012. This development was predomi-
nantly driven by a significant rise in Indonesia (from 1.1 
million in 2011 to 4.3 million in 2012). In fact, in 2012 
Indonesia for the first time reported the largest “ecstasy” 
seizures worldwide. Seizures of “ecstasy” also increased 
in Cambodia, China, Thailand and Viet Nam. Compared 
with 2012, more seizures of “ecstasy” also continued to 
be reported by Singapore and Hong Kong, China. At the 
same time, small quantities of “ecstasy” were also being 
produced domestically in Viet Nam. Given the relatively 
high concentration of seizures of “ecstasy” in Indonesia 
and its popularity as a substance of abuse in that coun-
try, close monitoring of the domestic “ecstasy” market in 
that country is required before any more definite state-
ments can be made about the regional trend.
(c) Precursors
475. The trafficking of precursors used in the manu-
facture of amphetamine-type stimulants remains one of 
the biggest challenges in precursor control. In particu-
lar, seizures of large quantities of pharmaceutical prep-
arations containing pseudoephedrine continued to be 
reported by several countries. As the illicit manufac-
ture of amphetamine-type stimulants in the region 
increased, significant amounts of pharmaceutical prep-
arations containing pseudo ephedrine were diverted 
from domestic distribution channels to supply clandes-
tine laboratories.
476. In order to circumvent national legislative control 
measures, illicit operations for the manufacture of 
amphetamine-type stimulants have also made use of 
other non-scheduled precursor chemicals. While legisla-
tive and administrative rules have been tightened by a 
number of countries, the sharing of pertinent informa-
tion between the industries and authorities concerned is 
of paramount importance to preventing the diversion of 
non-scheduled precursors. Given the rather dynamic and 
adaptive nature of such diversion attempts, enhanced col-
laboration between Governments and the private sector, 
at both the national and regional levels, is required for 
more effective control.
(d) Substances not under international 
control
477. Marketed as “bath salts”, “plant food” and incense 
to circumvent national regulatory and legislative controls, 
a range of new psychoactive substances (which include 
piperazines, synthetic cathinones and synthetic cannabi-
noids) have been reported in the region over the years. 
The trend of falsely marketing new psychoactive sub-
stances as “ecstasy” has gained popularity in Oceania and 
has also been found in East and South-East Asia, where 
Indonesia, Singapore and Hong Kong, China, reported 
seizures of so-called “ecstasy” tablets that in actual fact 
contained ketamine and other new psychoactive sub-
stances. As the abuse of synthetic cathinones and syn-
thetic cannabinoids has become more popular among 
young people in Singapore, tighter legislative measures 
have been introduced to restrict the circulation and con-
sumption of such substances.
478. East and South-East Asian countries were respon-
sible for more than half of global seizures of ketamine by 
volume. However, seizures were concentrated in a lim-
ited number of countries, while ketamine abuse has been 
widespread throughout the region. Between 2008 and 
2011, the total amount of ketamine seized in China and 
Hong Kong, China, made up almost 60 per cent of the 
global total. In 2013, nearly 9.7 tons were seized in China, 
almost twice as much as the year before. At the same 
time, 118 ketamine laboratories were dismantled, while 
none had been reported dismantled for the previous year. 
Owing to the lack of cases involving large seizures, the 
amount of ketamine seized in Hong Kong, China, 
dropped to less than 300 kg in 2013. In contrast to the 
geographical concentration of seizures of ketamine, abuse 
of the substance has been reported in Brunei Darussalam, 
China, Japan, Myanmar and Singapore, resulting in grow-
ing concern and attention among the authorities con-
cerned. Governments in the region strongly supported 
the adoption of the resolution on ketamine at the fifty-
seventh session of the Commission on Narcotic Drugs 
and sought tighter control measures for ketamine in 
order to prevent abuse.
479. The seizure of the plant-based psychoactive sub-
stances khat and kratom continued to be reported by 
some countries. Khat largely originated from native plants 
in the Horn of Africa and the Arabian Peninsula, although 
its cultivation was also reported by Indonesia. Between 
2008 and 2012, China and Hong Kong, China, seized a 
total of 6.4 tons. In 2013, another 300 kg of khat origi-
nating in India and Ethiopia were seized in Hong Kong, 
China. By contrast, kratom is locally produced in 
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South-East Asia, notably in Malaysia, Myanmar and 
Thailand. It is traditionally used by farmers in the region 
to enhance their productivity, and its continued abuse 
was reported in Malaysia, Myanmar and Thailand.
5. Abuse and treatment
480. As mentioned in previous reports, the lack of rep-
resentative surveys on household drug use or regular 
national assessments concerning the nature and extent 
of drug abuse has made it difficult to keep track of the 
latest trends in the region. Production cycles for sub-
stances of abuse have become shorter, and the market 
has become more complex, owing to the increasing vari-
ety of illicit drugs on offer. This has made the design and 
implementation of effective treatment and rehabilitation 
programmes even more dependent on up-to-date infor-
mation. Regardless of this, general population surveys 
and school surveys are still lacking in most East and 
South-East Asian countries. The Board urges all 
Governments concerned to establish regular monitoring 
systems and especially to implement drug use surveys so 
as to stay informed about the situation on the ground 
and facilitate the implementation of prevention and 
treatment programmes.
481. For the majority of countries, the abuse of amphet-
amine-type stimulants, in particular methamphetamine, 
remains the biggest concern. In the Greater Mekong sub-
region (specifically, the Lao People’s Democratic Republic, 
Cambodia and Thailand), methamphetamine pills remain 
the most common drug of abuse. The more potent form 
of methamphetamine, crystalline methamphetamine, is 
even more widely abused in some other countries, such 
as Brunei Darussalam, Japan, the Philippines and the 
Republic of Korea.
482. Both expert perception and treatment data have 
pointed towards an increasing abuse of amphetamine-
type stimulants in the region, particularly in countries 
where other drugs had been the primary drugs of abuse. 
For instance, the abuse of crystalline methamphetamine 
has recently been reported in Indonesia, where cannabis 
had long been the major drug of abuse. A similar situa-
tion has been reported in China, where opiates neverthe-
less remain the most commonly abused drugs. According 
to experts in China, there was a large increase in the 
abuse of amphetamine-type stimulants, alongside 
increases in the number of people receiving treatment for 
such abuse. In 2013, the number of abusers of 
amphetamine-type stimulants in China continued to 
increase, and comprised more than 35 per cent of peo-
ple receiving treatment. In Singapore, abusers of meth-
amphetamine made up the second-largest group receiving 
drug treatment in 2013.
483. In Indonesia, cannabis continues to be one of the 
main drugs of abuse, while heroin remains the major 
drug of abuse in China, Malaysia, Myanmar, Singapore 
and Viet Nam. In Myanmar, over 98 per cent of those in 
treatment had abused heroin, and a significant propor-
tion of them had also injected drugs. According to the 
latest estimates of UNODC and the Joint United Nations 
Programme on HIV/AIDS, an estimated 3,260,000 peo-
ple in East and South-East Asia were injecting drugs in 
2012. Among those, around 312,000 people were living 
with AIDS. In view of the higher prevalence of HIV 
among people who inject drugs, HIV testing and coun-
selling services have been provided and strengthened. 
Targeted treatment for this particular group has also been 
enhanced in Cambodia.
484. The abuse of drugs by young people has become 
a growing concern, with a growing diversity in the types 
of drugs abused and an increasing abuse of methamphet-
amine. In Myanmar, inhalant abuse, in particular glue-
sniffing, has continued to be observed, especially among 
street children. Also, a study in Myanmar on the abuse 
of amphetamine-type stimulants among secondary 
school students suggested that methamphetamine was 
the most abused drug, with a lifetime prevalence of 
1.5  per cent and an annual prevalence of 0.8 per cent. 
Similarly, expert perception in Thailand pointed to a rise 
in the abuse of methamphetamine among secondary 
school and university students. Increasing abuse of 
amphetamine-type stimulants was also reported among 
young people in Cambodia and the Lao People’s 
Democratic Republic.
485. Community-based treatment approaches have 
continued to gain popularity. The Government of 
Cambodia has further strengthened this approach,  having 
provided ongoing drug abuse treatment to around 1,300 
individuals in 2012 (87 per cent of whom were abusers 
of amphetamine-type stimulants). China has promoted 
community-based treatment approaches by designating 
38 national model units and 51 piloting sites, while the 
Government of the Lao People’s Democratic Republic has 
extended community-based treatment to include abuse 
of amphetamine-type stimulants. In 2012, Brunei 
Darussalam introduced a temporary release scheme for 
residents of a treatment centre prior to their definitive 
release; the aim was to facilitate their smoother reinte-
gration into society.
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South Asia
1. Major developments
486. Governments in the South Asia subregion con-
tinue to make notable efforts in responding to the threat 
posed by illicit drugs at the national and regional levels. 
The greatest drug-related challenges facing South Asia in 
2013 remained trafficking in Afghan heroin; the rise in 
manufacturing and trafficking of methamphetamine, in 
both pill and crystalline forms; the diversion of controlled 
substances from licit to illicit channels; the abuse of 
pharma ceutical preparations containing narcotic drugs 
and psychotropic substances; and the smuggling of such 
preparations from India to neighbouring countries. 
2. Regional cooperation
487. All of the countries in the subregion are members 
of the Colombo Plan for Cooperative Economic and 
Social Development in Asia and the Pacific. Through the 
Colombo Plan, the countries of the subregion have con-
tinued their close partnership with one another, and with 
the other 21 members of the Colombo Plan that are 
 outside of the subregion, on drug abuse prevention and 
control matters. 
488. The Colombo Plan’s Asian Centre for Certification 
and Education of Addiction Professionals successfully 
implemented several training events for national trainers 
on the universal treatment curriculum for substance use 
disorders in the region. In May 2014, the Centre rolled 
out the new universal prevention curriculum for sub-
stance use. A memorandum of understanding for part-
nership was signed by the Dangerous Drugs Board of the 
Philippines; the ASEAN Training Centre for Preventive 
Drug Education of the College of Education, University 
of the Philippines; and the Colombo Plan secretariat. 
3. National legislation, policy and 
action
489. In India, out of over 2 million registered cancer 
patients and an equal number of HIV/AIDS patients as 
of 2014, about a million people in of each of those groups 
suffer from moderate to severe pain. However, there is a 
continued low level of availability of and access to opi-
oids for pain relief in the country, despite the fact that 
India has long been a licit producer and exporter of opi-
ate raw material, namely opium, a source of pain man-
agement medication. In March 2014, the Indian 
Parliament adopted amendments to drug control legisla-
tion to enable uniform, simplified rules to be issued by 
the central Government, leading to the removal of the 
regulatory barriers that had hindered the availability of 
such drugs for pain relief.
490. The Government of India issued the Narcotic 
Drugs and Psychotropic Substances (Regulation of 
Controlled Substances) Order, 2013, by which it repealed 
the 1993 Order of the same name. The 2013 Order des-
ignates a total of 17 precursor chemicals as controlled 
substances and has three schedules: A, B and C. Five of 
those substances are listed in schedule A (the highest 
classification for controls); persons engaged in their 
 manufacture, distribution, transportation, sale, purchase, 
storage, consumption and destruction are required to 
obtain registration certificates from the Narcotics Control 
Bureau. Schedules B and C include all 17 precursor 
chemicals and requires those who engage in their export 
from or import into India to obtain a “no objection” cer-
tificate from the Narcotics Commissioner of the Central 
Bureau of Narcotics. With the 2013 Order, the Government 
hopes to track controlled substances from source to end 
user and strike a balance between the legitimate require-
ments of licit trade and an adequate enforcement regime 
to prevent the diversion of controlled substances.
491. The Government of India launched a system for 
online registration and submission of returns by manu-
facturers and wholesalers of psychotropic substances. The 
Government initiated the process of amending the rules 
of the Narcotic Drugs and Psychotropic Substances Act, 
1985, to incorporate mandatory provisions for online reg-
istration and the submission of online returns by manu-
facturers and wholesalers of psychotropic substances.
492. The Narcotics Control Bureau organized awareness 
programmes to reduce the threat of drug abuse in soci-
ety, especially among young students. The Bureau created 
awareness of drug abuse directly by addressing the stu-
dents, while also involving their parents, teachers and 
counsellors.
493. The Financial Action Task Force recognized that 
Bangladesh and Nepal had made significant progress in 
the area of combating money-laundering and financing 
of terrorism, and as a result removed those States from 
its regular follow-up process in February and June 2014, 
respectively.
494. The authorities of Bangladesh continued their efforts 
to raise awareness of and provide education on the dan-
gers of drug abuse. To that end, in 2013 they distributed 
some 4,200 posters, 49,310 leaflets and 14,400 stickers, and 
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organized 5,851 discussion meetings and 268 speeches at 
schools and colleges. According to figures released in 2014, 
the number of cases tried in drug courts in Bangladesh 
rose from 4,800 in 2012 to 5,200 in 2013.
495. The Maldives Customs Service set up an interdic-
tion unit at Ibrahim Nasir International Airport to 
 prevent trafficking of illicit drugs and other prohibited 
items by monitoring movements of passengers arriving 
in and departing from Maldives. 
496. Enforcement agencies in the region need aware-
ness-raising and training on the issue of trafficking in 
precursors and pharmaceutical preparations; capacity-
building for law enforcement officials in this regard 
would help those agencies to gain a better understand-
ing of the problem. Such capacity-building needs to be 
coupled with a strengthening of existing mechanisms for 
law enforcement coordination at the policy and opera-
tional levels.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
497. The South Asia region, owing to its location 
between the Golden Crescent (Afghanistan and Pakistan) 
and the Golden Triangle (Lao People’s Democratic 
Republic, Myanmar and Thailand), continued to be par-
ticularly vulnerable to the trafficking of opiates and her-
oin. In addition, widespread trafficking of cannabis, 
synthetic drugs and new psychotropic substances per-
sisted in 2013. 
498. The trend observed over the past several years, 
namely the diversion of pharmaceutical preparations con-
taining narcotic drugs and psychotropic substances from 
the Indian pharmaceutical industry, as well as trafficking, 
including through illegal Internet pharmacies, of those 
preparations, continued during the reporting period. The 
Government of India continued to take substantial meas-
ures to address the problem, including through legisla-
tive reform and the development of online systems.
499. In 2013, 12,818 cases of seizures of drugs were 
reported by the Narcotics Control Bureau of India, as 
compared with 10,796 cases in 2012, representing a sig-
nificant increase of 18.7 per cent. The quantities of her-
oin, cocaine and cannabis resin seized in 2013 were the 
largest in the past five years.
500. The broad trend that emerges from the data reported 
by the Narcotics Control Bureau indicates that most of the 
seizures made in India in 2013 pertained to three drugs: 
heroin (4,609 cases, or 36 per cent), cannabis (4,592 cases, 
or 36 per cent) and cannabis resin (2,430  cases, or 
19 per cent). The seizures of those drugs reflect an upward 
trend from 2012 to 2013, both in the number of seizures 
and the quantities seized.
501. The number of heroin seizures in India increased 
significantly, by 46 per cent, from 3,155 cases reported in 
2012 to 4,609 cases in 2013. The quantities of heroin 
seized in 2013 stood at the highest level in the past five 
years. In 2013, 1,450 kg of heroin were seized, against 
1,033 kg in 2012, an increase of 38 per cent. This could 
indicate increased levels of heroin of Afghan origin being 
trafficked into India. Almost 50 per cent was seized in 
the state of Punjab, which borders Pakistan. The larger 
consignments of Afghan heroin are first smuggled into 
India through Pakistan, and then smuggled out in smaller 
quantities to major drug consumer markets in Australia, 
Canada and Europe.
502. Cannabis, in terms of quantity, is the major illicit 
drug seized in India. The number of seizures of canna-
bis increased marginally (by 2.8 per cent), from 4,468 cases 
reported in 2012 to 4,592 cases in 2013). Indian agencies 
seized 91,792 kg of cannabis in 2013, up from 77,149 kg 
in 2012. However, the quantity of cannabis seized in 2013 
remained significantly less than the 173,128 kg seized in 
2010. Substantial quantities of cannabis are trafficked into 
India from Nepal. An associated trend is the trafficking 
of cannabis from north-eastern states of India to eastern 
and other states in the country.
503. The number of reported seizures of cannabis resin 
seizures increased by 19.6 per cent, from 2,013 cases in 
2012 to 2,430 cases in 2013. The quantity of cannabis 
resin seized in 2013 was the largest in five years. In 2013, 
4,407 kg of cannabis resin were seized, up from 3,385 kg 
in 2012. Other than domestic production of cannabis 
resin, Nepal is a major source for trafficking of this sub-
stance into India. The long, open border between India 
and Nepal is convenient for drug traffickers to exploit. 
Cannabis resin is also trafficked from India to other 
 destinations in Europe and the Americas by means of 
courier parcels.
504. In India, 78 seizure cases related to cocaine were 
reported in 2013, an 8 per cent increase over the 72 cases 
reported in 2012. The quantity of cocaine seized increased 
from 44 kg in 2012 to 47 kg in 2013. As was the case for 
heroin and cannabis resin, the number of cocaine sei-
zures was the highest in the past five years. Usually, 
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cocaine has been seized in small quantities in South Asia 
and its trafficking has historically been very limited; how-
ever, that may no longer be the case. In 2013, out of all 
the cocaine seized in India, 89 per cent (41.6 kg) was 
seized in Maharashtra and Delhi, which may indicate the 
development of a new domestic market for the drug, 
which is generally associated with affluent areas.
505. Seizures of opium decreased from 3,625 kg in 2012 
to 2,333 kg in 2013, a decrease of 35.6 per cent. It is sus-
pected that the opium seized in India is diverted from 
licit ly cultivated opium poppy, while some may also come 
from illicitly cultivated opium poppy. Seizures of morphine 
declined significantly in 2013: only 7 kg of morphine were 
seized, down from 263 kg seized in 2012. The Narcotics 
Control Bureau continued to use satellite imagery, field 
surveys and intelligence-gathering to track and eradicate 
illicit poppy cultivation. Eradication operations were 
undertaken by law enforcement authorities. In 2013, 
approximately 2,139 ha of illicit poppy and 2,524 ha of 
cannabis were identified and eradicated. Concerted efforts 
regarding the eradication of illicit poppy have yielded 
encouraging results, and the area needing to be cleared of 
illicit poppy cultivation has been declining since 2011.
506. The vulnerability of Bangladesh to drug trafficking 
continued to be exacerbated by its long and porous bor-
ders with India and Myanmar. Illicit cannabis and opium 
poppy cultivation takes place in areas of Bangladesh bor-
dering those two countries. There are anecdotal reports 
of illicit poppy cultivation in inaccessible areas of 
Bandarban district, which borders Myanmar. In 2013, 
11.62 kg of opium were seized, compared with 4.84 kg 
and 8.07 kg in 2012 and 2011, respectively.
507. Trafficking of codeine-based cough syrups (such as 
phensedyl, Recodex and Corex) from India to Bangladesh 
continued to be reported. Although the Government of 
Bangladesh banned phensedyl under the 1982 drug ordi-
nance, its medical use is allowed in India if produced in 
amounts that are under specific threshold levels. In 2013, 
close to 1 million bottles of codeine-based preparations 
were seized in Bangladesh, a decrease from the 1.3 mil-
lion bottles seized in 2012. The quantities of bulk codeine 
seized have been decreasing steadily since 2010.
508. Seizures of heroin in 2013 in Bangladesh remained 
at the same level (124 kg) as in the preceding year. Heroin 
trafficked into Bangladesh continued to be smuggled 
from India and, to some extent, from the Golden Triangle 
countries. 
509. Seizures of cannabis, trafficked from India (Tripura, 
Meghalaya and West Bengal states) to Bangladesh, 
declined in 2013, amounting to 35 tons, compared with 
38 tons in 2012. Neither illicit cultivation nor wild growth 
of cannabis was to be found in Bangladesh, owing to the 
nature of the land. 
510. Synthetic opiates such as buprenorphine and pethi-
dine in injectable form continue to be trafficked into 
Bangladesh. The illicit use of those substances is increas-
ing and is seen as an emerging threat in Bangladesh. 
Seizures of buprenorphine increased from 118,872 ampoules 
in 2011 to 131,114 ampoules in 2012. 
511. Recent trends point to an increase in the traffick-
ing of Afghan heroin in fairly large consignments through 
Sri Lanka. Average annual seizures, which stood at about 
35 kg in 2011 and 2012, increased to 350 kg in 2013. The 
largest single amount was 260 kg, seized by Sri Lankan 
customs from a container that had originated in Karachi, 
Pakistan. In July 2014, the port control unit of the 
Colombo container control project seized 93.76 kg of 
heroin from a container that had originated in Pakistan. 
Almost 82 tons of cannabis from India were seized dur-
ing the reporting period. The amount of cannabis seized 
decreased by 9.8 per cent from 2012 to 2013. However, 
the amount of heroin seized in 2013 increased by 
90.5  per  cent compared with the previous year.
512. While the first case of cocaine trafficking in Nepal 
was detected in 2012, in 2014 there were new instances 
of trafficking of cocaine to the country by carriers from 
Namibia, Pakistan and Thailand via Brazil and Peru.
(b) Psychotropic substances
513. The South Asia region is increasingly being used 
for illicit manufacture and use of amphetamine-type 
stimulants (ATS). Major seizures of ATS were observed 
in the north-eastern part of India, which borders 
Myanmar. The powder form of ATS is now increasingly 
being smuggled and illicitly manufactured in India, which 
is emerging as the main source of illicit ATS manufac-
tured and trafficked in the region. However, tablets con-
taining ATS that are trafficked in India are mostly 
smuggled into the country from Myanmar. With the 
exception of 2011, both the quantities of ATS seized and 
the number of seizures have been rising in India for the 
past five years. Although the seizure of 85 kg of ATS in 
2013 was more than double the quantity seized in 2012 
(41 kg), it remained significantly lower than the 474 kg 
seized in 2011. It should be noted that in 2011, out of a 
total of 474 kg of ATS seized, one single seizure accounted 
for 469 kg. In 2013, 23 seizures of ATS were reported, 
the highest level during the past five years. In 2013, the 
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Narcotics Control Bureau of India reported the disman-
tling of four illicit manufacturing facilities, from which 
about 28 kg of methamphetamines were seized. 
514. Seizures of methaqualone recorded a sharp rise, 
from 216 kg in 2012 to 3,205 kg in 2013, the largest quan-
tity during the past five years in India. Methaqualone is 
often trafficked by means of courier parcels to Australia, 
Canada, Ethiopia, South Africa, the United Kingdom and 
South-East Asia. 
515. In Bangladesh, “yaba” (methamphetamine) contin-
ued to be smuggled across the south-eastern border from 
Myanmar. The quantities seized by Bangladesh law 
enforcement agencies have been rapidly increasing dur-
ing the past five years. In 2013, 2.8 million “yaba” tablets 
were seized, compared with 1.95 million in 2012. Sharp 
increases in seizures have been recorded since 2011.
516. The Maldives Customs Service seized metham-
phetamine (3.1 kg) for the first time, at an airport. 
Maldives being a popular tourist destination, the possi-
bility of growth in the phenomenon of synthetic drugs 
remains high. 
517. Diazepam and buprenorphine ampoules are 
reported to be smuggled into Nepal from India. In 2013, 
43,000 ampoules of diazepam and 31,000 ampoules of 
buprenorphine were seized in Nepal, which was less than 
the 72,000 and 58,000 ampoules of those substances, 
respectively, seized in 2012. 
(c) Precursors
518. The number of reported seizures of ephedrine in 
India rose sharply, from 17 cases in 2012 to 61 in 2013. 
The quantity of ephedrine seized also rose, from 4,393 kg 
in 2012 to 6,655 kg in 2013. 
519. The diversion of ephedrine from legal production 
in India to illicit channels remains a major challenge for 
law enforcement agencies. Seizures of pharmaceutical 
preparations containing ephedrine and pseudoephedrine 
that are being trafficked from India to Myanmar, for the 
extraction of the precursors, are frequently reported by 
Indian drug law enforcement agencies. Instances of 
ephedrine and pseudoephedrine trafficking to South-East 
Asia were also reported in 2013. Drug smugglers in India 
appear to be gradually shifting to ephedrine trafficking 
because of its higher profit margins. 
520. In India, the number of seizures of acetic anhy-
dride in 2013 went up from three cases in 2012 to eight 
cases in 2013. However, the quantity of seized acetic 
anhydride remained very low.
521. Bangladesh has a growing chemical and pharma-
ceutical industry, and has recently emerged as a source 
and transit location for methamphetamine precursors 
such as ephedrine and pseudoephedrine. The drug-
related challenges facing Bangladesh authorities in 2013 
continued to be the diversion of precursor-based phar-
maceutical preparations from the legitimate market and 
the smuggling of shipments out of the country. 
(d) Substances not under international 
control
522. India continues to be a source country for the traf-
ficking of ketamine to South-East Asia. Ketamine is 
legally manufactured in India and, since February 2011, 
is a controlled substance under the Narcotic Drugs and 
Psychotropic Substances Act, 1985. In 2013, Indian law 
enforcement agencies seized 1,353 kg of ketamine, a sig-
nificant increase from the 407 kg seized in 2012. Seizures 
indicate that ketamine is trafficked out of the country by 
air, by means of both cargo and passengers. Instances of 
ketamine being trafficked to Myanmar, the United States 
and Africa have also been reported. Seizures indicate the 
possibility of clandestine diversion from pharmaceutical 
companies.
5. Abuse and treatment
523. The prevalence of drug abuse by injection in South 
Asia in 2012 among the population aged 15 to 64 was 
0.03 per cent, which was very low compared to the global 
average of 0.27 per cent according to UNODC.51
524. In the absence of any drug survey conducted in 
Bangladesh, there are no real estimates of the extent of 
the illicit drug market in the country. In Bangladesh, 
HIV prevalence was increasing until 2010 but is 
reported to have subsequently decreased. Department 
of Narcotics Control officials stated that assessment is 
based largely on their interaction with non- governmental 
organizations. 
525. In recent years, drug abuse has spread not only 
within the urban areas but also to the rural areas of 
Bangladesh. The abuse of cannabis has increased gradually 
 51 United Nations Office on Drugs and Crime, World Drug Report 
2014 (United Nations, 2014), table 3.
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among poor, marginalized people such as day labourers 
and the populations of disadvantaged areas of the country. 
The abuse of “yaba” (methamphetamine) and codeine-
based preparations continues to be widespread and still 
increasing in Bangladesh. Among street children, the abuse 
of glue and solvents by sniffing is common. According to 
a report based on the client monitoring system of 
Bangladesh, about 31 per cent of those who were admit-
ted for drug-related treatment in 2013 were treated for 
 heroin addiction, 27 per cent for cannabis addiction, 
20 per cent for buprenorphine addiction and 1 per cent for 
sedative, hypnotic or tranquillizer addiction. Four per cent 
of drug abusers who were admitted for treatment in 
Bangladesh in 2013 indicated that they abused codeine 
cough syrup. Women continued to appear to make up a 
very small proportion of those receiving drug treatment in 
Bangladesh. 
526. To identify the pattern of ATS abuse in India, 
UNODC conducted a study in the states of Manipur, 
Mizoram, Punjab, Tamil Nadu and West Bengal. The 
study evaluated the adverse health consequences related 
to abuse of ATS. It showed that methamphetamine pills 
and powder were the most commonly used forms of ATS. 
Most participants were in their early twenties and about 
half of them were found to be dependent users. A quar-
ter of the participants reported experiencing psychiatric 
problems after use of ATS, including paranoia, hallucina-
tions, depression and panic attacks. Eighteen per cent of 
the participants confirmed that they had been appre-
hended by the police after abusing ATS, which suggests 
a link between the use of ATS and crime. Following that 
study, plans were made to establish, with UNODC assis-
tance, two regional centres, one in Chennai (southern 
India), in collaboration with Psymed Hospital, and one 
in Mizoram (north-eastern India), in collaboration with 
the Presbyterian Hospital, Durtlang. Those centres would 
aim to develop comprehensive treatment models and 
standard operating procedures and guidelines for health-
care providers.
527. According to the National AIDS Control 
Organization of India, in 2013 there were approximately 
180,000 people who were injecting drugs in the country. 
The prevalence of HIV among that group was 7.2 per cent.
528. In 2013, a pilot project was initiated at the National 
Drug Dependence Treatment Centre of the All India 
Institute of Medical Sciences to offer methadone mainte-
nance treatment to drug users in India. The aim of the 
project was to test the effectiveness and feasibility of 
methadone maintenance treatment in the Indian context 
and to develop an action plan for rolling out the pro-
gramme. With a 36 per cent retention rate across all 
participating centres, the project was well received by 
drug users and their families as a treatment option.
529. The estimated number of registered drug users in 
Sri Lanka was 245,000, of which 200,000 used cannabis 
and 45,000 used opioids. In 2013, a total of 1,364 people 
received drug treatment in that country. Among them, 
1,141 were treated for opioid addiction and 223 for 
 cannabis addiction.
530. The first-ever network of and for women drug 
users in Nepal, called the Nepal Drug Users Prevention 
Association, was launched by UNODC in collaboration 
with Dristi Nepal, a non-governmental organization 
based in Kathmandu.
West Asia
1. Major developments
531. The political instability caused by situations of 
armed conflict and political strife in West Asia, particu-
larly in Iraq, Lebanon, the Syrian Arab Republic and the 
State of Palestine, has continued to weaken governance 
structures, hamper existing drug control efforts in the 
region and pose new challenges to those efforts.
532. The deterioration in the capacity of several States 
in the region to exercise effective control over their bor-
ders and territory has been exploited by traffickers seek-
ing to profit from lucrative illicit drug markets in the 
countries affected. Moreover, the humanitarian situation 
in the region caused by large numbers of refugees, inter-
nally displaced persons and injured civilians has strained 
the resources of States directly affected by the conflicts, 
as well as of neighbouring States taking in large numbers 
of refugees. The crisis situation in the Syrian Arab 
Republic clearly creates conditions favourable to the illicit 
manufacture and trafficking of tablets sold as Captagon 
(often containing amphetamine) destined for regional 
markets.
533. Afghanistan set a new record for opium poppy cul-
tivation in 2014, reaching 224,000 ha, 7 per cent more 
than the previous year. Production of opium also 
increased by 17 per cent over the previous year, to 
6,400 tons, as illicit opium poppy cultivation increased in 
the majority of poppy-cultivating provinces. Production 
of cannabis resin in Afghanistan was reported to have 
increased in 2012, despite the fact that cultivation of can-
nabis plant decreased. The majority of farmers surveyed 
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in 2013 mentioned the high income derived from the sale 
of illicit crops as the main reason for the cultivation of 
illicit opium poppy. 
534. The number of seizures of illicit drugs (narcotic 
drugs and psychotropic substances) in the Middle East 
subregion increased significantly from 2012 to 2013. 
Cannabis has always been and continues to be grown and 
consumed in the subregion, where a growing number of 
seizures of cannabis resin have been reported.
535. There is evidence that heroin trafficking routes lead-
ing out of Afghanistan have diversified, with greater traf-
ficking via Iran (Islamic Republic of), Pakistan, the Middle 
East and Africa now being reported, as well as increasing 
trafficking via maritime routes. Additionally, Afghan her-
oin is increasingly found in new markets as far away as 
South-East Asia and Oceania; it is possible that it is being 
sent to those markets to offset declines in heroin consump-
tion in Western and Central European markets. 
536. Countries in West Asia, whose geography and 
extensive coastlines and borders have made them par-
ticularly favourable for use as transit areas, have now also 
become countries of abuse and trafficking. Trafficking 
and abuse of cocaine and heroin in particular have 
emerged in some countries in the region.
537. Abuse of stimulants such as amphetamines and 
cocaine is increasingly problematic in parts of West Asia. 
Amphetamine dominates the market, and large seizures 
continue to be reported in the region, with over 12 tons 
seized in 2012, representing more than half of global sei-
zures. Seizures of methamphetamine have been reported 
throughout the region, from Afghanistan to Turkey, while 
abuse has been reported in Iran (Islamic Republic of), 
Israel and, to a lesser degree, Pakistan. Seizures of cocaine 
continue to increase, although prevalence of abuse still 
appears to be relatively low.
538. Growing political instability, civil conflict and 
insurgency in many countries in the region, as well as 
the spillover into neighbouring countries, threaten to 
reverse the region’s limited progress towards achieving 
the goals set out in the 2009 Political Declaration and 
Plan of Action on International Cooperation towards an 
Integrated and Balanced Strategy to Counter the World 
Drug Problem.
2. Regional cooperation 
539. Regional cooperation is essential in West Asia, as 
the region lies at a crossroads in the global trafficking of 
opiates, cannabis and precursor chemicals. Stability 
remains a primary concern in many countries of the 
region, as well as a concern of the Security Council, and 
much of the cooperation is increasingly focused on 
improving political stability in several countries, particu-
larly in Afghanistan, following the conclusion of the 
International Security Assistance Force (ISAF) mission.
540. The League of Arab States and the Cooperation 
Council for the Arab States of the Gulf (GCC) play a fun-
damental role in enhancing cooperation among countries 
in the region. Several meetings were held during the past 
year with a view to facilitating effective cooperation in 
drug control between Member States. 
541. Effective bilateral security coordination, in particu-
lar between Bahrain, Saudi Arabia and the GCC Criminal 
Information Centre to Combat Drugs, led to the preven-
tion of several attempts to smuggle tablets sold as 
Captagon and to the arrest of drug traffickers in the 
region.
542. Efforts were undertaken by UNODC to promote 
linkages and cooperation between similar regional infor-
mation-sharing groups, such as the GCC Criminal 
Information Center to Combat Drugs, the Central Asian 
Regional Information and Coordination Centre, the Joint 
Planning Cell and the Southeast European Law 
Enforcement Center, with the aim of more effectively 
countering international drug trafficking flows. An inter-
agency meeting entitled “Networking the networks: an 
interregional drug control approach to stem drug traf-
ficking” was held in Istanbul, Turkey, in December 2013, 
to identify priorities and avenues for such enhanced 
cooperation.
543. In February 2014, the Board participated in the 
first INTERPOL meeting of heads of drug control units 
in the Middle East and North Africa, which focused on 
the most commonly abused drugs, including tramadol, 
amphetamine-type stimulants and tablets sold as 
Captagon, and on large-scale interceptions of heroin.
3. National legislation, policy and 
action 
544. In December 2013, Afghanistan adopted the 
National Drug Demand Reduction Policy for the period 
2012-2016. Its main objectives are to prevent vulnerable 
groups, such as children and adolescents, from becom-
ing drug abusers, to reduce the social and health impact 
of drug abuse in affected communities, to provide access 
to high-quality standardized licensed therapeutic and 
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rehabilitation services for all drug abusers and to estab-
lish epidemiological and policy coordination centres to 
collect, analyse, disseminate and use drug demand data.
545. The Government of Turkey implemented its new 
national policy and strategy document on drugs for the 
period 2013-2018, which covers the activities of various 
ministries, public institutions and organizations regard-
ing supply reduction, demand reduction, international 
cooperation, data collection, research, evaluation and 
coordination at the national level. A new approach in 
demand reduction treats drug addiction as an important 
public health issue and promotes prevention activities, 
support for the medical treatment of drug addiction and 
the prioritization of social reintegration activities. In 
addition, a large number of non-scheduled new psycho-
active substances were placed under national control in 
Turkey in 2013 and 2014, including synthetic cannabi-
noids, cathinones and piperazines.
546. A number of other countries have amended legis-
lation in response to the growing threat posed by new 
psychoactive substances. In 2013, the Government of 
Israel added emergency scheduling powers to its existing 
drug control legislation, whereby new psychoactive sub-
stances may be expediently added to the urgent declara-
tions of substances prohibited for distribution, bringing 
such substances temporarily under control for one year 
while they undergo review for permanent listing under 
the Dangerous Drug Ordinance. In 2014, numerous addi-
tional new psychoactive substances were temporarily 
brought under control, while those added in 2013 were 
permanently added to the country’s drug control legisla-
tion. The legislative amendments empower Israeli law 
enforcement authorities to seize and destroy substances 
considered dangerous, thus making it the responsibility 
of the possessor to prove the harmlessness of the sub-
stances. In December 2013, Georgia’s law on narcotic 
drugs, psychotropic substances and precursors and nar-
cological assistance was amended to include several syn-
thetic cannabinoids, with the threshold for the minimum 
amount of illicit possession set at 0.05 g.
547. The Board notes with concern reports that the 
Council of State of Oman proposed to make use of the 
death penalty for offences related to drug trafficking into 
Oman. The Board wishes to draw attention to its state-
ment of 4 March 2014, in which it encouraged States that 
retain and continue to impose the death penalty for drug-
related offences to consider abolishing the death penalty 
for such offences. 
548. The Government of Kuwait is in the process of 
incorporating into its national legislation provisions for 
special investigative techniques, including controlled 
deliveries, in accordance with the provisions contained in 
article 1 of the 1988 Convention, in order to enhance 
cross-border operations.
549. In their efforts to better address growing illicit 
activities and drug trafficking, a number of laws on drug 
control, money-laundering and cybercrime have been 
adopted in the State of Palestine. In addition, a national 
plan on drug control, crime prevention and criminal jus-
tice reform for the 2014-2017 period was developed with 
the assistance of UNODC.
4. Cultivation, production, 
manufacture and trafficking 
(a) Narcotic drugs 
550. In 2014, illicit cultivation of opium poppy in 
Afghanistan set another record, at 224,000 ha, an increase 
of 7 per cent over the previous year and part of a long, 
continuing trend of increasing illicit cultivation. More 
than half of the country’s 34 provinces have opium poppy 
cultivation in excess of 100 ha, with illicit cultivation 
involving hundreds of thousands of households.
551. The vast majority (89 per cent) of Afghanistan’s 
illicit opium poppy cultivation took place in nine prov-
inces in the southern and western areas of the country, 
which include the country’s least secure provinces. 
Cultivation of opium poppy in Afghanistan is inversely 
related to security: as security deteriorates, illicit cultiva-
tion increases. As the ISAF mission comes to a close in 
2014, the Board is concerned that a deterioration in the 
security situation could result in yet further increases in 
illicit crop cultivation.
552. Eradication of opium poppy fields, one of the 
Afghan Government’s tools to reduce the amount of 
opium available for heroin manufacture, has yielded lit-
tle to no tangible effect on opium production. Between 
2009 and 2014, less than 4 per cent of the annual area 
under cultivation in Afghanistan was verifiably eradicated 
(see figure III below). The total area of opium poppy cul-
tivation eradicated decreased by 63 per cent between 
2013 and 2014, to 2,692 ha, or just 1.2 per cent of the 
total area under cultivation. Further declines in the total 
area of verified opium poppy eradication seen in 2014 
were the result in part of a decreasing security situation 
in main cultivating provinces, which resulted in unsafe 
conditions for manual eradication efforts led by provin-
cial governors.
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553. Farmers rely on the higher income derived from 
the sale of illicit crops. Additionally, alternative livelihood 
assistance is not available to all farmers in all areas of the 
country cultivating illicit crops. With little chance of illicit 
crops being eradicated and limited alternatives, the ben-
efits of cultivation of illicit crops far outweigh any risk to 
the farmers’ investment. The Board strongly urges the 
Government of Afghanistan, in partnership with the 
international community, to increase its efforts to reduce 
opium poppy cultivation.
Figure III. Opium poppy illicitly cultivated and 
eradicated in Afghanistan, 2009-2014
Sources: UNODC and Afghanistan, Ministry of Counter-Narcotics; 
and UNODC, World Drug Report 2014.
554. Afghanistan accounts for 80 per cent of the esti-
mated global illicit production of opium, according to 
UNODC 2013 estimates. Production of opium—which 
results in, among other things, illicit manufacture of mor-
phine and heroin—increased to 6,400 tons in 2014, an 
increase of 17 per cent over the previous year’s total. 
Despite some increase, Afghan opium yields in 2014 
(29 kg per ha) continued to be somewhat lower than the 
previous five-year average (31 kg/ha), mainly owing to 
poor weather conditions in parts of Afghanistan.
555. Although Afghan authorities have over the past 
decade made an increasing amount of drug seizures, only 
a small fraction of opium and related opiates (i.e., heroin 
and morphine) are seized in the country, averaging less 
than 3 per cent of the estimated annual opium produc-
tion between 2009 and 2013 (see figure IV below). This 
means that seizure represents only a small risk to traf-
fickers compared with the illicit income generated by 
Afghan drug trafficking, which UNODC estimates to be 
$2.2 billion annually, and the profits from which fuel an 
entrenched culture of corruption in Afghanistan, as well 
as in other countries throughout the region.
Figure IV. Opium produced illicitly, 2009-
2014, and opiates seized in Afghanistan, 
2009-2013
Sources: UNODC, World Drug Report 2014; UNODC and Afghani-
stan, Ministry of Counter-Narcotics, Afghanistan Opium Survey 
2014; and Afghanistan, Ministry of the Interior and the Counter-
Narcotics Police of Afghanistan, Annual Achievement Report  
for 2013.
* Seizure data for 2014 were not available at the time of  
publication.
556. The modest seizure rate in Afghanistan shifts the 
burden to neighbouring countries, particularly as culti-
vation and production levels increase. For example, the 
National Drug Control Headquarters of the Islamic 
Republic of Iran reported a considerable rise in seizures 
of opium, heroin and morphine in 2013, which increased 
14 per cent, 53 per cent and 49 per cent, respectively, 
from 2012. The increasing flow of opiates out of 
Afghanistan creates a domino effect further down the 
supply chain, such as in Armenia, where in January 2014 
customs officers discovered 928 kg of heroin hidden in a 
truck coming from the Islamic Republic of Iran en route 
to Turkey via Georgia.
557. Maritime routes that depart from ports in Iran 
(Islamic Republic of) and Pakistan are increasingly being 
utilized to smuggle Afghan heroin, as the use of physical 
barriers and monitoring posts along the eastern land bor-
der of the Islamic Republic of Iran has made overland 
trafficking increasingly difficult. Iranian authorities 
reported seizures of 7.5 tons of narcotic drugs as a result 
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of sharing intelligence with the country’s maritime neigh-
bours in the first 10 months of 2013. Seizures of heroin 
at seaports by the Pakistani authorities more than dou-
bled over the previous year, approaching 1.2 tons in 2013.
558. The amount of heroin seizures reported by the 
Jordanian authorities has more than doubled over the 
past three years, totalling 244 kg in 2013, compared with 
92 kg in 2011. Eighty per cent of the heroin seized in 
Jordan was destined for Israel. In June 2014, 24 kg of 
pure heroin were seized at the Dubai International 
Airport by Dubai Customs, the largest smuggling attempt 
in 10 years. 
559. With respect to heroin seizures in Bahrain, follow-
ing an exceptional level of seizures in 2012 (more than 
8 kg), the total quantity seized in 2013 dropped to 1.7 kg.
560. Afghanistan continues to be one of the largest 
known producers of cannabis resin, with total cannabis 
plant cultivation estimated to be 10,000 ha in 2012, yield-
ing an estimated 1,400 tons of resin, which is 8 per cent 
higher than the estimate for the previous year. The price 
of cannabis resin in Afghanistan declined in 2012, even 
as seizures in the country rose to nearly triple the amount 
of the previous year, reaching 160 tons. According to 
UNODC, no price decreases were reported in neighbour-
ing Kazakhstan, Kyrgyzstan or Pakistan, likely owing to 
the increased seizures reported in those countries. 
Pakistan, for example, reported seizing 105 tons of can-
nabis resin, an 80 per cent increase compared with 2012.
561. In 2013, although the number of seizures of opi-
ates in the Middle East subregion declined from the num-
ber in 2012, the quantity seized doubled. Illicit cultivation 
of cannabis plants continues in some areas of the Middle 
East, in particular the Bekaa valley in eastern Lebanon, 
where eradication remains a challenge. Cannabis plants, 
seeds and oil are frequently seized in the subregion.
562. More than 5 tons of cannabis were seized in Jordan 
in 2013, a considerable increase compared with the 
1.9  tons seized in 2011. According to the data provided 
to the Board by the Kuwaiti authorities, seizures of can-
nabis more than doubled during the past three years. In 
2013, the total quantity seized amounted to 1.1 tons, com-
pared with less than 500 kg in 2011. In contrast, seizures 
of narcotic drugs reported by Bahrain showed a signifi-
cant declining trend.
563. In 2013, seizures of cannabis resin in the Middle 
East subregion increased considerably. Israel reported sei-
zures of 1,594 kg of cannabis resin. Nearly 500 kg of can-
nabis resin were seized in Jordan, and total seizures 
reported by the Syrian Arab Republic amounted to 
267 kg, representing more than double the quantity seized 
in 2012. Furthermore, 12.5 kg were seized in Lebanon, 
representing an upturn compared with 2011, when 700 g 
were seized. In contrast, information made available to 
the Board shows that seizures of cannabis resin in Bahrain 
dropped from more than 2 kg in 2011 to 5 g in 2013.
564. Cannabis resin seized in Jordan in 2014 originated 
in Lebanon and Afghanistan. About 10 per cent of it was 
destined for the domestic illicit market and the rest for 
Israel and Saudi Arabia.
565. The increased use of alternative trafficking routes, 
including maritime routes, may be having an impact on 
opiate and cannabis seizures reported throughout Central 
Asia. For 2013, notwithstanding individual country dif-
ferences, seizures of opiate and cannabis substances were 
largely unchanged from 2012, with a little more than 
90  tons reported seized, according to the Central Asian 
Regional Information and Coordination Centre.
566. As has been noted with concern by the Board in 
the past two years, there has been an increasing flow of 
cocaine to West Asia. This is reflected in rising seizures, 
both in numbers and amounts, throughout West Asia, as 
trafficking groups possibly identify emerging markets in 
which to expand, in order to offset the declines seen in 
large established cocaine markets such as North America 
and Western Europe.
567. Israel and the United Arab Emirates were among 
the four Asian countries reporting the largest cocaine sei-
zures in 2012. The United Arab Emirates, a traditional 
transit country for large numbers of passengers, fuels new 
markets in Africa and Asia. Likewise, Jordan and the 
Syrian Arab Republic serve as transit countries, while 
other countries, including Israel and Lebanon, have 
emerged as destinations for cocaine. In 2012, 570 kg of 
cocaine were seized in Saudi Arabia, 204 kg in the United 
Arab Emirates, 171 kg in Israel and 66 kg in the Syrian 
Arab Republic.
568. The Israel Anti-Drug Authority estimates that 
some 3 tons of cocaine are smuggled into that country 
annually, increasingly in liquid form, often found in wine 
bottles or absorbed into clothing items. In Turkey, sei-
zures of cocaine have increased five-fold during the past 
five years, with 450 kg reported seized in 2013, as West 
African criminal groups increasingly supply cocaine to 
Turkish markets. Pakistan’s Anti-Narcotics Force also 
reported seizures of cocaine in 2013 and provided intel-
ligence that assisted in effecting significant seizures of 
cocaine abroad.
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(b) Psychotropic substances
569. Trafficking in amphetamine-type stimulants, such 
as tableted amphetamine (Captagon) and methampheta-
mine (“yaba”) and methamphetamine in crystalline form, 
continues to be of concern throughout West Asia. 
Growing use of synthetic drugs has been reported in a 
number of countries in the Middle East subregion, includ-
ing Jordan, Kuwait, Qatar and the United Arab Emirates. 
Operations conducted by States in the region regularly 
result in large seizures of amphetamine-type stimulants, 
including those sold as Captagon. In that context, the 
Board encourages Governments in the subregion to con-
tinue to enhance their efforts to monitor the situation 
regarding amphetamine-type stimulants, including in 
cooperation with the SMART programme of UNODC.
570. Trafficking among and abuse of amphetamine in 
countries in the Middle East continued to be regularly 
reported. However, although the number of seizures of 
that substance remained stable, the amounts seized 
declined noticeably. Amphetamine seized in Saudi Arabia 
fell to 977 kg in 2013, compared with 5.2 tons the year 
before.
571. Almost all countries in the Middle East reported 
seizures of tablets sold as Captagon in 2013, in particu-
lar Saudi Arabia, Lebanon, Jordan and Yemen (in order 
of largest total seizures). Total seizures increased notice-
ably, both in quantity and in number. Saudi Arabia con-
tinues to be the destination country of choice. The World 
Customs Organization reported that customs authorities 
in the Middle East seized 11 tons of Captagon in 2013 
and that Captagon was smuggled mostly in vehicles or 
by sea. Saudi Arabia reported seizures of nearly 8 tons of 
Captagon, followed by Lebanon and by Jordan, where 
more than 22 million Captagon tablets were seized.
572. Most of the Captagon tablets are smuggled through 
the unofficial land-border crossings between the Syrian 
Arab Republic and Jordan, and then transit Jordan, with 
Saudi Arabia as the main final destination.
573. Turkey reported seizing 105 kg of methampheta-
mine in 2013, a significant decrease from the more than 
500 kg of seizures reported in 2012. Methamphetamine 
is often trafficked via Turkey to East Asia (Indonesia, 
Japan, Malaysia, Singapore, Thailand and Viet Nam). 
Turkey and several other countries in the region continue 
to identify the Islamic Republic of Iran as the main source 
of methamphetamine seized. However, stronger interdic-
tion efforts in the Islamic Republic of Iran may be respon-
sible in part for the sharp decrease in seizures reported 
in Turkey.
574. The number of dismantled illicit methampheta-
mine laboratories in the Islamic Republic of Iran rose 
sharply, to 445 in 2013, more than double the number in 
the previous year. Seizures of methamphetamine in that 
country were also considerable, among the highest 
reported total seizures worldwide: 3.7 tons of metham-
phetamine were reported seized in the country in 2013, 
10 per cent more than in 2012 (see figure V below). 
Additionally, illicit methamphetamine manufacture 
appears to have spread to neighbouring Afghanistan, with 
the confirmed dismantling of a clandestine laboratory 
occurring for the first time in 2013. The laboratory was 
discovered in the south-western province of Nimroz, 
which borders the Islamic Republic of Iran.
Figure V. Seizures of methamphetamine in the 
Islamic Republic of Iran, 2009-2013
Sources: Islamic Republic of Iran, Drug Control in 2013 and the 
National Drug Control Headquarters (2014); and UNODC data for 
the period 2009-2012.
575. In Israel, the amount of methamphetamine inter-
cepted increased to 88 kg in 2013, more than double the 
quantity reported in 2012; the number of seizures fol-
lowed a similar upward trend.
576. Abuse of pharmaceuticals containing psychotropic 
substances, in particular benzodiazepines, continues to 
be a serious concern in parts of West Asia. Seizures of 
diazepam, alprazolam and clonazepam were regularly 
reported. 
577. The ability of many Governments in the region to 
accurately detect and report on the numerous, often con-
fusing, psychotropic and new psychoactive substances 
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encountered, such as methylphenidate, amphetamine and 
methamphetamine, is hampered by the limited technical 
capacity of their forensic laboratories. The UNODC inter-
national collaborative exercises programme allows foren-
sic laboratories to continuously monitor their drug-testing 
performance on a global scale, an essential element for 
any laboratory quality management system and, ulti-
mately, laboratory accreditation. Currently, however, only 
9 of 24 West Asian countries take part in the programme. 
The Board encourages all Member States in the region to 
take part in the international collaborative exercises pro-
gramme and other UNODC technical assistance pro-
grammes intended to strengthen the capacity of forensic 
laboratories.
(c) Precursors
578. Afghanistan is not a manufacturer of acetic anhy-
dride, a chemical needed for the manufacture of heroin, 
and this precursor is not legally allowed to enter the 
country. However, acetic anhydride continues to be smug-
gled into Afghanistan after domestic diversion in other 
countries. For example, in June 2013, customs authorities 
of the Islamic Republic of Iran intercepted approximately 
18 tons of acetic anhydride that had been shipped from 
China and were destined for Afghanistan. That seizure 
accounted for 54 per cent of the total amount of acetic 
anhydride seized in the Islamic Republic of Iran in 2013. 
Intelligence related to this seizure was communicated via 
PICS. However, not all countries in the region received 
the PICS automated alerts, as they were not registered 
with the system. The Board urges the remaining coun-
tries of West Asia not registered with PICS, namely 
Armenia, Kuwait, Oman, Saudi Arabia, the Syrian Arab 
Republic, Turkmenistan, Uzbekistan and Yemen, to reg-
ister with the system.
579. The Board noted in its annual report for 2013 that 
eight countries of West Asia, namely Bahrain, Georgia, 
Iran (Islamic Republic of), Israel, Kuwait, Turkmenistan, 
Uzbekistan and Yemen, had not requested to be informed 
of impending shipments of precursor chemicals prior to 
their departure from exporting countries, as outlined in 
article 12, paragraph 10 (a), of the 1988 Convention. 
Effective May 2014, the Government of Yemen requires 
pre-export notification for imports of all Table I and II 
substances. The action by Yemen notwithstanding, lack 
of action by the other countries in the region puts not 
only themselves, but also neighbouring countries, at 
heightened risk of diversion. The Board again urges 
countries that have not invoked their right to require 
pre-export notification for all substances included in 
Tables I and II of the 1988 Convention to do so without 
further delay.
(d) Substances not under international 
control
580. Trafficking and abuse of known medicaments and 
plant-based substances with psychoactive properties, 
such as khat (Catha edulis), that are not under inter-
national control continue to pose a more prominent 
problem in the region than do synthetic-based new 
psycho active substances, but abuse of new psychoactive 
substances is growing in parts of West Asia. Trafficking 
and abuse of tramadol, a synthetic opioid, continued to 
be reported in most countries in the Middle East, and 
abuse of khat continued to be reported on the Arabian 
peninsula.
581. The Board notes that tramadol, a synthetic opioid 
that is not under international control, has been placed 
under national control in most countries in the Middle 
East. Tramadol is a prescription-only medication and is 
already controlled under national legislation on psycho-
tropic substances and/or narcotic drugs in Bahrain, 
Jordan, Qatar and Saudi Arabia. Abuse of tramadol is 
reported by many countries in the West Asia subregion.
582. Turkey has reported significant increases in the 
trafficking of synthetic cannabinoids, referred to locally 
as “bonsai”, with seizures, effected primarily among street 
dealers, increasing 22-fold between 2011 and 2013. 
Synthetic cannabinoids are typically smuggled into 
Turkey from China, European countries and the United 
States. However, the Government also reported that in 
2013 it had dismantled facilities producing synthetic 
cannabinoids.
583. It is necessary for concerned Governments to share 
in a timely manner information on suspicious shipments 
of and trafficking in new psychoactive substances in order 
to support investigations into the points of manufacture, 
production and packaging, export and distribution of 
such substances. The Board’s international initiative on 
new psychoactive substances (Project Ion) coordinates 
practical activities for the gathering and sharing of infor-
mation as a means to support law enforcement and reg-
ulatory agencies, in line with the recommendation of the 
Commission on Narcotic Drugs in its resolution 57/9. 
The Board urges the remaining 11 Governments of West 
Asia that have not yet nominated law enforcement and 
regulatory focal points under Project Ion to do so with-
out delay.
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5. Abuse and treatment
584. Nearly 20 per cent of the world’s opiate abusers 
reside in West Asia, as increasing production of opium 
in Afghanistan has resulted in greater abuse of opium 
and heroin, primarily in that country and in neighbour-
ing countries located along the recently expanding traf-
ficking routes. For example, the annual prevalence of 
opiate abuse among adult Pakistanis aged 15-64 years has 
grown from 0.7 per cent in 2006 to 1.0 per cent in 2013, 
concurrent with increases in trafficking of opiates via 
Pakistan. In addition to Pakistan, UNODC estimates the 
current annual prevalence of opiate abuse among adults 
to be highest in Afghanistan (2.3-3 per cent), Azerbaijan 
(1.3-1.7 per cent) and the Islamic Republic of Iran 
(2.3 per cent).
585. Abuse of drugs in Afghanistan, in particular opi-
ates, appears to be increasing. The 2012 Afghanistan 
National Urban Drug Use Survey found that 1 in 10 
urban households had a person who had tested positive 
for drugs, most commonly for opiates. The study esti-
mated current drug abuse prevalence at 7.5 per cent of 
the general population aged 16 years and older, a figure 
notably higher than the previous estimates. As of 2013, 
109 drug treatment centres providing pretreatment, treat-
ment, post-treatment and aftercare services were operat-
ing throughout the country, and capacity had increased 
during the past two years, although the centres still had 
service capacity for less than 6 per cent of the estimated 
number of opiate-addicted persons.
586. Drug treatment capacity has also notably increased 
in the Islamic Republic of Iran, where the number of per-
sons receiving treatment in 2013 was 755,394, an 
18 per cent increase since 2009. In 2013, 5,223 drug treat-
ment centres were operating in the country, including 
those providing methadone substitution and buprenor-
phine substitution therapy to 267,844 and 24,029 persons, 
respectively.
587. The Board notes that a number of countries in the 
Middle East are devoting special attention and efforts to 
the treatment and rehabilitation of drug addiction. In that 
context, the Board notes that the opioid substitution 
treatment programme launched in Lebanon in 2012 is 
now fully operational, and that 949 patients were regis-
tered as of December 2013. In a similar effort, in 2013 
UNODC provided policy advice and technical assistance 
in the State of Palestine through the Ministry of Health, 
for the introduction of opioid substitution therapy.
588. Given the lack of reliable data on the extent of drug 
abuse in the region in general, governmental and 
non-governmental entities that specialize in drug addic-
tion treatment in Jordan are working together to create 
a national database on drug abuse. Establishing an accu-
rate estimate of the extent of the phenomenon of drug 
abuse will assist in the development of better-suited and 
tailored strategies.
589. The spread of disease through unsafe injecting 
practices, such as the sharing of used injecting equip-
ment, continues to be a significant problem in several 
countries in West Asia. The prevalence rates for opiate 
abuse by injection among the general population in 
Afghanistan, Iran (Islamic Republic of) and Pakistan are 
among the highest in the world, estimated to be 
1.5 per cent of the adult population in those three coun-
tries. Countries with a high prevalence of opiate abuse 
tend to have an elevated prevalence of people who inject 
drugs and are also living with HIV. For example, 
28.8  per  cent of people who inject drugs in South-West 
Asia were estimated to be HIV-positive, more than dou-
ble the global prevalence among people who inject drugs, 
which was estimated to be 13.1 per cent in 2012. The 
prevalence rate for South-West Asia largely reflects the 
high prevalence of HIV-positive people among people 
who inject drugs in Pakistan, estimated to be 37 per cent.
590. There is still a lack of sufficient and reliable data 
to assess the levels of HIV infection and transmission in 
order to be able to assess the extent of emerging HIV 
epidemics that have been reported among people who 
inject drugs in most countries in the Middle East. 
According to the findings of a medical study in Bahrain 
and Oman, 10-15 per cent of people who inject drugs are 
HIV-positive. Although the HIV epidemics among peo-
ple who inject drugs remain in their early phases, it is 
estimated that there are 626,000 people who inject drugs 
in the Middle East. In other countries, including Jordan, 
Lebanon, the Syrian Arab Republic and the State of 
Palestine, the transmission of HIV among this at-risk 
population was found to be limited.
D. Europe
1. Major developments
591. Most countries in Western and Central Europe 
have reported a decline in the prevalence of heroin abuse 
and in the number of people commencing treatment for 
heroin abuse for the first time, accompanied by an over-
all decrease in the quantity of heroin seized. However, 
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there are concerns that heroin is being partly replaced as 
a substance of abuse by synthetic opioids, such as fenta-
nyl, buprenorphine and methadone. In some countries, 
such substances now account for the majority of opioid 
treatment cases. In the subregion, deaths associated with 
heroin abuse are declining, while deaths linked to syn-
thetic opioids are on the rise. Changing patterns with 
regard to injecting drug abuse, with a possible trend away 
from injection of heroin to injection of synthetic opioids, 
amphetamine-type stimulants or new psychoactive sub-
stances, have also been noted in some countries of the 
subregion.
592. Eastern and South-Eastern Europe have a signifi-
cantly higher prevalence of injecting drug abuse, as well 
as of HIV among people who inject drugs, than the global 
average. Within those subregions, relatively high rates of 
injecting drug abuse were observed among the popula-
tions of Belarus, the Republic of Moldova, the Russian 
Federation and Ukraine.
593. The levels of opiate abuse in Eastern Europe, sup-
ported by the supply of heroin from Afghanistan, are sig-
nificantly higher than the global average. An increase in 
the proportion of admissions for treatment that were for 
cannabis abuse (from 8 per cent to 15 per cent) could be 
observed in Eastern and South-Eastern Europe between 
2003 and 2012.
594. In 2013, an increased use of the Balkan route for 
trafficking of illicit drugs could be observed, although the 
amounts involved were not as large as during the peak 
period of 2007. Seizures of heroin along the Balkan route 
increased, as heroin continued to be redistributed in the 
Netherlands and, to a lesser extent, Belgium for illicit 
markets in Western Europe.
595. In 2013, South-Eastern Europe continued to see an 
expansion in the trafficking of Albanian cannabis herb. 
At the same time, many countries of the subregion con-
tinued to experience an increase in the local production 
of cannabis herb, including a highly potent form of this 
substance.
596. The availability and abuse of new psychoactive 
substances remains a major public health challenge in 
Europe, with a record level of such substances newly 
identified in 2013 and an increasing involvement of 
organized criminal groups in the market. Governments 
are continuing to take measures to address the problem, 
at both the national and the regional levels, for instance 
by placing individual substances or groups of substances 
under national control or by introducing temporary bans 
on potentially harmful substances.
2. Regional cooperation
597. The seventy-third meeting of Permanent Corre-
spondents of the Pompidou Group of the Council of 
Europe, held in November 2013, resulted in the adoption 
of the Declaration on Protecting Public Health by 
Ensuring Essential Services in Drug Policy under 
Austerity Budgets. In the Declaration, the representatives 
of States participating in the meeting noted with concern 
changing patterns of drug abuse under circumstances of 
strict austerity measures and their impact on public 
health. The potential changes identified included: a pos-
sible risk of earlier onset of drug abuse; an increasing 
prevalence of injecting drug abuse, relapses, risk-taking 
and overdosing, particularly among vulnerable groups; 
and an increasing incidence of polydrug abuse. They 
committed the Pompidou Group to working on that issue 
and called on other international organizations and non-
member States to support the Group’s efforts to mitigate 
such consequences of economic crises and resulting 
 austerity measures, in particular by joining the Group’s 
efforts to create safeguards against stigmatization and 
 discrimination against people who abuse drugs.
598. The countries and areas of the western Balkans, 
including Albania, Bosnia and Herzegovina, Montenegro, 
Serbia, the former Yugoslav Republic of Macedonia and 
Kosovo,52 continued to strengthen cooperation with 
European Union member States in the area of drug con-
trol during the reporting period. In May 2014, represent-
atives of European Union member States and countries 
of the western Balkans met in Brussels to engage in a 
dialogue on drugs. At that meeting, which was the first 
since the adoption of the joint declaration of the European 
Union and the western Balkans on strengthening coop-
eration in the area of drug control and updating the 2009-
2013 action plan of the European Union and the western 
Balkans on drugs, participants discussed past achieve-
ments with regard to cooperation between the regions, 
as well as the most recent developments in drug moni-
toring and policy. The aforementioned declaration was 
adopted by ministers of home affairs of European Union 
member States and western Balkan States on 20 December 
2013 in Montenegro, demonstrating the commitment of 
all parties to strengthening national drug information 
systems. 
599. In April 2014, an agreement between the European 
Union and the Russian Federation on precursor chemi-
cals came into effect, aimed at strengthening cooperation 
 52 All references to Kosovo in the present publication should be un-
derstood to be in compliance with Security Council resolution 1244 
(1999).
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to prevent the diversion of precursors from legitimate 
trade by monitoring trade in precursors between the 
 parties and providing mutual assistance to prevent 
diversion. 
600. Bilateral cooperation in addressing drug traffick-
ing in the region continued to intensify among the coun-
tries of Eastern and South-Eastern Europe. In 2013, the 
Minister of Security of Bosnia and Herzegovina and the 
Ministers of Interior of Montenegro and Serbia signed a 
protocol on the establishment of the Joint Centre for 
Police Cooperation in Trebinje, Bosnia and Herzegovina. 
Bosnia and Herzegovina and Serbia signed a security 
agreement in November 2013 that established procedures 
for the exchange of information, police cooperation and 
measures to combat crime. 
3. National legislation, policy and 
action
601. In November 2013, regulations were adopted by 
the European Parliament and the Council of the European 
Union to introduce more stringent controls on acetic 
anhydride and place under control alpha-phenylace-
toacetonitrile (APAAN) and medicinal and veterinary 
 products containing ephedrine and pseudoephedrine. 
Those  regulations will take effect 18 months after their 
 adoption, namely in 2015. In July 2014, a new system 
controlling the sale of so-called “initial and auxiliary 
substances” entered into force in the Czech Republic. 
Initial substances covered included red phosphorus, 
which is used in the illicit manufacture of methamphet-
amine, and gamma-butyrolactone and 1,4-butanediol, 
which are used in the illicit manufacture of gamma-
hydroxybutyric acid.
602. In January 2014, the Ministry of Health of France 
authorized the sale of the cannabis-based medicine 
Sativex for treatment of patients suffering from multiple 
sclerosis. In June 2014, the Government of Slovenia 
approved a change in the Decree on Classification of 
Illicit Drugs which would allow doctors to prescribe reg-
istered medicinal products containing cannabinoids. In 
July 2014, regulations were signed in Ireland to allow 
authorized cannabis-based medicinal products to be 
legally prescribed by medical practitioners and used by 
patients. In 2013, stricter criteria were introduced in 
Iceland for the prescription of some specific substances, 
such as methylphenidate.
603. A supervised “drug-use facility” was established as 
a pilot initiative in October 2013 in Athens by the Greek 
Organization against Drugs. The Board looks forward to 
a continuing dialogue with Governments that have per-
mitted such “consumption rooms” and reiterates its con-
cern that such facilities could be inconsistent with the 
provisions of the international drug control conventions.
604. In May 2013, the Cabinet of Ministers of Ukraine 
adopted new rules for handling narcotic drugs, psycho-
tropic substances and precursors in medical establish-
ments, which substantially reduced the number of 
administrative obstacles to the use of these substances for 
medical purposes. The Government, through a decree 
adopted in September 2013, reduced the list of docu-
ments required to apply for licences required for activi-
ties involving controlled substances. In August 2013, the 
Government approved its State policy strategy on nar-
cotic drugs for the period until 2020, which focuses on 
treatment and rehabilitation of drug addicts based on 
international best practices.
605. The Administrative Code of the Russian Federation 
was amended in July 2013 to increase the penalty for 
driving under the influence of controlled substances. 
Under a law adopted in October 2013, judges were given 
the authority to consider the commission of any crimi-
nal offence while under the influence of alcohol or a con-
trolled substance as an aggravating circumstance, resulting 
in a more severe punishment for the offence. In November 
2013, a law was adopted to allow the courts to require 
offenders found to have a drug addiction to undergo 
medical treatment or social rehabilitation in addition to 
any sentence for the crime itself. In July 2013, national 
legislation was amended to incorporate measures related 
to deporting and banning entry into the Russian 
Federation of foreign nationals who had committed drug-
related offences. 
606. In January 2014, a presidential decree was adopted 
in Belarus on State regulation of the circulation of poppy 
seeds, which substantially restricted the supply of those 
seeds as a raw material for illicit markets in the country.
607. In 2013, the Government of Albania adopted a 
new strategy and action plan against organized crime. 
The Government undertook measures to ensure more 
effective control of the country’s borders through the 
modernization of police equipment and increased train-
ing of the Albanian Border Police. The Albanian Ministry 
of Education and Sport continued to implement projects 
on drug awareness and demand reduction in 2013.
608. In October 2013, the Government of Romania 
adopted its national anti-drug strategy for 2013-2020 and 
its action plan for 2013-2016. The national strategy 
reflects a balanced approach and is structured around two 
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pillars: drug demand reduction and drug supply reduc-
tion. It also contains three cross-cutting themes: (a) coor-
dination; (b) international cooperation; and (c) research, 
evaluation and information.
609. During the reporting period, the Government of 
Montenegro adopted several new strategic documents, 
including ones on an integrated border management 
strategy for the period 2014-2018, a framework action 
plan for implementation of that strategy, a framework for 
negotiations leading to an agreement on operational and 
strategic cooperation between Montenegro and the 
European Police Office (Europol), an anti-drug strategy 
for 2013-2020 and an action plan for 2013-2016.
610. In 2013, the Government of the Republic of 
Moldova transferred the Anti-Drug Department to the 
newly created General Police Inspectorate and established 
two regional units for the north and south of the coun-
try. The Administrative Code of that country was also 
revised to increase the sanctions for driving under the 
influence of alcohol, narcotic drugs, psychotropic sub-
stances or other substances with similar effects. 
611. Kosovo currently has six institutions for the treatment 
of drug abuse. During 2013 and the beginning of 2014, 
Kosovo Police focused on schools by organizing several 
debates and producing brochures to raise awareness among 
young people of the dangers of drug and alcohol abuse.
612. Countries in Europe are continuing to take legis-
lative measures to address the challenge posed by new 
psychoactive substances. In April 2014, the European 
Parliament endorsed a legislative proposal of the European 
Commission, made in September 2013 and reported 
upon by the Board in its annual report for 2013. Once 
adopted by Member States in the Council of the European 
Union, the law would provide for a shortened response 
time by the European Union—10 months instead of two 
years—to prevent the sale of new psychoactive substances 
deemed to be harmful, and would provide for the rapid 
withdrawal, for a period of one year, of such substances 
from the consumer market.
613. Following a risk assessment by the Scientific Com-
mittee of the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), in June 2014 the European 
Commission recommended to the Council of the 
European Union that control measures be applied to the 
substances 25I-NBOMe, AH-7921, methylenedioxypyro-
valerone (MDPV) and methoxetamine throughout the 
European Union. Meanwhile, Governments have contin-
ued to place numerous individual substances and groups 
of substances under national control. For example, in 
2013, 58 substances were placed under control in 
Lithuania, 35 were placed under control in the Czech 
Republic, 26 in Germany, 24 in Switzerland, 21 in Sweden, 
9 in Denmark, 5 in Estonia, 4 each in Finland and Italy 
and 2 in France. 
614. The criminal code of Hungary was amended in 
January 2014 to increase the duration of prison sentences 
for supplying new psychoactive substances. The offering or 
distribution of a small quantity (defined as no more than 
10 g) is punishable by up to one year in prison, and pos-
session of a quantity greater than 10 g can be punished by 
up to three years’ imprisonment. In Slovakia, a new section 
was added to national drug control legislation to control 
new psychoactive substances, establishing a category of 
“hazardous substances”, which could include, for a period of 
up to three years, substances for which there are suspected 
abuse and harmful effects. Penalties for the supply of such 
substances would be in accordance with consumer and 
health protection legislation rather than criminal law, while 
there would be no penalties for personal possession. The 
first list of such substances was issued in October 2013. In 
Latvia, following a legislative amendment in November 2013 
providing for temporary prohibition of new psychoactive 
substances for a period of up to 12 months, a temporary 
ban on eight substances was introduced. Criminal penalties 
were introduced in April 2014.
615. In the United Kingdom, an order reclassifying 
keta mine as a class B drug came into force in June 2014, 
with a final decision on the rescheduling of ketamine to 
be taken by the Government following public consulta-
tion. In June 2014, tramadol, lisdexamphetamine, zopi-
clone and zaleplon were placed under control in the 
United Kingdom, as were NBOMe and benzofuran, fol-
lowing a 12-month temporary ban. A decision to con-
trol khat came into effect in the same month. In July 
2014, the Government of the United Kingdom accepted 
the advice of its Advisory Council on the Misuse of 
Drugs to control the substance AH-7921 and to extend 
the generic definition of tryptamine under the Misuse 
of Drugs Act of 1971 to capture additional tryptamine 
compounds, including alpha-methyltryptamine (AMT) 
and 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine). 
Legislation to that effect was before Parliament.
616. In 2013, the Russian Federation expanded its 
national list of controlled substances to include 43 new 
psychoactive substances.
617. Following the appearance of new psychoactive 
substances in the former Yugoslav Republic of Macedonia, 
15 such substances were placed under national control in 
that country in 2013.
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4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
618. Increased use of the Balkan route for the traffick-
ing of illicit drugs was seen in 2013, albeit not to the 
same degree as during the peak period of 2007. The route, 
which is used mainly as a corridor for the transport of 
Afghan heroin, traverses the Islamic Republic of Iran 
(often via Pakistan), Turkey, Greece, Bulgaria and South-
Eastern Europe to reach the Western European market. 
The latest UNODC estimates suggest that between 60 and 
65 tons of heroin flow into South-Eastern Europe annu-
ally. An increasing number and amount of heroin sei-
zures were recorded in 2013 and in the initial months of 
2014 in some border areas of the countries located along 
the Balkan route. Between January and March 2014, sei-
zures of heroin in the former Yugoslav Republic of 
Macedonia along the Balkan route increased, while the 
quantities seized there during the first three months of 
2014 approached the total quantities seized in 2013. Some 
increase in seizures of heroin could be observed in 
Bulgaria in 2013. A substantial, almost 150 per cent, 
increase in seizures of heroin was observed in Romania 
in 2013 compared with 2012; authorities in that country 
reported that heroin entered its territory from Bulgaria. 
In 2013, Montenegrin authorities made the largest sei-
zures of heroin in the past two years along the country’s 
borders with Bosnia and Herzegovina and Serbia. Serbian 
authorities also observed increased heroin smuggling 
through the country in 2013.
619. Trafficking of heroin to the European Union along 
the so-called “southern route” is increasing, with heroin 
trafficked south from Afghanistan, via the Near and 
Middle East and Africa, as well as directly from Pakistan. 
Belgium and the Netherlands continue to be used for the 
transit of opiates trafficked along both the Balkan and 
southern routes. For example, opiates from Afghanistan 
arrive in the United Kingdom, mostly from Pakistan, but 
also via Belgium (where seizures of heroin increased 
sharply in 2013) and the Netherlands. All of the heroin 
trafficked by passenger aircraft to Belgium in 2013 arrived 
from East Africa.
620. Large-scale production of opiates in Afghanistan 
continues to represent a substantial component of the 
drug threat in the Russian Federation. The major route 
for Afghan opiates destined for illicit markets in the 
Russian Federation runs along the so-called “northern 
route” through the countries of Central Asia. Most of 
these drugs (almost 95 per cent) are trafficked across the 
border between the Russian Federation and Kazakhstan. 
The Russian Federation observed an increase in seizures 
of heroin in 2013 (to 2.4 tons, a 12.5 per cent increase 
from 2012).
621. Effective dismantling of several distribution chan-
nels for Afghan opiates in the Russian Federation led to 
an increase in the demand for homemade alternatives in 
the consumer market of that country. Thus, the Russian 
Federation is faced with the substitution of heroin with 
cheaper illicit drugs, such as acetylated opium and poppy 
straw extract. Smuggling and illicit distribution of poppy 
straw is carried out by organized criminal groups, mainly 
by disguising it as poppy imported for food purposes. In 
2013, the law enforcement agencies of the Russian 
Federation seized 2.2 tons of poppy straw.
622. Belarus continued to experience smuggling of 
poppy straw extract from the Russian Federation, as well 
as production of the substance from locally produced 
poppy straw. It also saw an increase in trafficking of 
Afghan heroin from the Russian Federation in large con-
signments along the so-called “northern route” for illicit 
markets in Belarus and in Western Europe, the Baltic 
States and Ukraine. Belarus also continued to see smug-
gling of methadone from the Russian Federation.
623. In Romania, the quantity of seized heroin increased 
by almost 150 per cent in 2013, from 45 kg seized in 2012 
to 112 kg in 2013.
624. The illicit cultivation of cannabis in Western and 
Central Europe, primarily for domestic consumption, 
continues to spread, with some countries reporting an 
increasing professionalization and scale of cultivation and 
others reporting a trend towards smaller-scale produc-
tion sites, such as residential properties. Criminal groups 
are involved in illicit cannabis cultivation in most coun-
tries of the subregion, and are reported to be moving 
towards the use of multiple, smaller sites in order to avoid 
detection. 
625. This increase in the cultivation of cannabis is 
reflected in the increasing number of seizures of canna-
bis herb in Western and Central Europe (which now 
exceeds the number of seizures of cannabis resin), along 
with an increasing number of seizures of cannabis plant. 
The quantity of cannabis plants seized also increased, by 
more than one third from 2011 to 2012, according to 
EMCDDA. Measured in terms of total quantity, seizures 
of cannabis resin still exceed those of cannabis herb. For 
example, EMCDDA reported 457 tons of resin seized in 
2012, compared with 105 tons of cannabis herb. Following 
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a decline since 2008, the amount of cannabis resin seized 
appears to be stabilizing. Customs seizures of cannabis 
resin in Spain, which accounts for around three quarters 
of the total quantity reported seized by customs services 
globally, increased from 105.6 tons in 2012 to 125.9 tons 
in 2013, while such seizures also increased in France, 
from 11 tons to 16.6 tons. During the same period, cus-
toms seizures of cannabis herb in Spain increased from 
just over 1 ton to 17.5 tons, representing the largest 
increase in such seizures in Europe reported by WCO. In 
Italy, where large-scale illicit cannabis cultivation is still 
detected in the southern part of the country, the quan-
tity of cannabis resin (36.4 tons) and cannabis herb 
(28.8  tons) seized in 2013 increased by 66 per cent and 
34 per cent, respectively. The amount of cannabis plant 
seized, however, decreased by almost 80 per cent.
626. In the United Kingdom, which represents about 
one quarter of the cannabis herb market in Europe, bor-
der seizures of cannabis resin and cannabis herb increased, 
while the quantity of domestically cultivated cannabis 
plants seized decreased. Overall, however, there was a 
43 per cent decrease in the combined amount of canna-
bis resin and cannabis herb seized in the United Kingdom 
between 2011/12 (41.7 tons) and 2012/13 (23.6 tons), and 
a 19 per cent decrease in the quantity of cannabis plants 
seized.
627. Trafficking of cannabis into Western and Central 
Europe remains characterized by the transport of canna-
bis resin by sea or air, mainly from Morocco, and the 
trafficking of cannabis herb in quantities of more than 
1 ton mainly from Albania, but also from other countries 
in South-Eastern Europe. There are indications that 
South-Eastern Europe, in particular the eastern Balkans, 
may be serving as a secondary route for the trafficking 
of cannabis resin from Morocco to Western Europe. The 
United Nations Office on Drugs and Crime indicates that, 
while there is no evidence of cannabis resin from 
Afghanistan being trafficked along the Balkan route, there 
have been reports of multi-ton shipments of cannabis 
resin being transported by sea from Pakistan directly to 
Western and Central Europe. Seizures of cannabis herb 
increased by two thirds in Greece from 2011 to 2012, 
with indications that the country may be developing into 
a trafficking hub for cannabis herb; a large decrease in 
cannabis cultivation was seen in that country in 2013. 
628. Illicit production and consumption of cannabis, 
especially a highly potent form of this substance, remained 
the main illicit drug challenges in South-Eastern Europe. 
In 2013, the subregion continued to see an expansion in 
the trafficking of Albanian cannabis. According to sei-
zures reported by customs services through the Customs 
Enforcement Network database of WCO, Albania was the 
source country of most of the cannabis smuggled into 
Europe, with about 9 tons of seizures made elsewhere 
attributed to Albania as a source country. Albanian can-
nabis herb is transported in shipments, which can weigh 
more than 1 ton, from ports in north-western Greece or 
across the Adriatic Sea for trafficking to destination mar-
kets in Italy, the United Kingdom and other countries in 
Western and Central Europe. The other route for Albanian 
cannabis herb appears to run north through Montenegro, 
Bosnia and Herzegovina, Croatia and Slovenia to Western 
Europe.
629. Bosnia and Herzegovina observed increasing 
indoor cultivation of a highly potent form of cannabis. 
In Montenegro, seizures of cannabis continued to increase 
(1.3 tons seized in 2013 compared with 1 ton in 2012). 
Serbia observed an increase in production of cannabis in 
2013; that trend is expected to continue in 2014, accord-
ing to Serbian authorities. In 2013, the Serbian Police 
 dismantled several laboratories used to produce a highly 
potent form of cannabis. Cannabis produced in Serbia 
was also reported to be sold in many Western European 
countries. Cannabis herb continues to account for the 
largest proportion of seizures of illicit drugs made in 
Romania (1,799 cases, or 59 per cent of all illicit drug 
seizures made in 2013). However, the amount of canna-
bis herb seized in Romania in 2013 (165 kg) was approx-
imately 50 per cent lower than a year earlier, and 
92 per  cent lower than in 2007. 
630. Cannabis cultivation in the vicinity of the south-
ern Albanian village of Lazarat continued on a large scale, 
potentially turning the village into one of the largest can-
nabis production areas in Europe. There is no official data 
on the quantity of cannabis cultivated in Lazarat, but, 
according to recent estimates, yearly production may 
have reached up to 800 tons, while total seizures of can-
nabis in Albania stood at 21 tons in 2013. Reportedly, 
between 4,000 and 5,000 persons work daily in Lazarat 
on cannabis plantations. The new Government of Albania 
has expressed its commitment to taking strong measures 
to deal with the situation in Lazarat. Significant quanti-
ties of cannabis originating in this village continued to 
be seized during police operations after the harvest 
period. As a result of a large-scale police operation involv-
ing more than 800 officers, carried out in June 2014, 
Albanian police arrested 30 suspected drug traffickers 
and destroyed about 55 tons of Cannabis sativa in Lazarat.
631. Seizures of cocaine in Western and Central Europe 
increased in 2012 to 71 tons, which constituted about 
99  per cent of overall seizures of cocaine in Europe. 
Increases were seen in countries that are typically used 
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for transit, such as Belgium, Portugal and Spain, while 
decreases were reported in countries that are known as 
significant consumer markets, such as France, Germany 
and Italy. Seizures in Belgium, France, Italy, the 
Netherlands and Spain accounted for 85 per cent of the 
quantities seized in the European Union in 2012. Belgium, 
the Netherlands, Portugal and Spain are the main points 
of entry for cocaine destined for Western European mar-
kets, with seizures amounting to between 10 and 20 tons 
in each of those countries in 2012. The amount of cocaine 
seized by customs authorities in Western Europe increased 
sharply, from 19.4 tons in 2012 to 34.6 tons in 2013, with 
significant increases noted in the Netherlands and Spain. 
632. It appears that most cocaine continues to be traf-
ficked directly from South America to Europe, although 
a smaller proportion continues to be trafficked via West 
Africa and some of the cocaine trafficked to West Africa 
actually transits Europe. Spain reported that 11 per cent 
of the cocaine seized in 2012 was destined for Nigeria, 
probably for subsequent re-export to Europe. The coun-
tries from which the largest amounts of cocaine seized 
in Europe in 2012 had been trafficked (when the origin 
of the substance was known) were Brazil (16 per cent, 
mainly reflecting cocaine originating in Bolivia (Pluri-
national State of) and Peru) and Venezuela (Bolivarian 
Republic of) (16 per cent, reflecting cocaine manufac-
tured in Colombia), followed by the Dominican Republic 
(14 per cent, mostly cocaine from Colombia), Argentina 
(14 per cent, mostly cocaine from Bolivia (Plurinational 
State of) and Peru), Colombia (11  per  cent), Peru 
(9 per cent) and Ecuador (5 per cent). The Balkan route 
is becoming less important for the trafficking of cocaine 
to Western and Central Europe, with seizures in South-
Eastern Europe having decreased from 2.2 tons in 2009 
to 350 kg in 2012. In 2013 in Denmark, large amounts 
of cocaine were seized after they had arrived directly 
from Central America, rather than through other tran-
sit countries or regions as in the past. To a lesser extent, 
use of countries in Western and Central Europe as tran-
sit points for cocaine trafficked to Oceania may be 
occurring.
633. According to the World Drug Report 2014, seizures 
of cocaine in Eastern Europe continue to be limited, con-
stituting only 0.2 per cent of overall seizures of cocaine 
in Europe. Aside from Latin America, countries in 
Eastern Europe cited only other European countries as 
transit countries for cocaine reaching their territory in 
2010-2012. The Baltic Sea region serves as the most likely 
entry point for cocaine entering the Russian Federation. 
Also, Constanța harbour in Romania remains an alterna-
tive route used by organized criminal groups to transport 
cocaine coming from Bolivia (Plurinational State of), 
Colombia and Venezuela (Bolivarian Republic of) to 
Europe. 
(b) Psychotropic substances
634. Illicit manufacture of amphetamine-type stimu-
lants continues in Western and Central Europe, mainly 
for consumption within the subregion but also to a lesser 
degree to supply other parts of Europe and beyond, such 
as West Asia. Amphetamine remains the synthetic stim-
ulant that is most widely available for illicit purposes in 
Europe, followed by “ecstasy” and methamphetamine. 
The amount of amphetamine seized in the European 
Union in 2012 declined to 5.5 tons from 5.9 tons in 2011, 
with seizures in Germany, the Netherlands and the United 
Kingdom accounting for more than half of the total. Illicit 
manufacture of amphetamine is reported to take place in 
Belgium and the Netherlands, as well as in Poland and 
the Baltic States. In Belgium in 2013, there was an increase 
in the amount of amphetamine-type stimulants seized 
and in the number of detected illicit laboratories that 
were used for the manufacture of amphetamine and 
“ecstasy”. 
635. Despite signs in recent years of increasing availa-
bility of methamphetamine in parts of the region, in  par-
ticular in Scandinavian countries, seizures of 
meth amphetamine in the European Union decreased by 
half, from 0.7 tons in 2011 to 0.34 tons in 2012, a level 
similar to that observed in 2009 and 2010. Whereas illicit 
amphetamine laboratories dismantled in Western and 
Central Europe have tended to be of a medium to indus-
trial scale, illicit methamphetamine laboratories, which 
have been more numerous and the majority of which have 
been detected in the Czech Republic, tend to be of a small 
scale. In 2013, 261  illicit methamphetamine laboratories 
were detected in the Czech Republic, representing an 
increase after a decline since 2011. The increasing quan-
tity of methamphetamine seized in that country is reported 
to reflect the increased commercialization of illicit meth-
amphetamine manufacture and distribution. A re-emer-
gence of trafficking in methamphetamine from West Asia 
to Western and Central Europe, for onward trafficking to 
South-East Asia and, to a lesser extent, for local consump-
tion has been noted.
636. Seizures of “ecstasy” tablets in the European Union 
in 2012 (4 million tablets) were at a level similar to that 
of the previous year, yet less than one fifth of the peak 
amount seized in 2002. More than half of the tablets 
seized in 2012 (2.4 million) were seized in the Netherlands 
(from where “ecstasy” is trafficked to other European 
countries), followed by the United Kingdom and Germany. 
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Germany and Ireland reported an increase in the amount 
of “ecstasy” seized in 2013, while the United Kingdom 
reported a decrease of about one third in the amount 
seized in England and Wales from 2011/12 to 2012/13. 
Several large sites for the illicit manufacture of “ecstasy” 
were dismantled in 2013 in Belgium and the Netherlands, 
where European “ecstasy” manufacture seems to be con-
centrated, indicating the possible recovery of the illicit 
market for the substance, following significant declines 
in the number of laboratories detected between 2002 and 
2010. Similarly, the MDMA content of “ecstasy” tablets, 
after decreasing until 2009, has increased in the past few 
years. In February 2014, Europol and EMCDDA issued 
a joint warning on “ecstasy” tablets containing high  levels 
of MDMA, following reports of deaths associated with 
such tablets in the Netherlands and the United Kingdom. 
637. Based on reported seizures, Romania experienced 
a significant increase in trafficking of amphetamine-type 
stimulants in 2013, with reported seizures of 27,596 tab-
lets of the substance in 2013 compared with 12,903 tab-
lets in 2012. Most of the seized tablets were “ecstasy” that 
had originated in the Netherlands. 
638. Belarus reported that amphetamine, methampheta-
mine and “ecstasy”, consumed illicitly in its domestic 
market, continued to be smuggled into the country from 
the Baltic States, Poland and the Russian Federation. A 
significant amount of these substances originated in the 
Russian city of St. Petersburg. The Russian Federation, on 
the other hand, reported that in 2013 it had detected and 
dismantled 26 illicit laboratories producing amphetamine- 
type stimulants. There are also reports of small illicit 
 laboratories producing those substances in small amounts 
in Belarus. 
(c) Precursors
639. Illicit manufacture of methamphetamine in Western 
and Central Europe is centred in two areas. In the Baltic 
States, manufacture, primarily using 1-phenyl-2- propanone 
(P-2-P), occurs mainly around Lithuania, for trafficking 
to Norway, Sweden and the United Kingdom. In the 
Czech Republic, Germany and Slovakia, methampheta-
mine is illicitly manufactured mainly from the precursors 
ephedrine and pseudoephedrine, with a view primarily to 
meeting domestic demand. In 2013, numerous large ship-
ments of APAAN continued to be trafficked from Asia, 
via Germany, mostly destined for the Netherlands, and 
new methods and routes for the shipment of precursors 
of P-2-P from Asia for use in illicit manufacture were 
noted in Poland. 
640. In 2013, the Russian Federation seized 248 kg of 
precursors, representing a substantial decrease from the 
amount seized in 2012, when 59 tons were seized in a 
single operation.
641. Romania reported that in 2013 there had been 
some attempts to smuggle non-controlled chemicals that 
could be easily converted into drug precursors, particu-
larly by citizens of countries that reported illicit produc-
tion of large quantities of synthetic drugs, namely Belgium 
and the Netherlands.
(d) Substances not under international 
control
642. The increasing range and availability of new psy-
choactive substances continues to pose a challenge in 
Europe. A record 81 such substances were identified for 
the first time by the European Union early warning sys-
tem in 2013, compared with 74 substances in 2012 and 
49 in 2011. Of those, 29 were synthetic cannabinoids, 14 
were phenethylamines and 7 were synthetic cathinones. 
Nine of the substances were active pharmaceutical ingre-
dients in medicines. As of May 2014, 37 new psycho active 
substances had been reported to the system. There is 
growing concern in Europe about the recent emergence 
of “new” synthetic opioids, such as AH-7921, MT-45, 
 carfentanil and ocfentanil, some of which are being 
 marketed as alternatives to heroin. 
643. The increasing involvement of organized criminal 
groups in the market for new psychoactive substances has 
been noted as a serious concern in Europe. While there 
is some clandestine manufacture of such substances in 
Europe, they are primarily sourced in bulk through legit-
imate means from Asia and then repackaged and mar-
keted in Europe as “legal highs” or “research chemicals”, 
or even sold on the illicit drug market. The Internet con-
tinues to be used for the sale of new psychoactive sub-
stances, with 651 sites selling such substances identified 
in the European Union in 2013, compared with 693 sites 
in 2012, 314 in 2011 and 170 in 2010. The sale of sub-
stances such as the plant kava (Piper methysticum) and 
the substance beta-phenyl-gamma-aminobutyric acid 
(phenibut) as “food supplements” is reportedly adding to 
the complexity of this online market. A number of coun-
tries noted a decrease in the number of online and phys-
ical outlets selling new psychoactive substances following 
the adoption of national legislative measures.
644. Customs seizures of khat increased significantly 
from 2012 to 2013 in France (from 2.6 tons to 34.2 tons) 
and Norway (from 6.4 tons to 12 tons), while decreases 
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were reported in Germany (from 27.7 tons to 14.7 tons) 
and Sweden (9.5 tons to 5.7 tons). In the Netherlands, 
where khat was placed under control in 2013, customs 
authorities seized 8.9 tons of the substance. Total seizures 
of khat by law enforcement in Germany decreased from 
45.3 tons in 2012 to 22.8 tons in 2013. 
645. While 80 per cent of drugs seized in Belarus in 
2013 were opium alkaloids extracted from poppy seeds, 
legislation adopted in January 2014 severely restricted 
the circulation of poppy seeds as a raw material for the 
illicit production of drugs. As a result, new psychoactive 
substances became the predominant drugs in the illicit 
market in Belarus. New psychoactive substances, such as 
synthetic cannabinoids, cathinones, including alpha- 
pyrrolidinopentiophenone (alpha-PVP) and MDPV, and 
phenethylamines such as 4-methylamphetamine, which 
were increasingly seized in Belarus in 2013, were smug-
gled into that country from China, Estonia and the 
Russian Federation.
646. The Russian Federation is also facing an increas-
ing challenge from new psychoactive substances. Between 
2012 and 2013, the country’s seizures of such substances 
increased by 50 per cent, amounting to 1,967 kg in 2013. 
The majority of these substances are trafficked from Asia.
647. In 2013, the total amount of new psychoactive sub-
stances seized in Romania increased considerably, to 
16.4 kg from 1.5 kg in 2012. Of those, tryptamines were 
the most seized (14.2 kg). In 2013, Romania made a sin-
gle significant seizure of 12 kg of 5-MeO-DALT, coming 
from Spain. In addition, 1.48 kg of dimethocaine, a local 
anaesthetic with stimulant properties, which had been 
delivered from Spain via commercial air services, were 
seized. During 2013, four clandestine laboratories were 
detected and dismantled by Romanian authorities; two of 
them had been intended for refining new psychoactive 
substances and two had been manufacturing such sub-
stances for personal use. 
5. Abuse and treatment
648. Cannabis remains the most prevalent drug of 
abuse in the European Union, with an estimated annual 
prevalence of 5.3 per cent among adults, 11.2 per cent 
among those aged 15-34 years and 13.9 per cent among 
those aged 15-24 years, according to EMCDDA. Almost 
1 per cent of adults in Europe are estimated to use can-
nabis on a daily or almost-daily basis. Cannabis is now 
the most frequently cited primary drug of abuse for first-
time admissions into treatment programmes, with the 
number of such cases stabilizing in 2012 following an 
increase during the 2006-2011 period. Cannabis-related 
medical emergencies are a growing problem in some 
higher-prevalence countries. 
649. While the prevalence of cannabis abuse in Western 
and Central Europe remains high, there are indications 
of an overall stabilizing trend. However, some countries 
with lower prevalence rates have recently reported 
increases in the level of cannabis abuse, while, in some 
countries with higher levels of cannabis abuse, there is 
evidence of decreasing levels of such abuse. Surveys con-
ducted in the European Union among people aged 15-24 
years found an overall decline in cannabis abuse between 
2004 and 2011, although the prevalence rate of lifetime, 
past-year and past-month use increased between 2011 
and 2014. Among people aged 15-24 years, past-year 
prevalence of cannabis abuse stood at 17 per cent in June 
2014, an increase from 14 per cent in 2011. The overall 
picture of trends relating to cannabis abuse in the subre-
gion is rendered more complex by the increasing diver-
sity in the types of “products” available, including 
high-potency cannabis herb and synthetic cannabis-like 
products.
650. According to the World Drug Report 2014, the pro-
portion of total treatment admissions in Eastern and 
South-Eastern Europe that were for cannabis abuse 
increased from 8 per cent in 2003 to 15 per cent in 2012, 
while opioids continued to dominate the demand for 
treatment in these subregions. 
651. Also according to the World Drug Report 2014, the 
level of opiate abuse in Eastern Europe, supported by the 
supply of heroin from Afghanistan, is significantly higher 
than the global average. The Russian Federation remained 
a major consumer market for illicit opiates, with signifi-
cant quantities of heroin flowing northwards from 
Afghanistan via Central Asia.
652. The annual prevalence of abuse of opioids, primar-
ily heroin, is estimated at 0.4 per cent among adults in 
Western and Central Europe, with the number of past-
year consumers of opiates estimated to have declined by 
almost one third from 2003 to 2012. Opioids account for 
a quarter of first-time treatment cases in the European 
Union. With most countries in the subregion reporting 
declining trends in heroin abuse, the number of people 
entering treatment for the first time for heroin abuse 
declined from a peak of 59,000 in 2007 to 31,000 in 2012. 
This has been accompanied by a long-term decline in drug 
overdose deaths and drug-related HIV infection (tradi-
tionally related to abuse of heroin by injection), which has 
also been declining, despite recent outbreaks of HIV infec-
tion among drug users in Greece and Romania. 
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653. A decrease was seen in overdose deaths, primarily 
those related to abuse of opioids, in Europe between 2009 
and 2012; however, the number of such deaths remains 
high and is increasing in some countries. In general, 
deaths related to heroin abuse are decreasing, while 
deaths related to synthetic opioids are increasing or 
already exceed those related to heroin in some countries. 
In Estonia between 2011 and 2012, there was a 38 per cent 
increase in overdose deaths, 80 per cent of which were 
related to fentanyl and its derivatives. 
654. In Western and Central Europe, heroin is being 
partly replaced by synthetic opioids, illicitly manufac-
tured or diverted from medical use, including fentanyl, 
buprenorphine and methadone. The problem is of par-
ticular concern in Estonia and Finland, where most peo-
ple receiving treatment for opioid abuse reported primary 
abuse of fentanyl and buprenorphine, respectively. Some 
countries have also noted an increase in drug abuse by 
injection of pharmaceutical opioids.
655. Limited availability of heroin in Belarus and the 
Russian Federation led to an increase in abuse of locally 
produced, and readily available, substances such as 
acetyl ated opium and poppy straw extract. In 2013, 
53  per  cent of those listed on the State drug abuse reg-
ister in Belarus had consumed homemade opium pro-
duced either from poppy straw or seeds of Papaver 
somniferum  L. plants. Also, the number of persons in 
Belarus who abuse metha done that has been obtained 
illicitly increased by 12.6  per  cent.
656. Belarus and Ukraine have significantly scaled up 
access to opioid substitution therapy, while the Republic 
of Moldova has continued to provide this therapy on a 
limited scale and the Russian Federation has continued 
to prohibit it. 
657. The annual prevalence of abuse of amphetamines 
in Western and Central Europe is estimated at 0.4 per cent 
of adults and 0.9 per cent of young adults (aged 15-34 
years), with prevalence rates ranging from 0 per cent to 
2.5 per cent and reportedly relatively stable in most coun-
tries of the subregion. Amphetamine is still more widely 
abused than methamphetamine in the subregion and is 
still a significant problem in large parts of Europe, espe-
cially in Northern Europe. The majority of countries with 
recent surveys reported a decreasing prevalence of abuse 
of amphetamine. The increased availability of metham-
phetamine and the expansion of its abuse, which was in 
the past mainly observed in the Czech Republic and 
Slovakia, to other countries in Western and Central 
Europe, especially Northern Europe, appears to be contin-
uing. However, the level of abuse of methamphetamine in 
the Czech Republic and Slovakia is reported to be stable 
or declining, with annual prevalence among young peo-
ple aged 15-34 years in the Czech Republic estimated at 
1 per cent. Nevertheless, both countries have reported an 
increase in recent years in the number of people entering 
treatment for abuse of methamphetamine, which in 2012 
accounted for 68.2 per cent of cases of treatment for drug 
abuse in the Czech Republic and 44.5 per cent of such 
cases in Slovakia. An analysis of wastewater in European 
cities identified higher concentrations of amphetamine in 
cities in Belgium and the Netherlands, while methamphet-
amine levels were highest in cities in the Czech Republic 
and Norway, with the increase in methamphetamine abuse 
reported to have levelled off in the latter country. The 
annual prevalence of “ecstasy” abuse in Western and 
Central Europe is estimated at 0.5 per cent among adults 
and 1 per cent among young adults aged 15-34 years, 
ranging from 0.1 per cent to 3.1  per cent depending on 
the country. Most countries in the subregion, including all 
countries with recent surveys, have reported declining 
trends with regard to abuse of “ecstasy”. 
658. Abuse of “ecstasy” in Eastern and South-Eastern 
Europe has remained above global average levels, with an 
annual prevalence rate of 0.6 per cent. The Russian 
Federation reported significant increases in the abuse of 
amphetamine, methamphetamine and “ecstasy” in 2013. 
Belarus also reported a significant increase in the abuse 
of amphetamine-type stimulants during the same period, 
except for “ecstasy”, which remained at the same level. 
Some increase in abuse of amphetamine-type stimulants 
was also reported in Bosnia and Herzegovina. A survey 
conducted in the Republic of Moldova in 2012 and 2013 
showed an increase in the abuse of methamphetamine in 
that country. 
659. Cocaine is still the most widely abused stimulant 
drug in Europe, yet its prevalence has decreased among 
young adults (aged 15-34) in the majority of countries 
that conducted surveys between 2012 and 2014, and in 
general in countries with a higher prevalence of abuse. 
The annual prevalence of cocaine abuse in Western and 
Central Europe was estimated at around 1 per cent among 
adults in 2012, compared with 1.3 per cent in 2010; and 
1.7 per cent among young adults aged 15-34 years in 
2012, compared with 2.1 per cent in 2010. However, some 
countries have reported increases in levels of cocaine 
abuse. Cocaine was cited as the primary drug of abuse 
by 18 per cent of people entering treatment for the first 
time, the number of which declined from a peak of 
38,000 in 2008 to 26,000 in 2012. Around 90 per cent of 
all treatment cases for cocaine as the primary substance 
of abuse were reported by Germany, Italy, the Netherlands, 
Spain and the United Kingdom.
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660. With a record number of new psychoactive sub-
stances identified in Europe in 2013, concerns remain 
about this public health challenge. A June 2014 survey of 
young people aged 15-24 years in the European Union 
found that the lifetime prevalence of abuse of such sub-
stances had increased from 5 per cent in 2011 to 
8  per  cent in 2014, with the most significant increases, 
to double-digit levels, seen in Ireland (from 16 per cent 
to 22 per cent), Spain (from 5 per cent to 13 per cent), 
Slovenia (from 7 to 13 per cent), France (from 5 to 
12  per  cent), Slovakia (from 3 to 10 per cent) and the 
United Kingdom (from 8 to 10 per cent). Deaths have 
been reported to be linked to the consumption of vari-
ous new psychoactive substances in Europe, including 
4,4’-DMAR (the para-methyl derivative of 4-methylami-
norex), AH-7921 (a synthetic opioid), MDPV (a synthetic 
cathinone derivative), MT-45 (an opioid) and methoxeta-
mine (marketed as an alternative to ketamine), which 
were the subject of recent reports by Europol and 
EMCDDA. In the United Kingdom, new treatment cases 
associated with ketamine and mephedrone increased in 
recent years, representing 10 per cent of treatment cases 
for young people and 2 per cent for adults.
661. According to a joint estimate made by UNODC, 
UNAIDS, the World Bank and WHO, based on the most 
recent available data (2012), the problem of injecting 
drug abuse is particularly stark in Eastern and South-
Eastern Europe, where the prevalence rate (1.26 per cent) 
is 4.6 times the global average (0.27 per cent). Within 
these subregions, relatively high rates of injecting drug 
abuse were observed in the Russian Federation 
(2.29 per cent), the Republic of Moldova (1.23 per cent), 
Belarus (1.11 per cent) and Ukraine (0.88-1.22 per cent), 
all of which stood well above the global average.
662. The number of people who inject drugs who are 
also living with HIV was particularly high in Eastern and 
South-Eastern Europe, where it was estimated that the 
prevalence of HIV among people who inject drugs was 
23.0 per cent (compared with a global average of 
13.1  per  cent) and more than half of the people who 
inject drugs were estimated to be living with hepatitis C. 
Within both subregions, a relatively high prevalence of 
HIV among people who inject drugs was observed in the 
Russian Federation (range: 18.4-30.7 per cent) and 
Ukraine (21.5 per cent). Also, the number of people who 
inject drugs who are newly diagnosed with HIV each year 
continues to be higher in both countries than in other 
countries in Eastern and South-Eastern Europe. According 
to the results of sentinel surveillance conducted in Belarus 
in 2013, HIV prevalence among people who inject drugs 
was 14.2 per cent, reaching over 40 per cent in some parts 
of the country.
663. In the European Union, 38 per cent of people 
entering treatment for opioid abuse and 23 per cent of 
people entering treatment for amphetamine abuse 
reported having injected the substances. Yet, the propor-
tion of new treatment clients reporting that they had 
injected drugs in the previous month fell between 2006 
and 2012. Some countries have reported changing  patterns 
of injecting drug abuse, for example, reflecting a possible 
move away from injection of heroin towards injection of 
pharmaceutical or synthetic opioids,  amphetamine-type 
stimulants and new psychoactive substances. While the 
number of newly reported HIV cases among people who 
inject drugs in the European Union and Norway decreased 
during the period from 2006 to 2010, an increase has been 
seen since 2010, mainly as a result of outbreaks of HIV 
among people who inject drugs in Greece and Romania. 
In 2010, Greece and Romania accounted for just over 
2 per cent of the total number of newly reported diagno-
ses of HIV among people who inject drugs in the 
European Union; by 2012, this figure had increased to 
37  per cent. In other countries of the region, the rate of 
new diagnoses of HIV among people who inject drugs is 
declining. Abuse of drugs by injection remains the most 
prevalent vector for transmission of hepatitis C in Europe, 
yet the rate of infection among those who inject drugs is 
reported to be declining.
E. Oceania
1. Major developments
664. Seizures and arrests in Oceania are at record highs 
for many drug types, with an increasing number of peo-
ple abusing drugs. Compared with other world regions, 
Oceania provides an expanding market for certain drugs, 
including cocaine, and levels of abuse among individuals 
in the region are high for most substances. Increases in 
drug seizures, particularly in Australia, have been attrib-
uted not only to the vigilance of law enforcement, but 
also to the increased activities of transnational organized 
criminal groups.
665. As the monetary value of drugs and precursors 
remains comparatively high throughout Oceania, the 
region has become susceptible to illicit manufacturing 
and trafficking. Growing markets for amphetamine-type 
stimulants and proximity to trafficking routes for differ-
ent illicit goods have led most countries in Oceania to 
see higher prevalence rates for the abuse of such drugs. 
The availability and abuse of new psychoactive sub-
stances, which are now widely found in most of Oceania, 
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has become one of the primary issues of concern for the 
region. The expanding market for such substances con-
tinues to develop rapidly and presents challenges to law 
enforcement within the region. The increase in demand 
for these substances in the region has specifically been 
affected by the inability of existing legislation to ensure 
that such substances are not available for abuse.
2. Regional cooperation
666. In April 2014 in Suva, the Oceania Customs 
Organization held its sixteenth annual conference, on the 
theme of communication and the sharing of information 
for better cooperation. Delegates from the Organization’s 
member countries discussed the need for strengthened 
border security. In April 2014, the secretariat of the 
Organization undertook an assessment visit to assist the 
Government of Palau on processes and products related 
to information-sharing and intelligence-sharing. The visit 
was carried out by the Working Group on Strengthening 
Information Management.
667. The Regional Security Committee of the Pacific 
Islands Forum held its annual meeting on 4 and 5 June 
2014 in Suva, drawing representatives from States mem-
bers of the Pacific Islands Forum and from regional law 
enforcement secretariats, such as the Pacific Immigration 
Directors’ Conference. Discussions at the meeting focused 
on trends relating to illegal activities and continuing 
security threats in the region. It was reported that one 
such continuing threat was the involvement of local 
 citizens in transnational criminal activities.
3. National legislation, policy and 
action
668. In 2013, New Zealand passed the Psychoactive 
Substances Act, which granted interim approvals for 
47 products containing new psychoactive substances and 
permitted the marketing of those products by 150 licensed 
retailers. However, after the National Poisons Centre, 
emergency rooms and treatment providers reported an 
increase in problems related to consumption of those sub-
stances, and public protests against the interim product 
approvals gained momentum, the Psychoactive Substances 
Amendment Act was approved and came into effect on 
8 May 2014. The Amendment Act revoked the interim 
product approvals and the interim retailer and wholesaler 
licences granted under the 2013 Act. The sale of all 
psycho active substances is now prohibited unless approved 
by the national regulatory authority following clinical 
 trials. To sell products containing such substances, 
companies must prove to an expert committee that the 
product in question poses only a “low risk of harm”. 
Pursuant to the Amendment Act, however, such clinical 
trials are no longer permitted to use animal testing to 
demonstrate the low risk of harm.
669. In July 2014, Australia’s Intergovernmental Com-
mittee on Drugs published the Framework for a National 
Response to New Psychoactive Substances. The Committee 
manages the ongoing work of the National Drug Strategy 
for 2010-2015, and the new framework will assist with 
information-sharing and communication regarding new 
psychoactive substances, harm assessment and schedul-
ing provisions. It is also aimed at national consistency 
and uniform treatment of drug analogues. In 2012 and 
2013, various states and territories of Australia passed 
legislative and regulatory amendments. In 2013, New 
South Wales passed the New Psychoactive Substances 
Act, and Queensland amended the Drugs Misuse Act 
1986 to create a new offence for trafficking in precursor 
chemicals used in the production of dangerous drugs.
670. With respect to forensic and data centres, Australian 
federal police officially launched the National Rapid Lab 
initiative in 2013 to streamline the prioritization and 
examination of forensic cases, particularly cases related 
to illicit drugs entering Australia through the postal sys-
tem. This programme helps fight drug trafficking by 
enhancing the national capability to identify the origin 
of dispatched drug packages, which often contain either 
methamphetamine or pseudoephedrine.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
671. In terms of abuse and seizures, cannabis remains 
the most prevalent drug of abuse in Oceania and domi-
nates the illicit drug market. In Australia, there are indi-
cations that consumption has generally continued to 
increase. Consumer access to cannabis is also increasing 
throughout the region. Australia recorded its highest-ever 
levels of seizure of cannabis at its border in 2012-2013, 
typically in the form of seeds, most commonly being 
transported via the postal system. By weight, seizures of 
cannabis in 2012-2013 were the second highest reported 
in Australia in the past decade.
672. In New Zealand, cannabis is also the most widely 
abused drug, with a generally stable prevalence rate of 
abuse. Throughout the region, cannabis is produced 
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predominantly at the local level, and there is a lack of 
any evidence of its trafficking to other regions. The  latest 
data from New Zealand show two coexisting trends: sta-
bility in the prevalence rate and a decrease in the num-
ber of seizures of cannabis herb between 2012 and 2013 
(from 5,877 seizures in 2012 to 4,872 seizures in 2013). 
In New Zealand, the National Cannabis and Crime 
Operation is conducted yearly during the summer har-
vesting season and accounts for most of the cannabis 
seized in any given year.
673. Illicit demand in Oceania for cocaine, although 
marked by annual fluctuations in seizures, appears to 
have growth potential over the long term. In Australia, 
illicit demand for and overall abuse of cocaine appears 
to be expanding; in 2012-2013, the number and weight 
of domestic seizures increased. Trends in Australia also 
show an increase in the number of seizures of cocaine at 
the border, with the postal system accounting for over 
94  per cent of such seizures in 2012-2013 and 56 coun-
tries identified as embarkation points for trafficking of 
the drug. Reporting for 2013 by New Zealand also shows 
a slight increase in seizures of cocaine.
674. Australia saw increased seizures of heroin at the 
country’s points of entry in 2012-2013, particularly via 
the postal service. The number of embarkation points for 
trafficked heroin increased from 19 countries in 2011-
2012 to 25 countries in 2012-2013. The majority of the 
heroin reaching Australia appears to be from South-East 
Asia, while reports continue to show that Afghan heroin 
is increasingly reaching the Oceania region. It should be 
noted that Australia did see a decrease in the number of 
seizures of heroin, but still experienced its third-highest 
reported number of seizures in the past decade. This 
resulted in 2013 in Australia no longer being among the 
top 10 countries for largest quantities of seized heroin, 
despite ranking eighth in 2012. New Zealand also 
reported that both heroin and pharmaceutical opioids 
saw some increase in abuse in 2013.
(b) Psychotropic substances
675. The market for amphetamine-type stimulants in 
Oceania appears to be growing, with methamphetamine 
the predominant drug of choice. Australia has reported an 
increase in the number and weight of seizures of such sub-
stances. The weight of seizures, for example, increased by 
310.4 per cent between 2011-2012 and 2012-2013. Arrests 
in Australia for crimes related to amphetamine-type stim-
ulants have also increased 131.3 per cent during the past 
decade, with 22,189 persons arrested in 2012-2013. 
Seizures at the Australian border of amphetamine-type 
stimulants (excluding “ecstasy”) increased in 2012-2013, 
by 85.6 per cent from the previous reporting year, to reach 
the highest level on record. The total weight of ampheta-
mine-type stimulants (excluding “ecstasy”) seized at the 
border increased by 515.8 per cent in 2012-2013.
676. Although the methamphetamine market in New 
Zealand is predominantly supplied by domestic  manu facture, 
reports show that, as in the previous year, more finished 
methamphetamine is being imported into the country. This 
may be in response to increased law enforcement pressure 
on precursor imports, or it may be a result of international 
criminal groups seeing an opportunity for considerable 
profit, owing to the very high price that people are willing 
to pay for methamphetamine in New Zealand. The range 
and origin of organized criminal groups and offenders 
involved in the manufacturing of methamphetamine in 
New Zealand appears to be increasing. “Ecstasy” remains 
in high demand throughout Oceania, with region-wide 
prevalence rates nearing 3 per cent.
(c) Precursors
677. With sustained smuggling of ephedrine and 
pseudo ephedrine, considerable illicit manufacture of 
methamphetamine continues in Oceania. In June 2014, 
ephedrine made up 74.3 per cent of all border seizures 
of precursor chemicals in New Zealand. According to 
New Zealand authorities, there is very little diversion of 
pseudoephedrine. The Government of that country has 
also reported that it is working with the Government of 
China to reduce the supply of methamphetamine and 
precursors entering New Zealand.
678. In Australia, the number of seizures at the border 
of amphetamine-type stimulant precursors (excluding 
“ecstasy”) increased by 11.3 per cent, from 937 in 2011-
2012 to 1,043 in 2012-2013. That was the highest num-
ber of such seizures in the past decade. Almost 
100 per cent, by weight, of “ecstasy” precursors seized in 
2012-2013 were comprised of safrole. A decrease during 
the past reporting year in clandestine laboratories was 
reported by Australia, although the 757 laboratories 
detected in 2012-2013 still represented the second- highest 
number reported in the past decade. The majority of these 
laboratories continued to be located in residential areas. 
The number of laboratories manufacturing “ecstasy”, 
although small, increased by 250 per cent to 7 laborato-
ries. A total of 53 clandestine laboratories manufacturing 
methamphetamine were detected by the New Zealand 
authorities in 2013; three of those facilities were also pro-
ducing “ecstasy” and gamma-butyrolactone. In addition, 
New Zealand has described how retailers in that country 
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work with the police to limit sales of toluene, which is 
commonly used in the manufacturing process.
(d) Substances not under international 
control
679. New psychoactive substances are found in most of 
Oceania, but data are available primarily only for New 
Zealand and Australia. Synthetic cannabinoids are the 
most common new psychoactive substances in those two 
countries, but the expanding market for new substances is 
a primary concern for the Governments of the region. New 
psychoactive substances are regularly being employed as 
substitute materials for MDMA in “ecstasy”-type tablets. 
Forensic analysis continues to identify either little or no 
MDMA in such tablets, finding that they consist mainly 
of a blend of other illicit drugs and/or unscheduled sub-
stances, including but not limited to piperazines, ketamine, 
methamphetamine, mephedrone, 4-methylethcathinone 
(the most common substance found in “ecstasy”-type tab-
lets) and caffeine. Australia has also indicated that the 
rapid emergence of new psychoactive substances is an 
increasing challenge for law enforcement and public health. 
It reported that, while the number of seizures at the bor-
der in 2012-2013 of substances containing drug analogues 
and new psychoactive substances had decreased, the weight 
of the seizures had more than doubled. New cathinone-
type substances accounted for the largest number of sei-
zures. Overall, Australia has indicated that monitoring and 
reporting on trends relating to new psychoactive sub-
stances is limited, owing to the difficulties in accurately 
recording data about such drugs.
5. Abuse and treatment
680. Cannabis continues to be the most commonly 
abused drug in the Oceania region, with an annual prev-
alence rate consistently above 10 per cent. The Board 
notes that the lack of comprehensive statistics on drug 
abuse in Pacific island countries does not permit a com-
plete assessment of either the overall drug control situa-
tion in Oceania or the capacity of the Governments of 
the region to address drug abuse as a public health issue 
and provide the necessary treatment.
681. Australia’s latest National Drug Strategy Household 
Survey reported overall stable levels during the 2010-2013 
period of consumption of cannabis (annual prevalence of 
10.2 per cent among those aged 14 years or older) and 
cocaine (2.1 per cent), but declines in abuse rates for 
some drugs, including heroin (from 0.2 to 0.1 per cent), 
“ecstasy” (from 3.0 to 2.5 per cent) and GHB, although 
the misuse of pharmaceuticals increased from 4.2 per cent 
in 2010 to 4.7 per cent in 2013.53 While overall abuse 
rates for amphetamines (methamphetamine and ampheta-
mine) remained stable (2.1 per cent), the percentage of 
amphetamine abusers who were abusing powder meth-
amphetamine decreased from 51 per cent to 20 per cent, 
while the percentage who opted for crystal methampheta-
mine more than doubled, from 22 per cent in 2010 to 
50 per cent in 2013.
682. In Australia, the prevalence rate in 2013 for past-
year abuse of new and emerging psychoactive substances 
by persons aged 14 years or older amounted to 
0.4 per cent, while the prevalence rate for past-year abuse 
of synthetic cannabinoids was 1.2 per cent of the same 
population. The prevalence rate for past-year abuse of 
“ecstasy” dropped from 3.0 per cent in 2010 to 2.5 per cent 
in 2013, while the prevalence rate for abuse of cocaine 
remained unchanged, at 2.1 per cent, throughout the 
entire period.
683. In New Zealand, 75 deaths were reported in 2013 
as being attributed at least indirectly to the abuse of 
drugs. Of the 6,597 persons brought into formal contact 
with the New Zealand police or criminal justice system 
in connection with personal drug-related offences, 
5,525  persons were held in connection with cannabis-
related offences. The latest figures from 2012 show that 
41,806 persons were receiving treatment for drug abuse, 
with over 37 per cent of them entering treatment for the 
first time. According to the Government of New Zealand, 
there are also approximately 15,000 persons in the coun-
try who have a severe problem with opioid abuse.
684. Abuse of amphetamine-related substances has 
remained a major concern for the Oceania region. In 
response, New Zealand in 2009 instituted its national 
action plan on tackling methamphetamine, which was 
aimed at promoting supply control measures and schedul-
ing the main precursor substances. As a result of the action 
plan, New Zealand reports that the past-year prevalence 
rate for the abuse of methamphetamine has dropped from 
2.2 per cent of the adult population in 2009 to 0.9 per cent 
in 2013, with a particular reduction in the number of per-
sons reporting initiation of abuse. Australia regularly pro-
vides information about the treatment methods available 
nationally for amphetamine-related substances, including 
counselling, therapeutic communities and self-help groups, 
while surveys have established that there is strong national 
support for treatment and rehabilitation.
 53 There is no average age group listed for this statistic, nor is there 
clarification about whether it means annual or lifetime prevalence, but it 
is likely to mean the annual rate.
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Chapter IV.
Recommendations to Governments,  
the United Nations and other relevant 
international and regional organizations
685 . The present chapter builds upon the most signifi-
cant conclusions in the previous chapters . As always, the 
Board would appreciate receiving feedback from 
Governments about their experiences and any difficulties 
in implementing the international drug control treaties .
A comprehensive,  integrated and balanced 
approach to the world drug problem
686 . A comprehensive and balanced approach remains 
at the heart of the international drug control conventions . 
In their implementation of the treaties, Governments are 
invited to implement the below recommendations . 
Recommendation 1: The Board invites Governments to 
encourage cooperation among all stakeholders at the 
national, regional and international levels . To that end, 
Governments should ensure the participation of all rele-
vant actors in the strategic planning, implementation and 
monitoring of drug control policies . 
Recommendation 2: The Board invites Governments to 
place equal emphasis on supply and demand reduction, 
taking into consideration the socioeconomic, sociocul-
tural, security and stability aspects that have an impact 
on the drug problem . Such an approach would require 
comprehensive measures, some of which do not fall 
squarely under the immediate authority or mandate of 
any single one of the various United Nations institutions 
concerned with drug control . Therefore, the Board invites 
all other relevant international organizations, in accord-
ance with their mandates, to lend their expertise in this 
effort and to support Governments in the implementa-
tion of this approach .
Recommendation 3: The Board invites Governments to 
ensure that all aspects of the drug problem are addressed 
in a balanced and comprehensive manner . National and 
local specificities in the manifestation of the drug con-
trol problem should be taken into account, while  making 
use of updated scientific evidence . In particular, Member 
States should provide political support, and appropriate 
resources, to efforts relating to prevention, treatment 
and rehabilitation; law enforcement; and countering 
money-laundering .
Recommendation 4: The Board invites Governments to 
address all factors that fuel the world drug problem in 
an effective and sustainable manner by including drug 
issues in the broader socioeconomic development agenda, 
and to incorporate all relevant human rights norms into 
drug-related policies, including as they relate to particu-
larly vulnerable populations such as children . 
Recommendation 5: The Board invites Governments to 
use the opportunity provided by the upcoming special 
session of the General Assembly on the world drug prob-
lem to be held in 2016 to make a critical assessment of 
existing drug control policies and of the extent to which 
the principle of a balanced, integrated and comprehen-
sive approach is reflected in practice, including with 
regard to political support and funding patterns .
Availability
687 . The dual aim of the international drug control sys-
tem is to ensure the availability and rational use of con-
trolled substances for medical and scientific purposes 
while preventing the trafficking in and abuse of such 
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substances. There continues, however, to be a severe 
imbalance globally in the consumption of drugs for pain 
relief and other medical conditions, with consumption 
concentrated primarily in industrialized countries. 
Recommendation 6: The Board reminds Governments of 
their obligation to ensure the availability of controlled 
substances for medical and scientific purposes. Member 
States should enhance their cooperation with the Board, 
WHO and other relevant stakeholders in this area, and 
make full use of the Board’s 2010 special report entitled 
Availability of Internationally Controlled Drugs: Ensuring 
Adequate Access for Medical and Scientific Purposes and 
the 2012 Guide on Estimating Requirements for Substances 
under International Control, developed by the Board and 
WHO. 
Recommendation 7: The Board invites countries to take 
all necessary measures to facilitate access to opioid anal-
gesics and psychotropic substances for those who need 
them, including through the provision of training to 
health professionals and the streamlining of administra-
tive procedures regulating prescriptions, adequate domes-
tic distribution and importation practices.
Cannabis
688. The 1961 Convention allows States parties to use 
cannabis for medical purposes. Reflecting concerns about 
abuse and diversion, the Convention establishes an addi-
tional set of control measures which should be imple-
mented in order for programmes for the use of cannabis 
for medical purposes to be compliant with the Convention. 
In that connection, the Board reiterates its invitation to 
WHO to evaluate the potential medical utility of canna-
bis and the extent to which cannabis poses a risk to 
human health.
Recommendation 8: All Governments that have estab-
lished programmes for the use of cannabis for medical 
purposes, or are considering such initiatives, are reminded 
of their reporting and licensing obligations under the 
international drug control treaties. Importantly, such 
programmes must ensure that the prescription of canna-
bis for medical purposes is performed with competent 
medical knowledge and supervision, and that such pre-
scription is based on sound medical practice. States par-
ties to the 1961 Convention in which such research is 
ongoing are invited to share their research results and 
any other data on the medical usefulness or otherwise of 
cannabis with WHO, INCB and all relevant international 
organizations.
Opium poppy cultivation
689. The Board’s review of the demand for and supply 
of opiate raw material for medical and scientific purposes 
indicates that the amount of opiate raw material availa-
ble for the manufacturing of narcotic drugs for medical 
purposes, including for pain relief, is more than sufficient 
to satisfy the current level of demand, as estimated by 
Governments, with both production and stocks continu-
ing to increase.
Recommendation 9: Cultivating and producing countries 
are urged to take into consideration article 29, paragraph 3, 
and article 30, paragraph 2, of the 1961 Convention, in 
which parties are required to prevent the accumulation of 
poppy straw in excess of quantities required for the nor-
mal conduct of business, taking into account the prevail-
ing market conditions.
Psychotropic substances
690. The voluntary submission of data on the consump-
tion of psychotropic substances is requested pursuant to 
Commission on Narcotic Drugs resolution 54/6, entitled 
“Promoting adequate availability of internationally con-
trolled narcotic drugs and psychotropic substances for 
medical and scientific purposes while preventing their 
diversion and abuse”. The provision of such data is a pre-
requisite for accurate analysis of consumption levels 
worldwide and for identifying any unusual indicators at 
an early stage.
Recommendation 10: All Governments that have not yet 
done so should put in place the necessary legislative and 
administrative mechanisms that will allow them to col-
lect data on the consumption of psychotropic substances 
for medical and scientific purposes and to furnish those 
data to the Board, in the same manner as for narcotic 
drugs. This will also promote the adequate availability of 
such substances.
Licit international trade
691. Over the past few years, the Board has spear-
headed efforts to develop an electronic tool to facilitate 
and expedite the work of competent national authorities 
and to reduce the risks of diversion of those substances. 
This new tool, the International Import and Export 
System (I2ES), will assist competent national authorities 
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by functioning in a way that ensures full compliance with 
the requirements set out in the international drug con-
trol conventions and safeguards the data therein.
Recommendation 11: The Board invites all Governments 
to provide both political and financial support to I2ES 
and to consider utilizing it as soon as possible. Only 
through its wide and early utilization will Governments 
be able to fully benefit from the advantages that the 
 system provides.
Precursors
692. Over the past 25 years, international cooperation in 
precursor control has brought about significant results in 
preventing the diversion of scheduled chemicals from 
international trade, but there is also a need to fine-tune 
the system to make it fit for the future. The 2014 report 
of the Board on the implementation of article 12 of the 
1988 Convention contains further details on that subject.
Recommendation 12: Governments and relevant regional 
and international organizations are invited to use the 
upcoming special session of the General Assembly on the 
world drug problem in 2016 to work with each other and 
with INCB to address the challenges identified in the 
2014 report of the Board on precursors. The Board con-
siders the following measures critical: preventing diver-
sion; enhanced private-public partnerships which also 
address non-scheduled chemicals and designer precur-
sors; and comprehensive and systematic application of all 
available tools, such as the PEN Online system, PICS, the 
international special surveillance list of non-scheduled 
substances, and the guidelines and model memorandums 
of cooperation with the chemical industry.
Recommendation 13: Governments should work closely 
with each other and with the Board in targeted operations 
under Project Prism and Project Cohesion, with a view to 
identifying and addressing trends in the illicit sourcing and 
trafficking of precursor chemicals. In these types of activ-
ities, seizures of precursors should not be considered the 
end, but rather the beginning, of investigations aimed at 
preventing similar incidents in the future.
Non-scheduled substances
693. Many Governments have reported a rapidly 
increasing number of detected non-scheduled new 
psycho active substances, and the abuse and trafficking of 
such substances is growing throughout the world. There 
is, however, a paucity of reliable information related to 
these substances.
Recommendation 14: Pursuant to Commission on 
Narcotic Drugs resolution 57/9, the Board calls on 
Member States to actively support WHO in critically 
assessing new psychoactive substances and in providing 
scheduling recommendations to the Commission; the 
United Nations Office on Drugs and Crime, so that it 
may collect comprehensive data through its early warn-
ing system; and INCB to enable its task force on new 
psychoactive substances to receive, coordinate and com-
municate operational information and intelligence to 
Project Ion focal points in order to support the identifi-
cation and dismantling of key sources and distribution 
networks of new psychoactive substances.
Promoting the consistent application of 
the international drug control treaties
694. In March 2014, at the high-level segment of the 
fifty-seventh session of the Commission on Narcotic 
Drugs, Government representatives adopted by consen-
sus a joint ministerial statement, in which they under-
scored that the three international drug control 
conventions constituted the cornerstone of the interna-
tional drug control system. The Board is concerned about 
initiatives, inconsistent with these conventions, that have 
legalized cannabis for non-medical purposes in Uruguay 
and some states of the United States.
Recommendation 15: The Board reiterates its position 
with regard to the legalization of non-medical use of 
scheduled substances and again urges all States to ensure 
full compliance with the treaties to which they are par-
ties and to refrain from policies and actions that could 
undermine the integrity of the international drug con-
trol system and may put their citizens at an increased 
health risk.
695. The Board notes the cooperation of the Government 
of Afghanistan with INCB, as well as the measures taken 
and the commitment expressed by that Government to 
effective drug control. Nevertheless, the deteriorating 
drug control situation in Afghanistan, particularly the 
recent increase in the area of illicit poppy cultivation, 
constitute a significant challenge in the country and 
globally.
Recommendation 16: The Government of Afghanistan 
should continue to strengthen its capacity in the areas of 
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drug interdiction, promotion of alternative livelihoods, 
and prevention and treatment of drug abuse in the coun-
try. The Board encourages the Government to continue 
seeking international assistance in addressing the drug 
problem and to strengthen its cooperation at the regional 
and international levels.
(Signed)
Lochan Naidoo
President
(Signed)
Sri Suryawati
Rapporteur
(Signed)
Andrés Finguerut
Secretary
Vienna, 14 November 2014
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Annex I.
Regional and subregional groupings used in the 
report of the International Narcotics Control 
Board for 2014
The regional and subregional groupings used in the report of the International Narcotics Control Board for 2014, 
together with the States in each of those groupings, are listed below.
Africa
Algeria Libya
Angola Madagascar
Benin Malawi
Botswana Mali
Burkina Faso Mauritania
Burundi Mauritius
Cameroon Morocco
Cabo Verdea Mozambique
Central African Republic Namibia
Chad Niger
Comoros Nigeria
Congo Rwanda
Côte d’Ivoire Sao Tome and Principe
Democratic Republic of the Congo Senegal
Djibouti Seychelles
Egypt Sierra Leone
Equatorial Guinea Somalia
Eritrea South Africa
Ethiopia South Sudan
Gabon Sudan
Gambia Swaziland
Ghana Togo
Guinea Tunisia
Guinea-Bissau Uganda
Kenya United Republic of Tanzania
Lesotho Zambia
Liberia Zimbabwe
 a Since 25 October 2013, “Cabo Verde” has replaced “Cape Verde” as the short name used in the United Nations.
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Central America and the Caribbean
Antigua and Barbuda Guatemala
Bahamas Haiti
Barbados Honduras
Belize Jamaica
Costa Rica Nicaragua
Cuba Panama
Dominica Saint Kitts and Nevis
Dominican Republic Saint Lucia
El Salvador Saint Vincent and the Grenadines
Grenada Trinidad and Tobago
North America
Canada United States of America
Mexico
South America
Argentina Guyana
Bolivia (Plurinational State of) Paraguay
Brazil Peru
Chile Suriname
Colombia Uruguay
Ecuador Venezuela (Bolivarian Republic of)
East and South-East Asia
Brunei Darussalam Mongolia
Cambodia Myanmar
China Philippines
Democratic People’s Republic of Korea Republic of Korea
Indonesia Singapore
Japan Thailand
Lao People’s Democratic Republic Timor-Leste
Malaysia Viet Nam
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South Asia
Bangladesh Maldives
Bhutan Nepal
India Sri Lanka
West Asia
Afghanistan Oman
Armenia Pakistan
Azerbaijan Qatar
Bahrain Saudi Arabia
Georgia State of Palestineb
Iran (Islamic Republic of) Syrian Arab Republic
Iraq Tajikistan
Israel Turkey
Jordan Turkmenistan
Kazakhstan United Arab Emirates
Kuwait Uzbekistan
Kyrgyzstan Yemen
Lebanon
Europe
Eastern Europe
Belarus Russian Federation
Republic of Moldova Ukraine
South-Eastern Europe
Albania Montenegro
Bosnia and Herzegovina Romania
Bulgaria Serbia
Croatia The former Yugoslav Republic of  Macedonia
 b Pursuant to General Assembly resolution 67/19 of 29 November 2012, Palestine has been accorded the status of a non-member observer State. The 
name “State of Palestine” is now used in all United Nations documents.
104  INCB REPORT 2013
Western and Central Europe
Andorra Liechtenstein
Austria Lithuania
Belgium Luxembourg
Cyprus Malta
Czech Republic Monaco
Denmark Netherlands
Estonia Norway
Finland Poland
France Portugal
Germany San Marino
Greece Slovakia
Holy See Slovenia
Hungary Spain
Iceland Sweden
Ireland Switzerland
Italy United Kingdom of Great Britain and
Latvia  Northern Ireland
Oceania
Australia Niue
Cook Islands Palau
Fiji Papua New Guinea
Kiribati Samoa
Marshall Islands Solomon Islands
Micronesia (Federated States of) Tonga
Nauru Tuvalu
New Zealand Vanuatu
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Annex II.
Current membership of the International 
Narcotics Control Board
Wayne Hall
Born in 1951 in Australia. Trained as a research psycho-
logist and worked as an epidemiologist. Currently Director 
of the Centre for Youth Substance Abuse Research at the 
University of Queensland and Professor of Addiction 
Policy at King’s College London. Formerly, Professor and 
National Health and Medical Research Council Australia 
Fellow, University of Queensland Centre for Clinical 
Research (2010-2013).
Professor of Public Health Policy, School of Population 
Health, University of Queensland (2006-2010); Professor 
and Director, Office of Public Policy and Ethics, Institute 
for Molecular Bioscience, University of Queensland (2001-
2005); Professor and Director, National Drug and Alcohol 
Research Centre, University of New South Wales (1994-
2001). Author and co-author of over 800 articles, chapters 
and reports on addiction, drug use epidemiology and men-
tal health. Member, World Health Organization Expert 
Committee on Drug Dependence (1996) and the Australian 
National Council on Drugs (1998-2001). 
Member of the International Narcotics Control Board 
(2012-2014).a Member of the Standing Committee on 
Estimates (2012-2014). Vice-Chair of the Standing 
Committee on Estimates (2013) and Member of the 
Committee on Finance and Administration (2013). 
David T. Johnson
Born in 1954. National of the United States. Vice-
President, Sterling Global Operations; retired diplomat. 
 a Resigned effective 24 July 2014.
Bachelor’s degree in economics from Emory University; 
graduate of the National Defence College of Canada.
United States Foreign Service officer (1977-2011). 
Assistant Secretary for the Bureau of International 
Narcotics and Law Enforcement Affairs, United States 
Department of State (2007-2011). Deputy Chief of Mission 
(2005-2007) and Chargé d’affaires, a.d., (2003-2005) 
United States Embassy, London. Afghan Coordinator for 
the United States (2002-2003). United States Ambassador 
to the Organization for Security and Cooperation in 
Europe (1998-2001). Deputy Press Secretary at the White 
House and Spokesman for the National Security Council 
(1995-1997). Deputy Spokesman at the State Department 
(1995) and Director of the State Department Press Office 
(1993-1995). United States Consul General, Vancouver 
(1990-1993).
Member of the International Narcotics Control Board 
(since 2012). Member of the Committee on Finance and 
Administration (since 2012). Chair of the Committee on 
Finance and Administration (2014).
Galina Korchagina
Born in 1953. National of the Russian Federation. Deputy 
Director of Research at the National Centre for Research 
on Drug Addiction, Ministry of Health, Russian Federation 
(since 2010). 
Leningrad Paediatrics Institute, Russian Federation 
(1976); Doctor of Medicine (2001). Doctor, boarding 
school, Gatchina, Leningrad region, (1976-1979). Head 
of the Organizational and Policy Division, Leningrad 
Regional Drug Clinic (1981-1989); Lecturer, Leningrad 
Regional Medical Academy (1981-1989); Head Doctor, 
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City Drug Clinic, St. Petersburg (1989-1994); Assistant 
Lecturer (1991-1996) and Professor (2000-2001), 
Department of Social Technologies, State Institute for 
Services and Economics; Assistant Lecturer (1994-2000), 
Associate Professor (2001-2002) and Professor (2002-
2008), Department for Research on Drug Addiction, St. 
Petersburg Medical Academy of Postgraduate Studies; 
Chief Professor and Head of the Department for Medical 
Research and Healthy Lifestyles, Herzen State Pedagogical 
University of Russia (2000-2008); Professor, Department 
for Conflict Studies, Faculty of Philosophy, St. Petersburg 
State University (2004-2008); and member of numerous 
associations and societies, including the Association of 
Psychiatrists and Drug Addiction Specialists of Russia 
and St. Petersburg, the Kettil Bruun Society for Social 
and Epidemiological Research on Alcohol, the 
International Council on Alcohol and Addictions and the 
International Society of Addiction Medicine. Head of the 
sociology of science aspects of medical and biological 
research section of the Research Council on the Sociology 
of Science and the Organization of Scientific Research, 
Saint Petersburg Scientific Centre of the Russian Academy 
of Sciences (2002-2008). Author of more than 100 pub-
lications, including more than 70 works published in the 
Russian Federation, chapters in monographs and several 
practical guides. Award for excellence in health protec-
tion, awarded by the Ministry of Health of the Union of 
Soviet Socialist Republics (1987). Consultant, Global 
Business Coalition on HIV/AIDS, Tuberculosis and 
Malaria (since 2006); co-trainer, World Health 
Organization (WHO) programme “Skills for change” 
(since 1995); participant in meetings of the Commission 
on Narcotic Drugs (2002-2008); expert on the epidemi-
ology of drug addiction, Pompidou Group of the Council 
of Europe (1994-2003); temporary representative, WHO 
(1992-2008).
Member of the International Narcotics Control Board 
(since 2010). Vice-Chair of the Standing Committee on 
Estimates (2011-2012). First Vice-President of the Board 
(2013).
Alejandro Mohar Betancourt 
Born in 1956. National of Mexico. Director General of 
the National Cancer Research Institute of Mexico (2003-
2013) and member of the National System of Researchers 
of Mexico, the National Academy of Medicine, the 
Mexican Academy of Sciences and the American Society 
of Clinical Oncology.
Doctor of Medicine, National Autonomous University of 
Mexico (UNAM) (1980); Postgraduate studies in 
anatomical pathology, National Institute of Nutrition 
(1985), Master of Sciences (1986) and Doctor of Sciences 
in Epidemiology (1990), Harvard School of Public 
Health. 
Recipient of academic and research support from the 
National Council on Science and Technology (CONACYT) 
and the Mexican Foundation of Health. Head of the 
Department of Epidemiology (1988-1989), Deputy 
Director of Clinical Research (1993-1999) and Director 
of Research (1999-2003), National Cancer Research 
Institute of Mexico. Lecturer and Research Associate, 
Harvard School of Public Health (1988-1990). Lecturer 
and Director of master’s and doctoral dissertations at the 
Faculty of Medicine, UNAM (since 1991). Coordinator 
of the Unit for Biomedical Research on Cancer, Biomedical 
Research Institute, UNAM (1998). Author of more than 
110 scientific and popular works, 70 of which appear in 
indexed journals, including “Intratypic changes of the E1 
gene and the long control region affect ori function of 
human papillomavirus type 18 variants”, “Screening 
breast cancer: a commitment to Mexico (preliminary 
report)”, “Impact of diabetes and hyperglycemia on sur-
vival in advanced breast cancer patients”, “Ovarian can-
cer: the new challenge in gynaecologic oncology?” and 
“Validation of the Mexican-Spanish version of the EORTC 
QLQ-C15-PAL questionnaire for the evaluation of health-
related quality of life in patients on palliative care”. 
Awarded various recognitions including the following: 
Miguel Otero Award for clinical research, General Health 
Council (2012); third place for best pharmacoeconomics 
work, Mexican College for Pharmacoeconomics and 
International Society for Pharmacoeconomics and 
Outcomes Research, Mexico chapter (2010); member of 
the Group of the 300 Most Influential Leaders of Mexico; 
recognition for participation in the meeting of the Global 
Health Strategic Operations Advisory Group of the 
American Cancer Society (2009); member of the Board 
of Governors of the National Autonomous University of 
Mexico (2008); Distinction of Edward Larocque Tinker 
Visiting Professor, Stanford University (2000); member of 
the External Advisory Group for the Mexico Report on 
Social Determinants of Health (2010); member of the 
jury for the Aaron Sáenz Annual Prize for Paediatric 
Research, Federico Gómez Children’s Hospital of Mexico 
and the “General y Lic. Aarón Sáenz Garza, A.C” 
Association (2010); member of the Global Health Strategic 
Operations Advisory Group of the American Cancer 
Society (2010); Certificate of Achievement for dedication 
and commitment to establishing a national cancer plan 
for Mexico, American Cancer Society (2006); member of 
the Scientific Committee of the Mexican Association of 
Pathologists (1993-1995).
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Member of the International Narcotics Control Board 
(since 2013). Member of the Standing Committee on 
Estimates (2014).
Marc Moinard
Born in 1942. National of France. Retired law officer. 
School of Political Sciences, Paris; Paris Law Faculty; 
Faculty of Arts, Poitiers. Public Prosecutor, Beauvais 
(1982-1983); Public Prosecutor, Pontoise (1990); Public 
Prosecutor, Lyon (1990-1991); Public Prosecutor, Bobigny 
(1992-1995); Public Prosecutor in the Court of Appeal, 
Bordeaux (1999-2005), introducing major reforms into 
the legal system involving: the creation of centres for legal 
advice and mediation; the provision of legal advice in 
deprived areas; the establishment of a new system of 
cooperation between the courts and the police services 
allowing for the immediate handling of criminal offences; 
and the creation of a new category of judicial personnel: 
assistant prosecutors.
Senior administrative posts in the Ministry of Justice: 
Director of Record Offices (1983-1986); President of the 
teaching board, National School of Clerks to the Court; 
Director of Legal Services; member of the Board of 
Directors, French National School for the Judiciary; 
Representative of the Minister of Justice in the Supreme 
Council of Justice (1995-1996); Director, Criminal 
Matters and Pardons (1996-1998); President, French 
Monitoring Centre for Drugs and Drug Addiction; 
Secretary-General, Ministry of Justice (2005-2008); 
President, Law and Justice Mission, responsible for the 
reform of the judicial map; President, Commission on 
Information Technology and Communication; Head of 
the International Affairs Service, Ministry of Justice. 
Lecturer, Paris Institute of Criminology (1995-2005); 
President, Fondation d’Aguesseau, a welfare body. 
Recipient of the following awards: Commander of the 
National Order of Merit; Commander of the Legion of 
Honour. 
Member of the International Narcotics Control Board 
(since 2010). Member of the Standing Committee on 
Estimates (2011-2013). Member of the Committee on 
Finance and Administration (2010-2012 and 2014). 
Lochan Naidoo
Born in 1961. National of South Africa. Family 
Practitioner, Durban, South Africa (since 1985). 
Bachelor of Medicine and Bachelor of Surgery (MBChB), 
University of Natal, South Africa (1983). Professional in 
Residence Programme: Hanley Hazelden (1995); Member 
of the South African Medical Association (since 1995); 
Member and Vice-Chairman of the Bayport Independent 
Practitioners Association (1995-2000). Certified Chemical 
Dependency Counsellor, National Board of Addiction 
Examiners (1996); Member of the American Society of 
Addiction Medicine (1996-1999). Diploma in Business 
Management, South African Institute of Management 
(1997). Founding member, International Society of 
Addiction Medicine (1999); Programme Designer and 
Principal Addictions Therapist of the Jullo Programme, a 
multidisciplinary treatment model for primary, secondary 
and tertiary prevention of addiction disorders and dual 
diagnoses (since 1994); Clinical Director, Serenity 
Addiction Treatment Unit, Merebank, Durban, South 
Africa (since 1995). Member of the KwaZulu-Natal 
Managed Care Coalition (since 1995); Member of the 
Durban South Doctors’ Guild (since 2000); Honorary 
Lecturer, Nelson R. Mandela School of Medicine, University 
of KwaZulu-Natal, South Africa (2005-2011). Curriculum 
Committee, undergraduate lifestyle medicine, University of 
KwaZulu-Natal (2005-2011). Drafter of the National 
Detoxification Policy and Procedure for the Department 
of Health of South Africa (2006); designer of the Roots 
Connect software program, an Internet-driven emotional 
and addiction psychoeducation delivery system (2007); 
Member of the Opiate Advisory Board of South Africa 
(2006-2008); Member of the Board, Central Drug Authority 
of South Africa (2006-2010); Member of the Governance 
Committee, Central Drug Authority of South Africa (2006-
2010). Member of the Expert Committee on Opiate 
Treatment (2007-2008); Central Drug Authority represent-
ative to the Western Cape Province, South Africa (2007-
2010); established “Roots HelpPoints” for early intervention 
and primary prevention among high-risk individuals 
(2008). Co-author of “Guidelines for opiate treatment in 
South Africa”, South African Medical Journal (2008). 
Member of the Suboxone Advisory Board (2009). 
Co-author of “Opiate treatment update”, South African 
Medical Journal (2010); Designer of Rehab Flow cloud 
computing software for addiction and co-morbidity man-
agement (2010); Management Committee Member of 
eThekweni District Mental Health and Substance Abuse 
Forum (2010). Rehabilitation and addictions trainer for 
health-care practitioners. Medical educator for undergrad-
uate and postgraduate medical practitioners (since 1995); 
Patron of Andra Maha Sabha of South Africa; founder, 
Merebank West Community Coalition (1995). Trustee, 
Merebank Community Trust (2000-2005). 
Chief Executive Officer of Healing Hills Specialist 
Psychiatric Hospital, South Africa. Designer of Roots 
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Online programme for prevention and aftercare of sub-
stance abuse disorders. Director of the Jullo Foundation, 
a non-profit organization for advocacy and delivery of 
care to addicts in Southern Africa.
Member of the International Narcotics Control Board 
(since 2010). Member of the Standing Committee on 
Estimates (2011). Member of the Committee on Finance 
and Administration (2011). First Vice-President of the 
Board (2012). President of the Board (2014).
Rajat Ray
Born in 1948. National of India. Retired Professor and 
Head of the Department of Psychiatry and Chief, National 
Drug Dependence Treatment Centre (NDDTC), All India 
Institute of Medical Sciences (AIIMS), New Delhi. 
Graduate of Medicine (MBBS), Medical College in 
Calcutta (1971). M.D. (Psychiatry), AIIMS (1977). 
Member of the faculty, Department of Psychiatry, 
National Institute of Mental Health and Neuro Sciences, 
Bangalore (1979-1988). Author of several technical 
reports and articles in peer-reviewed national and inter-
national journals. Assistant Editor, Addiction Biology. 
Member of the International Advisory Board, Mental 
Health and Substance Use: Dual Diagnosis, and the 
Editorial Board, of the scientific journal International 
Drug Sciences and Drug Policy.
Recipient of research support from various bodies at the 
national level (such as the Ministry of Health and Family 
Welfare and the Indian Council of Medical Research) and 
the international level (such as the United Nations Office 
on Drugs and Crime (UNODC) and WHO). Member of 
a study on HIV/AIDS, a collaborative project of NDDTC, 
AIIMS and the Centre for Interdisciplinary Research in 
Immunology and Disease, University of California, Los 
Angeles, United States of America. Member of the WHO 
Expert Advisory Panel on Drug Dependence and Alcohol 
Problems. Member of the expert group to discuss men-
tal health and substance use disorder at the primary care 
level, an activity of the WHO Regional Office for South-
East Asia. Member of the WHO expert group on regional 
technical consultation to reduce harmful use of alcohol. 
Coordinator of various activities in India on substance 
use disorder, sponsored by WHO (since 2004). Member 
of the National Drug Abuse Control Programme, India, 
and the Technical Guidelines Development Group on 
Pharmacotherapy of Opioid Dependence, a joint project 
of UNODC and WHO. Member and Chairperson of the 
Technical Resource Group on Injecting Drug Use, a 
project of the National AIDS Control Organization. 
Member of the project advisory committee on the pre-
vention of transmission of HIV among drug users in 
South Asian Association for Regional Cooperation mem-
ber States, a project of the UNODC Regional Office for 
South Asia. Member of the Subcommittee on Postgraduate 
Medical Education, Medical Council of India. Chairperson, 
Working Group on Classification of Substance-Related 
and Addictive Disorder, International Advisory Group for 
the Revision of ICD-10 Mental and Behavioural Disorders 
(since 2011); Principal investigator, WHO Project “Web-
Based Intervention (Portal) for Alcohol and Health”, 
Geneva (2010-2013); principal investigator, NDDTC, 
Global Fund to Fight AIDS, Tuberculosis and Malaria 
Round 9 and Nodal Regional Resource and Training 
Centre; Principal Coordinator, National Policy and 
Twelfth Five-Year Plan of India, covering the period 
2012-2017, areas relating to control of alcohol and drug 
problems, Ministry of Social Justice and Empowerment, 
Government of India; Principal Investigator, opioid sub-
stitution therapy in India: issues and lessons learned, a 
joint project of NDDTC, AIIMS, the National AIDS 
Control Organisation, the government of Punjab and the 
Department for International Development (UK aid)—
Technical Assistance Support Team, targeted intervention 
(2010-2013); member of the Expert Committee on 
Psychotropic Substances and New Drugs, Drug Controller 
General of India (2011). Reviewer and contributor, Indian 
Journal of Medical Research, official publication of the 
Indian Council of Medical Research (since 2010).
Member of the International Narcotics Control Board 
(since 2010). Member (since 2010), Chair (2011) and 
Vice-Chair (2014) of the Standing Committee on 
Estimates. Second Vice-President of the Board (2011). 
Ahmed Kamal Eldin Samak
Born in 1950. National of Egypt. Graduated with a Law 
and Police Licence in 1971. Worked in the field of anti-
narcotics for more than 35 years, until becoming the 
Minister Assistant of Police and Head of the Anti-
Narcotics General Administration of Egypt, which is 
considered the first organization of anti-narcotics in the 
world and was founded in 1929. Independent adviser 
in the field of anti-narcotics and crime. First-rank badge 
of honour on the occasion of the police festival (1992). 
Contributed to several missions, such as to Jordan, for 
anti-narcotics training (1988); India, for the signing of 
an agreement between India and Egypt to strengthen 
anti-narcotics and security cooperation to combat crime 
and terrorism (1995); France, for cooperation between 
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Egypt and INTERPOL relating to drugs and money-
laundering (1996); Palestine,b to participate in a 
regional anti- narcotics workshop (1999); Saudi Arabia, 
to participate in a training programme related to drug 
cases (2001); United Arab Emirates, to represent the 
Ministry of the Interior at the thirty-sixth session of the 
committee concerned with illegal trade in drugs (2001); 
Libyan Arab Jamahiriya,c to participate in the celebra-
tion of the International Day against Drug Abuse and 
Illicit Trafficking (2002); Kenya, to participate in the 
twelfth and seventeenth conferences of African national 
anti- narcotics department leaders (2002 and 2007); 
Mauritius, for the second ministerial anti-narcotics 
meeting (2004); Lebanon, to participate in the confer-
ence “Drugs are a social epidemic”, organized by 
Lebanese organizations for human rights (2004); Tunisia, 
to participate in the seven teenth to twenty-first Arab 
conferences of anti- narcotics department leaders (2003-
2007); United States (2004); Austria, to represent the 
Ministry at the forty-fifth, forty-sixth and forty-eighth 
to fiftieth sessions of the Commission on Narcotic 
Drugs (2002-2007); Saudi Arabia, as a member of a sci-
entific organization to prepare an article about arrest 
and investigation procedures (2007); United Arab 
Emirates, for the Regional Seminar for Strategic and 
Cooperative Planning in the Field of Anti-Narcotics 
(2007). Member of the National General Trust Fund for 
Anti-Narcotics and Addiction; and the Committee of 
National Strategy Planning on Anti-Narcotics.
Member of the International Narcotics Control Board 
(since 2012). Member of the Standing Committee on 
Estimates (2012 and 2014). 
Werner Sipp
Born in 1943. National of Germany. Lawyer (Universities 
of Heidelberg, Germany, and Lausanne, Switzerland, 
University Institute of European Studies, Turin, Italy).
Assistant lecturer in Public Law, University of Regensburg 
(1971-1977). Senior administrative posts in several fed-
eral ministries (1977-2008). Head of the Division for 
Narcotic Law and International Narcotic Drugs Affairs in 
the Federal Ministry of Health (2001-2008); Permanent 
Correspondent of Germany in the Pompidou Group of 
 b Pursuant to General Assembly resolution 67/19 of 29 November 
2012, Palestine has been accorded the status of a non-member observer 
State. The name “State of Palestine” is now used in all United Nations 
documents.
 c Since 16 September 2011, “Libya” has replaced “Libyan Arab Jama-
hiriya” as the short name used in the United Nations.
the Council of Europe (2001-2008); Legal Correspondent 
of Germany in the European Legal Database on Drugs, 
Lisbon (2002-2008); Chairman of the Horizontal Working 
Party on Drugs of the Council of the European Union 
(2007); Coordinator of the German delegation to the 
Commission on Narcotic Drugs (2001-2009). 
Expert Consultant to the German Federal Ministry of 
Health and Drug Commissioner of the Federal Gov-
ernment in international drug matters (2008-2009); 
Expert Consultant on drug issues to the Deutsche 
Gesellschaft für Internationale Zusammenarbeit (2008-
2011); Expert on several European Union drug projects 
(such as “Implementing the national strategy to fight 
drug abuse in Serbia” and the Central Asia Drug Action 
Programme.
Member of the International Narcotics Control Board 
(since 2012), Member of the Standing Committee on 
Estimates (since 2012). Rapporteur (2013). First Vice-
President of the Board (2014).
Viroj Sumyai
Born in 1953. National of Thailand. Retired Assistant 
Secretary-General of the Food and Drug Administration, 
Ministry of Public Health of Thailand, and clinical phar-
macologist specializing in drug epidemiology. Professor, 
Mahidol University (since 2001).
Bachelor of Science degree in chemistry (1976), Chiang 
Mai University. Bachelor’s degree in pharmacy (1979), 
Manila Central University. Master’s degree in clinical 
pharmacology (1983), Chulalongkorn University. Appren-
ticeship in narcotic drugs epidemiology at St. George’s 
University of London (1989). Doctor of Philosophy, 
Health Policy and Administration (2009), National 
Institute of Administration. Member of the Pharmaceutical 
Association of Thailand. Member of the Pharmacological 
and Therapeutic Society of Thailand. Member of the Thai 
Society of Toxicology. Author of nine books in the field 
of drug prevention and control, including Drugging 
Drinks: Handbook for Predatory Drugs Prevention and 
Déjà vu: A Complete Handbook for Clandestine Chemistry, 
Pharmacology and Epidemiology of LSD. Columnist, Food 
and Drug Administration Journal. Recipient, Prime 
Minister’s Award for Drug Education and Prevention 
(2005). 
Member of the International Narcotics Control Board 
(since 2010). Member (since 2010) and Chair (2012 and 
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2014) of the Standing Committee on Estimates. Chair of 
the Committee on Finance and Administration (2011). 
Second Vice-President of the Board (2012 and 2014). 
Chair of the Committee on Finance and Administration 
(2011 and 2013).
Sri Suryawati
Born in 1955. National of Indonesia. Professor and Head, 
Division of Medicine Policy and Management, Director 
of Centre for Clinical Pharmacology and Medicine Policy 
Studies, Gadjah Mada University, Yogyakarta. Educational 
background includes pharmacy (1979). Specialist in phar-
macology (1985); doctoral degree in clinical pharmaco-
kinetics (1994), certificate in medicine policy (1997). 
Lecturer in pharmacology/clinical pharmacology (since 
1980); supervisor for more than 130 master’s and doc-
toral theses in the areas of medicine policy, essential 
medi cines, clinical pharmacology, pharmacoeconomics 
and pharmaceutical management.
Member of the WHO Expert Advisory Panel for Medicine 
Policy and Management. Member of the Executive Board 
of the International Network for the Rational Use of 
Drugs (INRUD). Member of the WHO Expert Committee 
on the Selection and Use of Essential Medicines (2002, 
2003, 2005 and 2007). Member of the WHO Expert 
Committee on Drug Dependence (2002 and 2006). 
Member of the United Nations Millennium Project Task 
Force on HIV/AIDS, Malaria and Tuberculosis and 
Access to Essential Medicines (Task Force 5) (2001-2005). 
Consultant in essential medicine programmes and pro-
moting rational use of medicines in Bangladesh (2006-
2007), Cambodia (2001-2008), China (2006-2008), Fiji 
(2009), the Lao People’s Democratic Republic (2001-
2003), Mongolia (2006-2008) and the Philippines (2006-
2007). Consultant in medicine policy and drug evaluation 
in Cambodia (2003, 2005 and 2007), China (2003), 
Indonesia (2005-2006) and Viet Nam (2003). Facilitator 
in various international training courses in medicine pol-
icy and promoting the rational use of medicines, includ-
ing WHO and INRUD courses on promoting the rational 
use of medicines (1994-2007), training courses on hospi-
tal drugs and therapeutics committees (2001-2007) and 
international courses on medicine policy (2002-2003).
Member of the International Narcotics Control Board 
(2007-2012 and since 2013). Member (2008-2011 and 
since 2013), Vice-Chair (2009) and Chair (2010 and 
2013) of the Standing Committee on Estimates. Second 
Vice-President of the Board (2010 and 2013). Rapporteur 
(2011 and 2014).
Francisco E. Thoumi
Born in 1943, national of Colombia and the United States. 
Bachelor of Arts and Doctor of Philosophy in Economics. 
Senior member of the Colombian Academy of Economic 
Sciences and Corresponding Member of the Royal 
Academy of Moral and Political Sciences (Spain).
Professor at the University of Texas, Rosario University 
(Bogota) and California State University, Chico. Worked 
for 15 years in the research departments of the World 
Bank and the Inter-American Development Bank. 
Founder and Director, Research and Monitoring Center 
on Drugs and Crime, Rosario University (August 
2004-December 2007); Research Coordinator, Global 
Programme against Money-Laundering, Proceeds of 
Crime and the Financing of Terrorism; Coordinator 
for the World Drug Report, UNODC (August 
1999-September 2000); Researcher, Comparative Study 
of Illegal Drugs in Six Countries, United Nations 
Research Institute for Social Development, Geneva (June 
1991-December 1992); Fellow, Woodrow Wilson 
International Center for Scholars (August 1996-July 
1997); Research Coordinator, Research Programme on 
the Economic Impact of Illegal Drugs in the Andean 
Countries, United Nations Development Programme, 
Bogota (November 1993-January 1996).
Author of two books and co-author of one book on ille-
gal drugs in Colombia and the Andean region. Editor of 
three volumes and author of over 60 academic journal 
articles and book chapters on those subjects.
Member of the Friedrich Ebert Foundation Observatory 
of Organized Crime in Latin America and the Caribbean 
(since 2008) and the World Economic Forum’s Global 
Agenda Council on Organized Crime (2012-2014). 
Member of the International Narcotics Control Board 
(since 2012). Rapporteur (2012). Member of the Standing 
Committee on Estimates (2013). Member of the 
Committee on Finance and Administration (2014).
Raymond Yans
Born in 1948. National of Belgium. Graduate in Germanic 
philology and in philosophy (1972). 
Belgian Foreign Service: Attaché, Jakarta (1978-1981); 
Deputy-Mayor of Liège (1982-1989); Consul, Tokyo 
(1989-1994); Consul, Chargé d’affaires, Luxembourg 
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(1999-2003); Head of the Drug Unit, Ministry of Foreign 
Affairs (1995-1999 and 2003-2007); Chairman of the 
Dublin Group (2002-2006); Chairman of the European 
Union Drug Policy Cooperation Working Group during 
the Belgian Presidency of the European Union; charged 
with the national coordination of the ratification and 
implementation process of the Convention on Psychotropic 
Substances of 1971 and the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (1995-1998); liaison between the 
Ministry of Foreign Affairs and the National Police for 
drug liaison officers in Belgian embassies (2003-2005); 
participation in the launching by the European Union 
Joint Action on New Synthetic Drugs of an early warn-
ing system to alert Governments to the appearance of 
new synthetic drugs (1999); active in the creation of the 
Cooperation Mechanism on Drugs between the European 
Union, Latin America and the Caribbean (1997-1999). 
Author of numerous articles and speeches, including: 
“The future of the Dublin Group” (2004) and “Is there 
anything such as a European Union Common Drug 
Policy” (2005). Member of the Belgian delegation to the 
Commission on Narcotic Drugs (1995-2007); all the pre-
paratory sessions (on amphetamine-type stimulants, pre-
cursors, judicial cooperation, money-laundering, drug 
demand reduction and alternative development) for the 
twentieth special session of the General Assembly; 
European Union Seminar on Best Practices in Drug 
Enforcement by Law Enforcement Authorities, Helsinki 
(1999); Joint European Union/Southern African 
Development Community Conferences on Drug Control 
Cooperation, Mmabatho, South Africa (1995) and 
Gabarone (1998); UNODC/Paris Pact round tables, 
Brussels (2003), Tehran and Istanbul (2005); meetings of 
the High-level Dialogue on Drugs between the Andean 
Community and the European Union, Lima (2005) and 
Vienna (2006).
Member of the International Narcotics Control Board 
(since 2007). Member of the Standing Committee on 
Estimates (2007-2010). Member of the Committee on 
Finance and Administration (2007-2009). Rapporteur 
(2010). First Vice-President of the Board (2011). President 
of the Board (2012 and 2013). 
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About the International Narcotics Control Board
The International Narcotics Control Board (INCB) is an 
independent and quasi-judicial control organ, established 
by treaty, for monitoring the implementation of the inter-
national drug control treaties. It had predecessors under 
the former drug control treaties as far back as the time 
of the League of Nations.
Composition
INCB consists of 13 members who are elected by the 
Economic and Social Council and who serve in their per-
sonal capacity, not as government representatives. Three 
members with medical, pharmacological or pharmaceu-
tical experience are elected from a list of persons nomi-
nated by the World Health Organization (WHO) and 
10 members are elected from a list of persons nominated 
by Governments. Members of the Board are persons who, 
by their competence, impartiality and disinterestedness, 
command general confidence. The Council, in consulta-
tion with INCB, makes all arrangements necessary to 
ensure the full technical independence of the Board in 
carrying out its functions. INCB has a secretariat that 
assists it in the exercise of its treaty-related functions. The 
INCB secretariat is an administrative entity of the United 
Nations Office on Drugs and Crime, but it reports solely 
to the Board on matters of substance. INCB closely col-
laborates with the Office in the framework of arrange-
ments approved by the Council in its resolution 1991/48. 
INCB also cooperates with other international bodies 
concerned with drug control, including not only the 
Council and its Commission on Narcotic Drugs, but also 
the relevant specialized agencies of the United Nations, 
particularly WHO. It also cooperates with bodies outside 
the United Nations system, especially the International 
Criminal Police Organization (INTERPOL) and the 
World Customs Organization.
Functions
The functions of INCB are laid down in the following 
treaties: the Single Convention on Narcotic Drugs of 1961 
as amended by the 1972 Protocol; the Convention on 
Psychotropic Substances of 1971; and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988. Broadly speaking, INCB 
deals with the following:
  (a) As regards the licit manufacture of, trade in and 
use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs 
are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels 
does not occur. INCB also monitors Governments’ con-
trol over chemicals used in the illicit manufacture of 
drugs and assists them in preventing the diversion of 
those chemicals into the illicit traffic;
  (b) As regards the illicit manufacture of, traffick-
ing in and use of drugs, INCB identifies weaknesses in 
national and international control systems and contrib-
utes to correcting such situations. INCB is also responsi-
ble for assessing chemicals used in the illicit manufacture 
of drugs, in order to determine whether they should be 
placed under international control.
In the discharge of its responsibilities, INCB:
  (a) Administers a system of estimates for narcotic 
drugs and a voluntary assessment system for psycho-
tropic substances and monitors licit activities involving 
drugs through a statistical returns system, with a view to 
assisting Governments in achieving, inter alia, a balance 
between supply and demand;
  (b) Monitors and promotes measures taken by 
Governments to prevent the diversion of substances fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances and assesses such substances 
to determine whether there is a need for changes in the 
scope of control of Tables I and II of the 1988 Convention;
  (c) Analyses information provided by Governments, 
United Nations bodies, specialized agencies or other com-
petent international organizations, with a view to ensur-
ing that the provisions of the international drug control 
treaties are adequately carried out by Governments, and 
recommends remedial measures;
  (d) Maintains a permanent dialogue with Gov-
ernments to assist them in complying with their obliga-
tions under the international drug control treaties and, to 
that end, recommends, where appropriate, technical or 
financial assistance to be provided.
INCB is called upon to ask for explanations in the event 
of apparent violations of the treaties, to propose appro-
priate remedial measures to Governments that are not 
fully applying the provisions of the treaties or are encoun-
tering difficulties in applying them and, where necessary, 
to assist Governments in overcoming such difficulties. 
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If, however, INCB notes that the measures necessary to 
remedy a serious situation have not been taken, it may 
call the matter to the attention of the parties concerned, 
the Commission on Narcotic Drugs and the Economic 
and Social Council. As a last resort, the treaties empower 
INCB to recommend to parties that they stop importing 
drugs from a defaulting country, exporting drugs to it or 
both. In all cases, INCB acts in close cooperation with 
Governments.
INCB assists national administrations in meeting their 
obligations under the conventions. To that end, it pro-
poses and participates in regional training seminars and 
programmes for drug control administrators.
Reports
The international drug control treaties require INCB to 
prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation world-
wide so that Governments are kept aware of existing and 
potential situations that may endanger the objectives of 
the international drug control treaties. INCB draws the 
attention of Governments to gaps and weaknesses in 
national control and in treaty compliance; it also makes 
suggestions and recommendations for improvements at 
both the national and international levels. The annual 
report is based on information provided by Governments 
to INCB, United Nations entities and other organiza-
tions. It also uses information provided through other 
international organizations, such as INTERPOL and the 
World Customs Organization, as well as regional 
organizations.
The annual report of INCB is supplemented by detailed 
technical reports. They contain data on the licit move-
ment of narcotic drugs and psychotropic substances 
required for medical and scientific purposes, together 
with an analysis of those data by INCB. Those data are 
required for the proper functioning of the system of con-
trol over the licit movement of narcotic drugs and psy-
chotropic substances, including preventing their diversion 
to illicit channels. Moreover, under the provisions of arti-
cle 12 of the 1988 Convention, INCB reports annually to 
the Commission on Narcotic Drugs on the implementa-
tion of that article. That report, which gives an account 
of the results of the monitoring of precursors and of the 
chemicals frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances, is also pub-
lished as a supplement to the annual report.
Since 1992, the first chapter of the annual report has been 
devoted to a specific drug control issue on which INCB 
presents its conclusions and recommendations in order 
to contribute to policy-related discussions and decisions 
in national, regional and international drug control. The 
following topics were covered in past annual reports:
1992:  Legalization of the non-medical use of drugs
1993:  The importance of demand reduction
1994:  Evaluation of the effectiveness of the inter-
national drug control treaties
1995:  Giving more priority to combating 
money-laundering
1996:  Drug abuse and the criminal justice system
1997:  Preventing drug abuse in an environment of 
illicit drug promotion
1998:  International control of drugs: past, present 
and future
1999:  Freedom from pain and suffering
2000:  Overconsumption of internationally controlled 
drugs
2001: Globalization and new technologies: challenges 
to drug law enforcement in the twenty-first century
2002:  Illicit drugs and economic development
2003:  Drugs, crime and violence: the microlevel 
impact
2004:  Integration of supply and demand reduction 
strategies: moving beyond a balanced approach
2005: Alternative development and legitimate 
livelihoods
2006: Internationally controlled drugs and the 
unregulated market
2007: The principle of proportionality and drug-
related offences
2008: The international drug control conventions: 
history, achievements and challenges
2009: Primary prevention of drug abuse
2010: Drugs and corruption
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2011: Social cohesion, social disorganization and 
illegal drugs
2012: Shared responsibility in international drug 
control 
2013: Economic consequences of drug abuse
Chapter I of the report of the International Narcotics 
Control Board for 2014 is entitled “Implementation of a 
comprehensive, integrated and balanced approach to 
addressing the world drug problem”.
Chapter II presents an analysis of the operation of the 
international drug control system based primarily on 
information that Governments are required to submit 
directly to INCB in accordance with the international 
drug control treaties. Its focus is on the worldwide con-
trol of all licit activities related to narcotic drugs and 
psycho tropic substances, as well as chemicals used in the 
illicit manufacture of such drugs.
Chapter III presents some of the major developments in 
drug abuse and trafficking and measures by Governments 
to implement the international drug control treaties by 
addressing those problems.
Chapter IV presents the main recommendations addressed 
by INCB to Governments, UNODC, WHO and other 
 relevant international and regional organizations.
 United Nations system and drug control organs and their secretariat
General Assembly
Economic and Social 
Council
INCB Commission onNarcotic Drugs
UNODCa/INCB secretariatb
Key:
Direct connection (administrative or constitutional)
Reporting, cooperating and advising relationship 
a United Nations Office on Drugs and Crime.
b The INCB secretariat reports on substantive matters to INCB only.
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